House of Delegates
Approved Policies
2018 - 2022
**HOUSE OF DELEGATES’ EDUCATIONAL AFFAIRS REFERENCE COMMITTEE**

(200 series) - This reference committee reviews and considers matters relating to osteopathic education, osteopathic colleges, and postdoctoral training.

<table>
<thead>
<tr>
<th>Res. No.</th>
<th>Resolution Title</th>
<th>Submitted By</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>H-200</td>
<td>Osteopathic Manipulative Treatment (OMT) by Osteopathic Medical Students During Medical School Rotations, Promoting use of (H203-A/13)</td>
<td>BOE</td>
<td>APPROVED as AMENDED</td>
</tr>
<tr>
<td>H-201</td>
<td>Unified Graduate Medical Education (GME) Accreditation System Under the Accreditation Council for Graduate Medical Education (ACGME) – Proposed (H204-A/13)</td>
<td>BOE</td>
<td>REFERRED</td>
</tr>
<tr>
<td>H-202</td>
<td>Osteopathic Postdoctoral Training in all Specialty Areas (H206-A/13)</td>
<td>BOE</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-203</td>
<td>Substance Use Disorders Education (H207-A/13)</td>
<td>BOE</td>
<td>APPROVED as AMENDED</td>
</tr>
<tr>
<td>H-204</td>
<td>DO Degree Designation (H208-A/13)</td>
<td>BOE</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-205</td>
<td>Osteopathic-Focused Training Programs (H209-A/13)</td>
<td>BOE</td>
<td>REFERRED</td>
</tr>
<tr>
<td>H-206</td>
<td>Dual Degrees (H201-A/13)</td>
<td>BSGA</td>
<td>APPROVED as AMENDED</td>
</tr>
<tr>
<td>H-207</td>
<td>Acupuncture (H200-A/13)</td>
<td>BSAPH</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-208</td>
<td>Osteopathic Continuous Certification (H202-A/13)</td>
<td>BSGA</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-209</td>
<td>Sale of Health-Related Products and Devices (H254-A/04)</td>
<td>BOM - Ethics</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-210</td>
<td>Osteopathic Continuous Certification – Affordability of (H213-A/13)</td>
<td>BOS</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-211</td>
<td>Develop and Implement Curriculum on the Care of People with Developmental Disabilities</td>
<td>NYSOMS</td>
<td>APPROVED as AMENDED</td>
</tr>
<tr>
<td>H-212</td>
<td>Peer-to-Peer Suicide Prevention Training Amongst Osteopathic Medical Schools</td>
<td>IOA</td>
<td>APPROVED as AMENDED</td>
</tr>
<tr>
<td>H-213</td>
<td>Specialty Requirements for Osteopathic CME</td>
<td>MOMA / IOPA / KOMA</td>
<td>DISAPPROVED</td>
</tr>
<tr>
<td>H-214</td>
<td>Sex and Gender Based Medicine</td>
<td>BOT</td>
<td>APPROVED as AMENDED</td>
</tr>
<tr>
<td>H-215</td>
<td>Addiction Medicine CAQ</td>
<td>AOAAM</td>
<td>REFERRED</td>
</tr>
</tbody>
</table>
HOUSE OF DELEGATES’ REFERENCE COMMITTEE DESCRIPTIONS:

- Committee on Educational Affairs (200 series)
  This reference committee reviews and considers matters relating to osteopathic education, osteopathic colleges, and postdoctoral training.

<table>
<thead>
<tr>
<th>Res. No.</th>
<th>Resolution Title</th>
<th>Submitted By</th>
<th>Reference Committee</th>
</tr>
</thead>
<tbody>
<tr>
<td>H-200</td>
<td>Health Care Shortage in Rural America (H200-A/14)</td>
<td>BOE</td>
<td>Education</td>
</tr>
<tr>
<td>H-201</td>
<td>Graduate Medical Education – Increasing Opportunities (H201-A/14)</td>
<td>BOE</td>
<td>Education</td>
</tr>
<tr>
<td>H-202</td>
<td>Osteopathic Medical Education (H203-A/14)</td>
<td>BOE</td>
<td>Education</td>
</tr>
<tr>
<td>H-203</td>
<td>Assure GME Residency Positions to Graduates of U.S. Medical Schools (H205-A/14)</td>
<td>BFHP</td>
<td>Education</td>
</tr>
<tr>
<td>H-204</td>
<td>Uniformed Services Physicians Requiring and Assigned to Civilian Residency Programs – AOA Support of All Osteopathically Trained (H208-A/14)</td>
<td>BOE</td>
<td>Education</td>
</tr>
<tr>
<td>H-205</td>
<td>Graduates of LCME-Accredited Colleges of Medicine - Admission to Osteopathic Residency Programs (H207-A/14)</td>
<td>BOE</td>
<td>Education</td>
</tr>
<tr>
<td>H-206</td>
<td>Clinical Rotations for International Medical Students (H209-A/14)</td>
<td>BSGA</td>
<td>Education</td>
</tr>
<tr>
<td>H-207</td>
<td>Inhalation of Volatile Substances (H210-A/14)</td>
<td>BSAPh</td>
<td>Education</td>
</tr>
<tr>
<td>H-208</td>
<td>Integrity and Mission of COMs UHSC Granting the DO – Maintaining the (H211-A/14)</td>
<td>BOE</td>
<td>Education</td>
</tr>
<tr>
<td>H-209</td>
<td>Psychiatry Curriculum and Staffing (H212-A/14)</td>
<td>BOE</td>
<td>Education</td>
</tr>
<tr>
<td>H-210</td>
<td>Teenage Alcohol Abuse (H213-A/14)</td>
<td>BSAPh</td>
<td>Education</td>
</tr>
<tr>
<td>H-211</td>
<td>Mandatory CME Course Requirements (H214-A/14)</td>
<td>BSGA</td>
<td>Education</td>
</tr>
<tr>
<td>H-212</td>
<td>Community-Based Teaching Health Centers Residency Support (H217-A/14)</td>
<td>BOE</td>
<td>Education</td>
</tr>
<tr>
<td>H-213</td>
<td>Professional Liability Insurance – Trainee (H219-A/14)</td>
<td>BOE</td>
<td>Education</td>
</tr>
<tr>
<td>H-214</td>
<td>Influenza Vaccination Programs for Medical Schools (H308-A/14)</td>
<td>BOE</td>
<td>Education</td>
</tr>
<tr>
<td>H-215</td>
<td>Single Graduate Medical Education Accreditation System (H800-A/14)</td>
<td>BOT</td>
<td>Education</td>
</tr>
</tbody>
</table>
## 99th ANNUAL AOA HOUSE OF DELEGATES MEETING
### 2019 MEETING
#### RESOLUTION ROSTER
As of June 29, 2019

<table>
<thead>
<tr>
<th>Res. No.</th>
<th>Resolution Title</th>
<th>Submitted By</th>
<th>Reference Committee</th>
</tr>
</thead>
<tbody>
<tr>
<td>H-216</td>
<td>Statement of Support for the American Osteopathic Board of Neurology and Psychiatry</td>
<td>ACONP</td>
<td>Education</td>
</tr>
<tr>
<td>H-217</td>
<td>Board Certification Test Results</td>
<td>ACOFP</td>
<td>Education</td>
</tr>
<tr>
<td>H-218</td>
<td>Certification Component Development</td>
<td>ACOFP</td>
<td>Education</td>
</tr>
<tr>
<td>H-219</td>
<td>Osteopathic Manipulative Treatment Boot Camp</td>
<td>ACOFP</td>
<td>Education</td>
</tr>
<tr>
<td>H-220</td>
<td>American Osteopathic Association Specialty Board Certification</td>
<td>ACOFP / et al</td>
<td>Education</td>
</tr>
<tr>
<td>H-221</td>
<td>American Osteopathic Association Specialty Board Certification Terminology</td>
<td>ACOP</td>
<td>Education</td>
</tr>
<tr>
<td>H-222</td>
<td>H204-A/13 Unified GME Accreditation System Under the ACGME – Proposed and H209-A/13 Osteopathic Focused Training Programs</td>
<td>BOE</td>
<td>Education</td>
</tr>
<tr>
<td>H-223</td>
<td>Education of Students and Faculty on Obtaining Permission Before All Student and Patient Encounters</td>
<td>MOA</td>
<td>Education</td>
</tr>
<tr>
<td>H-224</td>
<td>AOA Board Certification Terminology</td>
<td>MOS</td>
<td>Education</td>
</tr>
<tr>
<td>H-225</td>
<td>Osteopathic Certification</td>
<td>MOS</td>
<td>Education</td>
</tr>
<tr>
<td>H-226</td>
<td>Osteopathic Content and Certification Standards</td>
<td>MOS</td>
<td>Education</td>
</tr>
<tr>
<td>H-227</td>
<td>Osteopathic Specialty Colleges And Certification</td>
<td>MOS</td>
<td>Education</td>
</tr>
<tr>
<td>H-228</td>
<td>Parental Leave Policies for Accreditation Council for Graduate Medical Education Residency</td>
<td>OOA</td>
<td>Education</td>
</tr>
<tr>
<td>H-229</td>
<td>Commendation of AMA Policy (AMA 955) on Equal Acceptance of COMLEX-USA for DO Students in all US Residency Programs</td>
<td>OPSC</td>
<td>Education</td>
</tr>
<tr>
<td>H-230</td>
<td>Classification of Osteopathic Medical Graduates as US Medical Graduates in Electron Residency Application Service</td>
<td>SOMA</td>
<td>Education</td>
</tr>
<tr>
<td>H-231</td>
<td>Recognition of COMLEX and USMLE as Equal Licensing Examinations Among Residency Programs</td>
<td>MAOP</td>
<td>Education</td>
</tr>
<tr>
<td>H-232</td>
<td>Addiction Medicine CAQ</td>
<td>FC</td>
<td>Education</td>
</tr>
</tbody>
</table>
SPECIAL MEETING OF THE
AOA HOUSE OF DELEGATES

OCTOBER 2020 MEETING

EDUCATIONAL AFFAIRS - RESOLUTION ROSTER

As of September 7, 2020

HOUSE OF DELEGATES’ REFERENCE COMMITTEE DESCRIPTION:

- Committee on Educational Affairs (200 series)
  This reference committee reviews and considers matters relating to osteopathic education, osteopathic colleges, and postdoctoral training.

<table>
<thead>
<tr>
<th>Res. No.</th>
<th>Resolution Title</th>
<th>Submitted By</th>
<th>Reference Committee</th>
</tr>
</thead>
<tbody>
<tr>
<td>H200</td>
<td>Graduate Medical Education – Training of US Medical School Graduates (H213-A/15)</td>
<td>BOE</td>
<td>Education</td>
</tr>
<tr>
<td>H201</td>
<td>Rural Sites – Osteopathic Education in (H214-A/15)</td>
<td>BOE</td>
<td>Education</td>
</tr>
<tr>
<td>H202</td>
<td>Directors of Medical Education Overseeing Osteopathic Postdoctoral Training Programs (H216-A/15)</td>
<td>BOE</td>
<td>Education</td>
</tr>
<tr>
<td>H203</td>
<td>Autopsies (H217-A/15)</td>
<td>BOE</td>
<td>Education</td>
</tr>
<tr>
<td>H204</td>
<td>Clarity Regarding Matching Service Listing of AOA Residencies with ACGME Pre-Accreditation Status (H219-A/15)</td>
<td>BOE</td>
<td>Education</td>
</tr>
<tr>
<td>H205</td>
<td>Blue Ribbon Commission Report (H223-A/15)</td>
<td>BOE</td>
<td>Education</td>
</tr>
<tr>
<td>H206</td>
<td>AOA to Support Education and Advocate for Policies Relating to Climate Change</td>
<td>MOA</td>
<td>Education</td>
</tr>
<tr>
<td>H207</td>
<td>Adoption of Specific Informed Consent Guideline for Sensitive Exams Under Anesthesia for Education Purposes</td>
<td>SOMA</td>
<td>Education</td>
</tr>
<tr>
<td>H208</td>
<td>Incorporating Continuing Medical Education Opportunities on Human Trafficking</td>
<td>SOMA</td>
<td>Education</td>
</tr>
<tr>
<td>H209</td>
<td>Incorporating Continued Medical Education Regarding Intellectual and Developmental Disabilities</td>
<td>SOMA</td>
<td>Education</td>
</tr>
<tr>
<td>H210</td>
<td>Recommendation of Buprenorphine Waiver Training in Osteopathic Medical Schools</td>
<td>BSAPH</td>
<td>Education</td>
</tr>
<tr>
<td>H211</td>
<td>Referred Res. No H-224 – A/2019 AOA Board Certification Terminology</td>
<td>BOS</td>
<td>Education</td>
</tr>
<tr>
<td>H212</td>
<td>Residency Redistribution of Center for Medicare/Medicaid Services Funding Following Single Accreditation Systems (SAS)</td>
<td>OPSC</td>
<td>Education</td>
</tr>
<tr>
<td>H213</td>
<td>Training High Quality Physicians in a Healthy and Safe Environment</td>
<td>MAOP</td>
<td>Education</td>
</tr>
<tr>
<td>H214</td>
<td>Audition Rotations for Osteopathic Medical Students</td>
<td>IOMA</td>
<td>Education</td>
</tr>
</tbody>
</table>
### House Of Delegates’ Reference Committee Description:
Committee on Educational Affairs (200 series)
This reference committee reviews and considers matters relating to osteopathic education, osteopathic colleges, and postdoctoral training.

<table>
<thead>
<tr>
<th>Res. No.</th>
<th>Resolution Title</th>
<th>Submitted By</th>
<th>Reference Committee</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>H-200</td>
<td>Maintenance of Primary Board Certification for Subspecialty Certification</td>
<td>AOAAM</td>
<td>Educational Affairs</td>
<td>NOT ADOPTED</td>
</tr>
<tr>
<td>H-201</td>
<td>Vital Nature of Board-Certified Physicians in Aerospace Medicine</td>
<td>AOCOPM</td>
<td>Educational Affairs</td>
<td>ADOPTED as AMENDED</td>
</tr>
<tr>
<td>H-202</td>
<td>Training High Quality Physicians in a Healthy and Safe Environment – WITHDRAWN BY AUTHOR</td>
<td>MAOP</td>
<td>Educational Affairs</td>
<td>WITHDRAWN</td>
</tr>
<tr>
<td>H-203</td>
<td>Physician Designation, Truth in Advertising and Residency/Fellowship Training Non-Physician Post-Graduate Medical Training</td>
<td>NYSOMS</td>
<td>Educational Affairs</td>
<td>ADOPTED as AMENDED</td>
</tr>
<tr>
<td>H-204</td>
<td>Protective Educational Environments for Lesbian, Gay, Bisexual, Transgender, and Queer/Questioning Youth</td>
<td>OOA</td>
<td>Educational Affairs</td>
<td>ADOPTED as AMENDED</td>
</tr>
<tr>
<td>H-205</td>
<td>Resolution Withdrawn</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>H-206</td>
<td>Optional Correct Pronoun Demographic on General Medical Education Applications</td>
<td>BEL</td>
<td>Educational Affairs</td>
<td>ADOPTED</td>
</tr>
<tr>
<td>H-208</td>
<td>Osteopathic Board Payment Reform – WITHDRAWN BY UNANIMOUS CONSENT</td>
<td>MOA</td>
<td>Educational Affairs</td>
<td>WITHDRAWN</td>
</tr>
<tr>
<td>H-209</td>
<td>Restoring An Equitable and Positive Learning Environment in Medical Training</td>
<td>MOA</td>
<td>Educational Affairs</td>
<td>REFERRED TO AUTHOR</td>
</tr>
<tr>
<td>H-210</td>
<td>Access To Healthcare-Developing a New Model of Administering Osteopathic Primary Care in the U.S. (SR-Source: H201-A-16)</td>
<td>BOE</td>
<td>Educational Affairs</td>
<td>ADOPTED</td>
</tr>
<tr>
<td>Res. No.</td>
<td>Resolution Title</td>
<td>Submitted By</td>
<td>Reference Committee</td>
<td>Action</td>
</tr>
<tr>
<td>---------</td>
<td>----------------------------------------------------------------------------------</td>
<td>--------------</td>
<td>----------------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>H-211</td>
<td>Depression ACCESS TO MENTAL HEALTH SERVICES AND Awareness in U.S. OSTEOPATHIC Medical Students (SR-Source: H203-A/16)</td>
<td>BOE</td>
<td>Educational Affairs</td>
<td>ADOPTED as AMENDED</td>
</tr>
<tr>
<td>H-212</td>
<td>Disaster Response Courses and Training Within Colleges of Osteopathic Medicine (SR-Source: H204-A/16)</td>
<td>BOE</td>
<td>Educational Affairs</td>
<td>ADOPTED as AMENDED</td>
</tr>
<tr>
<td>H-213</td>
<td>Academic Osteopathic Educators, Researchers or Administrators Educational Program Development (SR-Source: H205-A/16)</td>
<td>BOE</td>
<td>Educational Affairs</td>
<td>ADOPTED (SUNSET)</td>
</tr>
<tr>
<td>H-214</td>
<td>Uniform Title for Osteopathic Medical Students (SR-Source: H208-A/16)</td>
<td>BOE</td>
<td>Educational Affairs</td>
<td>ADOPTED</td>
</tr>
<tr>
<td>H-215</td>
<td>Tobacco Free AND VAPING FREE Colleges / Schools of Osteopathic Medicine (SR-Source: H209-A/16)</td>
<td>BORPH</td>
<td>Educational Affairs</td>
<td>ADOPTED as AMENDED</td>
</tr>
<tr>
<td>H-216</td>
<td>Rural Healthcare Provided by Current AOA-GME Programs – Preservation of (SR-Source: H211-A/16)</td>
<td>BOE</td>
<td>Educational Affairs</td>
<td>ADOPTED as AMENDED</td>
</tr>
<tr>
<td>H-217</td>
<td>Drug Stimulant Abuse in the Academic Setting – Education and Resources for (SR-Source: H213-A/16)</td>
<td>BOE</td>
<td>Educational Affairs</td>
<td>ADOPTED</td>
</tr>
<tr>
<td>H-218</td>
<td>Graduate Medical Education Funding and Incentives (SR-Source: H329-A/16)</td>
<td>CERA/BFH/CSHA</td>
<td>Educational Affairs</td>
<td>ADOPTED</td>
</tr>
<tr>
<td>H-219</td>
<td>Promotion Of Osteopathic Medicine to Disadvantaged High School Students (SR-Source: H402-A/16)</td>
<td>BORPH</td>
<td>Educational Affairs</td>
<td>ADOPTED</td>
</tr>
</tbody>
</table>
### HOUSE OF DELEGATES’ REFERENCE COMMITTEE DESCRIPTION:
Committee on Educational Affairs (200 series)
This reference committee reviews and considers matters relating to osteopathic education, osteopathic colleges, and postdoctoral training.

<table>
<thead>
<tr>
<th>Res. No.</th>
<th>Resolution Title</th>
<th>Submitted By</th>
<th>Reference Committee</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>H-200</td>
<td>Ensuring that Graduate Medical Education (GME) Programs Continue to Select Residents Based on Merit (SR- Source: H200-A/17)</td>
<td>BOE</td>
<td>Educational Affairs</td>
<td>Adopted as Amended</td>
</tr>
<tr>
<td>H-201</td>
<td>Ambulatory-Based Primary Care Residency Programs (SR- Source: H201-A/17)</td>
<td>BOE</td>
<td>Educational Affairs</td>
<td>Adopted</td>
</tr>
<tr>
<td>H-202</td>
<td>Joining Forces Initiative (SR- Source: H205-A/17)</td>
<td>BOE</td>
<td>Educational Affairs</td>
<td>Adopted</td>
</tr>
<tr>
<td>H-203</td>
<td>Disability Determinations (SR- Source: H206-A/17)</td>
<td>BOE</td>
<td>Educational Affairs</td>
<td>Adopted as Amended</td>
</tr>
<tr>
<td>H-204</td>
<td>Non-Gender Discrimination (SR - Source : H207-A/17)</td>
<td>BOE</td>
<td>Educational Affairs</td>
<td>Adopted for Sunset</td>
</tr>
<tr>
<td>H-205</td>
<td>Supervision for Osteopathic Manipulative Treatment (SR- Source: H209-A/17)</td>
<td>BOE</td>
<td>Educational Affairs</td>
<td>Adopted</td>
</tr>
<tr>
<td>H-206</td>
<td>Training Reaffirmation of Primary Care Physicians (SR - Source: H210-A/17)</td>
<td>BOE</td>
<td>Educational Affairs</td>
<td>Adopted as Amended</td>
</tr>
<tr>
<td>H-207</td>
<td>Clearly Articulated Protocol for Sleep Facilities and Safe Transportation in All Physician Residencies (SR- Source: H213-A/17)</td>
<td>BOE</td>
<td>Educational Affairs</td>
<td>Adopted for Sunset</td>
</tr>
<tr>
<td>H-208</td>
<td>Longitudinal Approach to Cultural Competency Dialogue on Eliminating Health Care Disparities (SR - Source: H215-A/17)</td>
<td>BOE</td>
<td>Educational Affairs</td>
<td>Adopted as Amended</td>
</tr>
<tr>
<td>H-209</td>
<td>United States Immigration Executive Order Impact on Medical Education (SR-Source: H222-A/17)</td>
<td>BOE</td>
<td>Educational Affairs</td>
<td>Adopted</td>
</tr>
<tr>
<td>H-210</td>
<td>Importance of Empathy in Osteopathic Medical Education and Practice (SR- Source: H226-A/17)</td>
<td>BOE</td>
<td>Educational Affairs</td>
<td>Adopted as Amended</td>
</tr>
<tr>
<td>H-211</td>
<td>Equivalency Policy for Osteopathic Continuous Certification (SR- Source: H227-A/17)</td>
<td>BOS</td>
<td>Educational Affairs</td>
<td>Adopted</td>
</tr>
<tr>
<td>H-212</td>
<td>Loan Deferment During Residency (SR - Source: H202-A/17)</td>
<td>BFHP</td>
<td>Educational Affairs</td>
<td>Adopted</td>
</tr>
<tr>
<td>Resolution Number</td>
<td>Description</td>
<td>Sponsor</td>
<td>Committee</td>
<td>Status</td>
</tr>
<tr>
<td>-------------------</td>
<td>------------------------------------------------------------------------------</td>
<td>---------</td>
<td>--------------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>H-213</td>
<td>Osteopathic Licensing (SR - Source: H208-A/17)</td>
<td>CSHA</td>
<td>Educational Affairs</td>
<td>Adopted</td>
</tr>
<tr>
<td>H-214</td>
<td>Osteopathically Recognized Graduate Medical Education Programs (SR - Source: H212-A/17)</td>
<td>BFHP</td>
<td>Educational Affairs</td>
<td>Adopted as Amended</td>
</tr>
<tr>
<td>H-215</td>
<td>Promoting Osteopathic Principles and Practices (OPP) in Continuing Medical Education (CME)</td>
<td>MOMA</td>
<td>Educational Affairs</td>
<td>Referred</td>
</tr>
<tr>
<td>H-216</td>
<td>Osteopathic Principles and Practices (OPP) and Educational Efforts to Incorporate Value-Based Care in All Levels of Osteopathic Medical Education</td>
<td>MOMA</td>
<td>Educational Affairs</td>
<td>Referred</td>
</tr>
<tr>
<td>H-217</td>
<td>Equality In Away Rotations/Sub-Internships for Osteopathic Medical Students</td>
<td>BEL</td>
<td>Educational Affairs</td>
<td>Adopted as Amended</td>
</tr>
<tr>
<td>H-218</td>
<td>Maintenance of Primary Board Certification for Subspecialty Certification</td>
<td>AOAAM</td>
<td>Educational Affairs</td>
<td>Disapproved</td>
</tr>
<tr>
<td>H-219</td>
<td>ABIM Board Eligibility</td>
<td>OPSC</td>
<td>Educational Affairs</td>
<td>Adopted as Amended</td>
</tr>
<tr>
<td>H-220</td>
<td>Physician Designation, Truth in Advertising and Residency/Fellowship Training Non-Physician Post Graduate Medical Training 2022</td>
<td>NYSOMS</td>
<td>Educational Affairs</td>
<td>Adopted as Amended</td>
</tr>
<tr>
<td>H-221</td>
<td>WITHDRAWN BY AUTHOR</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>H-222</td>
<td>WITHDRAWN BY AUTHOR</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>H-223</td>
<td>Osteopathic Education</td>
<td>IOMA</td>
<td>Educational Affairs</td>
<td>Adopted as Amended</td>
</tr>
</tbody>
</table>
Osteopathic Manipulative Treatment (OMT) by Osteopathic Medical Students During Medical School Rotations, Promoting use of

Policy Statement

The American Osteopathic Association supports and encourages osteopathic medical schools provide hands-on Osteopathic Manipulative Treatment (OMT) practice sessions to physicians teaching osteopathic medical students in order to increase their understanding about osteopathic manipulative treatment.

Source: H200-A/18

Status: 2013; 2018 Reaffirmed as Amended
Osteopathic Postdoctoral Training in all Specialty Areas

Policy Statement

The American Osteopathic Association urges the osteopathic profession to reaffirm itself as a complete profession of medicine and surgery and reaffirms its commitment to quality osteopathic postdoctoral training in all specialty areas.

Source: H202-A/18

Status: 1993; 1998 Reaffirmed as Amended, 2003 Reaffirmed as Amended; 2008 Reaffirmed; 2013 Reaffirmed; 2018 Reaffirmed
Substance Use Disorders Education

Policy Statement

The American Osteopathic Association recommends the inclusion of substance use disorders education in all osteopathic education.

Source: H203-A/18

Status: 2008; 2013 Reaffirmed; 2018 Reaffirmed as Amended
DO Degree Designation

Policy Statement

The American Osteopathic Association (AOA) enthusiastically embraces the heritage and philosophy of Dr. Andrew Taylor Still by reaffirming that DO be the recognized degree designation for all graduates of AOA Commission on Osteopathic College Accreditation (COCA) accredited colleges of osteopathic medicine in the United States.

Source: H204-A/18

Status: 2008; 2013 Reaffirmed as Amended; 2018 Reaffirmed
Dual Degrees

Policy Statement

The American Osteopathic Association (AOA) has set policy that osteopathic physicians should only use their DO degree earned from a college or institution that is accredited by the Commission on Osteopathic College Accreditation (COCA) when representing themselves as a physician. The AOA will remain vigilant for any false or erroneous information that may undermine the integrity of the profession or osteopathic medicine in the US and will work with the Federation of State Medical Boards (FSMB) and its constituent boards to inform them of attempts to misrepresent the practice of osteopathic medicine in the US or to misrepresent the education leading to the degree Doctor of Osteopathy or Doctor of Osteopathic Medicine.

Source: H206-A/18

Status: 1969; 1978 Reaffirmed; 1983 Reaffirmed as Amended, 1988 Reaffirmed; 1993 Reaffirmed; 1998 Reaffirmed as Amended; 2003 Reaffirmed as Amended; 2008 Reaffirmed as Amended; 2013 Reaffirmed; 2018 Reaffirmed as Amended
Acupuncture

Policy Statement

The American Osteopathic Association recognizes that acupuncture may be a part of the armamentarium of qualified and licensed physicians.

Source: H207-A/18

Osteopathic Continuous Certification

Policy Statement

The American Osteopathic Association encourages input from osteopathic physicians on maintenance of licensure, maintenance of certification and osteopathic continuous certification rules.

Source: H208-A/18

Status: 2013; 2018 Reaffirmed
Sale of Health-Related Products and Devices

Policy Statement

The American Osteopathic Association believes that it is appropriate for physicians to derive reasonable monetary gain from the sale of health-related products or devices that are both supported by rigorous scientific testing or authoritative scientific data and, in the opinion of the physician, are medically necessary or will provide a significant health benefit provided that such action is permitted by the state licensing board(s) of the state(s) in which the physician practices; and inappropriate and unethical for physicians to use their physician/patient relationship to attempt to involve any patient in a program for the patient to distribute health related products or devices in which distribution results in a profit for the physician.

Source: H209-A/18

Status: 1999; 2004 Reaffirmed as Amended; 2018 Reaffirmed
Osteopathic Continuous Certification – Affordability of

Policy Statement

The American Osteopathic Association will undertake every effort to make transparent the cost structure of Osteopathic Continuous Certification (OCC) and, wherever possible, to make the costs of OCC affordable to its members and its affiliate organizations.

Source: H210-A/18

Status: 2013; 2018 Reaffirmed
Develop and Implement Curriculum on the Care of People with Developmental Disabilities

Policy Statement

The American Osteopathic Association (AOA) reaffirms the ideals set in the Americans with Disabilities Act (ADA); and that the AOA encourage osteopathic medical schools to develop and implement curricula on the care of people with developmental disabilities.

Source: H211-A/18

Status: 2018
Peer-to-Peer Suicide Prevention Training Amongst Osteopathic Medical Schools

Policy Statement

The American Osteopathic Association recommend that the American Association of Colleges of Osteopathic Medicine (AACOM) encourage osteopathic medical schools to implement peer-to-peer suicide prevention training for incoming and all osteopathic medical students.

Source: H212-A/18

Status: 2018
Sex and Gender Based Medicine

Policy Statement

The American Osteopathic Association supports the inclusion of the evolving understanding of sex and gender-based medicine in medical education programs and curricula across the continuum.

Source: H214-A/18

Status: 2018
Health Care Shortage in Rural America

Policy Statement

The American Osteopathic Association encourages the development of teaching centers in rural Federally Qualified Health Centers and other eligible entities, so that residents can train and stay in these areas and practice osteopathic medicine.

Source: H200-A/19

Status: 2014; 2019 Approved as Amended
Graduate Medical Education – Increasing Opportunities

Policy Statement

The American Osteopathic Association supports the efforts to increase the number of graduate medical education training positions available to United States medical graduates.

Source: H201-A/19

Status: 2014; 2019 Reaffirmed
Uniformed Services Physicians Requiring and Assigned to Civilian Residency Programs – AOA Support of All Osteopathically Trained

Policy Statement

The American Osteopathic Association will continue to monitor, assist and support all osteopathic physicians who receive graduate medical education (GME) through the uniformed services process, removing barriers to osteopathic graduate medical education approval.

Source: H204-A/19

Status: 1998; 2004 Reaffirmed as Amended; 2009 Reaffirmed; 2014 Reaffirmed; 2019 Reaffirmed
Clinical Rotations for International Medical Students

Policy Statement

The American Osteopathic Association supports adequate quality rotations for medical students as they pursue clinical education; and, in concert with other healthcare organizations, federal, state and local governments, will oppose policies that provide an unfair advantage to internationally-educated medical students.

Source: H206-A/19

Status: 2009; 2014 Reaffirmed; 2019 Approved as Amended
Inhalation of Volatile Substances

Policy Statement

The American Osteopathic Association endorses continuing medical education and medical literature to enhance physician awareness of inhalation of volatile substances (huffing) and endorses campaigns to enhance public awareness of this crisis.

Source: H207-A/19

Status: 2009; 2014 Reaffirmed; 2019 Reaffirmed
Integrity and Mission of COMs UHSC Granting the DO – Maintaining the

Policy Statement

The American Osteopathic Association upholds and supports maintaining the integrity and mission of Colleges of Osteopathic Medicine and University Health Science Centers granting the Doctor of Osteopathic Medicine degree.

Source: H208-A/19

Status: 2009; 2014 Reaffirmed; 2019 Reaffirmed
Psychiatry Curriculum and Staffing

Policy Statement

The American Osteopathic Association supports the use of members of the American College of Osteopathic Neurology and Psychiatry and their commitment to serve as a resource for developing core competencies and learning objectives for osteopathic psychiatry both in undergraduate and graduate medical education.

Source: H209-A/19

Status: 2009; 2014 Reaffirmed; 2019 Reaffirmed
Teenage Alcohol Abuse

Policy Statement

The American Osteopathic Association endorses continuing medical education for health care professionals to aid them in educating lower and middle school students of the dangers of alcohol and endorses outreach programs to elementary “lower” and middle schools to create awareness of the dangers of alcohol.

Source: H210-A/19

Status: 2009; 2014 Reaffirmed; 2019 Reaffirmed
Mandatory CME Course Requirements

Policy Statement

The American Osteopathic Association opposes any federal attempts to impose any specific continuing medical education (CME) course requirements and will assist any affiliate societies in opposing additional attempts by states to impose specific CME course requirements.

Source: H211-A/19

Status: 2004; 2009 Reaffirmed; 2014 Reaffirmed; 2019 Reaffirmed
Community-Based Teaching Health Centers Residency Support

Policy Statement

The American Osteopathic Association supports community-based programs as a model of training for osteopathic primary care residents throughout the United States.

Source: H212-A/19

Status: 2014; 2019 Reaffirmed
Influenza Vaccination Programs for Medical Schools

Policy Statement

The American Osteopathic Association recommends and supports that all osteopathic medical schools have an ongoing influenza vaccination program for students.

Source: H214-A/19

Status: 2009; 2014 Reaffirmed; 2019 Reaffirmed
American Osteopathic Association Specialty Board Certification

Policy Statement

The American Osteopathic Association reaffirms its commitment to the inclusion of osteopathic principles and practice in every osteopathic board certification examination, regardless of specialty; Continues the opportunity for osteopathic certifying boards to develop and administer OMM/OMT practical examinations which are specific and appropriate for their specialty; Allows a requirement for specialty-specific content in CME for re-certification/continuing certification; and continues to encourage the Accreditation Council for Graduate Medical Education to include an osteopathic educational component in Osteopathic Recognized residencies.

Source: H220-A/19

Status: 2019
Education of Students and Faculty on Obtaining Permission Before All Student and Patient Encounters

Policy Statement

The American Osteopathic Association (AOA) encourage all colleges of osteopathic medicine to prepare their educators and graduates to learn and demonstrate aptitude concerning the knowledge and practice of obtaining permission; and, that the AOA promote and encourage both educators and students in the use of obtaining permission in all OMT and/or physical contact patient interactions – whether they be students in educational activities, standardized patients, or others.

Source: H223-A/19

Status: 2019
Classification of Osteopathic Medical Graduates as US Medical Graduates in Electronic Residency Application Service

Policy Statement

The American Osteopathic Association advocates to the American Association of Medical Colleges to adjust Electronic Residency Application Service filters based on medical school type such that Osteopathic applicants are included and recognized within the US Public or Private Medical Graduates category.

Source: H230-A/19

Status: 2019
Addiction Medicine CAQ

Policy Statement

That Osteopathic physicians who have completed an American Osteopathic Association (AOA) approved fellowships in Addiction Medicine be allowed to take the primary CAQ examination in Addiction Medicine; and, that a clinical practice pathway be developed and approved by the AOA conjoint examination committee in Addiction Medicine and be opened for three (3) years after the initial exam administration for qualified DOs who wish to become certified in the subspecialty of Addiction Medicine; and, that the AOA Finance Committee submits a fiscal impact of H215 – A/2018 titled “Addiction Medicine CAQ” to be $151,000 while noting that the net financial impact will be $0 in year 1.

Source: H232-A/19

Status: 2019
Graduate Medical Education – Training of US Medical School Graduates

Policy Statement

The American Osteopathic Association (AOA) advocates for the elimination of limitations on the number of funded graduate medical education positions to accommodate increases in US medical school enrollment; places great emphasis on establishing graduate medical education opportunities for osteopathic medical school graduates in geographic areas that lack adequate training capacity and as needed to meet future workforce needs.

Source: H200-A/20

Status: 2009; 2014 Referred; 2015 Reaffirmed as Amended; 2020 Reaffirmed
Rural Sites – Osteopathic Education in

Policy Statement

The American Osteopathic Association (AOA) encourages clinical rotations in rural settings by osteopathic medical students and graduates during their respective predoctoral and postdoctoral education programs.

Source: H201-A/20

Status: 1990; 1995 Reaffirmed as Amended; 2000 Reaffirmed; 2005 Reaffirmed; 2010 Reaffirmed; 2015 Reaffirmed; 2020 Reaffirmed
Directors of Medical Education Overseeing Osteopathic Postdoctoral Training Programs

Policy Statement

The American Osteopathic Association (AOA) will encourage the continued teaching of osteopathic principles and practices through but not limited to osteopathic recognition in graduate medical education programs and encourages osteopathic physicians to seek faculty and administrative positions in graduate medical education programs.

Source: H202-A/20

Status: 2010, 2015 Reaffirmed; 2020 Reaffirmed as Amended
Autopsies

Policy Statement

The American Osteopathic Association (AOA) encourages medical schools, private hospital systems and public medical facilities to allow the viewing of autopsies by medical students and residents for teaching purposes.

Source: H203-A/20

Status: 2010; 2015 Reaffirmed; 2020 Reaffirmed
Blue Ribbon Commission Report

Policy Statement

The American Osteopathic Association (AOA) encourages colleges of osteopathic medicine to collaborate with appropriate regulatory authorities, licensing boards, certifying boards, the National Board of Osteopathic Medical Examiners, and other stakeholders in their pursuit of innovative pilot studies to produce primary care, competency-based physician team leaders and the AOA will monitor the outcomes of these pilot programs and the route to board certification.

Source: H205-A/20

Status: 2015; 2020 Reaffirmed
Incorporating Continued Medical Education Regarding Intellectual and Developmental Disabilities

Policy Statement

The American Osteopathic Association (AOA) encourages continuing medical education opportunities regarding intellectual and developmental disability care for adults

Source: H209-A/20

Status: 2020 Reaffirmed as Amended
Audition Rotations for Osteopathic Medical Students

Policy Statement

The American Osteopathic Association (AOA), in partnership with interested stakeholders including, but not limited to, the Association of American Medical Colleges (AAMC) and the American Association of Colleges of Osteopathic Medicine (AACOM), has addressed the discriminatory practice of prohibiting medical students from visiting student rotations or charging different fees to medical students based solely on their osteopathic training; and, that the AOA work with any and all relevant organizations to seek necessary changes in institutional or residency policies and/or practices that prohibit visiting student rotations or charge inequitable fees to medical students based solely on their osteopathic training against osteopathic medical students or residents; and, that the AOA will continue to advocate for osteopathic medical students and residents with institutions, programs, and other relevant stakeholders when the AOA becomes aware of any instance of discrimination.

Source: H214-A/20

Status: 2020 Adopted as Amended
Vital Nature of Board-Certified Physicians in Aerospace Medicine

Policy Statement

The American Osteopathic Association recognizes the unique contributions and advanced qualifications of Aerospace Medicine professionals; and specifically opposes any and all efforts to remove, reduce or replace Aerospace Medicine physician leadership in civilian, corporate or government Aerospace Medicine programs and aircrew healthcare support teams. The AOA will advocate against further Aerospace medicine mid-level provider scope of practice expansions that threaten the safety, health, and wellbeing of aircrew, patients, support personnel and the flying public.

Source: H201-A/21

Status: 2021
Physician Designation, Truth in Advertising and Residency/Fellowship Training Non-Physician Post-Graduate Medical Training

Policy Statement

When the American Osteopathic Association (AOA) utilizes the term, “physician,” it is to mean, “DO or MD or a recognized international equivalent terminal degree in medicine,” and be used exclusively by graduates from educational programs provided by a college of osteopathic medicine or allopathic medicine accredited by the Commission on Osteopathic College Accreditation or the Liaison Committee on Medical Education leading to the DO or MD degree, or recognized international equivalent terminal degree in medicine. The AOA will work with the American Medical Association (AMA), and other relevant stakeholders to continue to advocate that the title of Physician Assistant (PA) be preserved, and that the proposed title change to “Physician Associate” be rejected, because the proposed use of “associate” is misleading and should be abandoned out of concern for the potential impact on patient care and safety.

Source: H203-A/21

Status: 2021
Protective Educational Environments for Lesbian, Gay, Bisexual, Transgender, and Queer/Questioning Youth

Policy Statement

The American Osteopathic Association recognizes the importance and supports advocacy that acknowledge LGBTQ identities, and the implementation of anti-bullying policies that specifically protect children from harassment based on sexual orientation or gender identity in educational settings.

Source: H204-A/21

Status: 2021
Protective Educational Environments for Lesbian, Gay, Bisexual, Transgender, and Queer/Questioning Youth

Policy Statement

The American Osteopathic Association recognizes the importance and supports advocacy that acknowledge LGBTQ identities, and the implementation of anti-bullying policies that specifically protect children from harassment based on sexual orientation or gender identity in educational settings.

Source: H206-A/21

Status: 2021
Access to Mental Health Services and Awareness in U.S. Osteopathic Medical Students

Policy Statement

The American Osteopathic Association recommends that there be increased mental health awareness amongst U.S. osteopathic medical students and that treatment options be available that are accessible, private and confidential for those affected.

Source: H211-A/21

Status: 2011; 2016 Reaffirmed; 2021 Reaffirmed as Amended
Disaster Response Training

Policy Statement

The American Osteopathic Association encourages disaster response training for osteopathic physicians and students.

Source: H212-A/21

Uniform Title for Osteopathic Medical Students

Policy Statement

The American Osteopathic Association recommends that students enrolled in accredited osteopathic medical schools be referred to as Osteopathic Medical Students (OMS); after the letters OMS, the level of study be identified by Roman Numerals I, II, III, and IV, and V, etc., such as OMS I, OMS II, OMS III, and OMS IV, and OMS V, etc.; unless prohibited by the institution in which they are doing a clinical rotation, students shall be identified by use of the OMS and appropriate Roman Numeral designation after their name (e.g., Jane Doe, OMS II, John Doe, OMS IV, etc.).

Source: H214-A/21

Status: 2006, 2011 Reaffirmed as amended; 2016 Reaffirmed; 2021 Reaffirmed
Tobacco Free and Vaping Free Colleges / Schools of Osteopathic Medicine

Policy Statement

The American Osteopathic Association commits to the goal of establishing and supporting tobacco-free and vaping-free colleges of osteopathic medicine at every Commission on Osteopathic College Accreditation (COCA) accredited colleges of osteopathic medicine.

Source: H215-A/21

Rural Healthcare Provided by Current GME Programs - Preservation of

Policy Statement

It is a priority of the American Osteopathic Association (AOA) to advocate for the development and preservation of residencies in rural and underserved communities.

Source: H216-A/21

Stimulant Abuse in The Academic Setting - Education and Resources for

Policy Statement

The American Osteopathic Association (AOA) will encourage the development of continuing medical education (CME) for physicians to recognize risk factors, ensure appropriate diagnosis, and subsequent treatment of conditions which utilize stimulants for academic performance which may be abused.

Source: H217-A/21

Graduate Medical Education Funding and Incentives

Policy Statement

The American Osteopathic Association (AOA) opposes cuts to graduate medical education (GME) funding for physician training (DO and MD); supports the distribution of federal funds for GME, prioritizing areas most in need for physician training (DO and MD) programs based upon geography and specialty; advocates for continued and expanded contribution by all payers for health care (including the federal government, the states, and local and private sources) to fund both the direct and indirect costs of GME; supports allowing health insurers who provide financial support for expansion or continuation of existing GME programs to include such sums as direct medical expenditures as part of the calculation of the Medical Loss Ratio of their health plans.

Source: H218-A/21

Promotion of Osteopathic Medicine to Disadvantaged High School Students

Policy Statement

The American Osteopathic Association encourages colleges of osteopathic medicine to identify and support outreach programs for disadvantaged high school students in their communities for successful health careers in osteopathic medicine.

Source: H219-A/21

Status: 2011; 2016 Reaffirmed; 2021 Reaffirmed
Residency Training in Canada – Equality Between COCA-Accredited and LCME-Accredited Medical School Graduates Seeking

Policy Statement

The American Osteopathic Association (AOA) supports efforts to restore the equal eligibility standards and criteria for Canadian residency training positions that existed prior to June 2014 for both United States Liaison Committee on Medical Education (LCME) and Commission on Osteopathic College Accreditation (COCA) accredited medical schools.

The AOA encourages relevant Canadian authorities to restore the post-graduate medical education eligibility rules in place prior to June 2014 and advocates Canadian authorities restore equal LCME and COCA eligibility that existed prior to June 2014.

Source: H220-A/21

Status: 2016; 2021 Reaffirmed
Ambulatory-Based Primary Care Residency Programs

Policy Statement

The American Osteopathic Association supports and advocates for development and implementation of ambulatory-based primary care residency programs; encourages the US Congress and state legislatures to strengthen its graduate medical education reimbursement policies to, at least, equivalently fund ambulatory-based primary care residency programs; and will lobby Congress and state legislatures to support legislation funding demonstration models of ambulatory-based primary care residency programs.

Source: H201-A/22

Status: 2012; 2017 Reaffirmed as Amended; 2022 Reaffirmed
Joining Forces Initiative

Policy Statement

The American Osteopathic Association (AOA) will continue to encourage the American Association of Colleges of Osteopathic Medicine (AACOM) to partner with the Association of American Medical Colleges (AAMC) to promote and develop curriculum that will help osteopathic and allopathic medical students prepare to care for the unique issues returning veterans and their families face; will encourage practicing osteopathic physicians to care for veterans and their families and to accept Tri-Care; will help develop continuing medical education that will help prepare the existing osteopathic work force to comprehend and be prepared to manage the unique issues faced by the veteran population and military families; will encourage the National Board of Osteopathic Medical Examiners (NBOME) to incorporate military service-related conditions in the development of case-based evaluation items for testing; and will support efforts to support veterans and military families by partnering with organizations such as Joining Forces and other organizations that help military members and their families.

Source: H202-A/22

Status: 2007; 2012 Reaffirmed; 2022 Reaffirmed
Education for Performance of Disability Assessment

Policy Statement

The American Osteopathic Association supports education, training, and involvement of osteopathic physicians in the process of impairment ratings as they may be used to establish disability determinations.

Source: H203-A/22

Status: 2002; 2007 Reaffirmed; 2012 Reaffirmed as Amended; 2017 Reaffirmed; 2022 Reaffirmed as Amended
Supervision for Osteopathic Manipulative Treatment

Policy Statement

The American Osteopathic Association strongly encourages all qualified supervising physicians to foster the appropriate utilization of osteopathic diagnosis and osteopathic manipulative treatment by students, interns and residents assigned to them.

Source: H205-A/22

Status: 1997; 2002 Reaffirmed; 2007 Reaffirmed; 2012 Reaffirmed; 2017 Reaffirmed; 2022 Reaffirmed
Training Reaffirmation of Primary Care Physicians

Policy Statement

The American Osteopathic Association (AOA) reaffirms its commitment to train competent and compassionate primary care physicians through undergraduate medical education, graduate medical education and continuing medical education.

Source: H206-A/22

Status: 1992; 1997 Reaffirmed; 2002 Reaffirmed as Amended; 2007 Reaffirmed; 2012 Reaffirmed as Amended; 2017 Reaffirmed; 2022 Reaffirmed as Amended
Longitudinal Approach to Cultural Competency Dialogue on Eliminating Health Care Disparities

Policy Statement

The American Osteopathic Association encourages evidence-based education and dialogue in cultural competency, the social determinants of health, and the physician’s role in eliminating health care disparities.

Source: H208-A/22

Status: 2017; 2022 Reaffirmed as Amended
The American Osteopathic Association strongly opposes any potential travel bans created against medical students, interns, residents, fellows, and physicians with visas or green cards and will work to support its patients, students, residents, fellows, and physicians affected by such policies.

Source: H209-A/22

Status: 2017; 2022 Reaffirmed
Importance of Empathy in Osteopathic Medical Education and Practice

Policy Statement

The American Osteopathic Association recognizes the importance of empathy in osteopathic medical education and practice and the relationship between empathy and well-being of physicians-in-training and in-practice.

Source: H210-A/22

Status: 2017; 2022 Reaffirmed as Amended
Equivalency Policy for Osteopathic Continuous Certification

Policy Statement

The American Osteopathic Association (AOA), through its Bureaus, Committees and Councils, will ensure that Osteopathic Continuous Certification (OCC) is comparable to other maintenance of certification programs so that OCC can be recognized by the federal government, state governments and other regulatory agencies and credentialing bodies as an equivalent of other national certifying bodies’ “maintenance” or “continuous” certification programs.

While the AOA supports the use of board certification as a mark of academic achievement, the AOA opposes any efforts to require OCC as a condition for medical licensure, insurance reimbursement, hospital privileges, network participation, malpractice insurance coverage or as a requirement for physician employment.

That the AOA through the Bureau of Osteopathic Specialists (BOS) will review the OCC process so as to make it more manageable and economically feasible.

Source: H211-A/22

Status: 2010; 2015 Reaffirmed as Amended; 2017 Reaffirmed as Amended; 2022 Reaffirmed
Loan Deferment During Residency

Policy Statement

The American Osteopathic Association (AOA) supports legislation that would allow medical students and resident physicians to defer the repayment of their federal medical school loans interest free until the completion of residency training.

Source: H212-A/22

Status: 2012; 2017 Reaffirmed as Amended; 2022 Reaffirmed
Osteopathic Licensing

Policy Statement

The American Osteopathic Association reaffirms its position that the only examinations able to fully evaluate the ability and competency of osteopathic physicians for licensure are the examinations developed by the National Board of Osteopathic Medical Examiners, Inc.

Source: H213-A/22

Osteopathically Recognized Graduate Medical Education Programs

Policy Statement

The American Osteopathic Association opposes any federal or state laws or regulations that would prevent the development of additional osteopathically recognized graduate medical education programs or training positions and the AOA will continue to take all measures possible to prevent the termination of distinctive osteopathic training programs.

Source: H214-A/22

Status: 1997; 2002 Reaffirmed as Amended; 2007 Reaffirmed; 2012 Reaffirmed as Amended; 2017 Reaffirmed as Amended; 2022 Reaffirmed as Amended
Certifying Residents for Board Eligibility

Policy Statement

The American Osteopathic Association (AOA) advocates within its resources on behalf of internal medicine residents and fellows, and program directors at the federal, state, and local level so that they be able to sit for internal medicine board certification of their choosing; and that the AOA advocate for all AOA board certified program directors to be able to certify that their residents are eligible for the relevant AOA and/or ABMS board certification of their choosing.

Source: H219-A/22

Status: 2017; 2022 Reaffirmed as Amended
The American Osteopathic Association (AOA) work with the American Medical Association (AMA) and other relevant stakeholders to assure that funds to support the expansion of postgraduate clinical training for non-physicians do not divert funding from physician (Graduate Medical Education) GME; and, that the AOA oppose non-physician healthcare providers from holding a seat on medical boards that provide oversight of physician undergraduate medical education, graduate medical education, certification or licensure, and advocate that a non-physician seat on these boards be held by non-medical public professionals.

Source: H220-A/22

Status: 2022 Reaffirmed as Amended
HOUSE OF DELEGATES’
PROFESSIONAL AFFAIRS REFERENCE COMMITTEE

(300 series) - This reference committee reviews and considers matters relating to osteopathic health care facilities, advocacy, legislation, membership and conventions.

<table>
<thead>
<tr>
<th>Res. No.</th>
<th>Resolution Title</th>
<th>Submitted By</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>H-300</td>
<td>Osteopathic Medicine Definition (H330-A/13)</td>
<td>BOE</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-301</td>
<td>Adolescents’ Bill of Rights (H300-A/13)</td>
<td>BFHP</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-302</td>
<td>Airline Medical Kits (H301-A/13)</td>
<td>BFHP</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-303</td>
<td>Durable Medical Equipment Claims Processing (H304-A/13)</td>
<td>BFHP</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-304</td>
<td>Discrimination Against Osteopathic Physicians (H306-A/13)</td>
<td>BFHP</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-305</td>
<td>Interference Laws (H307-A/13)</td>
<td>BHFP/BSGA</td>
<td>REFERRED</td>
</tr>
<tr>
<td>H-306</td>
<td>State GME Funding Alternatives (H308-A/13)</td>
<td>BSGA</td>
<td>REFERRED</td>
</tr>
<tr>
<td>H-307</td>
<td>Primary Care Physicians Mentoring Programs in Health Professional Shortage Areas (HPSAS) – Funding to Increase (H309-A/13)</td>
<td>BFHP</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-308</td>
<td>Alcohol and Tobacco – Advertising Ban on (H302-A/13)</td>
<td>BSAPH</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-309</td>
<td>Centers for Medicare and Medicaid Services (CMS) – Opposition to CMS’s Behavioral (H303-A/13)</td>
<td>BFHP</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-310</td>
<td>Government Funding Non-AOA or Non-LCME Medical Schools (H310-A/13)</td>
<td>BFHP</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-311</td>
<td>Primary Care Physicians in Health Professional Shortage Areas – Model Funding to Increase (H311-A/13)</td>
<td>BFHP</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-312</td>
<td>Evaluation and Management Documentation Guidelines (H313-A/13)</td>
<td>BSA</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-313</td>
<td>Health Care That Works For All Americans (H314-A/13)</td>
<td>BFHP</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-314</td>
<td>Health Care Providers Right of Conscience (H315-A/13)</td>
<td>BOM - Ethics</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-315</td>
<td>Human Cloning (H316-A/13)</td>
<td>BSAPH</td>
<td>REFERRED</td>
</tr>
<tr>
<td>Res. No.</td>
<td>Resolution Title</td>
<td>Submitted By</td>
<td>Reference Committee</td>
</tr>
<tr>
<td>---------</td>
<td>----------------------------------------------------------------------------------</td>
<td>--------------</td>
<td>---------------------</td>
</tr>
<tr>
<td>H-316</td>
<td>Insurance Carriers – Patient Accessibility of Diagnostic Services (H317-A/13)</td>
<td>BSA</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-317</td>
<td>Licensure of Interns and Residents (H318-A/13)</td>
<td>BSGA</td>
<td>DISAPPROVED</td>
</tr>
<tr>
<td>H-318</td>
<td>Managed Care Organizations – Osteopathic Discrimination by (H319-A/13)</td>
<td>BSGA</td>
<td>APPROVED as AMENDED</td>
</tr>
<tr>
<td>H-319</td>
<td>Managed Care – Patient-Physician Relationship and (H320-A/13)</td>
<td>BSA</td>
<td>APPROVED as AMENDED</td>
</tr>
<tr>
<td>H-320</td>
<td>Mandatory Assignment (H321-A/13)</td>
<td>BSA</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-321</td>
<td>Medical Records-Policy / Guidelines for the Maintenance, Retention, and Release of (H322-A/13)</td>
<td>BSA</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-322</td>
<td>Medicare (H323-A/13)</td>
<td>BFHP</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-323</td>
<td>Medicare-Equitable Payment (H324-A/13)</td>
<td>BFHP</td>
<td>APPROVED as AMENDED</td>
</tr>
<tr>
<td>H-324</td>
<td>Medicare User Fees (H325-A/13)</td>
<td>BFHP</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-325</td>
<td>Medicare Limiting Charge / Rbrvs System (H326-A/13)</td>
<td>BFHP</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-326</td>
<td>National Practitioner Data Bank (H327-A/13)</td>
<td>BFHP</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-327</td>
<td>Obesity – Health Plans Should Review Benefits for Treatment Of (H328-A/13)</td>
<td>BSAPH</td>
<td>APPROVED as AMENDED</td>
</tr>
<tr>
<td>H-328</td>
<td>Osteopathic Manipulative Treatment and Evaluation &amp; Management on the Same Day of Service – Payment for (H329-A/13)</td>
<td>BSA</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-329</td>
<td>Patient Confidentiality (H331-A/13)</td>
<td>BSA</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-330</td>
<td>Physician Fees And Charges (H333-A/13)</td>
<td>BSA</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-331</td>
<td>Physician Health Assistance (H334-A/13)</td>
<td>BOM</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-332</td>
<td>Prescription Plans – Restrictive (H335-A/13)</td>
<td>BSGA</td>
<td>APPROVED as AMENDED</td>
</tr>
<tr>
<td>H-333</td>
<td>Professional Liability Insurance Reform (H336-A/13)</td>
<td>BSGA</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-334</td>
<td>Rural Healthcare Payment Equity (H337-A/13)</td>
<td>BFHP</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-335</td>
<td>Tobacco Use (H338-A/13)</td>
<td>BSA</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-336</td>
<td>Uniform Billing (H339-A/13)</td>
<td>BSA</td>
<td>APPROVED</td>
</tr>
<tr>
<td>Res. No.</td>
<td>Resolution Title</td>
<td>Submitted By</td>
<td>Reference Committee</td>
</tr>
<tr>
<td>---------</td>
<td>----------------------------------------------------------------------------------</td>
<td>--------------</td>
<td>-----------------------</td>
</tr>
<tr>
<td>H-337</td>
<td>Uniform Pathway of Licensing of Osteopathic Physicians (H340-A/13)</td>
<td>BSGA</td>
<td>REFERRED</td>
</tr>
<tr>
<td>H-338</td>
<td>Uninsured – Access Health Care (H341-A/13)</td>
<td>BFHP</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-339</td>
<td>Veterans Hospitals and Clinics – OMT in (H342-A/13)</td>
<td>BFHP</td>
<td>APPROVED as AMENDED</td>
</tr>
<tr>
<td>H-341</td>
<td>Expert Witness &amp; Peer Review (H345-A/13)</td>
<td>BSGA</td>
<td>APPROVED as AMENDED</td>
</tr>
<tr>
<td>H-342</td>
<td>Office Based Surgery (H346-A/13)</td>
<td>BSGA</td>
<td>REFERRED</td>
</tr>
<tr>
<td>H-343</td>
<td>Physician Payment for Electronic Advice, Counseling and Treatment Plans (H347-A/13)</td>
<td>BSA</td>
<td>APPROVED as AMENDED</td>
</tr>
<tr>
<td>H-344</td>
<td>Pre-Filled Medical Necessity Form (H348-A/13)</td>
<td>BSA</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-345</td>
<td>Referrals and Consults – Non-Physician Disclosures (H349-A/13)</td>
<td>BSA</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-346</td>
<td>Scope of Practice Statement by the American Osteopathic Association for Osteopathic Manipulative Medicine (H350-A/13)</td>
<td>BSA</td>
<td>REFERRED</td>
</tr>
<tr>
<td>H-347</td>
<td>Uniform Emergency Volunteer Health Practitioners Act (UEHVPA) (H351-A/13)</td>
<td>BSGA</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-348</td>
<td>Social Media Guidelines – Implementation of (H352-A/13)</td>
<td>BOM</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-349</td>
<td>Terminology – Volunteer Osteopathic Medical Health Care Delivery (H353-A/13)</td>
<td>BIOM</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-350</td>
<td>Electronic Health Records – Increasing Drug… (H354-A/13)</td>
<td>BSA</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-351</td>
<td>Amendment to H332-A/16 “Timely Posting of Meeting Agendas/Materials and Approval of Meeting Minutes</td>
<td>MAOPS / et al</td>
<td>APPROVED as AMENDED</td>
</tr>
<tr>
<td>Res. No.</td>
<td>Resolution Title</td>
<td>Submitted By</td>
<td>Reference Committee</td>
</tr>
<tr>
<td>---------</td>
<td>----------------------------------------------------------------------------------</td>
<td>--------------</td>
<td>---------------------------</td>
</tr>
<tr>
<td>H-352</td>
<td>Availability of Epinephrine Products - The William G. Anderson, DO Initiative</td>
<td>NYSOMS</td>
<td>APPROVED as AMENDED</td>
</tr>
<tr>
<td>H-353</td>
<td>Direct to Consumer Advertising in Drugs</td>
<td>MOA</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-354</td>
<td>Equality in the Military - Transgender</td>
<td>NYSOMS</td>
<td>APPROVED as AMENDED</td>
</tr>
<tr>
<td>H-355</td>
<td>Federal Student Loan Program</td>
<td>TOMA</td>
<td>APPROVED as AMENDED</td>
</tr>
<tr>
<td>H-356</td>
<td>J.D. Sheffield, D.O.; ‘Texas’ First Osteopathic Physician State Legislator</td>
<td>TOMA</td>
<td>WITHDRAWN</td>
</tr>
<tr>
<td>H-357</td>
<td>OMED Education on Chronic Disease</td>
<td>MOA</td>
<td>APPROVED as AMENDED</td>
</tr>
<tr>
<td>H-358</td>
<td>Osteopathic Manipulative Treatment (OMT) for Low Back Pain (Response to RES. NO. H-334 - A/2017)</td>
<td>BOCER</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-359</td>
<td>Preventing Physician Burnout – Safe Haven Protection for Physicians</td>
<td>MAOPS</td>
<td>APPROVED as AMENDED</td>
</tr>
<tr>
<td>H-360</td>
<td>WITHDRAWN</td>
<td></td>
<td>-----</td>
</tr>
<tr>
<td>H-361</td>
<td>Reference Committee Review and Editing of Resolutions</td>
<td>NYSOMS</td>
<td>DISAPPROVED</td>
</tr>
<tr>
<td>H-362</td>
<td>Resolution Implementation</td>
<td>IOMA / et al</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-363</td>
<td>Special Licensing Pathways for Physicians</td>
<td>BSGA</td>
<td>APPROVED as AMENDED</td>
</tr>
<tr>
<td>H-364</td>
<td>Sunset Resolutions</td>
<td>NYSOMS</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-365</td>
<td>Nutrition at AOA Events</td>
<td>OPSO</td>
<td>APPROVED as AMENDED</td>
</tr>
<tr>
<td>H-366</td>
<td>Resolution Retention</td>
<td>IOMA</td>
<td>APPROVED</td>
</tr>
</tbody>
</table>
HOUSE OF DELEGATES’ REFERENCE COMMITTEE DESCRIPTIONS:

- Committee on Professional Affairs (300 series)
  This reference committee reviews and considers matters relating to osteopathic health care facilities, advocacy, legislation, membership and conventions.

<table>
<thead>
<tr>
<th>Res. No.</th>
<th>Resolution Title</th>
<th>Submitted By</th>
<th>Reference Committee</th>
</tr>
</thead>
<tbody>
<tr>
<td>H-300</td>
<td>Training – Extended Release-Long Acting (ER/LA) Opioid Risk Evaluation And Mitigation Strategy (REMS) (H300-A/14)</td>
<td>BSAPGH</td>
<td>Professional</td>
</tr>
<tr>
<td>H-301</td>
<td>Medical Websites and Smartphones/Tablet Computer Apps to Diagnose Illness – Use of (H301-A/14)</td>
<td>BSAPGH</td>
<td>Professional</td>
</tr>
<tr>
<td>H-302</td>
<td>Flu Pandemic – Osteopathic Treatment of (H305-A14)</td>
<td>BOCER</td>
<td>Professional</td>
</tr>
<tr>
<td>H-303</td>
<td>Direct-to-Consumer Marketing of Health Screening and Testing (H306-A/14)</td>
<td>BSAPGH</td>
<td>Professional</td>
</tr>
<tr>
<td>H-304</td>
<td>New Born HIV Testing (H307-A/14)</td>
<td>BSAPGH</td>
<td>Professional</td>
</tr>
<tr>
<td>H-305</td>
<td>CDC – HIV Proposed Rule Change (H313-A/14)</td>
<td>BSAPGH</td>
<td>Professional</td>
</tr>
<tr>
<td>H-306</td>
<td>Influenza Immunization for Health Care Workers and Educators (H314-A/14)</td>
<td>BSAPGH</td>
<td>Professional</td>
</tr>
<tr>
<td>H-307</td>
<td>Due Process for Alleged Impaired Physicians (H316-A/14)</td>
<td>BOM</td>
<td>Professional</td>
</tr>
<tr>
<td>H-308</td>
<td>Drug Formularies (H317-A/14)</td>
<td>BFHP</td>
<td>Professional</td>
</tr>
<tr>
<td>H-309</td>
<td>Home-Based Care for Frail Elderly (H318-A/14)</td>
<td>BOCER</td>
<td>Professional</td>
</tr>
<tr>
<td>H-310</td>
<td>Health Care Costs in Long Term Services and Support (H319-A/2014)</td>
<td>BOCER</td>
<td>Professional</td>
</tr>
<tr>
<td>H-311</td>
<td>Immunization Registries (H320-A/14)</td>
<td>BSA</td>
<td>Professional</td>
</tr>
<tr>
<td>H-312</td>
<td>National Practitioner Data Bank – Membership Action (H321-A/14)</td>
<td>BOM</td>
<td>Professional</td>
</tr>
<tr>
<td>H-313</td>
<td>Importation of Medications (H322-A/14)</td>
<td>BFHP</td>
<td>Professional</td>
</tr>
<tr>
<td>H-314</td>
<td>Any Willing Provider Legislation (H323-A/14)</td>
<td>BSGA</td>
<td>Professional</td>
</tr>
<tr>
<td>H-315</td>
<td>Use of the Term “Physician” “Doctor” and “Provider” (H324-A14)</td>
<td>BSGA</td>
<td>Professional</td>
</tr>
<tr>
<td>H-316</td>
<td>Physically Active Video Games – (Exergaming Health) Benefits (H325-A/14)</td>
<td>BSAPGH</td>
<td>Professional</td>
</tr>
<tr>
<td>H-317</td>
<td>Medicare – Prescription Assistance for Medicare Patients (H326-A/14)</td>
<td>BSA</td>
<td>Professional</td>
</tr>
<tr>
<td>H-318</td>
<td>Electronic Prescribing (H327-A/14)</td>
<td>BSGA</td>
<td>Professional</td>
</tr>
<tr>
<td>H-319</td>
<td>Cardiovascular Disease and Women (H328-A/14)</td>
<td>BSAPGH</td>
<td>Professional</td>
</tr>
<tr>
<td>H-320</td>
<td>Healthy Weight for Families (H329-A/14)</td>
<td>BSAPGH</td>
<td>Professional</td>
</tr>
<tr>
<td>H-321</td>
<td>Administrative Fees (H330-A/14)</td>
<td>BSA</td>
<td>Professional</td>
</tr>
<tr>
<td>Res. No.</td>
<td>Resolution Title</td>
<td>Submitted By</td>
<td>Reference Committee</td>
</tr>
<tr>
<td>---------</td>
<td>----------------------------------------------------------------------------------</td>
<td>--------------</td>
<td>---------------------</td>
</tr>
<tr>
<td>H-322</td>
<td>End-of-Life Care – Use of Placebos In (H331-A/14)</td>
<td>BOCER</td>
<td>Professional</td>
</tr>
<tr>
<td>H-323</td>
<td>Minorities in the Osteopathic Profession – Collecting Data (H332-A/14)</td>
<td>BOCER</td>
<td>Professional</td>
</tr>
<tr>
<td>H-324</td>
<td>Osteopathic Manipulative Treatment (OMT) of the Cervical Spine (H332-A/14)</td>
<td>BOCER</td>
<td>Professional</td>
</tr>
<tr>
<td>H-325</td>
<td>Right to Privately Contract (H334-A/14)</td>
<td>BSGA</td>
<td>Professional</td>
</tr>
<tr>
<td>H-326</td>
<td>Promoting Diversity in AOA Membership and Leadership (H334-A/14)</td>
<td>BOM</td>
<td>Professional</td>
</tr>
<tr>
<td>H-327</td>
<td>Abuse of Performance Enhancing Substances and Procedures (H337-A/14)</td>
<td>BSAPH</td>
<td>Professional</td>
</tr>
<tr>
<td>H-328</td>
<td>Diversity In Leadership Positions (H338-A/14)</td>
<td>BOM</td>
<td>Professional</td>
</tr>
<tr>
<td>H-329</td>
<td>Tobacco Use Status – Reporting in the Medical Record (H339-A/14)</td>
<td>BSAPH</td>
<td>Professional</td>
</tr>
<tr>
<td>H-330</td>
<td>Medical Costs Incurred by Patients for Services not Covered by their Insurance (H344-A/14)</td>
<td>BSA</td>
<td>Professional</td>
</tr>
<tr>
<td>H-331</td>
<td>Electronic Medical Record (EMR) – Student Access And Use (H345-A/14)</td>
<td>BOE</td>
<td>Professional</td>
</tr>
<tr>
<td>H-332</td>
<td>Testosterone Therapy: Long Term Effect On Health (H346-A/14)</td>
<td>BOCER</td>
<td>Professional</td>
</tr>
<tr>
<td>H-333</td>
<td>Compensation Tied to Patient Satisfaction Surveys – Osteopathic Physician (H348-A/14)</td>
<td>BSA</td>
<td>Professional</td>
</tr>
<tr>
<td>H-334</td>
<td>Availability of Biosimilar Products</td>
<td>BSA</td>
<td>Professional</td>
</tr>
<tr>
<td>H-335</td>
<td>Maternal Mortality</td>
<td>ACOOG</td>
<td>Professional</td>
</tr>
<tr>
<td>H-336</td>
<td>Extending Medicaid to 12 Months Postpartum</td>
<td>ACOOG</td>
<td>Professional</td>
</tr>
<tr>
<td>H-337</td>
<td>New Physician in Practice Definition</td>
<td>BEL</td>
<td>Professional</td>
</tr>
<tr>
<td>H-338</td>
<td>Hospital Consolidation – Opposition to</td>
<td>BFHP</td>
<td>Professional</td>
</tr>
<tr>
<td>H-339</td>
<td>Pharmacy Benefit Managers-Increased Regulation of</td>
<td>BSGA/BFHP</td>
<td>Professional</td>
</tr>
<tr>
<td>H-340</td>
<td>Background Checks and Firearms Safety Training as a Condition of Firearms Purchase</td>
<td>BFHP</td>
<td>Professional</td>
</tr>
<tr>
<td>H-342</td>
<td>Misaligned Incentives in Medicare Plans</td>
<td>FOMA</td>
<td>Professional</td>
</tr>
<tr>
<td>H-343</td>
<td>White Papers - Updating</td>
<td>IOMA</td>
<td>Professional</td>
</tr>
<tr>
<td>H-344</td>
<td>Development of a National Immunization Information Registry</td>
<td>IOMS</td>
<td>Professional</td>
</tr>
</tbody>
</table>
### 99th ANNUAL AOA HOUSE OF DELEGATES MEETING

**2019 MEETING**

**RESOLUTION ROSTER**

As of July 26, 2019

<table>
<thead>
<tr>
<th>Res. No.</th>
<th>Resolution Title</th>
<th>Submitted By</th>
<th>Reference Committee</th>
</tr>
</thead>
<tbody>
<tr>
<td>H-345</td>
<td>Consultant Reports Accessibility/ Availability- American Osteopathic Association</td>
<td>KOMA</td>
<td>Professional</td>
</tr>
<tr>
<td>H-346</td>
<td>Whistleblower Policy – American Osteopathic Association</td>
<td>KOMA</td>
<td>Professional</td>
</tr>
<tr>
<td>H-347</td>
<td>American Osteopathic Association – Organizational Health, Viability &amp; Transparency</td>
<td>KOMA</td>
<td>Professional</td>
</tr>
<tr>
<td>H-348</td>
<td>Expansion of Medicaid in all States</td>
<td>MOA</td>
<td>Professional</td>
</tr>
<tr>
<td>H-349</td>
<td>Support for OMT Privileges</td>
<td>OPSC</td>
<td>Professional</td>
</tr>
<tr>
<td>H-350</td>
<td>Anti-Intimidation Standards Among Physicians</td>
<td>POMA</td>
<td>Professional</td>
</tr>
<tr>
<td>H-351</td>
<td>Advocating for Women’s Right to Reproductive Healthcare Access and Support of Roe v. Wade</td>
<td>SOMA</td>
<td>Professional</td>
</tr>
<tr>
<td>H-352</td>
<td>Advocating for More DO Representation Within Medical TV Shows and Movies</td>
<td>SOMA</td>
<td>Professional</td>
</tr>
<tr>
<td>H-353</td>
<td>Decriminalization of Self-Induced Abortion</td>
<td>SOMA</td>
<td>Professional</td>
</tr>
<tr>
<td>H-354</td>
<td>De-Stigmatization of Mental Illness in Physicians</td>
<td>SOMA</td>
<td>Professional</td>
</tr>
<tr>
<td>H-355</td>
<td>Opposing Targeted Regulation of Abortion Providers (Trap Laws)</td>
<td>SOMA</td>
<td>Professional</td>
</tr>
<tr>
<td>H-356</td>
<td>Physician Psychological Trauma and Mental Health</td>
<td>MOA</td>
<td>Professional</td>
</tr>
<tr>
<td>H-357</td>
<td>Nutrition and Leading By Example</td>
<td>OPSO</td>
<td>Professional</td>
</tr>
<tr>
<td>H-358</td>
<td>Referred Resolution - H305-A/18 Interference Laws</td>
<td>BFHP/BSGA</td>
<td>Professional</td>
</tr>
<tr>
<td>H-359</td>
<td>Referred Resolution H306-A/18 - State Graduate Medical Education Funding Alternatives</td>
<td>BSGA</td>
<td>Professional</td>
</tr>
<tr>
<td>H-360</td>
<td>Referred Resolution H426-A/18 – Office Based Surgery</td>
<td>BSGA</td>
<td>Professional</td>
</tr>
<tr>
<td>H-361</td>
<td>Referred Resolution H340-A/13 – Uniform Pathway of Licensing of Osteopathic Physicians</td>
<td>BSGA</td>
<td>Professional</td>
</tr>
<tr>
<td>H-362</td>
<td>Safe Haven Non-Reporting Protection for Physicians – Support for</td>
<td>BSGA</td>
<td>Professional</td>
</tr>
</tbody>
</table>
SPECIAL MEETING OF THE
AOA HOUSE OF DELEGATES
OCTOBER 2020 MEETING
PROFESSIONAL AFFAIRS - RESOLUTION ROSTER
As of September 13, 2020

HOUSE OF DELEGATES’ REFERENCE COMMITTEE DESCRIPTION:

- Committee on Professional Affairs (300 series)
  This reference committee reviews and considers matters relating to osteopathic health care facilities, advocacy, legislation, membership and conventions.

<table>
<thead>
<tr>
<th>Res. No.</th>
<th>Resolution Title</th>
<th>Submitted By</th>
<th>Reference Committee</th>
</tr>
</thead>
<tbody>
<tr>
<td>H300</td>
<td>Intractable and/or Chronic Pain (Not Associated with End of Life Care) (H327-A/15)</td>
<td>BSGA</td>
<td>Professional</td>
</tr>
<tr>
<td>H301</td>
<td>Retail-Based Health Clinics and Urgent Care Centers (H303-A/15)</td>
<td>BSAPH</td>
<td>Professional</td>
</tr>
<tr>
<td>H302</td>
<td>Protecting American Students from Profit-Driven Foreign Medical Schools (H304-A/15)</td>
<td>BFHP</td>
<td>Professional</td>
</tr>
<tr>
<td>H303</td>
<td>Remove FDA Ban on Anonymous Sperm Donation from Men Who Have Sex with Men (H305-A/15)</td>
<td>BFHP / BSAPH</td>
<td>Professional</td>
</tr>
<tr>
<td>H304</td>
<td>Improving Competitive Edge for Membership in the AOA (H308-A/15)</td>
<td>BOM</td>
<td>Professional</td>
</tr>
<tr>
<td>H305</td>
<td>Tax Credit for Precepting (H312-A/15)</td>
<td>BSGA</td>
<td>Professional</td>
</tr>
<tr>
<td>H306</td>
<td>Site Neutral Reimbursement (H396-A/15)</td>
<td>BFHP</td>
<td>Professional</td>
</tr>
<tr>
<td>H307</td>
<td>Supporting the Use of OMM in the VA (H311-A/15)</td>
<td>BHFP</td>
<td>Professional</td>
</tr>
<tr>
<td>H308</td>
<td>Practice Rights of Osteopathic Physicians (H313-A/15)</td>
<td>BSGA</td>
<td>Professional</td>
</tr>
<tr>
<td>H309</td>
<td>Retail Medical Clinics in Facilities Selling Tobacco, Nicotine or Vaping Products (H314-A/15)</td>
<td>BSAPH</td>
<td>Professional</td>
</tr>
<tr>
<td>H310</td>
<td>Osteopath and Osteopathy - Use of the Term (H315-A/15)</td>
<td>BIOM</td>
<td>Professional</td>
</tr>
<tr>
<td>H311</td>
<td>Patient Access in Rural Areas (H317-A/15)</td>
<td>BSGA</td>
<td>Professional</td>
</tr>
<tr>
<td>H312</td>
<td>Physician Office Laboratories (H318-A/15)</td>
<td>BFHP</td>
<td>Professional</td>
</tr>
<tr>
<td>H313</td>
<td>Postgraduate Compensation (H319A/15)</td>
<td>BOE</td>
<td>Professional</td>
</tr>
<tr>
<td>H314</td>
<td>Second Opinion, Surgical Cases (H320-A/15)</td>
<td>BSA</td>
<td>Professional</td>
</tr>
<tr>
<td>H315</td>
<td>Uniformed Services: Endorsement of Physicians Serving in the Uniformed Services (H322-A/15)</td>
<td>BFHP</td>
<td>Professional</td>
</tr>
<tr>
<td>H316</td>
<td>Emergency Medical Services for Children, Support of (H323-A/15)</td>
<td>BFHP</td>
<td>Professional</td>
</tr>
<tr>
<td>H317</td>
<td>Physician Incentives to Underserved Areas (H324-A/15)</td>
<td>BSGA</td>
<td>Professional</td>
</tr>
<tr>
<td>H318</td>
<td>Vaccines Shortages (H326-A/15)</td>
<td>BFHP</td>
<td>Professional</td>
</tr>
<tr>
<td>H319</td>
<td>Medicare Balance Billing (H329-A/15)</td>
<td>BFHP</td>
<td>Professional</td>
</tr>
</tbody>
</table>
## PROFESSIONAL AFFAIRS - RESOLUTION ROSTER

As of September 13, 2020

<table>
<thead>
<tr>
<th>Res. No.</th>
<th>Resolution Title</th>
<th>Submitted By</th>
<th>Reference Committee</th>
</tr>
</thead>
<tbody>
<tr>
<td>H320</td>
<td>Electronic Prescribing of Controlled Substances (H332-A/15)</td>
<td>BSA</td>
<td>Professional</td>
</tr>
<tr>
<td>H321</td>
<td>Professional Organization -- Physicians Choosing to Which They Belong (H334-A/15)</td>
<td>BOM</td>
<td>Professional</td>
</tr>
<tr>
<td>H322</td>
<td>Prescription Drug Diversion and Abuse – Education, Research, and Advocacy (H335-A/15)</td>
<td>BSGA</td>
<td>Professional</td>
</tr>
<tr>
<td>H323</td>
<td>Buprenorphine Maintenance Treatment Insurance Coverage (H336-A/15)</td>
<td>BSA</td>
<td>Professional</td>
</tr>
<tr>
<td>H324</td>
<td>Violence Against Healthcare Staff (H337-A/15)</td>
<td>BSGA</td>
<td>Professional</td>
</tr>
<tr>
<td>H325</td>
<td>Low Back Pain Clinical Practice Guidelines, Revision of (H338-A/15)</td>
<td>BOCER</td>
<td>Professional</td>
</tr>
<tr>
<td>H326</td>
<td>Addressing the Effects of Climate on National Health</td>
<td>SOMA</td>
<td>Professional</td>
</tr>
<tr>
<td>H327</td>
<td>Adverse Childhood Experiences Screening</td>
<td>SOMA</td>
<td>Professional</td>
</tr>
<tr>
<td>H328</td>
<td>Inclusion of Patient Education on Organ Donation as a Component of a Primary Care Visit</td>
<td>SOMA</td>
<td>Professional</td>
</tr>
<tr>
<td>H329</td>
<td>Inequalities in Medicaid Funding Affecting U.S. Territories</td>
<td>SOMA</td>
<td>Professional</td>
</tr>
<tr>
<td>H330</td>
<td>Improving Insulin Affordability</td>
<td>SOMA</td>
<td>Professional</td>
</tr>
<tr>
<td>H331</td>
<td>Medication for Opioid Use Disorder Insurance Coverage</td>
<td>AOAAM</td>
<td>Professional</td>
</tr>
<tr>
<td>H332</td>
<td>Recruitment and Retention of Native Americans in Medicine</td>
<td>SOMA</td>
<td>Professional</td>
</tr>
<tr>
<td>H333</td>
<td>WITHDRAWN</td>
<td>SOMA</td>
<td>Professional</td>
</tr>
<tr>
<td>H334</td>
<td>Sustainability at AOA Events</td>
<td>MOA</td>
<td>Professional</td>
</tr>
<tr>
<td>H335</td>
<td>H357-A/19 Nutrition and Leading By Example</td>
<td>OPSC</td>
<td>Professional</td>
</tr>
<tr>
<td>H336</td>
<td>REFERRED RESOLUTION: H324-A/14 Use of the Term “Physician” “Doctor” and “Provider”</td>
<td>BSGA</td>
<td>Professional</td>
</tr>
<tr>
<td>H337</td>
<td>CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016</td>
<td>IOMA</td>
<td>Professional</td>
</tr>
</tbody>
</table>
**House of Delegates’ Reference Committee Description:**
Committee on Professional Affairs (300 series)
This reference committee reviews and considers matters relating to osteopathic health care facilities, advocacy, legislation, membership and conventions.

<table>
<thead>
<tr>
<th>Res. No.</th>
<th>Resolution Title</th>
<th>Submitted By</th>
<th>Reference Committee</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>H-300</td>
<td>Medication For Opioid Use Disorder (MOUD) Availability for Incarcerated Individuals and/or Individuals Under Correctional Control</td>
<td>AOAAM</td>
<td>Professional Affairs</td>
<td>ADOPTED as AMENDED</td>
</tr>
<tr>
<td>H-301</td>
<td>Availability of Modalities of Prescribing</td>
<td>OOA</td>
<td>Professional Affairs</td>
<td>ADOPTED as AMENDED</td>
</tr>
<tr>
<td>H-302</td>
<td>Improving Insulin Affordability</td>
<td>SOMA</td>
<td>Professional Affairs</td>
<td>ADOPTED as AMENDED</td>
</tr>
<tr>
<td>H-303</td>
<td>Direct Acting Therapy for Hepatitis C Limitations</td>
<td>OOA</td>
<td>Professional Affairs</td>
<td>ADOPTED as AMENDED</td>
</tr>
<tr>
<td>H-304</td>
<td>Extension of the Shelf-Life Extension Program (SLEP) by the FDA</td>
<td>OOA</td>
<td>Professional Affairs</td>
<td>ADOPTED as AMENDED</td>
</tr>
<tr>
<td>H-305</td>
<td>Increasing Voter Access Amongst FOR Hospitalized Patients</td>
<td>SOMA</td>
<td>Professional Affairs</td>
<td>ADOPTED as AMENDED</td>
</tr>
<tr>
<td>H-306</td>
<td>Support of Continued Funding for Americorps National Service Programs</td>
<td>SOMA</td>
<td>Professional Affairs</td>
<td>ADOPTED as AMENDED</td>
</tr>
<tr>
<td>H-307</td>
<td>Appropriate PPE Usage PROVISIONS</td>
<td>BEL</td>
<td>Professional Affairs</td>
<td>ADOPTED as AMENDED</td>
</tr>
<tr>
<td>H-308</td>
<td>Referred Sunset Res. No. H300-A/20; H327-A/15 intractable and / or Chronic Pain (Not Associated with End of Life Care)</td>
<td>CSHA</td>
<td>Professional Affairs</td>
<td>ADOPTED as AMENDED</td>
</tr>
<tr>
<td>Res. No.</td>
<td>Resolution Title</td>
<td>Submitted By</td>
<td>Reference Committee</td>
<td>Action</td>
</tr>
<tr>
<td>---------</td>
<td>----------------------------------------------------------------------------------</td>
<td>--------------</td>
<td>----------------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>H-309</td>
<td>Conflicts of Interest</td>
<td>MAOP</td>
<td>Professional Affairs</td>
<td>ADOPTED as AMENDED</td>
</tr>
<tr>
<td>H-310</td>
<td>Resolution Withdrawn</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>H-311</td>
<td>Revision of the Invocation to Support Inclusive and Interfaith Language</td>
<td>MOA</td>
<td>Professional Affairs</td>
<td>ADOPTED as AMENDED</td>
</tr>
<tr>
<td>H-312</td>
<td>Support of State Societies (SR-Source: H207-A/16)</td>
<td>BOM</td>
<td>Professional Affairs</td>
<td>ADOPTED for Sunset</td>
</tr>
<tr>
<td>H-313</td>
<td>Center of Excellence for Stroke (SR-Source: H306-A/16)</td>
<td>BFHP</td>
<td>Professional Affairs</td>
<td>ADOPTED as AMENDED</td>
</tr>
<tr>
<td>H-315</td>
<td>Patient Care at Extended Long Term Care Facilities (SR-Source: H308-A/16)</td>
<td>BFHP</td>
<td>Professional Affairs</td>
<td>ADOPTED</td>
</tr>
<tr>
<td>H-316</td>
<td>Osteopathic Term Protection (SR-Source: H310-A/16)</td>
<td>CSHA</td>
<td>Professional Affairs</td>
<td>ADOPTED</td>
</tr>
<tr>
<td>H-317</td>
<td>Cyberbullying through Social Media (SR-Source: H316-A/16)</td>
<td>BORPH</td>
<td>Professional Affairs</td>
<td>ADOPTED</td>
</tr>
<tr>
<td>H-318</td>
<td>Firearms – Commission of A Crime While Using a Firearm (SR-Source: H318-A/16)</td>
<td>CSHA/BFHP</td>
<td>Professional Affairs</td>
<td>ADOPTED</td>
</tr>
<tr>
<td>H-319</td>
<td>Good Samaritan Acts (Hold Harmless Agreement) Performed on Commercial Aircraft (SR-Source: H319-A/16)</td>
<td>CSHA/BFHP</td>
<td>Professional Affairs</td>
<td>ADOPTED</td>
</tr>
<tr>
<td>H-320</td>
<td>Medicaid Pharmaceutical Benefits (SR-Source: H320-A/16)</td>
<td>CSHA</td>
<td>Professional Affairs</td>
<td>ADOPTED as AMENDED</td>
</tr>
<tr>
<td>H-321</td>
<td>Medication Shortages (SR-Source: H330-A/16)</td>
<td>BFHP</td>
<td>Professional Affairs</td>
<td>ADOPTED as AMENDED</td>
</tr>
<tr>
<td>H-322</td>
<td>Health Insurance Availability to Osteopathic Medical Students (SR-Source: H337-A/16)</td>
<td>BFHP</td>
<td>Professional Affairs</td>
<td>ADOPTED</td>
</tr>
<tr>
<td>H-323</td>
<td>Behavioral Health Services – Funding and Access (SR-Source: H338-A/16)</td>
<td>BFHP</td>
<td>Professional Affairs</td>
<td>ADOPTED as AMENDED</td>
</tr>
<tr>
<td>H-324</td>
<td>Physician Gag Rules – Opposition to Patients in Emergency Departments (SR-Source: H340-A/16)</td>
<td>BFHP</td>
<td>Professional Affairs</td>
<td>ADOPTED</td>
</tr>
<tr>
<td>Res. No.</td>
<td>Resolution Title</td>
<td>Submitted By</td>
<td>Reference Committee</td>
<td>Action</td>
</tr>
<tr>
<td>---------</td>
<td>----------------------------------------------------------------------------------</td>
<td>--------------</td>
<td>----------------------</td>
<td>----------------------</td>
</tr>
<tr>
<td>H-325</td>
<td>Congressional Budget Office Fiscal Scoring (SR-Source: H343-A/16)</td>
<td>BFHP</td>
<td>Professional Affairs</td>
<td>ADOPTED as AMENDED</td>
</tr>
<tr>
<td>H-326</td>
<td>Pain Related Education Requirements (SR-Source: H344-A/16)</td>
<td>CSHA</td>
<td>Professional Affairs</td>
<td>ADOPTED as AMENDED</td>
</tr>
<tr>
<td>H-327</td>
<td>Non-Physician Health Care Clinician (SR-Source: H346-A/16)</td>
<td>BFHP</td>
<td>Professional Affairs</td>
<td>ADOPTED</td>
</tr>
<tr>
<td>H-328</td>
<td>Eugenic Selection with Preimplantation Genetic Diagnosis (SR-Source: H349-A/16)</td>
<td>BFHP</td>
<td>Professional Affairs</td>
<td>REFERRED</td>
</tr>
<tr>
<td>H-329</td>
<td>Tricare Health Insurance for our Military (SR-Source: H350-A/16)</td>
<td>BFHP</td>
<td>Professional Affairs</td>
<td>ADOPTED</td>
</tr>
<tr>
<td>H-330</td>
<td>Osteopathic Manipulative Treatment (OMT) in the CDC Chronic Pain Management Guidelines – Inclusion of (SR-Source: H351-A/16)</td>
<td>BORPH</td>
<td>Professional Affairs</td>
<td>ADOPTED as AMENDED</td>
</tr>
<tr>
<td>H-331</td>
<td>Baby Friendly SUPPORT OF BREASTFEEDING Hospital Initiative (BFHI) (SR-Source: H403-A/16)</td>
<td>BORPH</td>
<td>Professional Affairs</td>
<td>ADOPTED as AMENDED</td>
</tr>
<tr>
<td>H-332</td>
<td>Organ And Tissue Donation and Transplantation Initiatives – Commitment to (SR-Source: H411-A/16)</td>
<td>BORPH</td>
<td>Professional Affairs</td>
<td>ADOPTED</td>
</tr>
<tr>
<td>H-333</td>
<td>Vaccine Supply and Distribution (SR-Source: H416-A/16)</td>
<td>BORPH</td>
<td>Professional Affairs</td>
<td>ADOPTED</td>
</tr>
<tr>
<td>H-334</td>
<td>Health Literacy (SR-Source: H426-A/16)</td>
<td>BORPH</td>
<td>Professional Affairs</td>
<td>ADOPTED</td>
</tr>
<tr>
<td>H-335</td>
<td>Onsite Lab Work No. 1 (SR-Source: H600-A/16)</td>
<td>CERA</td>
<td>Professional Affairs</td>
<td>ADOPTED</td>
</tr>
<tr>
<td>H-336</td>
<td>Managed Care Referrals (SR-Source: H602-A/16)</td>
<td>CERA</td>
<td>Professional Affairs</td>
<td>ADOPTED</td>
</tr>
<tr>
<td>H-337</td>
<td>Medicare Physician Payment for Osteopathic Manipulative Treatment (SR-Source: H621-A/16)</td>
<td>CERA</td>
<td>Professional Affairs</td>
<td>ADOPTED</td>
</tr>
<tr>
<td>H-338</td>
<td>Drug Plan Coverage Denials (SR-Source: H628-A/16)</td>
<td>CERA</td>
<td>Professional Affairs</td>
<td>ADOPTED</td>
</tr>
<tr>
<td>Res. No.</td>
<td>Resolution Title</td>
<td>Submitted By</td>
<td>Reference Committee</td>
<td>Action</td>
</tr>
<tr>
<td>---------</td>
<td>----------------------------------------------------------------------------------</td>
<td>--------------</td>
<td>----------------------</td>
<td>--------------</td>
</tr>
<tr>
<td></td>
<td>Classification of Diseases (ICD) Coding Definitions</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(SR-Source: H630-A/16)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>H-341</td>
<td>Appropriate Payment Mechanisms for Physician-Led Team-Based Health Care</td>
<td>CERA/CSHA</td>
<td>Professional Affairs</td>
<td>ADOPTED as</td>
</tr>
<tr>
<td></td>
<td>(SR-Source: H636-A/16)</td>
<td></td>
<td></td>
<td>AMENDED</td>
</tr>
<tr>
<td>H-342</td>
<td>Human Immunodeficiency Virus (HIV)</td>
<td>BORPH</td>
<td>Professional Affairs</td>
<td>ADOPTED as</td>
</tr>
<tr>
<td></td>
<td>(SR-Source: H408-A/16)</td>
<td></td>
<td></td>
<td>AMENDED</td>
</tr>
<tr>
<td>H-343</td>
<td>Improving Access to Physician-Led Care</td>
<td>BOT</td>
<td>Professional Affairs</td>
<td>ADOPTED</td>
</tr>
<tr>
<td>H-344</td>
<td>Reforming the Health IT Landscape to Improve the Patient and Clinician Experience</td>
<td>BOT</td>
<td>Professional Affairs</td>
<td>ADOPTED</td>
</tr>
</tbody>
</table>
HOUSE OF DELEGATES’ REFERENCE COMMITTEE DESCRIPTIONS:
Committee on Professional Affairs (300 series)
This reference committee reviews and considers matters relating to osteopathic health care facilities, advocacy, legislation, membership and conventions.

<table>
<thead>
<tr>
<th>Res. No.</th>
<th>Resolution Title</th>
<th>Submitted By</th>
<th>Reference Committee</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>H-300</td>
<td>Defining New Physicians in Practice (SR - Source: H349-A/17)</td>
<td>BEL</td>
<td>Professional Affairs</td>
<td>Adopted</td>
</tr>
<tr>
<td>H-301</td>
<td>State Licensure of Managed Care Organizations (MCO) Medical Directors (SR-Source: H302-A/17)</td>
<td>BFHP</td>
<td>Professional Affairs</td>
<td>Adopted</td>
</tr>
<tr>
<td>H-303</td>
<td>Advance Directives (SR- Source: H305-A/17)</td>
<td>BFHP</td>
<td>Professional Affairs</td>
<td>Adopted</td>
</tr>
<tr>
<td>H-304</td>
<td>Interstate Opioid Database (SR- Source: H331-A/17)</td>
<td>BORPH</td>
<td>Professional Affairs</td>
<td>Adopted as Amended</td>
</tr>
<tr>
<td>H-305</td>
<td>Improve Life-Saving Access to Epinephrine (SR- Source: H333-A/17)</td>
<td>BORPH</td>
<td>Professional Affairs</td>
<td>Adopted as Amended</td>
</tr>
<tr>
<td>H-306</td>
<td>Family And Medical Leave Act (FMLA) Documentation (SR- Source: H307-A/17)</td>
<td>BFHP</td>
<td>Professional Affairs</td>
<td>Disapproved (Sunset)</td>
</tr>
<tr>
<td>H-307</td>
<td>Prescription Drugs (SR - Source: H308-A/17)</td>
<td>BFHP</td>
<td>Professional Affairs</td>
<td>Adopted</td>
</tr>
<tr>
<td>H-308</td>
<td>Federally Funded Health Clinics (SR - Source: H309-A/17)</td>
<td>BFHP</td>
<td>Professional Affairs</td>
<td>Adopted as Amended</td>
</tr>
<tr>
<td>H-310</td>
<td>Preservation of Antibiotics for Medical Treatment (SR - Source: H312-A/17)</td>
<td>BFHP</td>
<td>Professional Affairs</td>
<td>Adopted</td>
</tr>
<tr>
<td>H-311</td>
<td>Guidelines for Nutritional and Dietary Supplements (SR - Source: H315-A/17)</td>
<td>BFHP</td>
<td>Professional Affairs</td>
<td>Adopted</td>
</tr>
<tr>
<td>H-312</td>
<td>Sexual Harassment (SR- Source: H316-A/17)</td>
<td>CSHA</td>
<td>Professional Affairs</td>
<td>Adopted as Amended</td>
</tr>
<tr>
<td>H-313</td>
<td>Due Process in Agency Determinations (SR- Source: H317-A/17)</td>
<td>BFHP</td>
<td>Professional Affairs</td>
<td>Adopted as Amended</td>
</tr>
<tr>
<td>H-314</td>
<td>Ethical And Sociological Considerations for Medical Care (SR - Source: H318-A/17)</td>
<td>BFHP</td>
<td>Professional Affairs</td>
<td>Adopted</td>
</tr>
<tr>
<td>H-315</td>
<td>Regulation of Health Care (SR- Source: H319-A/17)</td>
<td>CSHA</td>
<td>Professional Affairs</td>
<td>Adopted as Amended</td>
</tr>
<tr>
<td>Resolution</td>
<td>Description</td>
<td>Sponsor</td>
<td>Affair</td>
<td>Status</td>
</tr>
<tr>
<td>------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>-----------------</td>
<td>------------</td>
<td>----------------------</td>
</tr>
<tr>
<td>H-316</td>
<td>Occupational Safety and Health Administration (OSHA) Regulations</td>
<td>BFHP</td>
<td>Professional Affairs</td>
<td>Adopted</td>
</tr>
<tr>
<td></td>
<td>(SR - Source: H320-A/17)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>H-317</td>
<td>Patient Safety</td>
<td>BFHP</td>
<td>Professional Affairs</td>
<td>Adopted as Amended</td>
</tr>
<tr>
<td></td>
<td>(SR - Source: H321-A/17)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>H-318</td>
<td>Promotion of School Based Health Education</td>
<td>CSHA</td>
<td>Professional Affairs</td>
<td>Adopted as Amended</td>
</tr>
<tr>
<td></td>
<td>(SR - Source: H325-A/17)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>H-319</td>
<td>Recoupment Laws</td>
<td>BFHP</td>
<td>Professional Affairs</td>
<td>Adopted</td>
</tr>
<tr>
<td></td>
<td>(SR - Source: H326-A/17)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>H-320</td>
<td>Right to Practice and Payment for Osteopathic Manipulative Treatment</td>
<td>CSHA</td>
<td>Professional Affairs</td>
<td>Adopted</td>
</tr>
<tr>
<td></td>
<td>(SR - Source: H329-A/17)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>H-321</td>
<td>Equity in Medicare &amp; Medicaid Payments</td>
<td>CSHA</td>
<td>Professional Affairs</td>
<td>Adopted as Amended</td>
</tr>
<tr>
<td></td>
<td>(SR - Source: H339-A/17)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>H-322</td>
<td>Naloxone</td>
<td>CSHA</td>
<td>Professional Affairs</td>
<td>Adopted as Amended</td>
</tr>
<tr>
<td></td>
<td>(SR - Source: H340-A/17)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>H-323</td>
<td>Shared Principles of Primary Care</td>
<td>BFHP</td>
<td>Professional Affairs</td>
<td>Adopted</td>
</tr>
<tr>
<td></td>
<td>(SR - Source: H342-A/17)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>H-324</td>
<td>Eugenic Selection with Preimplantation Genetic Diagnosis</td>
<td>BFHP</td>
<td>Professional Affairs</td>
<td>Adopted as Amended</td>
</tr>
<tr>
<td></td>
<td>(SR - Source: H349-A/16)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>H-325</td>
<td>Interference Laws - Amendment to American Osteopathic Association Policy</td>
<td>IOMA</td>
<td>Professional Affairs</td>
<td>Adopted as Amended</td>
</tr>
<tr>
<td></td>
<td>H358-A/19</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Osteopathic Medicine Definition

Policy Statement

The American Osteopathic Association holds as policy the definition of osteopathic medicine as a complete system of medical care with a philosophy that combines the needs of the patient with the current practice of medicine, surgery and obstetrics; that emphasizes the concept of body unity, the interrelationship between structure and function; and that has an appreciation of the body's ability to heal itself.

Source: H300-A/18

Adolescents’ Bill of Rights

Policy Statement

The American Osteopathic Association advocates that all medical facilities that provide care for adolescents post an “Adolescents’ Bill of Rights” which clearly articulates state and local applicable laws of consent and confidentiality regarding health care for adolescents who have not reached the age of majority.

Source: H301-A/18

Status: 2003; 2008 Reaffirmed; 2013 Reaffirmed; 2018 Reaffirmed
Airline Medical Kits

Policy Statement

The American Osteopathic Association supports the current Federal Aviation Administration (FAA) Final Rules on Airline Emergency Equipment.

Source: H302-A/18

Status: 1998, 2003 Reaffirmed as Amended; 2008 Reaffirmed as Amended; 2013 Reaffirmed; 2018 Reaffirmed
Durable Medical Equipment Claims Processing

Policy Statement

The American Osteopathic Association remains committed to providing cost effective healthcare and supports a reexamination of federal policy regarding the timely processing of claims for durable medical equipment.

Source: H303-A/18

Status: 1993; 1998 Reaffirmed as Amended, 2003; 2008 Reaffirmed; 2013 Reaffirmed as Amended; 2018 Reaffirmed
Discrimination Against Osteopathic Physicians

Policy Statement

The American Osteopathic Association (AOA) will continue to ensure that legislation and regulatory policy specifies that any reference at the national level in an executive order, an administrative regulation, or in the federal revised statutes to “medical doctor”, “MD”, “physician”, “allopathic physician”, an allopathic medical specialty board, or reference to any medical student, or postgraduate, shall include and pertain to a “doctor of osteopathic medicine”, “DO”, AOA specialty board, and osteopathic medical students and postgraduates.

Source: H304-A/18

Status: 2013; 2018 Reaffirmed
Primary Care Physicians Programs in Health Professional Shortage Areas (HPSAS) – Funding to Increase

Policy Statement

The American Osteopathic Association (AOA) encourages state and federal agencies to provide funds to US osteopathic and allopathic medical schools to develop and maintain informational curricula programs, and mentor US citizens and permanent residents from federally designated Health Professional Shortage Areas (HPSAS), from high school through the first year in primary care practice which encourages long-term primary care medical practice in HPSAS; further, the AOA encourages state and federal agencies to provide loan forgiveness for graduates of osteopathic and allopathic medical schools for the loans related to their medical school education for each year they deliver the informational curriculum and mentoring services to US citizens and permanent residents from federally designed HPSAS from high school through the first year in primary care practice, which encourages long-term primary care practice in federal designated HPSAS.

Source: H307-A/18

Status: 2013; 2018 Reaffirmed
Alcohol and Tobacco – Advertising Ban on

Policy Statement

The American Osteopathic Association endorses a ban on all advertising of tobacco and alcohol.

Source: H308-A/18

Status: 1988; 1993 Reaffirmed as Amended; 1998 Reaffirmed; 2003 Reaffirmed as Amended; 2008 Reaffirmed; 2013 Reaffirmed; 2018 Reaffirmed
Government Funding Non-AOA or Non-LCME Medical Schools

Policy Statement

The American Osteopathic Association will advocate for policies that promote and prioritize access for United States citizens and permanent residents who attend Commission on Osteopathic College Accreditation (COCA) and Liaison Committee on Medical Education (LCME) certified medical schools to post-graduate training programs at U.S.-based institutions, by advocating for policies that restrict access to student loans for students attending non-COCA and non-LCME certified medical schools; oppose agreements between U.S. hospitals and other health care entities that receive local, state and federal funds that discriminate against or restrict training opportunities for students of COCA and LCME accredited colleges of medicine; limit agreements between non-COCA and non-LCME certified medical schools and U.S. institutions that receive local, state or federal funding in which there is training of non-COCA or non-LCME certified medical schools for longer than 12 weeks in order to promote equal access for U.S. citizens and permanent residents; promote a structure that ensures that federal or state funding provided to U.S. institutions for the training of medical students be proportional to the percentage of AOA and LCME medical school students that it trains; prohibit the use of local, state and federal funds for non-U.S. citizens that attend non-COCA or non-LCME certified medical schools; and distribute local, state and federal funding for U.S. citizens and permanent residents that attend non-COCA or non-LCME certified medical schools proportionally to U.S. citizens and permanent residents who attend COCA or LCME certified medical schools.

Source: H310-A/18

Status: 2013; 2018 Reaffirmed as Amended
Physicians in Health Professional Shortage Areas – Model Funding to Increase

Policy Statement

The American Osteopathic Association encourages state and federal US medical student funding agencies to provide loans to US citizens and permanent residents who commit to practice in federally designated Health Professional Shortage Areas (HPSAs) and encourages state and federal US medical student funding agencies to provide medical school loan forgiveness for US citizens and permanent residents for each year they practice in a federally designated HPSA.

Source: H311-A/18

Status: 2013; 2018 Reaffirmed as Amended
Policy Statement

The American Osteopathic Association:

1. Advocates the use of an independent profession/specialty matched medical peer review process for physicians identified as outliers.

2. Opposes the continuation of random pre-payment audits of claims.

3. Advocates that any auditing of outpatient medical records be conducted on a retrospective post-payment basis and is statistically sound using determinations in effect at the time of claim.

4. Opposes the practice that requires physicians to repay alleged over-payments before all appeal remedies have been exhausted.

5. Advocates immunity from Medicare sanctions for physicians voluntarily participating in Medicare sponsored alternative payment models.

6. Advocates that Centers for Medicare and Medicaid Services (CMS) develop educational programs that help physicians identify mistakes or misunderstandings with their coding so as to avoid civil penalties.

Source: H312-A/18

Status: 2003; 2008 Reaffirmed as Amended; 2013 Reaffirmed as Amended; 2018 Reaffirmed
Health Care That Works for All Americans

Policy Statement

The American Osteopathic Association has a priority goal to encourage the US Congress for passage of legislation to further the national health care debate; that this public debate address the major issues that threaten the ability of osteopathic physicians to provide quality, cost-efficient health care to their communities, including the availability of affordable health insurance for all citizens, inclusion of osteopathic physicians, training institutions, and osteopathic manipulative services on payor reimbursement, and the fundamental question of Professional Liability Tort Reform; and that follow up activity assures that Congress enacts the appropriate legislation that assures the accomplishments of the above-listed goals.

Source: H313-A/18

Status: 2003; 2008; 2013 Reaffirmed; 2018 Reaffirmed as Amended
Health Care Providers Right of Conscience

Policy Statement

The American Osteopathic Association policy states that all osteopathic physicians are ethically bound to inform patients of available options with regard to treatment and if an osteopathic physician has an ethical, moral or religious belief that prevents him or her from providing a medically-approved service, they should recuse themselves from that aspect of care and/or refer the patient to another provider.

Source: H314-A/18

Status: 2003; 2008; 2013 Reaffirmed; 2018 Reaffirmed as Amended
The American Osteopathic Association (AOA) is opposed to discrimination against osteopathic physicians by payors; and urges that federal and state legislation must clearly state that any and all payors must accept as sufficient professional credentials all licenses properly granted by state boards of medicine or osteopathic medicine, and all specialty certifications granted by boards approved by the AOA or American Board of Medical Specialties.

Source: H318-A/18

Status: 1993; 1998 Reaffirmed as Amended, 2003; 2008; 2013 Reaffirmed as Amended; 2018 Reaffirmed as Amended
Healthcare Practice – Patient-Physician Relationship and
Policy Statement

The American Osteopathic Association believes that it is the responsibility of the osteopathic physician to advocate for the rights of his/her patients, regardless of any contractual relationship and that the patient-physician relationship shall not be altered by any system of healthcare practice which may place economic considerations above the interest of patients.

Source: H319-A/18

Status: 1998, 2003 Reaffirmed; 2008; 2013 Reaffirmed as Amended; 2018 Reaffirmed as Amended
Medical Records-Policy / Guidelines for the Maintenance, Retention, and Release of

Policy Statement

The American Osteopathic Association urges osteopathic physicians to become familiar with the applicable laws, rules, or regulations on retention of records and patient access to medical records in their states; and approves the following Policy/ Guidelines for the Maintenance, Retention, and Release of Medical Records.

Source: H321-A/18

Status: 1998; 2003 Reaffirmed as Amended; 2008; 2013 Reaffirmed as Amended; 2018 Reaffirmed
Medical Records-Policy / Guidelines for the Maintenance, Retention, and Release of

Policy Statement

The American Osteopathic Association urges osteopathic physicians to become familiar with the applicable laws, rules, or regulations on retention of records and patient access to medical records in their states; and approves the following Policy/ Guidelines for the Maintenance, Retention, and Release of Medical Records.

Source: H321-A/18

Status: 1998; 2003 Reaffirmed as Amended; 2008; 2013 Reaffirmed as Amended; 2018 Reaffirmed
Medicare

Policy Statement

The American Osteopathic Association declares its continued support of the Medicare program, the continued availability of quality medical care at a reasonable cost and comprehensive Medicare reform to ensure that Medicare beneficiaries receive necessary services.

Source: H322-A/18

Medicare User Fees

Policy Statement

The American Osteopathic Association opposes any legislation that would establish Medicare user fees.

Source: H324-A/18

Status: 1998, 2003 Reaffirmed as Amended; 2008; 2013 Reaffirmed; 2018 Reaffirmed
Medicare Limiting Charge / RBRVS System

Policy Statement

The American Osteopathic Association opposes Medicare's limiting charge ceiling.

Source: H325-A/18

Obesity – Health Plans Should Include Benefits for Treatment of
Policy Statement

The American Osteopathic Association supports the inclusion of medical, surgical and nutritional counseling and physical conditioning as a paid benefit for members of all health plans for the prevention and treatment of obesity.

Source: H327-A/18

Status: 2003; 2008; 2013 Reaffirmed as Amended; 2018 Reaffirmed as Amended
Osteopathic Manipulative Treatment and Evaluation & Management on the Same Day of Service – Payment for

Policy Statement

The American Osteopathic Association supports payment for osteopathic manipulative treatment (OMT) and evaluation and management services separately when performed on the same day of service.

Source: H328-A/18

Status: 1998, 2003 Reaffirmed as Amended; 2008; 2013 Reaffirmed as Amended; 2018 Reaffirmed
Patient Confidentiality

Policy Statement

The American Osteopathic Association policy supports that in such cases where the physician is bound by law to protect patient confidentiality, the physician shall only be required to provide information that can be disclosed under law and where possible, the physician shall be allowed to submit narrative reports or only copies of the part of a medical record that is pertinent in lieu of a complete record.

Source: H329-A/18

Status: 1993; 1998 Reaffirmed; 2003 Reaffirmed as Amended; 2008; 2013 Reaffirmed; 2018 Reaffirmed
Physician Fees and Charges

Policy Statement

The American Osteopathic Association upholds the following policy on Physician Fees and Charges.

Source: H330-A/18

Physician Health Assistance

Policy Statement

The American Osteopathic Association supports continued assistance in the rehabilitation of the impaired osteopathic physicians through its Bureau of Membership.

Source: H331-A/18

Professional Liability Insurance Reform

Policy Statement

The American Osteopathic Association continues support of professional liability insurance reform that includes the following eight principles: limitations on non-economic damages - including provisions that afford states the opportunity to maintain or establish laws governing limitations on non-economic damages; prohibiting “loss of chance” liability; periodic payment of future expenses or losses; offsets for collateral sources; joint and several liability reform; limitations on attorney contingency fees; establishment of uniform statutes of limitations; and establishment of alternative professional liability insurance reforms which may include but are not limited to – health courts, non-binding arbitration and I’m sorry clauses.

Source: H333-A/18

Rural Healthcare Payment Equity

Policy Statement

The American Osteopathic Association endorses equity in reimbursement for rural physicians as part of the strategy to increase the availability of quality healthcare in rural areas.

Source: H334-A/18

Tobacco Use

Policy Statement

The American Osteopathic Association supports third-party coverage of evidence-based approaches for the treatment of tobacco use and nicotine withdrawal.

Source: H335-A/18

Status: 1998; 2003 Reaffirmed as Amended; 2008 Reaffirmed as Amended; 2013 Reaffirmed; 2018 Reaffirmed
Uniform Billing

Policy Statement

The American Osteopathic Association opposes charging a fee or other penalty to physicians for the payment claims that they submit for care provided to Medicare and Medicaid patients.

Source: H336-A/18

Status: 1993; 1998 Reaffirmed as Amended, 2003; 2008; 2013 Reaffirmed; 2018 Reaffirmed
Uninsured – Access Health Care

Policy Statement

The American Osteopathic Association supports federal and state efforts to increase access to affordable health care coverage through initiatives that expand coverage to the uninsured through the efficient use of both private and public resources and supports efforts to reform programs such as Medicaid, Medicare, and State Child Health Insurance Program (SCHIP) to provide coverage to populations that would otherwise lack health care coverage and ultimately, access to needed health care services.

Source: H338-A/18

Status: 2003; 2008; 2013 Reaffirmed; 2018 Reaffirmed
Expert Witness & Peer Review

Policy Statement

The American Osteopathic Association approves the Expert Witness and Peer Review policy.

Source: H341-A/18

Status: 2008; 2013 Reaffirmed as Amended; 2018 Reaffirmed as Amended
Physician Payment for Electronic Advice, Counseling and Treatment Plans

Policy Statement

The American Osteopathic Association strongly encourages payers to include as a benefit for physicians to receive payment parity for professional advice, consultation and development of patient treatment plans provided to patients, family members or designee via telemedicine.

Source: H343-A/18

Status: 2008; 2013 Reaffirmed as Amended; 2018 Reaffirmed as Amended
Pre-Filled Medical Necessity Form

Policy Statement

The American Osteopathic Association (AOA) encourages physicians to verify directly with patients that the patient is in need of supplies; further, the AOA supports disclosure regarding medical necessity and making it inappropriate for supply companies to provide physicians with medical necessity certification forms on which the quantity or indication of a need for a product is pre-filled.

Source: H344-A/18

Status: 2008; 2013 Reaffirmed; 2018 Reaffirmed
Referrals and Consults – Non-Physician Disclosures

Policy Statement

The American Osteopathic Association recommends that a patient referred to a physician specialist should be seen and evaluated by a physician specialist. Any care by a non-physician in a specialist’s office / clinic should be disclosed to the patient and referring physician before the care is provided.

Source: H345-A/18

Status: 2008; 2013 Reaffirmed; 2018 Reaffirmed
Uniform Emergency Volunteer Health Practitioners Act (UEVHP)

Policy Statement

The American Osteopathic Association supports enactment of the following Uniformed Emergency Volunteer Health Practitioners Act (UEVHPA) as written by the National Conference of Commissioners on Uniform State Laws and amended by the AOA.

Source: H347-A/18

Status: 2008; 2013 Reaffirmed; 2018 Reaffirmed
UNIFORM EMERGENCY VOLUNTEER HEALTH PRACTITIONERS ACT  
(UEVHPA)

SECTION 1. SHORT TITLE. This [act] may be cited as the Uniform Emergency Volunteer Health Practitioners Act.

SECTION 2. DEFINITIONS. In this [act]:

(1) “Disaster relief organization” means an entity that provides emergency or disaster relief services that include health or veterinary services provided by volunteer health practitioners and that:
   (A) is designated or recognized as a provider of those services pursuant to a disaster response and recovery plan adopted by an agency of the federal government or [name of appropriate governmental agency or agencies]; or
   (B) regularly plans and conducts its activities in coordination with an agency of the federal government or [name of appropriate governmental agency or agencies].

(2) “Emergency” means an event or condition that is an [emergency, disaster, or public health emergency] under [designate the appropriate laws of this state, a political subdivision of this state, or a municipality or other local government within this state].

(3) “Emergency declaration” means a declaration of emergency issued by a person authorized to do so under the laws of this state [, a political subdivision of this state, or a municipality or other local government within this state].

(4) “Emergency Management Assistance Compact” means the interstate compact approved by Congress by Public Law No. 104-321, 110 Stat. 3877 [cite state statute, if any].

(5) “Entity” means a person other than an individual.

(6) “Health facility” means an entity licensed under the laws of this or another state to provide health or veterinary services.

(7) “Health practitioner” means an individual who is an MD or a DO, and licensed under the laws of this or another state to provide health services.

(8) “Health services” means the provision of treatment, care, advice or guidance, or other services, or supplies, related to the health or death of individuals or human populations, to the extent necessary to respond to an emergency, including:
   (A) the following, concerning the physical or mental condition or functional status of an individual or affecting the structure or function of the body:
      (i) preventive, diagnostic, therapeutic, rehabilitative, maintenance, or palliative care; and
      (ii) counseling, assessment, procedures, or other services;
   (B) sale or dispensing of a drug, a device, equipment, or another item to an individual in accordance with a prescription; and
   (C) funeral, cremation, cemetery, or other mortuary services.

(9) “Host entity” means an entity operating in this state which uses volunteer health practitioners to respond to an emergency.

(10) “License” means authorization by a state to engage in health or veterinary services that are unlawful without the authorization. The term includes authorization under the laws
of this state to an individual to provide health or veterinary services based upon a national certification issued by a public or private entity.

(11) “Person” means an individual, corporation, business trust, trust, partnership, limited liability company, association, joint venture, public corporation, government or governmental subdivision, agency, or instrumentality, or any other legal or commercial entity.

(12) “Scope of practice” means the extent of the authorization to provide health granted to a health practitioner by a license issued to the practitioner in the state in which the principal part of the practitioner’s services are rendered, including any conditions imposed by the licensing authority.

(13) “State” means a state of the United States, the District of Columbia, Puerto Rico, the United States Virgin Islands, or any territory or insular possession subject to the jurisdiction of the United States.

(14) “Volunteer health practitioner” means a health practitioner who provides, whether or not the practitioner receives compensation for those services. The term does not include a practitioner who receives compensation pursuant to a preexisting employment relationship with a host entity or affiliate which requires the practitioner to provide health services in this state, unless the practitioner is not a resident of this state and is employed by a disaster relief organization providing services in this state while an emergency declaration is in effect.

Legislative Note: Definition of “emergency”: The terms “emergency,” “disaster,” and “public health emergency” are the most commonly used terms to describe the circumstances that may lead to the issuance of an emergency declaration referred to in this [act]. States that use other terminology should insert the appropriate terminology into the first set of brackets. The second set of brackets should contain references to the specific statutes pursuant to which emergencies are declared by the state or political subdivisions, municipalities, or local governments within the state.

Definition of “emergency declaration”: The references to declarations issued by political subdivisions, municipalities or local governments should be used in states in which these entities are authorized to issue emergency declarations.

Definition of “state”: A state may expand the reach of this [act] by defining this term to include a foreign country, political subdivision of a foreign country, or Indian tribe or nation.

SECTION 3. APPLICABILITY TO VOLUNTEER HEALTH PRACTITIONERS.
This [act] applies to volunteer health practitioners registered with a registration system that complies with Section 5 and who provide health in this state for a host entity while an emergency declaration is in effect.

SECTION 4. REGULATION OF SERVICES DURING EMERGENCY.
(a) While an emergency declaration is in effect, [name of appropriate governmental agency or agencies] may limit, restrict, or otherwise regulate:
   (1) the duration of practice by volunteer health practitioners;
   (2) the geographical areas in which volunteer health practitioners may practice;
   (3) the types of volunteer health practitioners who may practice; and
any other matters necessary to coordinate effectively the provision of health or veterinary services during the emergency.

(b) An order issued pursuant to subsection (a) may take effect immediately, without prior notice or comment, and is not a rule within the meaning of [state administrative procedures act].

(c) A host entity that uses volunteer health practitioners to provide health services in this state shall:

(1) consult and coordinate its activities with [name of the appropriate governmental agency or agencies] to the extent practicable to provide for the efficient and effective use of volunteer health practitioners; and

(2) comply with any laws other than this [act] relating to the management of emergency health, including [cite appropriate laws of this state].

SECTION 5. VOLUNTEER HEALTH PRACTITIONER REGISTRATION SYSTEMS.

(a) To qualify as a volunteer health practitioner registration system, a system must:

(1) accept applications for the registration of volunteer health practitioners before or during an emergency;

(2) include information about the licensure and good standing of health practitioners which is accessible by authorized persons; and

(3) meet one of the following conditions:

(A) be an emergency system for advance registration of volunteer health-care practitioners established by a state and funded through the Health Resources Services Administration under Section 319I of the Public Health Services Act, 42 USC Section 247d-7b [as amended];

(B) be a local unit consisting of trained and equipped emergency response, public health, and medical personnel formed pursuant to Section 2801 of the Public Health Services Act, 42 U.S.C. Section 300hh [as amended];

(C) be operated by a:

(i) disaster relief organization;

(ii) licensing board;

(iii) national or regional association of licensing boards or health practitioners;

(iv) health facility that provides comprehensive inpatient and outpatient health-care services, including a tertiary care and teaching hospital; or

(v) governmental entity; or

(D) be designated by [name of appropriate agency or agencies] as a registration system for purposes of this [act].

(b) While an emergency declaration is in effect, [name of appropriate agency or agencies], a person authorized to act on behalf of [name of governmental agency or agencies], or a host entity, may confirm whether volunteer health practitioners utilized in this state are registered with a registration system that complies with subsection (a). Confirmation is limited to obtaining identities of the practitioners from the system and determining whether the system indicates that the practitioners are licensed and in good standing.
Upon request of a person in this state authorized under subsection (c), or a similarly authorized person in another state, a registration system located in this state shall notify the person of the identities of volunteer health practitioners and whether the practitioners are licensed and in good standing.

A host entity is not required to use the services of a volunteer health practitioner even if the practitioner is registered with a registration system that indicates that the practitioner is licensed and in good standing.

Legislative Note: If this state uses a term other than “hospital” to describe a facility with similar functions, such as an “acute care facility”, the final phrase of subsection (b)(4) should include a reference to this type of facility – for example, “including a tertiary care, teaching hospital, or acute care facility.”

SECTION 6. RECOGNITION OF VOLUNTEER HEALTH PRACTITIONERS LICENSED IN OTHER STATES.

While an emergency declaration is in effect, a volunteer health practitioner, registered with a registration system that complies with Section 5 and licensed and in good standing in the state upon which the practitioner’s registration is based, may practice in this state to the extent authorized by this [act] as if the practitioner were licensed in this state.

A volunteer health practitioner qualified under subsection (a) is not entitled to the protections of this [act] if the practitioner is licensed in more than one state and any license of the practitioner is suspended, revoked, or subject to an agency order limiting or restricting practice privileges, or has been voluntarily terminated under threat of sanction.

SECTION 7. NO EFFECT ON CREDENTIALING AND PRIVILEGING.

In this section:

1. “Credentialing” means obtaining, verifying, and assessing the qualifications of a health practitioner to provide treatment, care, or services in or for a health facility based upon a unified national standard.

2. “Privileging” means the authorizing by an appropriate authority, such as a governing body, of a health practitioner to provide specific treatment, care, or services at a health facility subject to limits based on factors that include license, education, training, experience, competence, health status, and specialized skill.

This [act] does not affect credentialing or privileging standards of a health facility and does not preclude a health facility from waiving or modifying those standards while an emergency declaration is in effect.

SECTION 8. PROVISION OF VOLUNTEER HEALTH OR VETERINARY SERVICES; ADMINISTRATIVE SANCTIONS.

Subject to subsections (b) and (c), a volunteer health practitioner shall adhere to the scope of practice for a similarly licensed practitioner established by the licensing provisions, practice acts, or other laws of this state.

Except as otherwise provided in subsection (c), this [act] does not authorize a volunteer health practitioner to provide services that are outside the practitioner’s scope of practice, even if a similarly licensed practitioner in this state would be permitted to provide the services.
(c) [Name of appropriate governmental agency or agencies] may modify or restrict the health or veterinary services that volunteer health practitioners may provide pursuant to this [act]. An order under this subsection may take effect immediately, without prior notice or comment, and is not a rule within the meaning of [state administrative procedures act].

(d) A host entity may restrict the health or veterinary services that a volunteer health practitioner may provide pursuant to this [act].

(e) A volunteer health practitioner does not engage in unauthorized practice unless the practitioner has reason to know of any limitation, modification, or restriction under this section or that a similarly licensed practitioner in this state would not be permitted to provide the services. A volunteer health practitioner has reason to know of a limitation, modification, or restriction or that a similarly licensed practitioner in this state would not be permitted to provide a service if:

(1) the practitioner knows the limitation, modification, or restriction exists or that a similarly licensed practitioner in this state would not be permitted to provide the service; or

(2) from all the facts and circumstances known to the practitioner at the relevant time, a reasonable person would conclude that the limitation, modification, or restriction exists or that a similarly licensed practitioner in this state would not be permitted to provide the service.

(f) In addition to the authority granted by law of this state other than this [act] to regulate the conduct of health practitioners, a licensing board or other disciplinary authority in this state:

(1) may impose administrative sanctions upon a health practitioner licensed in this state for conduct outside of this state in response to an out-of-state emergency;

(2) may impose administrative sanctions upon a practitioner not licensed in this state for conduct in this state in response to an in-state emergency; and

(3) shall report any administrative sanctions imposed upon a practitioner licensed in another state to the appropriate licensing board or other disciplinary authority in any other state in which the practitioner is known to be licensed.

(g) In determining whether to impose administrative sanctions under subsection (f), a licensing board or other disciplinary authority shall consider the circumstances in which the conduct took place, including any exigent circumstances, and the practitioner's scope of practice, education, training, experience, and specialized skill.

Legislative Note: The governmental agency or agencies referenced in subsection (c) may, as appropriate, be a state licensing board or boards rather than an agency or agencies that deal[s] with emergency response efforts.

SECTION 9. RELATION TO OTHER LAWS.

(a) This [act] does not limit rights, privileges, or immunities provided to volunteer health practitioners by laws other than this [act]. Except as otherwise provided in subsection (b), this [act] does not affect requirements for the use of health practitioners pursuant to the Emergency Management Assistance Compact.
(b) [Name of appropriate governmental agency or agencies], pursuant to the Emergency Management Assistance Compact, may incorporate into the emergency forces of this state volunteer health practitioners who are not officers or employees of this state, a political subdivision of this state, or a municipality or other local government within this state.

Legislative Note: References to other emergency assistance compacts to which the state is a party should be added.

SECTION 10. REGULATORY AUTHORITY.
[Name of appropriate governmental agency or agencies] may promulgate rules to implement this [act]. In doing so, [name of appropriate governmental agency or agencies] shall consult with and consider the recommendations of the entity established to coordinate the implementation of the Emergency Management Assistance Compact and shall also consult with and consider rules promulgated by similarly empowered agencies in other states to promote uniformity of application of this [act] and make the emergency response systems in the various states reasonably compatible.

Legislative Note: References to other emergency assistance compacts to which the state is a party should be added.

SECTION 11. CIVIL LIABILITY FOR VOLUNTEER HEALTH PRACTITIONERS; VICARIOUS LIABILITY.
Civil liability should be limited to those instances where both malicious intent is demonstrated, and the plaintiff has met a clear and convincing standard for the burden of proof.
Social Media Guidelines – Implementation of

Policy Statement

The American Osteopathic Association supports the use of appropriate social media by osteopathic physicians as a method to promote our profession and practices.

Source: H348-A/18

Status: 2013; 2018 Reaffirmed
Electronic Health Records – Increasing Drug

Policy Statement

The American Osteopathic Association supports ongoing evaluation and improvement of increasing drug interaction severity warnings in electronic health records (EHR) and will collaborate with EHR companies to correct inappropriate severity warnings.

Source: H350-A/18

Status: 2013; 2018 Reaffirmed
Timely Posting of Meeting Agendas/Materials and Approval of Meeting Minutes

Policy Statement

Agendas and meeting materials for American Osteopathic Association (AOA) meetings will be sent to committee members and posted to a dedicated webpage on the AOA website at least ten (10) business days prior to the respective meeting. The minutes from AOA meetings will be submitted to the respective committee members for review and comment no later than ten (10) business days following the conclusion of the meeting. Committee members shall then review and provide feedback for AOA staff to incorporate and submit to the committee chair and/or vice chair within ten (10) business days. The committee chair and/or vice chair shall then have ten (10) business days to review and approve any revisions.

AOA staff shall then distribute revised minutes to committee members within ten (10) business days of their approval by the committee chair and/or vice chair, and then they shall be posted to a dedicated website accessible to members no later than ten (10) business days following final approval.

Meeting materials containing sensitive or confidential information may be redacted with the authorization of the appropriate bureau or committee chair and AOA legal counsel prior to being placed on the public website but shall never be redacted in the official minutes of record. No bureau or committee recommendations may be considered by any other AOA body until the minutes of the meeting have been finally approved. Note: “appropriate members” will be defined as members of the bureau, committee or board at the time the meeting was held; and that AOA staff leadership be held accountable by the AOA Board of Trustees for immediately, appropriately and consistently implementing this policy to promote organizational transparency and protect AOA volunteers in the performance of their fiduciary duties.

Source: H351-A/18

Status: 2018
Direct to Consumer Advertising in Drugs

Policy Statement

The American Osteopathic Association (AOA) opposes any and all direct-to-consumer (DTC) advertising by pharmaceutical industries; and the AOA amend its current policy H325-A/15 to read:

H325-A/15 PRESCRIPTION DRUGS - Opposition of direct to consumer advertising of prescription drugs. The American Osteopathic Association opposes direct to consumer advertising of prescription medicines and will work with legislative bodies and advocacy organizations to make direct to consumer advertising of pharmaceuticals illegal in the united states consistent with World Health Organization recommendations.

The American Osteopathic Association (AOA), as the main representative of the osteopathic profession, support that all uniformed service personnel, which includes military physicians, DO or MD, who are physically and operationally qualified are to be recognized as members of the military in the United States without regard to race, color, creed, national origin, medical degree, gender, gender identity or sexual preference; and that the AOA oppose any attempt, either by legislation, directive or hierarchal order, that seeks to infringe upon this status.

Source: H353-A/18

Status: 2001; 2003 Reaffirmed as Amended, 2005; 2010 Reaffirmed as Amended; 2015 Reaffirmed; 2018 Reaffirmed
Equality in the Military – Transgender

Policy Statement

The American Osteopathic Association (AOA), as the main representative of the osteopathic profession, support that all uniformed service personnel, which includes military physicians, DO or MD, who are physically and operationally qualified are to be recognized as members of the military in the United States without regard to race, color, creed, national origin, medical degree, gender, gender identity or sexual preference; and that the AOA oppose any attempt, either by legislation, directive or hierarchal order, that seeks to infringe upon this status.

Source: H354-A/18

Status: 2018
The American Osteopathic Association (AOA) recommends that the Federal Student Loan Program reduce interest rates; the AOA recommend that the Federal Student Loan Program defer any interest to the loan until training is completed and that all student interest be tax deductible regardless of income.

Source: H355-A/18

Status: 2018
Osteopathic Manipulative Treatment (OMT) for Low Back Pain (Response to RES. NO. H-334 - A/2017)

Policy Statement

The American Osteopathic Association supports the attached white paper entitled “Osteopathic Manipulative Treatment (OMT) for Low Back Pain.”

Osteopathic Manipulative Treatment (OMT) and Low Back Pain

Background

The American Osteopathic Association first published clinical practice guidelines for Osteopathic Manipulative Treatment (OMT) for Patients with Low Back Pain in 2010. The revision of the guidelines was approved by the AOA House of Delegates in 2015 and published in the JAOA in 2016.

The summary of the guidelines states:
The American Osteopathic Association recommends that osteopathic physicians use Osteopathic Manipulative Treatment (OMT) in the care of patients with low back pain. These guidelines update the AOA guidelines for osteopathic physicians to utilize OMT for patients with nonspecific acute or chronic LBP. Evidence from systematic reviews and meta-analyses of randomized clinical trials (Evidence Level 1a) supports this recommendation.2

Both versions of the guidelines were accepted for inclusion in the National Guideline Clearinghouse (NGC). NGC is an initiative of the Agency for Healthcare Research and Quality (AHRQ), U.S. Department of Health and Human Services. (https://www.guideline.gov/). The NGC mission is to provide physicians and other health care professionals, health care providers, health plans, integrated delivery systems, purchasers and others an accessible mechanism for obtaining objective, detailed information on clinical practice guidelines and to further their dissemination, implementation, and use.

The current guidelines are based on a systematic review of the literature on OMT for patients with low back pain and a meta-analysis of all randomized controlled trials of OMT for patients with low back pain in ambulatory settings by Franke et al.3 Additionally, they build upon the 2010 AOA Clinical Practice Guidelines for Low Back Pain1 and the 2005 systematic review by Licciardone et al.4 on which the previous guidelines were based. Franke et al.’s conclusions further strengthen the findings that OMT reduces LBP. Franke et al. specifically state that clinically relevant effects of OMT were found for reducing pain and improving functional status in patients with acute and chronic nonspecific LBP and for LBP in pregnant and postpartum women at 3 months post treatment. 3

Evidence review for the 2015 Guidelines

In August 2014, a member of the AOA Low Back Pain Task Force conducted a literature search using keywords including back pain, low back pain, Osteopathic Manipulative Treatment (OMT), osteopathic, manual therapy and randomized controlled trials (RCT) in PubMed,
CINAHL, Science Direct, and Springer Link databases from 2003-2014. During this search, the systematic review by Franke et al. published in August 2014 was discovered and a determination was made to base the revised guidelines on this publication. At the same time, personal communications yielded two additional articles by Hensel5 and Licciardone6 published after the literature review by Franke et al. No other studies were identified.

Two members of the AOA Low Back Pain Task Force reviewed the research design of these studies according to the methods used in the Franke et al. systematic review and determined that both articles met the rigorous criteria applied by the Franke et al researchers. As stated in the Franke et al. publication: “Only randomized clinical trials were included; specific back pain or single treatment techniques studies were excluded. Outcomes were pain and functional status. GRADE was used to assess quality of evidence.” Franke et al. also concluded that “larger, high-quality randomized controlled trials with robust comparison groups are recommended.”

Both Hensel’s and Licciardone’s studies were larger than any previous studies and were high quality RCTs with robust comparison groups. The Task Force concluded that these studies were of high quality and low bias in the sense that they incorporated randomization, blinding, baseline comparability between groups, and addressed patient compliance and attrition. The Task Force agreed that these two articles would have met the inclusion criteria of the Franke et al. team and would have been included in the Franke et al. systematic review had they been published earlier. The Task Force believes that the conclusions of the studies support the guidelines and are not contradictory to them. Therefore, they were included in the AOA guidelines.

Results
As stated in the 2016 AOA Guidelines for Osteopathic Manipulative Treatment (OMT) for Patients with Low Back Pain2, OMT significantly reduces pain and improves functional status in patients, including pregnant and postpartum women, with nonspecific acute and chronic LBP.

**OMT versus other interventions for acute and chronic nonspecific low back pain:**
Franke et al.3 found that in acute and chronic non-specific LBP, moderate-quality evidence suggested OMT had a significant effect on pain relief (MD: -12.91, 95% CI: -20.00 to -5.82) and functional status (SMD: -0.36, 95% CI: -0.58 to -0.14).

**OMT versus other interventions for chronic nonspecific low back pain:**
More specifically, in chronic nonspecific LBP, the evidence from Franke et al.3 suggested a significant difference in favor of OMT regarding pain (MD: -14.93, 95% CI: -25.18 to -4.68) and functional status (SMD: -0.32, CI: -0.58 to -0.07).

**OMT versus untreated for nonspecific low back pain in postpartum women:**
For nonspecific LBP postpartum, Franke et al.3 found that moderate-quality evidence suggested a significant difference in favor of OMT for pain (MD: -41.85, 95% CI: -49.43 to -34.27) and functional status (SMD: -1.78; 95% CI: -2.21 to -1.35).

**OMT versus usual obstetric care, sham ultrasound, and untreated for nonspecific low back pain in pregnant women:**
When examining nonspecific LBP in pregnancy, Franke et al.3 found low-quality evidence that suggested a significant difference in favor of OMT for pain (MD: -23.01; 95% CI: -44.13 to -1.88) and functional status (SMD: -0.80; 95% CI: -1.36 to -0.23).
Two other important studies published subsequent to the Franke et al. systematic review address LBP in pregnant women and enhance the findings of Frank et al. Hensel et al.5 found that OMT was effective for mitigating pain and functional deterioration compared with usual care only; however, OMT did not differ significantly from placebo ultrasound treatment. In yet another study conducted by Licciardone et al.6, the investigators found that during the third trimester of pregnancy OMT has medium to large treatment effects in preventing progressive back-specific dysfunction.

Next Steps
Since the systematic review for the current guidelines was completed, additional studies supporting the use of OMT for low back pain have been published.7-11 Licciardone et al. found that an OMT regimen for chronic low back pain showed significant and relevant measures for recovery7, and that subgroup analysis by baseline levels of chronic low back pain is a simple strategy to identify patients who have substantial improvement with OMT.8 Hensel et al. evaluated the safety of an OMT protocol9 during the third trimester of pregnancy and determined that the protocol is safe with regard to labor and delivery outcomes.10 In a systematic review and meta-analysis, Franke et al. looked at the effectiveness of OMT for low back pain in pregnant or postpartum women and found that OMT produces clinically relevant benefits for this population.11

The current guidelines were approved by the AOA House of Delegates in 2015 and thus will sunset in 2020. Therefore, the AOA will need to revise the guidelines for submission to the 2020 HOD. The National Guideline Clearinghouse also requires a revision every five years for posting to their website. (Please note that as of this writing, funding to support the NGC has not yet been secured beyond July 16, 2018; NGC has established a cut-off date of March 5, 2018 for guideline submissions. The future of the NGC is still unclear.) Revision of the guidelines will require a new systematic review and meta-analysis of the literature. Staff anticipates beginning the revision process for the guidelines in the spring of 2019.

References


Source: H358-A/18

Status: 2018
Special Licensing Pathways for Physicians

Policy Statement

The American Osteopathic Association (AOA) oppose the creation of special licensing pathways which allow physicians who are not currently enrolled in an AOA or Accreditation Council for Graduate Medical Education (ACGME) accredited training program ("residency"), or who have not completed at least one year of post-graduate U.S. medical education accredited by the AOA or ACGME, to practice medicine under limited supervision by a fully trained and licensed physician.

Source: H363-A/18

Status: 2018
Sunset Resolutions

Policy Statement

The American Osteopathic Association supports that when a sunsetting resolution is presented for review and is recommended for Disapproval, the submitting organization must offer a thorough explanatory statement as to the reason this recommendation is offered; and that the substitution of another resolution that is sunsetting the same year, that the current numbered resolution must be presented as opposed to the expiring year resolution; and that when a Sunsetting resolution is presented for review and recommended for disapproval based on the substitution of another resolution that has been enacted in another year and is not sunsetting, that the more current resolution and policy must be presented for easier review to make certain that the intent and policy are indeed being covered; and when there are recommendations made to alter or enhance, other than for spelling, grammar and clarification and all else of what would be considered “editorial”, a resolution that is due for sunsetting and is being presented for approval, that a significant explanatory statement must be presented.

Source: H364-A/18

Status: 2018
Training – Extended Release-Long Acting (ER/LA) Opioid Risk Evaluation and Mitigation Strategy (REMS)

Policy Statement

The AOA encourages osteopathic physicians whose practice includes the prescribing of Extended Release-Long Acting (ER/LA) Opioids to complete ER/LA Opioid Risk Evaluation and Mitigation Strategy (REMS) training to ensure that ER/LA opioids are prescribed, when indicated, in a manner that enhances patient well-being and does not contribute to individual or public harm.

Source: H300-A/19

Status: 2014; 2019 Reaffirmed
Flu Pandemic – Osteopathic Treatment of

Policy Statement

The American Osteopathic Association supports the active utilization of osteopathic manipulative treatment, along with other recognized and approved medical interventions, in the treatment of flu pandemics and other infectious outbreaks; and will conduct programs to disseminate appropriately training in osteopathic manipulative treatment.

Source: H302-A/19

Status: 2009; 2014 Reaffirmed as Amended; 2019 Reaffirmed
Direct-to-Consumer Marketing of Health Screening and Testing

Policy Statement

The American Osteopathic Association is against direct-to-consumer marketing of medical tests and exams that may be unnecessary and encourages its members to educate their patients about which services are appropriate based on US Preventive Services Task Force recommendations and other nationally recognized clinical practice guidelines.

Source: H303-A/19

Status: 2009; 2014 Reaffirmed; 2019 Reaffirmed as Amended
New Born HIV Testing

Policy Statement

The American Osteopathic Association recommends HIV testing immediately with expeditious reporting of results of newborns whose mothers' HIV status is unknown and where clinically indicated.

Source: H304-A/19

Status: 2003; 2009 Reaffirmed; 2014 Reaffirmed as Amended; 2019 Reaffirmed
Influenza Immunization for Health Care Workers and Educators

Policy Statement

The American Osteopathic Association strongly supports and recommends influenza vaccinations for all health care workers and educators according to current guidelines of the Centers for Disease Control and Prevention.

Source: H306-A/19

Status: 2009; 2014 Reaffirmed as Amended; 2019 Reaffirmed
Due Process for Alleged Impaired Physicians

Policy Statement

The American Osteopathic Association believes that, except in the case of summary suspension necessary to protect patients from imminent harm, no adverse action be taken against the staff privileges of a physician by a hospital, managed care organization or insurer based on a claim of physician impairment without a suitable due process hearing in accordance with medical staff bylaws to determine the facts related to the allegations of impairment, and, where appropriate, a careful clinical evaluation of the physician.

Source: H307-A/19

Status: 1999; 2004 Reaffirmed; 2009 Reaffirmed; 2014 Reaffirmed; 2019 Reaffirmed
Drug Formularies

Policy Statement

The American Osteopathic Association (AOA) supports drug formularies which allow for an expeditious appeal process with a further peer to peer review option.

Source: H308-A/19

Status: 1999; 2004 Reaffirmed; 2009 Reaffirmed; 2014 Reaffirmed as Amended 2014; 2019 Reaffirmed
Home-Based Care for Frail Elderly

Policy Statement

The American Osteopathic Association encourages all parties with economic and clinical responsibility to develop programs and systems to assist the frail elderly patient population and provide appropriate access to healthcare services.

Source: H309-A/19

Status: 1999; 2004 Reaffirmed as Amended; 2009 Reaffirmed; 2014 Reaffirmed as Amended
       2019 Reaffirmed
Health Care Costs in Long Term Services and Support

Policy Statement

The American Osteopathic Association reaffirms its commitment to the development and implementation of programs that improve the efficiency of long term services and support and ensure the delivery of quality care.

Source: H310-A/19

Status: 1984; Revised 1989; Reaffirmed 1994; Revised 1999; Reaffirmed 2004; Reaffirmed as Amended 2009; Reaffirmed as Amended 2014; Reaffirmed as Amended 2019
The American Osteopathic Association believes that adverse membership actions which do not involve professional competence or conduct such as nonpayment of dues, CME deficiencies and other association matters shall not be reported to the National Practitioner Data Bank (NPDB) unless otherwise required by law; and that final actions of expulsion of members from the American Osteopathic Association shall, when all appeal mechanisms have been exhausted by the osteopathic physicians, be reported to the National Practitioner Data Bank.

Source: H312-A/19

Status: 1999; Reaffirmed 2004; 2009; 2014; Reaffirmed 2019
Importation of Medications

Policy Statement

The American Osteopathic Association supports the importation of medications that may be imported under the authority of the US Food and Drug Administration and encourages its members to assist patients in utilizing the many programs that are available to provide patients with free or reduced cost medications.

Source: H313-A/19

Status: 2004; Reaffirmed 2009; 2014; Reaffirmed 2019
Any Willing Provider Legislation

Policy Statement

The American Osteopathic Association encourages and supports the passage of legislation that will ensure the freedom of patients and physicians to enter into private contracts for health care services without regard to restrictions by any third party carrier; supports legislation that will allow any qualified physician (DO/MD) to negotiate with any third party carrier the terms for service to be provided; and supports legislation that will require any third party carrier to provide prompt and complete explanation to any requesting physician (DO/MD) whom it may deem unqualified.

Source: H314-A/19

Status: 2004; Reaffirmed 2009; 2014; Reaffirmed 2019
Physically Active Video Games – (Exergaming Health) Benefits (H325-A/14)

Policy Statement

The American Osteopathic Association recommends: (1) osteopathic physicians should be aware of the potential benefits of exergaming; (2) physicians should consider recommending exergaming as a component of a person’s exercise program or when situational circumstances prohibit other types of exercise; and (3) additional research that demonstrates the benefits of exergaming.

Source: H-316-A/19

Status: 2009; 2014 Reaffirmed as Amended; 2019 Reaffirmed
Medicare – Prescription Assistance for Medicare Patients

Policy Statement

The American Osteopathic Association supports legislation to eliminate the coverage gap (donut hole) in Medicare Part D and the restrictions that limit patients from utilizing prescription discounts and vouchers.

Source: H317-A/19

Status: 2009; Reaffirmed 2014; Reaffirmed as Amended 2019
Electronic Prescribing
Policy Statement

The American Osteopathic Association (AOA) supports electronic prescribing (e-prescribing) for non-scheduled pharmaceuticals.

The AOA supports e-prescribing for all scheduled pharmaceuticals on a voluntary basis without CMS monetary penalty and without state sanctioned civil or criminal penalties.

The AOA encourages pharmacies to utilize e-prescribing systems that are in compliance with state and federal law.

The AOA supports the following principles in its advocacy efforts relating to the development of e-prescribing standards:

• SAFETY: Safety alerts should be prioritized and readily distinguishable from commercial messages; these messages should be allowed to be suppressed for efficiency.

• E-PRESCRIBING drugs should be listed with both generic and name brands.

• PRIVACY: Information on patients’ medication should be current, comprehensive, accurate and maintained in compliance with HIPAA.

• TRANSPARENCY: Third part involvement must be transparent and disclosed to the prescribing physician and patient.

• DESIGN: Financial interests should not dictate the design of systems (i.e., all drugs should be available). Standards must require fail-safes in any system to prevent the introduction of health care errors.

• INTEGRATION: Systems and should integrate with existing healthcare technology and existing workflow (i.e., download of patient data from EMR).

• SCALABILITY: Any standards should be broad-based and applicable to all healthcare delivery systems.

TIMING: These standards should be in place at the earliest possible time to allow software vendors and practitioners adequate time to become compliant with said standards and perform all necessary testing prior to the implementation.

Source: H318-A/19

Status: 2004; Reaffirmed as Amended 2009; Reaffirmed as Amended 2014; Reaffirmed as Amended 2019
Cardiovascular Disease and Women

Policy Statement

The American Osteopathic Association:

(1) encourages its members to participate in continuing medical education programs on cardiovascular disease (CVD) in women;

(2) urges osteopathic state and specialty associations to offer CME on CVD in women, as part of their educational offerings;

(3) encourages its members to participate in national initiatives on women’s health, especially cardiovascular health such as the National Heart, Lung, and Blood Institute’s The Heart Truth (Red Dress) campaign;

(4) will continue to recognize national women’s health week and national women’s check-up day; and

(5) encourages appropriately designed studies on contributors to CVD in women.

Source: H319-A/19

Status: 2004; 2009; Reaffirmed as Amended 2014; Reaffirmed as Amended 2019
Healthy Weight for Families

Policy Statement

The American Osteopathic Association encourages participation of its members in personal health promotion; strongly recommends osteopathic medical schools incorporate personal health promotion as a part of their graded curriculum; strongly recommends participation of its members in outreach efforts to engage with local school districts in order to develop and improve wellness policy interventions to reduce childhood obesity; strongly recommends the state and specialty associations to collaborate with local school districts and major local employers to enhance wellness policy development, implementation, data assessment and improvements; encourages its members to participate in national and local initiatives on obesity.

Source: H320-A/19

Status: 2004; 2009 Reaffirmed; 2014 Reaffirmed as Amended; 2019 Reaffirmed
The American Osteopathic Association has determined that it is ethical for an osteopathic physician to charge patients fair and reasonable administrative fees as long as the patient is informed of these fees in advance, and the charging of administrative fees does not violate contractual or state law.

Source: H321-A/19

Status: 2004; 2009 Reaffirmed; 2014 Reaffirmed as Amended 2014; 2019 Reaffirmed
End-of-Life Care – Use of Placebos In (H331-A/14)

Policy Statement

The AOA approves the attached position paper on Use of Placebos for Pain Management in End-of-Life Care and will be updated according to the current literature.

USE OF PLACEBOS FOR PAIN MANAGEMENT IN END-OF-LIFE CARE

The placebo effect of medication can be a significant resultant action of any prescription. However, the substitution of a placebo in place of effective pain medication has been widely recognized as unethical, ineffective and potentially harmful. A number of organizations have advised against the use of placebo substitution, including the American Pain Society, Agency for Healthcare Policy and Research, World Health Organization, the Healthcare Facilities Accreditation Program, Joint Commission on Accreditation of Healthcare Organizations, Education on End-of-Life Care Project (co-sponsored by the American Medical Association), American Nursing Association, and the American Society of Pain Management Nurses.

This white paper describes the literature and rationale in support of the AOA’s position on the controversial subject of the use of placebos for pain management in terminally ill patients.

I. Definition of Terms
   A. Placebo, placebo substitution, placebo effect and nocebo response

A placebo is a substance presumed to be pharmacokinetically inert. Placebo substitution means the substitution of a physiologically inactive substance for a comparison with the physiologically active substance. Placebo effect is the positive psychosomatic response of an individual to a treatment; in contrast, the nocebo response is a negative psychosomatic response to a treatment.\(^\text{(10)}\) The placebo effect is an important adjunct in the treatment of symptoms. The alleviation of symptoms has an inherent positive psychological component; patients who perceive their symptoms to be relieved by the treatment and trust in their treating physician’s treatment plan and/or prescription for the symptom relief are more likely to obtain relief.\(^\text{(2)}\)

Placebo responses are necessary for controlled clinical trials in which the patient is informed that a placebo may indeed be utilized. Physiologic responses to placebo can be pleasant or unpleasant to the patient. An unpleasant effect attributable to administration of a placebo is called a “nocebo response”. A pleasant effect is called a “positive placebo response”. It has been noted that, “a positive placebo response simply speaks to the strength of an individual’s central control processes (i.e., mind) to recruit their descending inhibitory system to block pain. The trained osteopathic physician knows that pain relief occurs both in the mind and in the body.”\(^\text{(4)}\) The basis of the placebo effect in a therapeutic physician-patient relationship also involves good communication skills as well as listening to the patient.\(^\text{(4, 11, 12)}\)

To summarize, a placebo is a type of treatment, necessarily used in controlled clinical trials, that has no inherent physiological action yet is designed to mimic a therapy with a known active physiologic effect. Positive changes resulting from placebo administration would be due to expectations of success by the patient. Thus, the use of placebo effect is based on the patient’s
perception of the role of the placebo agent with symptom relief. The placebo response may be enhanced with a positive patient-physician relationship.

B. Addiction, substance abuse and dependence, tolerance, withdrawal and pseudo-addiction.

Some physicians inappropriately justify using placebo in pain management to avoid “addicting” the patient. Addiction, as defined by the American Academy of Pain Medicine,\(^{(13)}\) “is a primary, chronic, neurobiologic disease, with genetic, psychosocial, and environmental factors influencing its development and manifestations. It is characterized by behaviors that include one or more of the following: impaired control over drug use, compulsive use, continued use despite harm, and craving.”

Substance abuse is defined as psychological and physical dependence on substances. Some physicians are concerned that prescribing narcotics may lead to substance abuse and therefore may attempt to use a placebo to assess whether the patient truly requires narcotics for pain relief. However, there is no scientific basis for using placebo in the assessment of the patient in pain who has or may have the potential for a substance abuse. The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V)\(^{(14)}\), lists definitive criteria for diagnosis of psychological and physical dependence on substances. This text categorizes “Substance-Related Disorders” but does not utilize the term addiction; further, nowhere in the DSM-V is placebo administration utilized with criteria for diagnosing various forms of substance abuse. Substance dependence is defined as a cluster of cognitive, behavioral and physiological symptoms. The essential feature of a substance dependent individual is continuous use of the substance despite significant substance-related problems, such as deleterious effects on occupation, relationships, health, and others.

Physicians may become uncomfortable with requests for increased dosages of pain medications, fearing that a patient is manifesting a substance-related disorder. A better understanding of the concepts of tolerance, physical dependence, physiological dependence withdrawal symptoms and pseudo-addiction, may help physicians understand and more effectively treat these patients.

Tolerance represents a markedly diminished effect that can occur with continued use of most medications; the degree depends upon the daily dose and length of use. The need for medication titration, either due to development of tolerance or to incomplete responsiveness, is a part of routine medical care. Tolerance occurs due to compensatory changes in receptors and/or increased clearance resulting from induction of various metabolic pathways. The problem of tolerance should therefore be anticipated as a possible outcome in prescription pain medications.

Withdrawal is defined by the DSM-V\(^{(14)}\) as a maladaptive behavioral change having physiological and cognitive concomitants, which occurs when blood or tissue concentrations of a substance decline in an individual who had maintained prolonged use of the substance, frequently inappropriately. Examples of withdrawal include the onset of seizures or delirium tremens in a newly abstinent alcohol chemically dependent individual. Pseudo-addiction is the term used to describe the behavior of a patient in pain who is receiving an insufficient amount and/or an inappropriate dosing frequency of administration of the prescribed pain medication. In an effort to obtain relief, the patient in pain would request more frequent and/or increased medication. Such “drug seeking behavior” has been deemed as “proof” of “addiction.” The reason for such requests is frequently that the patient is under-dosed,
II. Legal Considerations in the Use of Placebos in Pain Management

While there are no specific laws governing the use of placebos in any circumstance, there is a considerable amount of legislation regarding a patient’s right to pain management. There are several state statutes that address this issue, some of which are based on the Federation of State Medical Boards’ Model Guidelines for the Use of Controlled Substances for the Treatment of Pain. This document clarifies that legislative statutes accepting these guidelines understand the ongoing increased scientific knowledge of pain management, and thus have no need to modify legislation as the science of pain management changes. This document does not mention placebo usage.

The American Bar Association (ABA) adopted a resolution concerning the promotion of pain management in all patients with chronic pain. This resolution states, “…that the American Bar Association urges federal, state and territorial governments to support fully the rights of individuals suffering from pain to be informed of, choose, and receive effective pain and symptom evaluation, management and ongoing monitoring as part of basic medical care, even if such pain and symptom management may result in analgesic tolerance, physical dependence or as an unintended consequence shorten the individual’s life.” Placebo substitution for active pain medicine without informed consent on the part of the patients clearly violates the nature and substance of the ABA’s position. Additionally, in two Supreme Court decisions regarding the right to assisted suicide, the court promoted the right of individuals to appropriate palliative care and pain management.

While there is little case law concerning tort or administrative findings against physicians for inadequate pain management, this is likely to change in the near future. The main barrier to malpractice claims for inadequate pain management is use of the customary local standard to determine what constitutes ordinary care. The courts are steadily moving away from this standard to a national standard which uses clinical guidelines as the determinant of ordinary care. This is seen in the decision in the case of Nowatske v. Oserloh, where the court stated, “should customary medical practice fail to keep pace with development and advances in medical science, adherence to custom might constitute a failure to exercise ordinary care…”

Guidelines developed by the Agency for Healthcare Policy and Research, now the Agency for Healthcare Research and Quality, the American Pain Society, the Healthcare Facilities Accreditation Program as well as the Joint Commission on Accreditation of Healthcare Organizations are good examples of sources the courts are using to determine ordinary practice. These guidelines do not support the use of placebo in any fashion except in approved research studies when the appropriate patient informed consent has been obtained. Therefore, the physician thus cannot justify the use of placebo for pain management by attempting to diagnose “addiction” or with support from any of the above regulatory agencies.

Furthermore, under California’s elder abuse statute, a physician was successfully sued by the deceased’s family for inadequate pain management at the end of life.

III. Adverse Effects of Placebo Use

Pain is a universal experience and is subjective by nature. Despite the common colloquialism, “I feel your pain,” no individual can truly experience another’s pain. There are no laboratory tests or consistently reliable physical findings for assessment of pain. Patient self-report remains the gold standard for pain assessment. Use of a placebo in place of an effective pain medication
for attempting to determine whether the patient at end-of-life is really in pain is under no circumstances appropriate.

There is a concern if a physician deceives the patient and substitutes a placebo treatment in the place of a known effective treatment without informing the patient. Deception has no place within the therapeutic relationship and is counter-productive. A physician may counsel a patient that “this treatment may be effective in treating your condition,” but evidence-based medicine cannot guarantee a treatment outcome.

In this era of informed consent, deception of the patient poses many problems, including erosion of the trust individuals and society as a whole have for physicians. There are methods of using placebos and the placebo effect that do not involve deceit, e.g., clinical trials or the use of placebo as one of the trial agents for neurolytic block. This one narrow exception uses the placebo trial as part of the treatment selection for neurolytic blockade, a highly specialized procedure performed by a few skilled pain management physicians with appropriate informed consent.

Substituting placebo for accepted forms of pain treatment is under-treatment of the condition. Under-treatment of pain, as detailed in the American Bar Association’s 2000 report, is an ongoing problem. (25) While there have been reports of placebo efficacy in pain management, placebo control of pain occurs in fewer patients and for shorter duration than active pain treatments. (7, 26) It has also been argued that the prescription of an ineffective placebo in place of effective pain medication can act as a “suicidogen,” whereby an individual in pain who is given inadequate medication for relief may be prompted to hasten his/her death. (6) In the clinical setting, substitution of a placebo for an active pain medication, even with the consent of the patient, is clinically suspect because better treatment alternatives exist and there are risks associated with the use of placebos. It is therefore inappropriate to substitute a placebo for a medication known to be effective in the treatment of a patient with the verified pain of a terminal illness.

Additionally, placebos are associated with side effects (3) and potentially precipitate hyperalgesia (27) or withdrawal in patients previously treated with pain medications.

IV. Summary
Exquisite management of end-of-life pain is a medical imperative. Use of a placebo in place of known effective pain medication for determining whether the patient is really in pain is under no circumstances appropriate. Use of placebos does not meet the accepted criteria to diagnose substance abuse, commonly referred to by some physicians as “addiction.” There is no medical justification for the use of placebos to assess or treat pain at end of life. The only appropriate use of a placebo is in approved clinical research with informed consent.

References
Source: H322-A/19

Status: 2004; 2009; 2014 Reaffirmed as Amended; 2019 Reaffirmed
Osteopathic Manipulative Treatment (OMT) of the Cervical Spine

Policy Statement

The American Osteopathic Association, in the hopes of advancing the science of osteopathic medicine adopts the following position:

These recommendations are provided for osteopathic educators and physicians making decisions regarding the instruction of cervical spinal manipulation and the care of patients. As such, they cannot substitute for the individual judgment brought to each clinical situation by a patient's physician. Like all reference resources, they reflect the best understanding of the science of medicine at the time of publication, but they should be used with the understanding that continued research is needed.

AMERICAN OSTEOPATHIC ASSOCIATION
OSTEOPATHIC MANIPULATIVE TREATMENT OF THE CERVICAL SPINE

Background and Statement of Issue

Treating chronic pain continues to be an important health issue for osteopathic physicians. Chronic pain affects over 100 million Americans over the age of 18 and negatively impacts their quality of life. In addition, it costs $600 billion a year in healthcare costs and loss of productivity. Back and neck pain are two leading causes of chronic pain and they are amongst the leading causes of people living with disabilities in the United States (U.S.) as well as worldwide. More specifically, back and neck pain are ranked in the top 8 diseases and injuries in the U.S. regarding years lived with disability (YLDs) and in the top 6 globally. Cervical spine manipulation is one option for treating back and neck pain.

Concerns continue to arise regarding the safety of cervical spine manipulation. Specifically, concerns center on the potential development of serious adverse events such as stroke and cervical artery dissection after spinal manipulation. Since spinal manipulation is an option available to osteopathic physicians to incorporate into the care of their patients, it is important to examine these concerns and develop a position on the issue. This paper will present the evidence behind the benefit of cervical spine manipulation, explore the potential harms and make a recommendation about its use.

Benefit

Spinal manipulation has been reviewed in various systematic reviews and meta-analyses over the past three decades. The majority of the studies conducted on spinal manipulation focus on low back pain for which the evidence has shown spinal manipulation has clear benefits. For neck pain, however, there are fewer studies and the findings vary, but there is some evidence that conclude spinal manipulation benefits patients presenting with neck pain. This evidence indicates that the benefits of spinal manipulation include relief of acute neck pain, and reduction in neck pain as measured by validated instruments in sub-acute and chronic neck pain compared with muscle relaxants or usual medical care. Bronfort et al. specifically concluded that for
patients with chronic neck pain, there is moderate evidence that (1) manipulation and mobilization are superior to general practitioner management in the short term, (2) high-technology exercise results in more pain improvement than manipulation in the long term for a mix of patients with acute and chronic pain, and (3) mobilization is superior to physical therapy and general medical care and similar to manipulation in both the short and long term.

Benefits of spinal manipulation for areas beyond the low back and neck include short-term relief from tension-type headaches. Manipulation relieves cervicogenic headache and is comparable to commonly used first line prophylactic prescription medications for tension-type headache and migraine.

Harm
Overall
The literature presents varying conclusions on the harms of spinal manipulative treatment (SMT). In a 2017 review of risks associated with spinal manipulation, 46% percent of the studies reviewed found spinal manipulation to be safe, 42% percent were neutral (did not find harm/benefit); and the remaining 12% percent concluded that spinal manipulation was unsafe because of the possibility of serious adverse events. Nevertheless, the existence of any adverse effect should not be trivialized.

Studies have noted that there are two types of adverse effects as a result of SMT. The first type is considered to be mild adverse events that are short-term and non-serious such as dizziness, fatigue, and muscle soreness/discomfort. These side effects occur in 23-83% of patients. The second type of adverse events is more serious and includes cervical artery dissection, stroke, spinal cord injuries, and other serious conditions outcomes related to vertebrobasilar accidents (VBAs). Currently, much of the literature discusses vertebrobasilar insufficiency or vertebralbasilar ischemia (VBI) which is a type of VBA and is often determined to be the link to the more serious adverse events. Nonetheless, serious adverse events are seen as a rarity, and it is estimated that they occur in the range of every 20,000 to 250,000,000 manipulation performed.

Most of the reported cases of adverse outcomes have involved thrust or High Velocity/Low Amplitude (HVLA) types of manipulative treatment. Unfortunately, many of the reported cases do not distinguish the type of manipulative treatment provided.

VBAs
VBAs account for 1.3 in 1000 cases of stroke, making them a rare event. Approximately 5% of patients with a VBA die as a result, while 75% have a good functional recovery. The most common risk factors for VBAs are migraine, hypertension, oral contraceptive use and smoking. Elevated homocysteine levels, which have been implicated in cardiovascular disease, may be a risk factor for a VBA.

The risk of a VBA occurring spontaneously, is nearly twice the risk of a VBA resulting from cervical spine manipulation. A study done in 1999 reviewing 367 cases of VBA reported from 1966-1993 showed 115 cases related to cervical spine manipulation; 167 were spontaneous, 58 from trivial trauma and 37 from major trauma.

A study in 2002 conducted by Haldeman et al., reported that a VBA following cervical spine manipulation was unpredictable. The authors, however, concluded that a VBA following cervical spine manipulation was “idiosyncratic and rare”. Further review of the data showed that 25% of the cases presented with sudden onset of new and unusual headache and neck pain often associated with other neurologic symptoms that may have represented a dissection in progress.
Complications from cervical spine manipulation most often occur in patients who have had prior manipulation uneventfully and without obvious risk factors for a VBA. Most vertebrobasilar artery dissections occur in the absence of cervical manipulation, either spontaneously or after trivial trauma or common daily movements of the neck, such as backing out of the driveway, painting the ceiling, playing tennis, sneezing, or engaging in yoga exercises. In some cases manipulation may not be the primary culprit for causing the dissection, but an aggravating factor or coincidental event.

It has been proposed that thrust techniques that use a combination of hyperextension, rotation and traction of the upper cervical spine will place the patient at greatest risk of injuring the vertebral artery. In a retrospective review of 64 medical legal cases, information on the type of manipulation was available in 39 (61%) of the cases. Fifty-one percent (51%) involved rotation, with the remaining 49% representing a variety of positions including lateral flexion, traction and isolated cases of non-force or neutral position thrusts. Only 15% reported any form of extension.

Cervical Artery Dissection (CAD)
CAD occurs at a rate of 2.9 per 100,000 individuals every year in the general population, and a large majority (89%) of the individuals diagnosed with CAD have no symptoms or no significant disability that prohibits them from being productive within the following three months of the event. Among those with symptoms, headaches and neck pain are the predominant symptoms for CAD. This creates a dilemma for physicians because cervical spine manipulation is often sought to treat these medical issues. Thus, it is difficult to determine if manipulation causes CAD or if CAD existed at the time of treatment.

Limitations of Studies and Concerns with Pre-manipulation Screening
Due to the design of studies (case reports or retrospective surveys), infrequent reporting of adverse events, and the rare occurrence of many of the more serious complications, it is difficult to determine a causal relationship between SMT and the serious adverse effect. Thus the lingering question of whether or not pre-existing pathologies may have existed prior to the patient receiving SMT remains.

In Malone et al., the authors reported that cervical spine manipulation may worsen preexisting cervical disc herniation or even cause cervical disc herniation. This report describes complications such as radiculopathy, myelopathy, and vertebral artery compression by a lateral cervical disc herniation. The incidence of these types of complications could be lessened by rigorous adherence to published exclusion criteria for cervical spine manipulation.

Another noteworthy point to highlight is that the literature does not clearly distinguish the type of provider (i.e. M.D., D.O., D.C. or P.T.) or manipulative treatment (manipulation vs. mobilization) provided in cases associated with serious adverse effects. This information may help to understand the mechanism of injury leading to serious adverse effects, as there are differences in education and practice among the various professions that utilize this type of treatment. It is duly noted that the osteopathic approach strictly limits the “thrust”, which is more commonly referred to as “impulse” in osteopathic practicums, to the physiologic barrier as opposed to the chiropractic approach may extend to the paraphysiologic space.

Additionally, pre-manipulation screening tools, that might be used to identify a patient’s risk for VBA and cervical artery dissection have been widely criticized because they have been found to be unreliable and difficult to validate. These studies have examined the DeKleyn’s test and others like it and determined the tests are unreliable.
for demonstrating reproducibility of ischemia or risk of injuring the vertebral artery.\textsuperscript{36-43}

For this reason, researchers and groups such as the Bone and Joint Decade Task Force on Neck Pain and Its Associated Disorders recommend that all health care providers conduct a thorough patient history, physical examination and patient self-assessment to rule out certain pre-existing conditions.\textsuperscript{13,44}

**Alternative Treatments**

**Non-steroidal anti-inflammatory drugs (NSAIDs)**

NSAIDs such as ibuprofen and aspirin are the most commonly prescribed medications for neck pain. More than 30 million people worldwide use NSAIDs regularly.\textsuperscript{45} In fact, 5\% of all medical visit outcomes in the U.S. include a prescription for NSAIDS.\textsuperscript{46} NSAIDs offer temporary relief, but long-term use, gender, age, strength of dose as well as consumption of multiple medications simultaneously may be associated with serious risks affecting the gastrointestinal (GI), renal and cardiovascular systems.\textsuperscript{47,48} Eighty-one percent (81\%) of GI bleeds related to NSAID use occur without prior symptoms.\textsuperscript{49} Research in the United Kingdom has shown NSAIDs will cause 12,000 emergency admissions and 2,500 deaths per year due to GI tract complications.\textsuperscript{30} The annual cost of GI tract complications in the U.S. is estimated at $3.9 billion, with up to 103,000 hospitalizations and at least 16,500 deaths per year therein making GI toxicity from NSAIDs the 15th most common cause of death in the United States.\textsuperscript{49-51}

**Epidural steroid injections**

Epidural steroid injections (ESIs) are a popular treatment for neck pain.\textsuperscript{50} Complications to ESIs generally occur because of needle placement or drug administration. Common risks associated with needle placement include subdural injection, intrathecal injection and intravascular injection.\textsuperscript{51} Subdural injection occurs in \(~1\)% of procedures, intrathecal injection occurs in \(~0.6-10.9\)% of procedures, and intravascular injection, the most significant risk, occurs in \(~2\)% of procedures.\textsuperscript{51} Other risks include cervical epidural abscess, dural puncture, spinal cord trauma, infection, hematoma, nerve damage, vascular injury and cerebral vascular or pulmonary embolus.\textsuperscript{52,53} Complications that may arise from drug administration include osteoporosis, Cushing’s syndrome, avascular necrosis of bone, and steroid myopathy. While complications due to needle placement or administration of steroids are rare, they have been reported in the literature.\textsuperscript{52,53}

**Conclusion**

Osteopathic manipulative treatment of the cervical spine, including but not limited to HVLA treatment, is effective for low back and neck pain and is safe. Because of the rarity of serious adverse events, trainees and practicing physicians should be provided with sufficient information so they are advised of the potential risks and able to communicate the potential risks to their patients. Prior to recommending cervical spine manipulations, physicians should conduct a thorough patient exam and medical history review to try to identify any preexisting conditions that may indicate the patient is at risk for a serious adverse event. Additionally, it is recognized that there is a need for research to distinguish the risk of VBA and CAD associated with manipulation done by specific provider types as well as research to determine the nature of the relationship between the different types of manipulative treatment and VBA and CAD.

It is the position of the American Osteopathic Association that all modalities of osteopathic manipulative treatment of the cervical spine, including HVLA, should continue to be taught at all levels of education, and that osteopathic physicians should continue to offer this form of treatment to their patients. Physicians should use a combination of medical history reviews and physical exams, diagnostic studies, and best
judgment to determine if a patient has any pre-existing conditions that place the patient at risk of suffering a serious adverse event.

Special Acknowledgements
In crafting the updated Position Statement, the Bureau of Osteopathic Clinical Education and Research (BOCER) would like to thank the Osteopathic Manipulation Medicine and Osteopathic Manipulative Treatment (OMM/OMT) Research Task Force for its input, and a special thank you to Hollis King, DO, PhD, who served as an outside contributor.

References
randomized controlled trial. Journal of Manipulative and Physiological Therapeutics, 15, 570-575.
neck pain likely to benefit from thrust joint manipulation to the cervical spine. Journal of Orthopaedic and Sports Physical Therapy, 42(7), 577-591.


Source: H324-A/19

Status: 2004; 2009 Reaffirmed; 2014 Reaffirmed; 2019 Reaffirmed
Right to Privately Contract

Policy Statement

The American Osteopathic Association supports the fundamental right of physicians to privately contract with patients without penalties and regardless of payor, supports changes in statutes and regulations to allow physicians individually and as defined groups to negotiate fair contracts with private sector and public sector health plans.

Source: H325-A/19

Status: 2009; 2014 Reaffirmed; 2019 Reaffirmed
Promoting Diversity in AOA Membership and Leadership

Policy Statement

The American Osteopathic Association reaffirms its commitment to promote diversity underrepresented into the osteopathic profession; endorses programs to encourage increased diversity in enrollment at colleges of osteopathic medicine; and will work to identify and encourage such qualified individuals for participation in those osteopathic affiliate and national activities which foster leadership opportunities.

Source: H326-A/19

Status: 1979 Reaffirmed; 1983 Reaffirmed as Amended; 1988 Reaffirmed; 1994 Reaffirmed; 1999 Reaffirmed; 2004 Reaffirmed as Amended; 2009 Reaffirmed as Amended; 2014 Reaffirmed as Amended; 2019 Reaffirmed as Amended
Abuse of Performance Enhancing Substances and Procedures

Policy Statement

The American Osteopathic Association:

(1) supports efforts to eliminate the abuse of performance enhancing substances, known as doping, for the purpose of enhancing athletic performance or physical appearance.

(2) supports the efforts of the United States Anti-Doping Agency (USADA) and its program in accordance with the World Anti-Doping agency (WADA) code and the WADA International Standards (IST) to protect clean athletes and ensure their rights to compete on a fair and level playing field, free from the pressures of performance enhancing drugs; and

(3) encourages education of athletes, the public and physicians of the dangers of these substances.

Source: H327-A/19

Status: 1989; 1994 Reaffirmed as Amended; 1999 Reaffirmed; 2004 Reaffirmed as Amended; 2009 Reaffirmed as Amended; 2014 Reaffirmed as Amended; 2019 Reaffirmed
Diversity in Leadership Positions

Policy Statement

The American Osteopathic Association supports increased awareness of and encourages diversity in its leadership positions and encourages its divisional and specialty societies to do the same.

Source: H328-A/19

Status: 1999, 2004 Reaffirmed; 2009 Reaffirmed; 2014 Reaffirmed as Amended 2014; 2019 Reaffirmed
Tobacco Use Status – Reporting in the Medical Record

Policy Statement

The American Osteopathic Association supports the U.S. Preventive Services Task Force (USPSTF) guideline on tobacco use cessation that specifically recommends identifying tobacco use status on each patient visit to increase the likelihood of physician intervention with their patients who use tobacco.

Source: H329-A/19

Status: 1999; 2004 Reaffirmed as Amended; 2009 Reaffirmed; 2014 Reaffirmed; 2019 Reaffirmed
Testosterone Therapy: Long Term Effect on Health

Policy Statement

The American Osteopathic Association requests that the National Institutes of Health fund independent research of the long term risk/benefits of testosterone therapy.

Source: H332-A/19

Status: 2014; 2019 Reaffirmed
Compensation Tied to Patient Satisfaction Surveys – Osteopathic Physician

Policy Statement

The American Osteopathic Association supports participation in patient satisfaction surveys without minimal impact on physician payment.

Source: H333-A/19

Status: 2014; 2019 Reaffirmed as Amended
Availability of Biosimilar Products

Policy Statement

The American Osteopathic Association (AOA) supports policies that strengthen the biosimilar market while preserving the physician-patient relationship and protecting patient safety; and, that FDA approved drugs should be accessible to patients, and, that the decision on which biologic or biosimilar should be used rest with the patient and the physician; and, that the AOA supports payor coverage of all FDA-approved biologics and biosimilars to enhance patient access and choice.

Source: H334-A/19

Status: 2019 Reaffirmed as Amended
Maternal Mortality

Policy Statement

The American Osteopathic Association (AOA) supports:

(1) the important work of maternal mortality review committees;

(2) work with state and relevant specialty medical societies to advocate for state and federal legislation to establish and maintain Maternal Mortality Review Committees; and

(3) work with state and relevant specialty medical societies to secure funding from state and federal governments that fully supports the start-up and ongoing work of state Maternal Mortality Review Committees.

Source: H335-A/19

Status: 2019 Reaffirmed as Amended
Extending Medicaid to 12 Months Postpartum

Policy Statement

The American Osteopathic Association support state legislation, Section 1115 waiver applications, and federal legislation to extend Medicaid coverage to 12-months postpartum.

Source: H336-A/19

Status: 2019
Hospital Consolidation – Opposition to

Policy Statement

The American Osteopathic Association opposes further consolidations of hospitals and health systems that are absent of sufficient evidence of and commitment to protect patients' access to quality and affordable care and physicians' ability to negotiate equitable relationships with hospitals and payors.

Source: H338-A/19

Status: 2019 Reaffirmed as Amended
Pharmacy Benefit Managers-Increased Regulation of
Policy Statement

BACKGROUND
The rising cost of drugs is a major concern in the U.S., where consumers pay two to six times more for prescription drugs than the rest of the world\(^1\). Between 2007 and 2017, drug spending in the U.S. increased by 40%, an increase largely attributable to existing drugs rather than new drugs entering the market\(^2\). Increased drug prices have resulted in patient noncompliance, with sometimes fatal consequences, as patients are either unable to afford their prescription medications or are forced to choose between buying them or other necessities like food and shelter.

There are a number of factors that distinguish the U.S. health care system and drug spending from other industrialized nations; for one, almost all countries except the U.S. have policies in place to lower drug prices, including price controls and cost-effectiveness thresholds\(^3\). By contrast, the U.S. government does not directly regulate drug prices, instead leaving it up to individual insurers to negotiate prices with drug makers. This fragmented and opaque system often results in different prices for different buyers, a power imbalance that favors corporate entities at the expense of consumers.

While numerous factors contribute to prescription drug pricing and affordability in the U.S., for purposes of this policy paper we will focus on the role of pharmacy benefit managers (PBMs)\(^4\).

PHARMACY BENEFIT MANAGERS
PBMs are companies hired by insurers, employers, and government entities to manage prescription drug programs on behalf of health plan beneficiaries\(^5\). Originating several decades ago as processors of prescription drug claims for insurers, for which they earned a flat fee, PBMs initially lowered drug prices by forming large networks of health plan customers which enabled them to negotiate discounts with drug makers. Since then, consolidation among PBMs has concentrated an 85% market share in the hands of three major players (CVS Caremark, Express Scripts and OptumRX), and drug prices have risen as a result\(^6\).

PBMs affect numerous aspects of the drug supply chain, and they are adept at leveraging their power with drug makers, employers and pharmacies to extract profits that they keep for themselves rather than passing them on to patients. As a result, patients pay cost shares that do not reflect the actual lower cost of the drug, which increases out-of-pocket costs and co-pays.

The following represents a summary of PBM revenue sources:

*Rebates.* PBMs decide which drugs will be covered on a prescription drug plan or plan formulary, and drug makers often pay “rebates” or other fees to PBMs to have their drugs included. Drug makers then pass these costs on to consumers in the form of higher drug prices.

PBMs also determine which pharmacies will be included in a prescription drug plan's network and how much they will be paid. Sometimes, PBMs entice plan sponsors to require beneficiaries to use a mail order pharmacy – usually one with financial ties to the PBM – for certain medications.
Prior Authorization. PBMs use prior-authorization requirements to steer patients to formulary drugs regardless of their efficacy, by requiring them to obtain prior authorization if they or their providers prefer to continue the original (non-formulary) drug. This can result in harm to patients who may miss doses or experience other negative effects from adjusting to a new drug, which may not be as effective as the one they were previously stable on.

Spread pricing. “Spread pricing” refers to the difference between what a PBM charges an insurer for a drug and what it reimburses the pharmacy for it. Neither the insurer nor the pharmacy knows what the PBM charges or reimburses the other for a particular drug, and PBMs take advantage of this lack of transparency to pocket the spread.

Gag clauses (partially mooted by the federal Patient Right to Know Drug Prices and the Know the Lowest Price Acts of 2018). Prior to the passage of the aforementioned Acts in October 2018, PBMs in most states could utilize “gag clauses” to prevent pharmacists from telling customers when their copayment amount would exceed the out-of-pocket cost of a drug. PBMs then kept the customer’s overpayment, known as a “clawback,” as profit. The Acts banned gag clauses, giving pharmacists the option – but not requiring them – to tell patients when a drug would cost less out-of-pocket.

Direct and Indirect Remuneration (DIR) Fees. DIR refers to the monies that a PBM may collect from a dispensing pharmacy to offset member costs. The Centers for Medicare and Medicaid Services (CMS) originally created DIR as a way to track rebates and other price adjustments applied to Medicare Part D prescription drug plans that were not captured at the point of sale and that resulted in savings to a PBM, and ultimately to CMS (in theory).

Since its inception, DIR has transformed into a catchall term for any fees a pharmacy pays to a PBM, including fees to participate in the PBM’s network or fees paid for failing to meet certain quality measures. PBMs have also begun expanding the use of DIR from just Medicare Part D plans to commercial plans, and pocketing the savings. While some DIR fees are legitimate, many are assessed in an arbitrary and opaque manner that prevents pharmacies from fully understanding how much they will be reimbursed for a prescription when entering into a PBM contract. In addition, many of the fees are charged retroactively which impacts the ability of independent pharmacies in particular to budget for, and ultimately implement, new patient services.

STATE ACTION
There is a growing desire among states to regulate PBMs, but approaches vary from state to state. Besides the gag clause ban, which Congress enacted nationally in 2018, state legislative proposals typically include one or more of the following elements: requirements that PBMs register with the state, requirements for certain mandatory disclosures by PBMs, and prohibitions on PBMs incentivizing the use of mail-order pharmacies.

As of December 2018, 23 states require PBMs to be licensed by a state agency. The agency promulgates rules for licensure, which may include state approval of compensation arrangements between PBMs and pharmacies to ensure that reimbursement rates are fair and reasonable, or requirements that PBMs disclose aggregate rebates to purchasers.

Thirteen states require substantial disclosures by PBMs, and sometimes by insurers as well, to promote transparency regarding rebates and the extent to which PBMs pass them on to insurers, and ultimately to patients, in the form of premium reductions or decreased cost-sharing requirements.

Three states currently have laws preventing PBMs from requiring or incentivizing patients to use mail-order pharmacies, which could drive some independent pharmacies out of business, thereby costing patients access to other services that their local pharmacies may provide. All
major PBMs have their own mail-order pharmacies, which allow them to tightly control formularies and steer patients towards drugs for which they receive financial benefits, as well as to reap rewards from spread pricing. Large PBMs can also exclude other independent mail-order pharmacies from their networks and negotiate prices that allow them to undercut competitors, which raises antitrust questions.

PBMs were originally created to save consumers money, and increased regulation by states could theoretically drive up operating costs and reduce savings for consumers; however, extensive consolidation among PBMs has since tilted the balance of power away from consumers and obscured prices as well as the ability of outsiders to determine PBMs' real effect on the costs of the drug supply chain. States have little power to prevent future PBM mergers, thus increased regulation and transparency requirements may be their only effective tools.

RECOMMENDATIONS
The AOA adopts the following statements as its official position on PBMs:

State and federal governments should work to ensure that PBMs function as originally intended; that is, to save patients money. In order to accomplish this goal, a multi-pronged approach that incorporates various elements below in order to target PBMs’ various revenue sources and address misaligned incentives should be considered.

PBMs should be required to publicly disclose any rebates or other “financial benefits” that they receive from other members of the drug supply chain and pass through a certain percentage to the plan sponsor. They should also be prevented from utilizing prior authorization requirements to steer patients to formulary drugs or mail-order pharmacies to which they have financial ties.

In order to improve the viability of independent pharmacies and preserve competition, PBMs should be prohibited from charging pharmacies retroactive DIR fees.

Capping patient copayments at the pharmacy reimbursement rate or the cost without insurance would help address PBM clawbacks.

THE AOA SUPPORTS HEALTH POLICY WHICH PROMOTES MAKING LIFE SAVING MEDICATIONS (I.E. EPINEPHRINE FOR ANAPHYLAXIS, NALOXONE FOR DRUG OVERDOSE, AND INSULIN/GLUCAGON FOR DIABETES) FREE FOR UNINSURED PATIENTS AND A FULLY COVERED BENEFIT FOR INSURED PATIENTS.

The U.S. Department of Justice should enforce antitrust protections to prevent additional PBM market consolidation, which is likely to lead to further drug formulary restrictions and reductions in the number of – and PBM reimbursement for – independent pharmacies.

Lastly, governmental action to improve PBM transparency is key. The Federal Trade Commission (FTC) has the unique power to shed light on the effect of PBMs on the drug supply chain through its Section 6(b) authority and accompanying subpoena power. Section 6(b) allows the FTC to “conduct wide-ranging economic studies that do not have a specific law enforcement purpose,” and it could exercise this authority to obtain PBM rebate and fee information and to analyze PBMs’ effects on drug pricing.

References
4. https://www.nap.edu/read/24946/chapter/5
5. https://www.ncpanet.org/advocacy/the-tools/pbm-resources

Source: H339-A/19

Status: 2019 Reaffirmed as Amended
Human Cloning White Paper

Policy Statement

The American Osteopathic Association has adopted the following white paper:

White Paper – Human Cloning

BACKGROUND
Somatic cell nuclear transfer (SCNT) or, to use the more common vernacular, cloning is the process of creating genetic duplication of a cell or an organism naturally or artificially. The National Institute of Health (NIH) describes “cloning” as a process “that can be used to produce genetically identical copies of a biological entity.” More specifically, the National Human Genome Research Institute (NHGRI) of NIH, identifies three categories of artificial cloning: gene, reproductive and therapeutic. The latter two types of cloning are often lumped together as “human cloning,” which is controversial and the focus of much debate.

TYPES OF CLONING

Gene Cloning
Gene cloning (also known as DNA cloning or molecular cloning) is the process wherein genes or segments of DNA are copied. DNA cloning is beneficial to medicine because the technology allows doctors to treat patients by replacing flawed genes associated with inherited diseases with healthy ones. Gene cloning is primarily seen in genetically engineered food and in animals to help them grow stronger. This type of cloning does not have the possibility of creating an adult living creature.

Reproductive Cloning
Reproductive cloning is the process of using SCNT to obtain eggs that could develop into an adult living creature. The mature somatic cell is transferred into another egg cell and allowed to develop into an embryo in a test-tube and then implanted into the womb of a living creature. The hope is that the outcome will be a birth with the same genetic makeup as the living creature from which the mature somatic cell was taken. Reproductive cloning experimentation has been occurring for many decades but has primarily focused on animals as opposed to human beings. In 1979, mice were cloned by splitting mouse embryos. In 1996, the lamb, Dolly was successfully cloned. In 1998, several calves were cloned. Another notable cloning of a mammal was in 2003, when an endangered ox, Banteg, was cloned. While there have been a few successfully cloned mammals, there have been no verified successful attempts to clone a human embryo/being.

Therapeutic (Research) Cloning
Therapeutic cloning is the process of creating a cloned embryo in an effort to produce embryonic stem cells to help understand the epidemiology of diseases and to develop new treatments. Therapeutic cloning involves some of the same techniques used in reproductive cloning. However, the stem cells are harvested from the embryo during the test tube phase, therein destroying the embryo.

ARGUMENTS FOR OR AGAINST CLONING
In the United States and worldwide, cloning remains a moral and ethical point of consternation. There are arguments both for and against the use of cloning, but there appears to be a consensus amongst many that cloning an actual human being is not acceptable.5,6 Therapeutic cloning is often the center of most debates for many regarding balancing patient care, morals and ethics.

Arguments against therapeutic and reproductive cloning6:

- Reproductive and therapeutic cloning leads to the destruction of human embryos which many see as viable human life.
- Reproductive cloning usurps the divine plan or interferes with the natural order.
- Cloning violates human dignity and treats human beings as commodities or items to be manufactured.
- Cloning causes risks to human health; the majority of implanted embryos die in gestation or result in births with significant abnormalities. In addition, the need for human embryos may cause women in poverty to compromise health due to incentives to sell embryos.

Arguments for therapeutic and reproductive cloning6:

- Reproductive and therapeutic cloning presents a unique ability to research and identify treatments to address human diseases by providing insight to researchers on developmental and pathogenic events not discoverable otherwise.
- Cloning may lead to alleviation of human suffering and cures for costly and debilitating diseases by providing genetically matched tissue for transplantation.
- Cloning promotes scientific inquiry.

LEGISLATION IN THE U.S. ON CLONING
Currently, the federal government does not explicitly prohibit cloning. However, the government does prohibit the use of federal funds for cloning, regardless of the purpose (therapeutic or reproductive cloning).6,7 The NIH primarily conducts gene cloning. NIH relies on federal funding which is prohibited from being used in therapeutic or reproductive cloning activities, and accordingly, NIH researchers have not cloned any mammals nor have any of the institutions or centers supported human cloning activities.

The Food and Drug Administration (FDA) has weighed in on human reproductive cloning. In a 1998 letter about human cloning, the FDA claimed jurisdiction over clinical research using cloning technology for reproductive purposes. The FDA equated using cloning technology to the same process as developing new drugs.8 In a second letter dated March 28, 2001, regarding Cloning Technology, the agency reiterated its jurisdiction over clinical research using such technology. The FDA explicitly stated that the process is subject to the Health Service Act and the Federal Food, Drug and Cosmetic Act. also indicated that all approval responsibilities for any human clinical use of any therapies derived from cloning research fell within its purview.9

In an effort to address the void left by the federal government, several state legislatures have provided guidance on human cloning.7
Eight (8) states prohibit human cloning for any purpose – no reproductive or therapeutic cloning (cloned human embryos for embryonic stem cell research as well as to implant in a uterus for childbirth) – Arizona, Arkansas, Indiana, North Dakota, Oklahoma, South Dakota and Virginia

Six (6) states prohibit state funding of human cloning for any purpose – Arizona, Arkansas, Indiana, Louisiana, Maine and Nebraska

Ten (10) states have “clone and kill” laws which allow therapeutic cloning research, but prohibit cloning of embryos to be implanted for childbirth (reproductive cloning) – California, Connecticut, Illinois, Iowa, Maryland, Massachusetts, Missouri, Montana, New Jersey and Rhode Island

Five (5) states allow state funding for embryonic stem cell research (therapeutic cloning or in vitro fertilization) – California, Illinois, Missouri, Maryland and New York

Two (2) states have legislation that precludes health professionals from being compelled to participate in human cloning (healthcare rights of conscience laws) – Idaho and Louisiana

Twenty-six (26) states and the District of Columbia do not have any legislation addressing therapeutic (biomedical research) and/or reproductive (to produce children) cloning. These data were pulled from sources dated between 2015 through 2019. To the best of BSAPH’s knowledge, these policies remain in effect as of May 1, 2019.

KEY ORGANIZATIONS SUPPORTING THERAPEUTIC/RESEARCH CLONING

Many key organizations have made position statements regarding the benefits it views in therapeutic cloning and accordingly expressed their support. In addition, these organizations have declined to support cloning for reproductive purposes. These organizations include:

American Association for the Advancement of Science (AAAS) – The AAAS has a statement on Human Cloning that states it endorses a legally enforceable ban on efforts to implant a human cloned embryo for the purpose of reproduction. AAAS recognizes that the health risks associated with reproductive cloning make such cloning unconscionable. The AAAS, however, does encourage continued dialogue as new technology advances emerge.

Also, AAAS supports stem cell research (genetic and therapeutic cloning) which has potential health benefits. The AAAS calls for strict monitoring of the process and developments and appropriate oversight through regulation.

American Association of Medical Colleges (AAMC) – On its website under the Advocacy section, the AAMC expressly supports ongoing research into SCNT and endorses legislation that would allow therapeutic/research cloning. Additionally, the AAMC recommends a ban on all forms of reproductive cloning.

American Bar Association (ABA) - The ABA addressed this issue in 2002 and 2004. ABA supports law and policy prohibiting reproductive cloning.

American Medical Association (AMA) - The AMA does not endorse reproductive cloning. However, if in the future reproductive cloning is permitted, the AMA acknowledges that physicians must be educated and understand somatic cell donors must provide informed consent.
consent. Additionally, any child produced through reproductive cloning is recognized as a human-being. Code of Medical Ethics Opinion 4.2.6.15

The AMA says physicians can determine whether they will participate in stem cell research or use its products. The AMA implores clinician researchers to be able to articulate the risks and benefits of embryonic stem cell use for research purposes. In addition, AMA encourages physicians to allow their commitment to the welfare of patients to guide them in their professional standards. Code of Medical Ethics Opinion 7.3.16

National Academies of Medicine, Sciences and Engineering (National Academies) - The National Academies, based on recommendations generated by 2002 joint panel, recommends a legally enforceable ban on the practice of human reproductive cloning, but does support using SCNT to produce stem cells for developing new medical therapies for life-threatening diseases and advancing knowledge.17

AOA AND HUMAN CLONING
The osteopathic community and the AOA have discussed this issue at length since 1998. Recognizing the moral and ethical dilemmas of human cloning, AOA has continued to monitor the issue and provide updates to its constituents in order to facilitate a discussion.

After reviewing the existing literature on cloning, the American Osteopathic Association (AOA) adopts the following policies:

1. The AOA does not endorse the practice of human cloning for purposes of reproduction (efforts to implant a human cloned embryo for the purpose of reproduction).
2. The AOA recognizes the benefits and harms of human cloning for therapeutic (research) purposes with respect to embryos, donors and patients suffering from debilitating and life-threatening diseases and conditions. Physicians shall have the autonomy to determine whether or not they will participate in therapeutic cloning. They should carefully weigh all ethical and moral aspects of the process and determine what is best for the well-being of patients, society as a whole, and the advancement of medical knowledge and practice.
3. The AOA shall review its policy in light of any new evidence that will be generated by research entities as well as monitor state and federal legislation in the field and update the policy as necessary.

REFERENCES


10. HB1399 (April 2019).


Source: H341-A/19

Status: 2019
Misaligned Incentives in Medicare Plans

Policy Statement

The American Osteopathic Association (AOA) support efforts to align patient’s behaviors with cost-effective, reportable high quality care; and, that the AOA will work to identify these misaligned incentives, and advocate for changes to the medicare program that support physicians in delivering high-value care and discourage plans from preventing patients from seeking lower cost-effective treatment options; and, that the AOA will seek to educate third party payers and Pharmacy Benefit Managers to align patient and physician incentives, and, that the AOA will advocate against misaligned payment and quality incentives in Federal Healthcare programs that do not promote improved health outcomes; and, that the AOA works to educate the NCQA regarding the need to modify HEDIS rules.

Source: H342-A/19

Status: 2019 Reaffirmed as Amended
White Papers – Updating

Policy Statement

When policies which are or include a “white paper” as a part of the policy are reviewed as part of the regular policy review process, the reviewing entity shall review and update all statistics, studies, and other data to ensure that these references are the most up-to-date statistics, studies, and data that are available; and, that the reviewing entity shall affirm in an explanatory statement that all statistics, studies, and other data have been reviewed and are the most current available.

Source: H343-A/19

Status: 2019 Reaffirmed
Whistleblower Policy – American Osteopathic Association

Policy Statement

The American Osteopathic Association (AOA) encourages its employees and members and/or volunteers to disclose and report concerns regarding perceived violations of federal and state laws and regulations and perceived financial irregularities.

Source: H346-A/19

Status: 2019
Support for OMT Privileges

Policy Statement

The American Osteopathic Association (AOA) support and advocate for all physicians who desire to practice osteopathic manipulative treatment (OMT) within medical systems and hospitals; and, that the AOA create guidelines that can be distributed upon request to hospitals, medical systems, and other interested entities that standardize credentialing and privileging processes, including proctoring and approval of privileges to practice OMT.

Source: H349-A/19

Status: 2019
Opposing Targeted Regulation of Abortion Providers (TRAP Laws)

Policy Statement

The American Osteopathic Association oppose the Targeted Regulation of Abortion Providers (TRAP laws) that impede and discriminate against a physician’s ability to provide appropriate care to patients seeking family planning services, including abortion.

Source: H355-A/19

Status: 2019
Interference Laws

Policy Statement

The American Osteopathic Association (AOA) approved the following policy paper and recommendations to assist in responding to state and federal proposals and agencies that attempt to adopt interference laws.

A number of states have pursued legislation that dictates how physicians treat and counsel patients during a medical exam. These laws interfere with the patient-physician relationship and undermine physician judgment and represent a departure from evidence-based medicine. As a result, these laws are collectively referred to as “interference laws.”

**H307-A/13 INTERFERENCE LAWS**

The American Osteopathic Association approved the following policy paper and recommendations to assist in responding to state and federal proposals and agencies that attempt to adopt interference laws (2013).

A number of states have pursued legislation that dictates how physicians treat and counsel patients during a medical exam. These laws interfere with the patient-physician relationship and undermine physician judgment and represent a departure from evidence-based medicine. As a result, these laws are collectively referred to as “interference laws.”

Interference laws fall into one of four different classifications.\(^1\) The first prevents physicians from asking their patients about risk factors that may affect their health or the health of their families (Physician “GAG laws”). One example of a GAG law is a 2011 Florida law which barred physicians from asking questions about a patient’s gun ownership.\(^2\) The law was enjoined in 2012 on first amendments grounds, a decision which was upheld by a federal appeals court in 2017.\(^3\) Although 14 other states have considered similar laws, none have passed.\(^4\)

The second type of interference law requires physicians to discuss specific treatments that may not be appropriate or medically necessary.\(^5\) One example of this is New York’s palliative care information act of 2011, which requires health care providers to offer to discuss end-of-life options and palliative care services with terminally ill patients, without discretion as to how and when to raise the issues.\(^6\) Some argue that requiring physicians to discuss this subject with all patients is inappropriate, because physicians are not able to use their judgment to determine if or when patients should receive such sensitive information.

The third type of interference law requires physicians to provide tests or treatments which are not supported by evidence, including ones that are invasive or required without the patient’s consent.\(^7\) Examples of this are laws which require physicians who perform abortions to first perform a fetal ultrasound. It is argued that a fetal ultrasound is medically unnecessary and there is no legitimate medical purpose for requiring one in this circumstance.

The fourth and final type of interference law places restrictions on the content of information that physicians can disclose to patients.\(^8\) Examples of this include laws which limit a physician from providing information about the dangers of chemicals used in the hydraulic fracturing process, also known as “fracking.”
Impact on the Osteopathic Medical Profession and the Patient-Physician Relationship

Interference laws threaten the osteopathic medical profession, in particular due to the intrusion into the patient-physician relationship, which is an essential component of the osteopathic care model’s emphasis on preventive medicine and treatment of the whole patient. The patient-physician relationship is based on ethical principles of trust, confidentiality, respect, autonomy, and open communication between the physician and patient.

Another critical element of osteopathic medical practice in general and the patient-physician relationship in particular is the concept of physician and patient autonomy and “patient-centered” care. The Institute of Medicine (IOM) defines patient-centered care as “providing care that is respectful of and responsive to individual patient preferences, needs and values, and ensuring that patient values guide all clinical decisions.” Patient-centered care is an essential element in the practice of evidence-based medicine. The American Osteopathic Association (AOA) supports the use of evidence-based medicine and the implementation of “appropriate methods to optimize natural healing and to address the primary cause of disease.”

The patient-physician relationship is a critical aspect of osteopathic care, due in large part to a partnership that is created between the physician and patient which relies heavily on communication. “Osteopathic physicians (DOs) consider the impact that lifestyle and community have on the health of each individual, and they work to break down barriers to good health. DOs are trained to look at the whole person, and osteopathic physicians integrate the patient into the health care delivery process as a partner.” Interference laws which prevent DOs from discussing certain health-related subjects such as the safe storage of firearms or the health implications of fracking undermine this partnership and violate the osteopathic principle of preventive medicine. DOs help prevent pediatric deaths by counseling caregivers on the importance of seatbelt and helmet use, but without the ability to adequately counsel a patient on the importance of safe firearm storage they may be unable to help prevent similar deaths from improperly stored firearms. “The purpose of a firearms inquiry is so that the practitioner can determine what subject matters require further follow-up in the practice of preventive medicine.” The AOA rejects any censorship of professional communication, supports enactment of legislation protecting the patient-physician relationship and opposes any attempt to interfere with the patient-physician relationship.

Additionally, interference laws that require DOs to discuss treatments which are not medically necessary or are not supported by evidence-based guidelines violates the osteopathic principle of treating the whole patient and can undermine patient trust. In Kansas, for example, physicians are required to provide misleading information to patients regarding an unproven link between breast cancer and abortion. Twenty-three states currently require health care providers to refer patients to state-created “informed consent” materials, and according to a 2016 audit by Rutgers university, 31 percent of the information included in these materials was found to be medically inaccurate. Blanket requirements that DOs provide information on a particular treatment, or medically inaccurate information, to all patients prevents them from exercising their independent medical judgment and treating the whole patient in an objective, evidence-based manner. Similarly, interference laws which require DOs to perform certain procedures or treatments violate the osteopathic principle of providing individualized patient-centered care. If a DO is required to perform a certain procedure or treatment for every patient, there is no individualized assessment as to what is in a particular patient’s best interests and there is no discussion with the patient because the patient has no choice. Instead of individualized care, this is a “one size fits all” approach. Ultimately, DOs are prevented from rendering individualized, evidence-based care, and patients are prevented from being involved in patient-centered care.
**Legal Challenges**

Two types of interference laws have been challenged in court. Florida’s controversial Firearm Owner’s Privacy Act, which restricted physicians from asking patients about firearm ownership, was enjoined in June 2012 when a Florida district court found that it violated physicians’ First Amendment rights, a decision which was upheld by a federal appeals court in 2017. In granting the injunction, the judge stated the law “chills practitioners’ speech in a way that impairs the provision of medical care and may ultimately harm the patient.”\(^{18}\) The court also held that physician questioning did not violate patients’ Second Amendment rights stating, “the law does not affect nor interfere with a patient’s right to continue to own, possess, or use firearms. Protecting the right to keep and bear arms is irrelevant to this law.”\(^{19}\) In addition, a similar 2012 law which prevented physicians in Pennsylvania from discussing how fracking chemicals may be affecting their patients’ health was struck down by the state supreme court in 2016.\(^{20}\)

Mandatory ultrasound laws have also been challenged on First Amendment grounds. North Carolina’s mandatory ultrasound law was struck down as a violation of physician and patient First Amendment rights. The court held that “the Act goes well beyond requiring disclosure of those items traditionally a part of the informed consent process. In this case, the state compels the provider to physically speak and show the state’s non-medical message to patients unwilling to hear or see that message.”\(^{21}\) Conversely, a nearly identical Kentucky law was upheld by a federal appeals court, which found that the law was reasonably related to the “informed consent” process and did not violate the First Amendment rights of physicians and patients.\(^{22}\) Significantly, the circuit split between the courts sets up a probable hearing by the United States Supreme Court on the issue of mandatory ultrasound laws.

Mandatory ultrasound laws have also been challenged in court on Fourteenth Amendment Substantive Due Process grounds. A mandatory ultrasound law in Oklahoma was ruled to be unconstitutional as a violation of patients’ Fourteenth Amendment due process rights, because it placed an “undue burden” on a woman’s right to seek an abortion.\(^{23}\)

**Efforts of Medical Associations**

Several medical associations have developed policies or taken action in opposition to interference laws. In 2015, the American Medical Association (AMA) Reaffirmed a 2011 resolution which opposes any intrusion into patient-physician relationships and supports physician judgment. In May 2018, the American Academy of Family Physicians (AAFP), the American Academy of Pediatrics, the American College of Obstetricians and Gynecologists and the American College of Physicians issued a set of joint principles based upon their organizations’ policies which oppose governmental interference with physicians’ obligations to provide comprehensive, evidence-based information to patients.\(^{25}\)

The American Bar Association (ABA) also has policy specifically opposing laws which prevent physicians from asking patients about firearm ownership. The ABA policy states that these laws clearly violate the First Amendment rights of physicians and patients, and physician questioning does not in any way violate Second Amendment rights of patients.\(^{26}\)

Finally, several state medical associations have adopted resolutions on the issue of interference laws. Many of these policies are very basic and simply state the association’s opposition to any interference with the patient-physician relationship. Additionally, these policies often promote the use of evidence-based medicine, seek to preserve physician judgment and support litigation which blocks the enforcement of interference laws.
Conclusion
The AOA supports the protection of the patient-physician relationship as especially paramount to the osteopathic medical profession. The osteopathic care model is based upon the treatment of the whole patient and the use of preventive medicine. The patient-physician relationship is a fundamental aspect of osteopathic care, due in large part to a partnership that is created between the physician and patient which relies heavily on communication and trust. Interference laws encroach on this relationship and undermine the osteopathic care model by preventing DOs from providing treatment in a manner that is based upon evidence they believe is best for their patients.

The AOA affirms that legislation which interferes with the patient-physician relationship impairs the autonomy of osteopathic physicians and prevents osteopathic physicians from using their independent medical judgment based on years of rigorous education and training.

The AOA asserts that physicians must be able to communicate freely with patients without fear of government intrusion in order to assure safe, comprehensive and effective medical treatment.

The AOA considers legislation that undermines physician judgment to be a barrier to evidence-based medicine. The AOA supports the use of evidence-based medicine to ensure high quality patient care. Statutorily required medical practices interfere with evidence-based medicine by mandating a "one size fits all approach," thereby preventing an individualized assessment of what is in a particular patient's best interests.

The AOA affirms that legislation which interferes with the patient-physician relationship undermines patient-centered care. Patient-centered care actively involves the patient in making decisions regarding their own medical care. Statutorily required medical practices prevent patients from being involved in making medical decisions, because the patient has no choice.

The AOA believes that the ethical principle of informed consent is undermined when patients are statutorily required to undergo certain treatments or procedures, because the patient has no choice.

The AOA opposes all legislation at the state and federal level that requires physicians to discuss or perform certain treatments or procedures not supported by evidence-based guidelines, because such legislation undermines physician judgment.

The AOA opposes all legislation at the state and federal level which prevents physicians from discussing certain health-related risk factors with their patients, because such legislation violates the First Amendment rights of physicians and patients and is in conflict with evidence-based medical best practices.

The AOA believes that physicians should be free to counsel patients on end-of-life care on a case-by-case basis rather than as a result of an across-the-board mandate.

The AOA supports legal challenges to interference laws that violate First Amendment and Fourteenth Amendment rights of physicians and patients under the State and Federal Constitutions.

The AOA will monitor state and federal interference laws on an ongoing basis and update this policy as needed.

References

3. Id.

4. Id.

5. Weinberger, *supra*.


7. Weinberger, *supra*.

8. Id.


12. AACOM, *supra*.


17. Id.


23. Protecting the Patient-Physician Relationship: Keeping External Interference Out of the Practice of Medicine.

Source: H358-A/19

Status: 2019
State Graduate Medical Education Funding Alternatives

Policy Statement

The following policy paper and the recommendations provided within are approved to assist the American Osteopathic Association (AOA) in responding to policy proposals aimed at funding graduate medical education (GME) at the state-level; the AOA will work with the osteopathic community to encourage and support state-level GME funding initiatives that encompass the principles outlined within this paper.

AOA POLICY PAPER:
STATE GRADUATE MEDICAL EDUCATION FUNDING

BACKGROUND
Physician training requires students to attend four years of medical school, usually paying those costs out-of-pocket or through loans. Following successful completion of medical school, their training continues as medical residents. Medical residents see and treat patients under the supervision of more experienced physicians. This training usually takes place in hospitals though residents often rotate to ambulatory sites such as clinics and physician offices. On average, this residency training takes four years to complete, although highly specialized fields may require longer training.

By and large, overall funding for graduate medical education (GME) comes from patient care revenues. However, the federal government is currently the largest single funder of GME, providing approximately $15.9 billion in funding through the Centers for Medicare and Medicaid Services (CMS) in 2018. Nearly two-thirds of this funding comes from Medicare, with the majority of the remainder funded through medicaid. Additional funding is provided by the Department of Defense, the Department of Veterans Affairs and the U.S. Public Health Service. In providing Medicare funding, Congress has acknowledged that training physicians is a public good. Despite that acknowledgement, there have been periodic calls to remove GME from Medicare and Medicaid and secure other sources of funding. So far, Congress has neither acted on these recommendations nor have other entities stepped up to assume a greater share of the financial responsibility (relative to Medicare or Medicaid) for physician training.

With CAPS on the federal budget, GME funding has been and will continue to be relatively flat. Additionally, the Trump Administration has supported both consolidation and reduction of GME funding as part of a comprehensive approach to reducing overall federal spending. Additionally, in December 2018, the congressional budget office issued recommendations to consolidate and reduce federal payments for GME at teaching hospitals. Conversely, medical schools, hospitals and medical associations see a need to increase funding and residency slots to help train physicians and fill projected workforce shortages and are working at both the state and federal levels to achieve increased funding for GME.

There are two mechanisms through which Medicare and Medicaid distribute GME funding: Direct Medical Education (DME) and Indirect Medical Education (IME) payments. DME payments are based on resident salaries, supervision and other educational costs. IME payments are based on additional operating costs of a hospital with a GME program. One of the greatest obstacles to federal GME funding is the Balanced Budget Act of 1997 which limited the
number of allopathic and osteopathic residents a hospital can count for purposes of DME and IME payment. The law also reduced the IME multiplier over a four-year period, however, the Balanced Budget Refinement Act of 1999 and the Medicare, Medicaid and SCHIP Benefits Improvement and Protection Act of 2000 delayed the IME reduction. Additionally, the Budget Control Act of 2011 enacted a series of automatic budget cuts that included a 2% cut for IME payments which took effect on April 1, 2013.7

**MEDICARE**

The formula for determining Medicare payments to hospitals for direct costs of approved GME programs is established in section 1886(h) of the Social Security Act.9 A DME payment is determined by multiplying a hospital-specific, base-period per resident amount by the weighted number of full-time equivalent residents working in all areas of the hospital and the hospital’s Medicare share of total inpatient days.10 The Affordable Care Act amended section 1886(h)(4)(E) to allow a hospital to count residents training in non-hospital settings if the residents are engaged in patient care activities and if the hospital incurs the costs of the stipends and fringe benefits of the resident during the time residents spend in that setting.11

![Figure I. Medicare DME Payment Formula](image)

As previously mentioned, IME payments are based on additional operating costs of a GME program. The factors for IME payment generally include sicker/more complex patients, maintaining stand-by capacity for certain specialized services (e.g., burn units), residents ordering more tests and trainees being less efficient in providing care. IME payments provide for the legitimate increase in costs training hospitals incur.12 IME payments are calculated by adding the individual intern/resident-to-bed ratio into a formula already established in the Medicare statute. The current IME adjustment is calculated using a multiplier set at 1.35, which means that a teaching hospital will receive an increase of approximately 5.5% in Medicare payments for every 10-resident increase per 100 beds.

**MEDICAID**

Despite federal law not requiring state Medicaid programs to support GME, Medicaid is the second largest funder of GME programs. A majority of states have implemented mechanisms within their Medicaid programs to supplement federal funding of GME. In most cases, Medicaid GME funding is structured similarly to Medicare, providing direct and indirect payments. The most recent data available estimates that Medicaid paid Approximately $4.3 billion to GME programs in 2015, up from $3.87 in 2012.13, 14 Despite the fact that much of that funding came from matching federal payments, three states reported that they explicitly reduced their Medicaid spending on GME, and another seven reported at least a ten percent reduction in Medicaid GME payments between 2012 and 2015.15

In 2005, 47 states provided $3.18 billion through Medicaid to support GME.16 By 2015, only 42 states and the District of Columbia (DC) supported GME through their Medicaid program.17 Arizona, Massachusetts, Montana, Rhode Island, Vermont and Wyoming have since ended GME funding, citing budget shortfalls, and Michigan and Tennessee reported that they recently considered ending funding as well.18, 19
Medicaid Fee-for-Service
Forty states and the District of Columbia make DME and/or IME payments under the Medicaid fee-for-service program. A fee-for-service program is a payment model where services are unbundled and paid for separately.20 Fourteen states and DC fund DME and/or IME programs using a calculation method similar to Medicare’s GME funding formula, sometimes in addition to other methods which usually include variations of a per-resident or lump-sum amount. The per-resident or lump-sum amounts are based on the “hospital’s share of total Medicaid revenues, costs or patient volumes.” Twenty-nine states reported calculating payments solely by “some other method” in 2015.21

Medicaid Managed Care
Capitated managed care is a state’s use of risk-based capitation payments within their Medicaid program. This typically includes contracting with one or multiple managed care organizations (MCOs) to administer the Medicaid program for a defined population of Medicaid patients.22 Thirty-nine states and DC use capitated Medicaid managed care programs.

Sixteen states and DC directly pay teaching hospitals or other teaching programs under Medicaid for DME and/or IME payments.23 This represents an increase in the number of states who have made direct payments under managed care since 2012.24 States who make direct Medicaid payments indicate that they wish to help train future physicians who will service Medicaid beneficiaries and that using Medicaid funds to fund GME programs will help advance state health policy goals.

Twelve states recognize and include Medicaid DME and/or IME payments in their capitated payment rates to managed care organizations. Half of these states – Iowa, Kansas, Kentucky, Michigan, Minnesota, and Mississippi – require MCOs to distribute the negotiated payments to teaching hospitals. The other six assume MCOs will distribute the payments.25

ALIGNING GME FUNDING WITH HEALTH POLICY PRIORITIES
States continue to look to align GME funding with other health policy goals. This can include increased funding for training in certain specialties, addressing workforce shortages in rural and underserved areas and increasing faculty positions to train new physicians. A 2016 study revealed that thirty-two states linked Medicaid GME payments to a state policy goal of increasing the size of the physician workforce, compared to 22 states in 2012.26

Florida and Kansas
In an effort to promote accountability in the use of GME funds, Florida and Kansas link Medicaid GME payments to stated state policy goals. In Florida, this applies to both fee-for-service (FFS) and managed care Medicaid programs, while Kansas focuses solely on FFS payments.27 Like most states, Florida and Kansas have focused on encouraging training in primary care specialties and increasing access to care in rural and medically underserved areas.

Kansas also uses GME payments to promote an increased supply of physicians serving the Medicaid population, and funds teaching hospitals as well as teaching sites in non-hospital settings. In Florida, GME payments have been extended to individual teaching physicians under FFS. The State also uses alternative sources to fund residency programs in addition to Medicaid and Medicare, including the statewide Medicaid residency program and the graduate medical education startup bonus program.28 The former was created in 2013 with $80 million in recurring state and matching federal funds to support payments to hospitals with accredited residency programs, while the latter was created in 2015 with $100 million allocated to educating and training physicians in specialties which are in a statewide deficit. In 2018, the Florida legislature appropriated $242.3 million to these programs.29
Texas
In 2014, the Texas legislature allocated $12 million to several initiatives which together created 100 new residency positions across nine new primary care and two non-primary care programs. In 2015, the legislature consolidated these initiatives into a single GME expansion program, to which it appropriated $49.5 biennially. This resulted in an increase in per-resident funding from $65,000 to $75,000 per year and the creation of 130 new residency positions in 2016-2017.

Since 2009, the Texas Health and Human Services Commission (HHSC) has also provided supplemental funding to five state-owned teaching hospitals for approved medical residency training programs. The HHSC reimburses each hospital directly using a calculation that is based upon the hospital’s self-reported Medicaid inpatient days and resident full-time equivalents. HHSC also separately provides IME payments to teaching hospitals to offset their higher patient care costs relative to non-teaching hospitals, including costs related to supervising and maintaining resident records.

These increases follow years of cuts to GME funding, including a 50% cut in 2012-2013, which led to the elimination of the Texas higher education coordinating board (THECB) primary care residency program and the THECB GME program in 2019.

Utah
In 1997, Utah created the Utah Medical Education Council (UMEC) to address the state’s physician shortage and coordinate GME funding that would be better aligned with the state’s workforce needs. UMEC is a quasi-governmental body whose responsibilities include assessing the physician workforce demands, developing and suggesting policy, finding and disbursing GME funds, addressing physician shortages in rural locations and managing the GME funds from CMS.

To better address the state’s GME funding needs, Utah applied for, and was granted, a CMS waiver that placed GME funding into a funding pool, rather than directing money to hospitals. By pooling all of the state’s GME funding, UMEC was able to distribute the funds directly to hospitals and programs based on specific workforce needs and objectives. The waiver resulted in a 29% increase between 1997 and 2007, from 442 residents in 25 programs to 568 residents in 30 programs. But ultimately ended on June 30, 2010. According to UMEC’S most recent (2016) report, the state has averaged 202 residents per year between 2006 – 2016, representing an apparent decline from levels under the waiver.

ADDITIONAL GME FUNDING MODELS
There are several other GME funding models that have the potential to provide revenue for GME programs. These models differ based on who would receive payment, how funds would be allocated among recipients, what mechanisms would be needed to assure accountability and whether payment would be linked to the achievement of specific performance measures. These models are not mutually exclusive and could be combined to enhance stability and accommodate GME policy objectives. In some cases, a combination of several models would be necessary to pay for different kinds of costs to address specific educational or workforce objectives.

All-Payor System
Several states have experimented with variations on an all-payor system, which combines funding from all public and private sources to pay for state GME programs, but only Maryland’s is currently operational. Although private payors rarely finance GME directly, the higher rates that they pay to teaching institutions help to subsidize GME programs.
Maryland implemented their all-payor system in 1977. Prior to 2014, the state used a prospective, diagnosis-based payment model, which kept the rate of increased spending per admission below the national rate, although it was less successful at containing overall hospital spending due to increased admission rates. Since 2014, Maryland has used a payment model that requires each hospital to monitor both the number and cost of admissions. Payment rates are established by the quasi-governmental Health Services Cost Review Commission, and all payors must pay a given hospital the same rate for the same service, but each hospital negotiates its own rates. Maryland has built costs associated with GME funding, as well as surcharges to support an “uncompensated care pool” and a public plan for residents with chronic health conditions, into its rate-setting system. Maryland also has a Medicare waiver that allows it to set Medicare payment rates. Historically, Maryland had to keep its Medicare costs below national growth for hospital payments per admission in order to maintain its waiver, but the test under the current waiver focuses on the per capita growth in hospital spending.

New York previously operated an all-payor system that levied a “covered lives assessment” tax on private health insurers based upon member fees by region and type of insurance. The moneies collected went into two pools, one that subsidized care for individuals who were unable to pay and another that funded GME. In the late 2000s, however, the GME funding pool was reallocated toward uncompensated care in teaching hospitals, and other “high priority” items.

Health Care Provider Model
Medicare pays for GME through a health care provider model. This approach links payments for clinical training to patient care activities. Because the indirect payment adjustment is intended to reflect the impact of teaching activity on a hospital's patient care costs, this model is particularly appropriate for IME payment.

Several variants of this model have been proposed to encourage more training in nonhospital settings. These variants include a direct pay approach whereby payment would follow the resident training in a nonhospital site; pro rata payment of hospitals and nonhospital sites based on agreements among the entities or a fixed allocation developed in accordance with national cost data; or payment to the entity that bears substantially of the costs of the nonhospital rotations. The first two variants would create substantial administrative burdens. Although less burdensome and disruptive, the third option appears less likely to achieve its stated goal. A voucher or “set-aside” system also could be established whereby a specified share of payment for direct training costs would be earmarked for nonhospital settings.

The principle advantage of the provider model is that regulatory, cost reporting, auditing and compliance mechanisms already are in place and well established. To this extent, these mechanisms have created persistent problems, which is also a disadvantage. This model also fails to provide financial support for training that occurs outside of patient care settings (e.g., much of the training in preventative medicine).

Education Model
Under this approach, payment would be made to a program sponsor, which would be held accountable for the way funds are allocated and expended. Sponsors could be universities, medical schools, colleges of osteopathic medicine, hospitals, consortia or any other entity whose primary purpose is providing education and/or health care services (e.g., a health department, public health agency, organized health care delivery system or hospital system.) Because this model treats direct GME costs as costs of education not patient care, adherents suggest that greater weight will be placed on educational needs as training decisions are made. In return for payment, the program sponsor (or its designees) would assume all (or substantially all) of the direct costs of operating the GME program. Allocation of GME costs and payments would be established through written agreements between the sponsor and clinical training.
sites. Because IME is a hospital cost, this model would not provide an adequate basis for IME payment.

The principle advantage of this approach is its focus on education. Unfortunately, it also would require a major shift in program accountability and funding, particularly when training occurs in community teaching hospitals rather than academic medical centers, where medical schools and hospitals are linked through common ownership or other longstanding corporate or strategic ties. This approach could also discourage hospitals from maintaining or starting GME programs.

As a variant to this model, vouchers could be given directly to residents so that they could purchase their own GME. Unlike the vouchers mentioned in conjunction with the provider model, these vouchers would permit residents to control funding for their graduate training, allowing monies to flow to all training sites. In theory, this approach would enhance competition among GME programs. It is not clear, however, how much effect it would have because programs already compete for residents and rotation sites.

Besides the disadvantages mentioned above, this approach would require a new regulatory mechanism for determining which residents qualify for funding and how many positions would be funded. It also fails to address national physician workforce needs or to assure that adequate resources are available in needed specialties and geographic areas. Implementing this approach could result in substantial year-to-year fluctuations in program size, undermining the stability of existing programs and making faculty and resource allocations difficult. Residents could also be hard pressed to hold their programs accountable once training decisions are made.

Planning Model
Under this approach, funding would be channeled through planning or coordinating bodies such as GME consortia, state GME, physician workforce commissions or task forces. The primary function of these bodies would be to assess the health care needs of their communities and to allocate funds based on local workforce considerations.

Because this approach ties training and funding decisions to local health care needs, it could provide the states, payers and consumers a stronger role in allocating funds to meet workforce objectives. According to the Council on Graduate Medical Education, however, existing evidence tends to suggest that reliance on consortia to assume such a role may be premature. Adopting this model would also require development of a new regulatory mechanism to assure accountability. Payment to state entities or consortia provides little incentive to nonteaching hospitals to initiate new GME programs.

Performance Model
This model links payment to the achievement of specific performance measures or objectives. Funding could also be used to support specific projects or demonstrations on infrastructure development or particular workforce goals.

While this approach encourages innovation and quality enhancement, it is more suitable as a supplemental funding mechanism than as a primary source of GME payment. This model is also dependent on well-defined quality measures and workforce priorities. Neither may be sufficiently well developed to support all GME funding decisions at this time. This approach could also result in substantial year-to-year fluctuation in payments if all funding decisions are based on meeting specific performance measures.

CONCLUSION
With federal and state budgets look to cut spending, GME programs are particularly vulnerable. AOA policy, “affirms its support for maintaining and enhancing the quality of teaching
programs.” As states address shortfalls in federal GME funding, the AOA encourages all viable models to be examined. While all-payor systems have proven effective in some states, each state is different and may require its own unique GME funding system. Additionally, as states and the federal government implement health insurance exchanges, we encourage the exploration of using a portion of any health plan surcharge to fund GME. This will help address concerns related to workforce shortages as the covered population grows.

The AOA supports states creation of alternative GME funding mechanisms and the alignment of this funding with their states health care priorities. Most important, within these priorities are training those specialties with the largest workforce shortages and providing care to those residents in the greatest needs (those in rural and underserved areas).

The AOA believes that state GME funding must account for osteopathic programs that incorporate the holistic approach to medicine, including the promotion of osteopathic principles and tenets.

The AOA believes that state GME funding should focus on programs that address comprehensive health care systems that deliver care through a variety of settings. This includes training residents in hospitals, rural clinics, community-based centers and patient-centered medical homes. These programs should also provide training in advancing technologies within the delivery of care.

The AOA believes that state GME funding should emphasize the importance of both basic and clinical research in an effort to advance the practice of medicine and the care patients receive.

The AOA supports the physician-led, team-based model of care. The AOA believes that state GME funding should promote this model of care by promoting interprofessional education, so that physicians can not only learn to lead the health care team, but also better understand the skills and abilities each member brings to that team.

Finally, this policy is intended to complement AOA Policy, H329-A/2016 Graduate Medical Education funding and incentives, and the AOA should continue to support the osteopathic community in its efforts to increase GME funding.

References
3. Id.
4. Id.

10. Id.


15. Henderson, supra.

16. Id.

17. Metzler, supra.


19. Id.

20. Id.

21. Id.


23. Id.

24. Henderson 2013, supra.

25. Id.

26. Id.

27. Id.

28. Id.


30. Id.


33. Id.

34. Id.

35. Id.

36. Id.


39. Id.
40. Id.
41. Id.
44. AOA Policy H319-A/15.

Source: H359-A/19

Status: 2019
Office Based Surgery

Policy Statement

The American Osteopathic Association approves the following Policy Statement on Office-Based Surgery.

OFFICE-BASED SURGERY

Background
A number of surgical procedures that were once only performed in hospitals or ambulatory surgery Centers (ASCS) can now be performed in a physician’s office. Of the 80 million outpatient surgeries performed in the US in 2009, the most recent year for which comprehensive data is available, it is estimated that over 12 million were performed in physicians’ offices. Proponents of office-based surgery assert that many procedures can be performed safely and effectively in a physician’s office due to advances in technology, anesthesia, and laparoscopic techniques. In addition, many argue that office-based surgery is easier to schedule and more comfortable for patients than surgery performed in a hospital. Perhaps most significant, however, is the reported cost savings for office-based surgery compared to surgery performed in a hospital. One study reported that the average cost of an Unicompartmental Knee Arthroplasty done in an office setting was an average of $20,500 less than the average charge of $46,845 for the same procedure in the hospital.

Despite these benefits, the practice of office-based surgery has been controversial due to the lack of established rules and regulations. At the beginning of the 21st century, the fact that most states did not regulate office-based surgery led some observers to compare it to the “Wild West.” As of 2014, 29 states had enacted rules, regulations or guidelines that specifically applied to office-based surgery. These regulations help to ensure that office-based surgery is conducted with appropriate equipment, adequately trained personnel and established patient safety standards. However, because this practice remains unregulated in many states, the concern that surgery performed in a physician’s office may not be as safe as surgery performed in a hospital or licensed ASC persists.

While the media has reported a number of stories of tragic outcomes following office-based surgery, the actual rate of morbidity and mortality following These procedures is hard to determine because adverse event reporting is required in less than half of all states.

According to a 2017 Florida report that compared risk-adjusted hospitalization rates following surgical procedures across physician offices, freestanding ASCS, and hospital outpatient departments in Florida, rates were generally higher for office-based procedures, especially more complex procedures.

Although office-based surgery may be appropriate for many surgical patients, proper attention must be given to patient safety in order to minimize adverse events.

Need for Office-Based Surgery Rule Development
States have taken different approaches to the regulation of office-based surgery. A number of state medical boards have adopted guidelines or rules for physicians to follow when performing office-based procedures. A position statement issued by the North Carolina medical board on this issue contains recommendations on physician credentialing, emergencies, performance
improvement, medical records, equipment and supplies, and personnel. Any failure to comply puts a physician at risk of disciplinary action by the board.⁷

In many states, office-based surgery centers are exempt from licensure requirements that apply to hospitals and ASCS because the procedures that they perform are considered to be relatively low-risk. Some states require centers to register with a state agency such as the department of health, while others do not require any general oversight, and surgical practitioners are regulated by state medical licensing boards in the normal course of their physician oversight duties.⁸

Classification of Office-Based Surgery
Office-based surgical procedures are usually classified based on the level of anesthesia used. Typically the procedures are classified into three groups: Level 1, 2, and 3 or Class A, B, and C.⁹ While not uniform, these classifications are often referred to by state medical boards and state legislators; therefore, understanding the different levels is an important basis for a discussion of office-based surgery. First, Level 1 surgical procedures are minor procedures performed under topical, local, or infiltration block anesthesia without preoperative sedation. Second, Level 2 surgical procedures are minor or major procedures performed in conjunction with oral, parenteral or intravenous sedation or under analgesic or dissociative drugs. Finally, Level 3 surgical procedures utilize general anesthesia or major conduction block anesthesia and require the support of bodily functions.¹⁰

Physicians and Staff in the Office-Based Surgical Facility
One of the reasons for the large number of adverse consequences associated with office-based surgery is the fact that many individuals, both physicians and non-physicians, performing office-based surgery lack the expertise to perform the surgery and administer the anesthesia in the first place. For example, a 2010 study found that nearly 40% of physicians offering liposuction in southern California had no specific surgical training.¹¹ Further, four deaths have been reported since 2013 at a single south Florida clinic where cosmetic surgery is performed by physicians who are not formally trained or board certified in plastic surgery.¹² While no single medical discipline has a monopoly on proper qualifications for performing office-based surgery, such incidents may spur state licensing boards to consider instituting licensure by specialty or board certification as opposed to an unlimited scope of practice.

Equipment Required
Equipment used in office-based surgery must be kept in excellent working condition and replaced as necessary. The type of monitoring equipment required in office-based settings depends on the type of anesthesia used and individual patient needs. However, every facility must have emergency supplies immediately available, including emergency drugs and equipment appropriate for cardiopulmonary resuscitation. This includes a defibrillator, difficult airway equipment, and drugs and equipment necessary for the treatment of malignant hyperthermia.

Transfer Agreement
Emergencies occasionally arise during surgery requiring patients to receive a level of care higher than that available in the office-based setting. Provisions must be in place to provide this care in a comprehensively outfitted and staffed facility located nearby should it be needed.

Adverse Incident Reporting
Adverse events that may occur in office-based surgical facilities include patient deaths, cardio-respiratory events, anaphylaxis or adverse drug reactions, infections, and bleeding episodes. Reporting of adverse incidents to an appropriate state entity is an important patient safety measure.
**Regulation of Office-Based Surgery**

Unlike hospitals and ambulatory surgery centers, not all office-based surgical facilities are subject to regulations on emergencies, fire, sanitation, drugs, staff, training, and unanticipated patient transfers. Common sense dictates that states should take steps to ensure that patients who undergo surgery in physicians’ offices receive the same standard of care as patients in ambulatory surgery centers or hospitals.

**Conclusion**

The practice of office-based surgery will likely continue to grow in the coming years. The following statements represent the AOA’s position on the appropriate use of office-based surgery:

The AOA firmly believes that steps must be taken to ensure that office-based surgery is as safe for patients as hospital- or ambulatory care center-based surgery;

The AOA supports state licensing boards in surveying their licensees or researching the issue of office-based surgery regulation to determine if office-based surgery rule development is necessary;

The AOA believes that Level 1 and Level 2 procedures are acceptable to be performed in an office-based setting. However, Level 3 procedures should only be performed in an office setting that has been accredited by an accreditation organization such as the Joint Commission, the American Association for Accreditation of Ambulatory Surgery Facilities (AAAASF), the Accreditation Association for Ambulatory Health Care (AAAHC) or the AAAHC’S healthcare facilities accreditation program;

The AOA believes that surgery performed in a physician’s office must be done by a physician or non-physician clinician qualified by education and training to perform that specific procedure with appropriate physician oversight;

The AOA believes that only health care providers who have completed the appropriate education and training should perform office surgical procedures;

The AOA believes that a physician must administer the anesthesia or if a non-physician clinician administers the anesthesia, a supervising physician must be physically present in the office-based surgical facility during the administration of anesthesia and remain physically available until the patient has fully recovered and has been discharged from anesthesia care. In case of an emergency, personnel with training in advanced resuscitative techniques should be immediately available until the patient is discharged;

The AOA believes office-based surgical facilities must have the appropriate medications, equipment, and monitors necessary to perform the surgery and administer the anesthesia in a safe manner. The equipment and monitors must be maintained, tested, and inspected according to the manufacturer’s specifications;

The AOA believes physicians and non-physician clinicians who perform office-based surgery shall be responsible for coordinating and ensuring appropriate care for patients who require emergent, unexpected postoperative transfer and/or hospitalization. Written protocols must be in place for timely transfer to an accredited hospital located within reasonable proximity to the office. Office personnel must be appropriately trained in emergency protocols in order to be able to respond when emergency or extended services are needed to protect the health or well-being of the patients;

The AOA supports reporting of adverse incidents related to surgical procedures performed in an office setting to a state entity, as required and appropriate, provided that these disclosures will be considered confidential and protected from discovery or disclosure; and
The AOA supports the position that state medical licensing boards are the appropriate entity to create and implement regulations regarding office-based surgery.


5 Id.


Source: H360-A/19

Status: 2008; 2013 Reaffirmed as Amended; 2018 Reaffirmed; 2019 Reaffirmed
Uniform Pathway of Licensing of Osteopathic Physicians

Policy Statement

The American Osteopathic Association states that the examination of the National Board of Osteopathic Medical Examiners must remain as the avenue for the licensure of osteopathic physicians and supports a uniform pathway of licensing osteopathic physicians through the mechanisms of the National Board of Osteopathic Medical Examiners, to be effective after 12/31/19.

Source: H361-A/19

Status: 1991; 1993 Reaffirmed as Amended; 1998 Reaffirmed; 2003 Reaffirmed; 2008 Reaffirmed; 2013 Reaffirmed as Amended; 2019 Reaffirmed as Amended
Safe Haven Non-Reporting Protection for Physicians – Support for Policy Statement

The following policy paper and recommendations be adopted as the American Osteopathic Association’s (AOA) position on safe haven non-reporting protections for physicians and medical students; and that upon approval of safe haven non-reporting as organizational policy, the AOA’s Bureau of State Government Affairs will be tasked with developing a model act for consideration by the 2020 AOA House of Delegates.

AOA POLICY PAPER: SAFE HAVEN NON-REPORTING PROTECTIONS FOR PHYSICIANS

BACKGROUND

Burnout among US medical students, residents and practicing physicians is a significant problem that negatively impacts medical professionals as well as the patients that they serve. Physicians in the US report symptoms of burnout at nearly double the rate of other US workers after controlling for work hours and other factors, and between 2011 and 2014, this percentage increased by 9%. Further, twenty to forty percent of medical students, interns and residents report experiencing symptoms of burnout.

Burnout is characterized by a “wide array of signs, symptoms and related conditions, including fatigue, loss of empathy, detachment, depression and suicidal ideation.” It has also been shown to negatively impact a physician’s prescribing habits, test ordering, risk of malpractice suits, and whether patients adhere to their recommendations. Although the aforementioned description does not explicitly reference substance use disorders, we will hereafter reference symptoms of burnout, mental health and substance use issues (and their treatment) interchangeably.

Even when resources are available to help physicians and students address symptoms of burnout; however, both groups report similar concerns about pursuing them. For purposes of this policy paper, we will focus on concerns regarding lack of confidentiality and possible disciplinary or discriminatory action by schools, employers, state medical licensing boards and other academic or professional entities.

REPORT OF THE FSMB WORKGROUP ON PHYSICIAN WELLNESS AND BURNOUT

The Federation of State Medical Boards (FSMB) convened a Workgroup on Physician Wellness and Burnout (Workgroup) to study the issue of physician burnout and draft recommendations to help groups in the medical community better address this issue. The Workgroup found that although numerous resources exist to help medical students and physicians experiencing symptoms of burnout or impairment through academic institutions, medical licensing boards and state physician health programs, social and professional pressures make students and physicians reluctant to seek treatment or to report seeking it. Both medical students and physicians cited fears that seeking help would result in documentation on academic or
professional records which could lead to discrimination or denial of a medical license, and ultimately jeopardize their ability to practice medicine.

According to a poll conducted by the FSMB and the Medical Society of the State of New York, a state that does not currently include any questions about mental health or substance use on medical licensure applications, sixty-nine percent of physician respondents who were experiencing symptoms of burnout reported that they would be significantly less likely to seek treatment if they were required to report it on a licensing application or renewal.6

Further, despite evidence showing that a past history of mental health or substance use disorders does not reliably predict future risk to the public, most state licensing applications still contain questions about applicants’ histories with these issues. As of 2017, 43 states asked questions about both mental and physical health conditions on their medical licensing applications, but just 23 limited all questions to disorders causing functional impairment and only six limited them to current problems.7

Although a similar number of medical licensing boards asked about both mental and physical health, questions about the latter tended to be much more lenient and vague while questions about the former were much more specific and probing.8 Boards were significantly more likely to ask if physicians had ever been diagnosed, treated or hospitalized for a mental health or substance use disorder than for a physical disorder, and unlike questions about physical disorders, the questions were not limited to just those conditions that might currently affect a physician’s ability to practice.

Responses by medical licensing boards to disclosures made by physicians about their mental health were also unpredictable and varied greatly from state to state. Some boards asked for a doctor’s note, others requested all medical records related to an applicant’s history and treatment, others required applicants to appear before the board to defend their ability to practice medicine and still others required applicants to undergo ongoing monitoring or practice under a restricted license.

In addition to the deterrent effect that questions from medical licensing boards regarding mental health appear to have on physicians’ willingness to seek help when needed or report seeking it, courts have found that many such questions run afoul of the Americans with Disabilities Act (ADA). The ADA protects individuals with disabilities, including psychiatric disabilities, from discrimination. Professional licensing bodies are not exempt from the requirements of the ADA, and courts have stated that “[public entities] may not administer a licensing or certification program in a manner that subjects qualified individuals with disability to discrimination on the basis of disability.”6 Public entities such as a medical licensing board also may not “impose or apply eligibility criteria that screen out or tend to screen out an individual with a disability … unless such criteria can be shown to be necessary for the provision of the service, program, or activity being offered.”5

In order to encourage medical students and physicians to seek appropriate treatment for mental health and substance use disorders, and ensure that medical licensing boards comply with the ADA, the FSMB encourages medical licensing boards to adopt policies that support physician “safe haven non-reporting.”

“Safe haven non-reporting” allows physicians who are receiving appropriate treatment for mental health or substance use issues who are monitored and in good standing with their confidential treatment program to (re)apply for licensure without having to disclose their treatment to the board. Only disclosures related to issues that are not being appropriately treated and could inhibit a physician’s ability to safely practice medicine would be required.

RECOMMENDATIONS

The AOA adopts the following statements as its official position on “safe haven non-reporting:”

The presence or history of a mental health or substance use disorder does not automatically render a physician unfit to practice medicine, and the AOA opposes discrimination or disciplinary action against a physician or medical student based solely on the presence of such a disorder, without taking into consideration the individual’s behavior or treatment.

The AOA urges state medical licensing boards to regard physical and mental health disorders similarly and refrain from asking about past history of mental health or substance use diagnoses or treatment on licensure applications or renewals. Instead, the AOA encourages boards to focus on whether any current physical or mental disorders are present which may impair that individual’s ability to safely practice medicine. The AOA further encourages state medical licensing boards to offer a “safe haven non-reporting” option for physician applicants who are undergoing appropriate treatment for current mental health or substance use disorders. This alternative helps to ensure confidentiality of such treatment for the individual physician while ensuring patient safety.

If medical licensing boards decide to use questions related to mental health or substance use disorders on a medical licensure application or renewal, the AOA encourages boards to consider phrasing them similarly to questions about physical health. For example:

“Are you currently suffering from any condition for which you are not being appropriately treated that impairs your judgment or that would otherwise adversely affect your ability to practice medicine in a competent, ethical and professional manner? (Yes/No)”

“Appropriate treatment” includes physician participation provided through state physician health programs accredited by the Federation of State Physician Health Programs, or programs following similar standards and guidelines, and adherence to treatment recommendations.

Finally, the AOA encourages medical educational and professional entities, as well organizations throughout the medical community, to support and educate students and physicians about confidential treatment and “safe haven non-reporting” options, in order to encourage these individuals to seek appropriate treatment without fear of documentation, disciplinary action or other repercussions.

References
2. Lapinski, et al. "


5. *Id* at 3.

6. *Id* at 3.


Source: H362-A/19

Status: 2019
Retail-Based Health Clinics and Urgent Care Centers

Policy Statement

The American Osteopathic Association recommends that retail-based health clinics and urgent care centers adhere to the following principles and standards to guide their establishment and operation.

1. Retail-based health clinics and urgent care centers must establish arrangements by which their health care practitioners have direct access to and supervision by physicians at levels that meet or exceed respective state laws.

2. Retail-based health clinics and urgent care centers must encourage patients to establish care with a primary care physician to ensure continuity of care. If a patient’s conditions or symptoms are beyond the scope of services provided by the clinic, that patient must immediately be referred to an appropriate physician or emergency facility. Also, retail-based health clinics urgent care centers should be encouraged to use electronic health records as a means of communicating information with the patient’s primary physician and facilitating continuity of care.

3. Whether by electronic communication, or some other acceptable means, retail-based health clinics urgent care centers must send detailed information on services provided to the patient’s primary care physician in a timely manner to ensure continuity of care.

4. The clinic must have a well-defined and limited scope of clinical services. These services must not exceed the on-site health provider’s scope of practice, as determined by state law.

5. Retail-based health clinics and urgent care centers must use standardized medical protocols developed from evidence-based practice guidelines for non-physician practitioners.

6. Retail-based healthcare clinics and urgent care centers must comply with all applicable standards of state and federal regulations expected of physician offices.

7. Retail-based healthcare clinics and urgent care centers must not expand into programs offering patient care for the management of chronic and complex conditions.

Retail-based healthcare clinics located in or affiliated with a pharmacy must inform patients that any medication prescribed or recommended may be purchased at the patient’s pharmacy of choice.

Source: H301-A/20

Status: 2006; 2011 Reaffirmed as Amended; 2015 Revised; 2020 Reaffirmed as Amended
Protecting American Students from Profit-Driven Foreign Medical Schools

Policy Statement

The American Osteopathic Association (AOA) will officially adopt and advocate for the position that federal student loans shall be restricted from medical schools not subject to the accreditation standards of the Commission on Osteopathic College Accreditation or the Liaison Committee on Medical Education.

Source: H302-A/20

Status: 2015; 2020 Reaffirmed
Tax Credit for Precepting

Policy Statement

The American Osteopathic Association (AOA) will support legislation to implement precepting tax credits.

Source: H305-A/20

Status: 2015; 2020 Reaffirmed as Amended
The American Osteopathic Association (AOA) supports that payments from all payers should reflect the resources required to provide patient care in each setting.

The AOA supports that payments for all sites of care should account for costs incurred in that setting and should take into account the nature of the patient population served by each type of provider and other factors, such as, but not limited to, the provision of care coordination, access to after-hours care, emergency care, quality activities, and regulatory compliance costs.

The AOA supports that efforts should be made to collect comprehensive and reliable data regarding the extent of actual cost differences among sites of service, the impact of current site of service differentials on patient access; the extent to which recent site of service shifts are attributable to payment differentials; and the potential impact of the elimination or reduction of such differentials on providers’ ability to cover their reasonable costs.

The AOA supports that pending collection of such data, private and public payers should avoid reductions in payment that create or aggravate existing site of service differentials for services that are demonstrably similar in terms of nature, scope, and patient population.

The AOA supports that Medicare patients should be provided access to data regarding differences in copayment requirements among various sites of service.

Source: H306-A/20

Status: 2015; 2020 Reaffirmed as Amended
Practice Rights of Osteopathic Physicians

Policy Statement

The American Osteopathic Association (AOA) and its component societies are encouraged to support osteopathic physicians and their practices by:

(1) working with the American Osteopathic Information Association to educate physicians as to the importance of compliance, risk management, and risk agreements with managed care, billing and coding, documentation, and fraud and abuse issues.

(2) Identifying supportive state and federal agencies, professional liability insurance companies, and physicians with expertise on these issues.

(3) Encouraging government agencies and insurance companies to utilize only expert witnesses who are osteopathic physicians in peer review, fraud and abuse, civil and criminal cases involving osteopathic physicians and boards with “like osteopathic specialty”.

(4) AOA and state society leadership of any needs, trends, or issues of concern related to the above, which will enhance the rights and practices of our fellow osteopathic physicians.

Source: H308-A/20

Status: 1999; 2004 Reaffirmed as Amended; 2009 Reaffirmed as Amended; 2015 Reaffirmed; 2020 Reaffirmed as Amended
Retail Medical Clinics in Facilities Selling Tobacco, Nicotine or Vaping Products

Policy Statement

The American Osteopathic Association (AOA) discourages the placement of medical practices and limited-service clinics in retail settings that promote and sell tobacco because it is contrary to the efforts and standards of the health care community at large.

Source: H309-A/20

Status: 2010; 2015 Reaffirmed as Amended; 2020 Reaffirmed as Amended
Osteopath and Osteopathy - Use of the Term

Policy Statement

The American Osteopathic Association (AOA) policy both officially in our publications and individually on a conversational basis, is to preferentially use the term “osteopathic physician” in place of the word “osteopath” and the term “osteopathic medicine” in place of the word “osteopathy;” and that the words “osteopath” and “osteopathy” be reserved in the United States for the following purposes:

(1) previously named entities within the osteopathic medical profession;
(2) historical, sentimental, and informal discussions; and
(3) osteopaths with a limited scope of practice.

Source: H310-A/20

Status: 1994; 2000 Reaffirmed; 2005 Reaffirmed as Amended; 2010 Reaffirmed as Amended; 2015 Reaffirmed as Amended; 2020 Reaffirmed
Physician Office Laboratories

Policy Statement

The American Osteopathic Association supports the development and expansion of Waived Physician Office Laboratory testing and will work to ensure that physician office laboratory certification be as non-intrusive into the practice of medicine as possible; and will seek assurances that access to any laboratory tests deemed medically necessary by the physician, not be limited by unnecessary regulations.

Source: H312-A/20

Status: 1990; 1995 Reaffirmed as Amended; 2000 Reaffirmed, 2005 Reaffirmed; 2010 Reaffirmed; 2015 Reaffirmed as Amended; 2020 Reaffirmed
Postgraduate Compensation

Policy Statement

The American Osteopathic Association (AOA) supports the development and expansion of Waived Physician Office Laboratory testing and will work to ensure that physician office laboratory certification be as non-intrusive into the practice of medicine as possible; and will seek assurances that access to any laboratory tests deemed medically necessary by the physician, not be limited by unnecessary regulations.

Source: H313-A/20

Status: 1990; 1995 Reaffirmed as Amended; 2000 Reaffirmed, 2005 Reaffirmed as Amended; 2010 Reaffirmed; 2015; 2020 Reaffirmed as Amended
Second Opinion, Surgical Cases

Policy Statement

The American Osteopathic Association (AOA) believes that AOA members who are board certified, or board eligible and qualified by their training and experience to render a second surgical opinion in any given case, be recognized and utilized as qualified and reimbursed by entities underwriting such opinions and that this policy statement in no way advocates the institution of any mandatory second surgical opinion programs, by any entity.

Source: H314-A/20

Status: 1980; 1985 Reaffirmed as Amended; 1990 Reaffirmed; 1995 Reaffirmed; 2000 Reaffirmed as Amended; 2005 Reaffirmed as Amended; 2010 Reaffirmed as Amended; 2015 Reaffirmed as Amended; 2020 Reaffirmed
Uniformed Services: Endorsement of Physicians Serving in the Uniformed Services

Policy Statement

The American Osteopathic Association (AOA) will continue to assist the Surgeons General of the uniformed services and the American public in maintaining and assuring the highest quality of healthcare by its representatives in the uniformed services and recognizes the annual anniversary of osteopathic physicians being commissioned in the military.

Source: H315-A/20

Status: 1985; 1990 Reaffirmed as Amended; 1995 Reaffirmed; 2000 Reaffirmed; 2005 Reaffirmed; 2010 Revised; 2015 Revised; 2020 Reaffirmed as Amended
Emergency Medical Services for Children - Support of

Policy Statement

The American Osteopathic Association (AOA) supports the availability to state of the art emergency medical care for ill and injured children and adolescents; that pediatric services are well integrated into an emergency medical service system backed by optimal resources; and the entire spectrum of emergency services, including primary prevention of illness and injury, acute care, and rehabilitation, are provided to children and adolescents as well as adults, no matter where they live, attend school or travel. The federal Emergency Medical Services for Children (EMSC) program achieves these goals and as such, AOA supports full funding and reauthorization of this program when needed.

Source: H316-A/20

Status: 2005, 2010 Reaffirmed; 2015 Reaffirmed as Amended; 2020 Reaffirmed as Amended
Physician Incentives to Underserved Areas

Policy Statement

The American Osteopathic Association (AOA) will support federal and state legislation to increase physician loan repayment programs and tax deductions/credits for individuals who practice in underserved rural and urban areas.

Source: H317-A/20

Status: 2005; 2010 Reaffirmed; 2015 Reaffirmed; 2020 Reaffirmed
Medicare Balance Billing

Policy Statement

The American Osteopathic Association (AOA) supports enactment of federal legislation that promotes equitable balance billing practices within Medicare that facilitate continued physician participation in Medicare.

Source: H319-A/20

Status: 2010; 2015 Reaffirmed; 2020 Reaffirmed as Amended
Prescription Drug Diversion and Abuse – Education, Research, and Advocacy

Policy Statement

The American Osteopathic Association (AOA) will advance knowledge and understanding of appropriate use of prescription drugs through the education of the public and osteopathic medical education at all levels.

The AOA will work with other associations representing health care professionals to educate on the indicators of potential prescription drug abuse, misuse and diversion. The AOA will encourage the Institute of Medicine and other private and public organizations/agencies to conduct further research into development of reliable outcome indicators for assessing the effectiveness of measures proposed to reduce prescription drug abuse, misuse and diversion.

The AOA will advocate for evidence-informed use of state prescription monitoring programs, tamper resistant drug formulas and support efforts to assist state osteopathic medical associations in developing physician drug abuse, misuse and diversion awareness and prevention education programs.

The AOA supports policies that do not hinder patient access to and coverage of appropriate pharmacologic and non-pharmacologic treatments. It is a right of all patients to have access to medically appropriate intervention and/or treatment for conditions, including acute and chronic pain. It is the right of all physicians, to provide medically appropriate intervention and treatment modalities that will achieve safe and effective treatment, including pain control, for all their patients.

The AOA will not support any program which limits access to prescription drugs for patients with legitimate need and will not support any program which reduces the provider’s ability to inform the patient’s care. In addition, it is in the best interest of all patients not to confine, or seek to regulate medications, including opioid/opiate, by limiting their use to a small number of selected specialties of medicine. This would also extend to modalities now developed, or yet to be developed, such as long-acting opioid/opiate preparations. These exclusionary strategies will limit access for patients with medical indications for therapy, complicate delivery of care, and add to pain and suffering of patients.

The AOA will continue to cooperate with the pharmaceutical industry, law enforcement, and government agencies to stop prescription drug abuse, misuse and diversion as a threat to the health and well-being of the American public.

The AOA opposes the imposition of administrative or financial deterrents that decrease access to and coverage of prescription drugs with abuse-deterrent properties.

Source: H322-A/20

Status: 2015; 2020 Reaffirmed
Buprenorphine Maintenance Treatment Insurance Coverage

Policy Statement

The American Osteopathic Association (AOA) recommends that state Medicaid administrators remove any arbitrary and restrictive limits for buprenorphine coverage and that state Medicaid administrators and third-party payers recognize that chronic disease management includes a combination of psychotherapeutic and pharmacological interventions that will yield the best outcomes for patients with opioid use disorder.

Source: H323-A/20

Status: 2015; 2020 Reaffirmed
Violence Against Healthcare Staff

Policy Statement

The American Osteopathic Association (AOA) supports legislation to hold patients and their associates (that includes friends, family, and anyone who accompanies them) accountable for physical assault and verbal threats to health care staff by upgrading penalties under federal and relevant state law and legislation from misdemeanors to felonies where applicable.

Source: H324-A/20

Status: 2015; 2020 Reaffirmed as Amended
Low Back Pain Clinical Practice Guidelines - Revision of Policy Statement

The American Osteopathic Association (AOA) approves the attached Guidelines for Patients with Low Back Pain.

American Osteopathic Association Guidelines for Osteopathic Manipulative Treatment (OMT) for Patients with Low Back Pain

Executive Summary:
The American Osteopathic Association recommends that osteopathic physicians use Osteopathic manipulative treatment (OMT) in the care of patients with low back pain. Evidence from systematic reviews and meta-analyses of randomized clinical trials (Evidence Level 1a) supports this recommendation.

1. Overview material: Provide a structured abstract that includes the guideline’s release date, status (original, revised, updated), and print and electronic sources.

The current guidelines are available through the AOA web site and National Guidelines Clearinghouse, AHRQ. The guideline is partially based upon the following study:


The format used for this guideline is in accordance with the 2013 (Revised) Criteria for Inclusion of Clinical Practice Guidelines in NGC and uses the 2011 definition of clinical practice guideline developed by the Institute of Medicine (IOM): “Clinical practice guidelines are statements that include recommendations intended to optimize patient care that are informed by a systematic review of evidence and an assessment of the benefits and harms of alternative care options”.

ABSTRACT

Background
Osteopathic manipulative treatment (OMT) is a distinctive modality commonly used by osteopathic physicians to complement conventional treatment of musculoskeletal disorders, including those that cause low back pain. OMT is defined in the Glossary of Osteopathic Terminology as: “The therapeutic application of manually guided forces by an osteopathic physician (US Usage) to improve physiologic function and/or support homeostasis that has been altered by somatic dysfunction. OMT employs a variety of techniques” (see Appendix 1 for list). Somatic dysfunction is defined as: “Impaired or altered function of related components of the somatic (body framework) system: skeletal, artrodial and myofascial structures, and their related vascular, lymphatic, and neural elements. Somatic dysfunction is treatable using osteopathic manipulative treatment.”
This guideline updates the AOA guideline for osteopathic physicians to utilize OMT for patients with nonspecific acute or chronic LBP published in 2010 on the National Guideline Clearinghouse.¹

Methods
This guideline update process commenced with literature searches that included electronic databases, personal contact with key researchers of OMT and low back pain, and internet search engines. Early in the process, the AOA discovered the systematic literature review conducted by Franke, Franke and Fryer (2014)² which serves as the basis for this updated guideline.

Franke et al searched electronic databases, reference lists and personal communications. Their inclusion criteria consisted of randomized clinical trials of adults (>18 years of age) with nonspecific back pain treated by osteopathic physicians or osteopaths who used their clinical judgment as opposed to a standard predetermined protocol. Studies with pregnant and postpartum participants were also included. Studies excluded from the review were those where co-interventions were not performed on both comparison groups; the OMT intervention could not be assigned an effect size; participants had specific back pain from pathology (i.e., fracture, tumor, metastasis, inflammation, infection); or the intervention consisted of a single manual technique (see Appendix 2 for the list of references in Franke et al).

The primary outcomes for the Franke et al review were pain and functional status. The authors measured pain using the visual analogue scale (VAS), number rating scale (NRS), or the McGill Pain Questionnaire. Functional status was measured using the Roland-Morris Disability Questionnaire, Oswestry- Disability Index, or other valid instrument. The point of measurement for both outcomes was the first 3 month interval.

Studies were independently reviewed using a standardized form. The mean difference (MD) or standard mean difference (SMD) with 95% confidence intervals (CIs) and overall effect size were calculated at 3 months post treatment. GRADE approach, as recommended by the updated Cochrane Back Review Group method guidelines, was used to assess quality of evidence.

Results
The authors of the systematic review identified 307 studies. Thirty-one were evaluated and 16 excluded. Of the 15 studies included in the review, 6 were retrieved from the grey literature in Germany, 5 from the United States, 2 from the United Kingdom, and 2 from Italy. Ten studies investigated effectiveness of OMT for nonspecific LBP, 3 studies examined the effect of OMT for LBP in pregnant women, and 2 studied the effect of OMT for LBP in postpartum women. All studies reported on the effect of OMT on pain, and all but one reported on back pain specific functional status. There were a total of 1502 participants included in the qualitative and quantitative analysis.

OMT significantly reduces pain and improves functional status in patients, including pregnant and postpartum women, with nonspecific acute and chronic LBP. Franke et al found that in acute and chronic non-specific LBP, moderate-quality evidence suggested OMT had a significant effect on pain relief (MD: -12.91, 95% CI: -20.00 to -5.82) and functional status (SMD: -0.36, 95%CI: -0.58 to -0.14). More specifically, in chronic nonspecific LBP, evidence suggested a significant difference in favor of OMT regarding pain (MD: -14.93, 95%CI: -25.18 to -4.68) and functional status (SMD: -0.32, CI: -0.58 to -0.07). When examining nonspecific LBP in pregnancy, low-quality evidence suggested a significant difference in favor of OMT for pain (MD, -23.01; 95% CI, -44.13 to -1.88) and functional status (SMD, -0.80; 95% CI, -1.36 to -0.23). Conversely for nonspecific LBP postpartum, Franke et al found that moderate-quality
evidence suggested a significant difference in favor of OMT for pain (MD, -41.85; 95% CI, -49.43 to -34.27) and functional status (SMD, -1.78; 95% CI, -2.21 to -1.35).

Conclusions
Clinically relevant effects of OMT were found for reducing pain and improving functional status in patients with acute and chronic nonspecific LBP and for LBP in pregnant and postpartum women at 3 months post treatment.

OMT significantly reduces low back pain. The level of pain reduction is clinically important, greater than expected from placebo effects alone, and may persist through the first year of treatment. Additional research is warranted to elucidate mechanistically how OMT exerts its effects, to determine if OMT benefits extend beyond the first year of treatment, and to assess the cost-effectiveness of OMT as a complementary treatment for low back pain.

2. Focus: Describe the primary disease/condition and intervention/service/technology that the guideline addresses. Indicate any alternative preventive, diagnostic or therapeutic interventions that were considered during development.

These guidelines are intended to assist osteopathic physicians in appropriate utilization of OMT for patients with low back pain. Other alternative preventive, diagnostic and therapeutic interventions considered during development of these guidelines were those noted in the following published guidelines for physicians caring for patients with low back pain:


BACKGROUND
Historically, low back pain has been the most common reason for visits to osteopathic physicians. More recent data from the Osteopathic Survey of Health Care in America has confirmed that a majority of patients visiting osteopathic physicians continue to seek treatment for musculoskeletal conditions. A distinctive element of low back care provided by osteopathic physicians is osteopathic manipulative treatment (OMT). A comprehensive evaluation of spinal manipulation for low back pain undertaken by the Agency for Health Care Policy and Research in the United States concluded that spinal manipulation can be helpful for patients with acute low back problems without radiculopathy when used within the first month of symptoms. Nevertheless, because most studies of spinal manipulation involve chiropractic or physical therapy, it is unclear if such studies adequately reflect the efficacy of OMT for low back pain. Although the professional bodies that represent osteopaths, chiropractors, and physiotherapists in the United Kingdom developed a spinal manipulation package consisting of three common manual elements for the UK Back pain Exercise and Manipulation (UK BEAM) trial, there are no data on the comparability of profession specific outcomes. It is well known that OMT comprises a diversity of techniques. These OMT techniques are not adequately represented by the UK BEAM trial package. Professional differences in spinal manipulation are more pronounced in research studies, in which chiropractors have focused almost exclusively on high-velocity-low amplitude techniques. For example, a major trial of chiropractic manipulation as adjunctive treatment for childhood asthma used a high-velocity-low amplitude thrust as the active treatment. The simulated treatment provided in the sham manipulation arm of this chiropractic trial, which ostensibly was used to provide no therapeutic effect, bore a marked similarity to OMT. Because differences in professional background and training...
lend themselves to diverse manipulation approaches, clinicians have been warned about generalizing the findings of systematic reviews to practice.\textsuperscript{15} In addition to professional differences in the manual techniques themselves, osteopathic physicians in the United States, unlike allopathic physicians or chiropractors, can treat this condition simultaneously using both conventional primary care approaches and complementary spinal manipulation. This represents a unique philosophical approach in the treatment of low back pain. Consequently, there is a need for empirical data that specifically address the efficacy of OMT for conditions such as low back pain.\textsuperscript{16}

These guidelines are based on a systematic review of the literature on OMT for patients with low back pain and a meta-analysis of all randomized controlled trials of OMT for patients with low back pain in ambulatory settings.\textsuperscript{2}

3. Goal: Describe the goal that following the guideline is expected to achieve, including the rationale for development of a guideline on this topic.

The goal of these guidelines is to enable osteopathic physicians as well as other physicians, other health professionals, and third party payers, to understand the evidence underlying recommendations for appropriate utilization of OMT, which is not detailed in the current sets of guidelines developed by other physicians. The American Osteopathic Association does not believe it is appropriate for other professionals to create guidelines for utilization of OMT since it is not a procedure or approach used by those physicians. It is, however, the purview and duty of the American Osteopathic Association to inform its members and the public about the appropriate utilization of OMT.

4. Users/setting: Describe the intended users of the guideline (e.g., provider types, patients) and the settings in which the guideline is intended to be used.

These guidelines are to be used by osteopathic physicians in application of OMT to patients with nonspecific low back pain, which can be defined as tension, soreness, or stiffness in the lower back region with an unidentified cause\textsuperscript{2}, in the ambulatory setting.

5. Target population: Describe the patient population eligible for guideline recommendations and list any exclusion criteria.

Patients with nonspecific low back pain of musculoskeletal origin are eligible for guideline recommendations. Patients with visceral disease conditions that refer pain to the low back are excluded from these guidelines. Other conditions of exclusion are when the following are the identified source of the low back pain: vertebral fracture; vertebral joint dislocation; muscle tears or lacerations; spinal or vertebral joint ligament rupture; inflammation of intervertebral discs, spinal zygapophyseal facets joints, muscles or fascia; skin lacerations; sacroiliitis; ankylosing spondylitis; or masses in or from the low back structures that are the source of the pain. Exclusion from this guideline does not imply that OMT is contraindicated in these conditions.

6. Developer: Identify the organization(s) responsible for guideline development and the names/credentials/potential conflicts of interest of individuals involved in the guideline’s development.


7. Funding source/sponsor: Identify the funding source/sponsor and describe its role in developing and/or reporting the guideline. Disclose potential conflict of interest.

This project was funded by the American Osteopathic Association. The AOA Bureau of Osteopathic Clinical Education and Research convened a Task Force on the Low Back Pain
Clinical Practice Guidelines to revise the guidelines. Upon approval of these recommendations by the AOA Board of Trustees and the AOA House of Delegates, the guidelines will be submitted to the National Guidelines Clearinghouse for public record and access. As the guidelines were developed based on the peer reviewed scientific literature, no conflict of interest is claimed by the developers. A well rounded, objective perspective is presented. Any views from an osteopathic perspective that is not supported by the scientific literature is stated and clearly identified so the reader is able to discern any potential for bias.

8. Evidence collection: Describe the methods used to search the scientific literature, including the range of dates and databases searched, and criteria applied to filter the retrieved evidence.

This guideline update process commenced with literature searches that included electronic databases, personal contact with key researchers of OMT and low back pain, and internet search engines. Early in the process, the AOA discovered the systematic literature review conducted by Franke, Franke and Fryer (2014) which serves as the basis for this updated guideline.

Franke et al\textsuperscript{2} searched electronic reference databases, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, CINAHL, PEDro, OSTMED.DR, and Osteopathic Web Research using the following search terms: low back pain, back pain, lumbopelvic pain, dorsalgia, osteopathic manipulative treatment, OMT, and osteopathic medicine. In addition to the listed databases, the authors conducted searches in an ongoing trial database (metaRegister of Controlled Trials). To enhance their search, the authors tracked citations of identified trials, and manually searched reference lists for other relevant papers.

The authors reviewed all the studies using a standardized form, and all mean differences (MD) and standard mean differences (SMD) were calculated with 95% confidence intervals (CIs). Overall effect size was calculated at the 3-month post treatment follow-up. GRADE approach, as recommended by the updated Cochrane Back Review Group method guidelines, was used to assess quality of evidence.

9. Recommendation grading criteria: Describe the criteria used to rate the quality of evidence that supports the recommendations and the system for describing the strength of the recommendations. Recommendation strength communicates the importance of adherence to a recommendation and is based on both the quality of the evidence and the magnitude of anticipated benefits or harms.

Franke et al\textsuperscript{2} evaluated the methodological quality of the studies using the Risk of Bias tool of the Cochrane Back Review Group. Studies were scored as ‘low risk’, ‘high risk’, or ‘unclear’, and included assessments of randomization, blinding, baseline comparability between groups, patient compliance, and dropping out. Per the Cochrane Back Review Group, studies received a ‘low risk’ score when a minimum of 6 criteria were met and it was determined that the study had no serious flaws (e.g., a drop-out rate over 50%). Disagreements about the quality of the studies were resolved through discussion and consensus. Franke et al used Review Manager to analyze the data for the meta-analysis. The authors converted the NRS and VAS scores from the included studies to a 100-point scale for the pain measurement, and calculated the mean difference (MD) with 95% CIs for the random effects model.

Franke et al conducted other noteworthy analysis. They used the standard mean difference (SMD) was also used in a random effects model to determine functional status. The authors grouped the 1 study examining acute LBP and the 3 studies examining patients with both acute and chronic LBP together for the purpose of their meta-analyses. Overall, they created four groups: (1) acute and chronic LBP; (2) chronic LBP (duration of pain more than 3 months); (3) LBP in pregnant women; and (4) LBP in postpartum women.
Franke et al also assessed the clinical relevance of each study using the Cochrane Back Review Group recommendations. A small effect was defined as MD less than 10% of the scale and SMD less than 0.5. A medium effect was defined as MD 10% to 20% of the scale and SMD from 0.5 to 0.8. A large effect was defined as MD greater than 20% of the scale and SMD greater than 0.8.

10. Method for synthesizing evidence: Describe how evidence was used to create recommendations, e.g., evidence tables, meta-analysis, decision analysis.

Due to the applicability of the Franke et al review to this updated guideline and consequently, the reliance thereon, the AOA will describe how the authors synthesized their evidence.

**OMT versus other interventions for acute and chronic nonspecific low back pain**

Franke et al² analyzed the effect of OMT for pain in acute and chronic LBP using ten studies with 12 comparison groups and 1141 participants. Six studies reported a significant effect of OMT on pain, 3 studies showed a non-significant effect, and 3 studies reported a non-significant effect in favor of the control treatment. Collectively, the studies showed moderate-quality evidence that OMT had a significant effect on pain relief (MD:-12.91, 95% CI: −20.00 to −5.82).

For functional status, the authors based their results on 9 studies with 10 comparisons groups and 1046 participants. The studies revealed moderate-quality evidence that a significant difference in favor of OMT existed (SMD:-0.36, 95%CI: −0.58 to −0.14). Four studies reported a significant effect of OMT, 3 studies reported a non-significant effect, and 1 study reported a non-significant effect in favor of the control group.

**OMT versus other interventions for chronic nonspecific low back pain**

For nonspecific LBP, Franke et al² analyzed 6 studies with 7 comparisons and 769 participants. This analysis revealed moderate-quality evidence that a significant difference in favor of OMT existed (MD:-14.93, 95%CI:-25.18 to −4.68).

For functional status outcomes, the authors reviewed 3 studies which reported a significant improvement for OMT. One study reported a non-significant effect for OMT, and 1 study reported an effect for the control group. Collectively, the analysis showed moderate-quality evidence for a significant difference in favor of OMT (SMD:-0.32, CI:-0.58 to −0.07).

**OMT versus usual obstetric care, sham ultrasound, and untreated for nonspecific low back pain in pregnant women**

For LBP in pregnant women, the authors reviewed three studies with 4 comparisons and 242 participants. Two studies showed a significant improvement following OMT, and 1 study showed a non-significant improvement. The final analysis of these studies resulted in low-quality evidence for a significant difference in favor of OMT for LBP in pregnant women (MD, −23.01; 95% CI, −44.13 to −1.88) and functional status (SMD, −0.80; 95% CI, −1.36 to −0.23).²

Hensel, et al¹⁷ found that OMT was effective for mitigating pain and functional deterioration compared with usual care only; however, OMT did not differ significantly from placebo ultrasound treatment. The authors concluded that OMT is a safe, effective adjunctive modality to improve pain and functioning during the third trimester.
OMT versus untreated for nonspecific low back pain in postpartum women

Franke et al reviewed two studies focusing on OMT for LBP in postpartum women. Both studies reported significant improvement following OMT. The moderate-quality evidence showed a significant difference in favor of OMT for pain (MD, -41.85; 95% CI, -49.43 to -34.27) and functional status (SMD, -1.78; 95% CI, -2.21 to -1.35).

DISCUSSION
Efficacy of OMT
The overall results clearly demonstrate a statistically significant reduction in low back pain with OMT. Subgroup meta-analyses to control for moderator variables demonstrated that OMT significantly reduced low back pain vs active treatment or placebo control and vs no treatment control. If it is assumed, as shown in a review¹⁸, that the effect size is -0.27 for placebo control vs no treatment in trials involving continuous measures for pain, then the results of our study are highly congruent (i.e., effect size for OMT vs no treatment [-0.53] = effect size for OMT vs active treatment or placebo control [-0.26] + effect size for placebo control vs no treatment [-0.27]). It has been suggested that the therapeutic benefits of spinal manipulation are largely due to placebo effects.¹⁸ A preponderance of results from our sensitivity analyses supports the efficacy of OMT vs active treatment or placebo control and therefore indicates that low back pain reduction with OMT is attributable to the manipulation techniques, not merely placebo effects. Also, as indicated above, OMT vs no treatment control demonstrated pain reductions twice as great as previously observed in clinical trials of placebo vs no treatment control.¹⁸ The clinical significance of our findings is readily evident when compared with nonsteroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors. A recent meta-analysis of the efficacy of these drugs included 23 randomized placebo controlled trials for osteoarthritic knee pain, representing over 10,000 subjects, and measured pain outcomes up to three months following randomization.²⁰ This study found an overall effect size of -0.32 (95% CI, -0.24 - -0.39) and effect size of -0.23 (95% CI, -0.16 - -0.31) when drug non-responders were not excluded from the analyses. Thus, our effect size of -0.26 (95% CI, -0.48 - -0.05) for OMT in trials vs active treatment or placebo control suggests that OMT provides an analgesic effect comparable to nonsteroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors. Unlike the meta-analysis of nonsteroidal anti-inflammatory drugs,²⁰ however, Licciardone et al found that OMT also significantly reduced pain during the three to 12 month period following randomization.²¹ Thus, OMT for low back pain may eliminate or reduce the need for drugs that can have serious adverse effects.²² Because osteopathic physicians provide OMT to complement conventional treatment for low back pain, they tend to avoid substantial additional costs that would otherwise be incurred by referring patients to chiropractors or other practitioners.²³ With regard to back pain, osteopathic physicians make fewer referrals to other physicians and admit a lower percentage of patients to hospitals than allopathic physicians,³ while also treating back pain episodes with substantially fewer visits than chiropractors.²⁴ Although osteopathic family physicians are less likely to order radiographs or prescribe nonsteroidal anti-inflammatory drugs, aspirin, muscle relaxants, sedatives, and narcotic analgesics for low back pain than their allopathic counterparts, osteopathic physicians have a substantially higher proportion of patients returning for follow-up back care than allopathic physicians.²⁶ In the United Kingdom, where general practitioners may refer patients with spinal pain to osteopaths for manipulation, it has been shown that OMT improved physical and psychological outcomes at little extra cost.²⁶

Licciardone et al²⁷, in the Osteopathic Health outcomes In Chronic low back pain (OSTEOPATHIC) Trial studied OMT and ultrasound therapy for short term relief of nonspecific chronic low back pain. The authors found that the patients receiving OMT showed moderate to
substantial improvements in low back pain which met or exceeded the Cochrane Back Review Group criterion for a medium effect size in relieving chronic low back pain.

11. Prerelease review: Describe how the guideline developer reviewed and/or tested the guidelines prior to release.

Guidelines were reviewed by the Bureau of Osteopathic Clinical Education and Research, the AOA Board of Trustees, and the AOA House of Delegates.

12. Update plan: State whether or not there is a plan to update the guideline and, if applicable, an expiration date for this version of the guideline. The guidelines will be updated every 5 years.

13. Definitions: Define unfamiliar terms and those critical to correct application of the guideline that might be subject to misinterpretation.

OMT referred specifically to manual treatment provided by osteopathic physicians, or other physicians who had demonstrated training and proficiency in OMT, such as those practitioners in Europe who may have undertaken osteopathic conversion programs.

14. Recommendations and rationale: State the recommended action precisely and the specific circumstances under which to perform it. Justify each recommendation by describing the linkage between the recommendation and its supporting evidence. Indicate the quality of evidence and the recommendation strength, based on the criteria described in 9.

Based on this meta-analysis (evidence level 1a – see Table 1) of RCTs on OMT for patients with low back pain, it is recommended that OMT be utilized by osteopathic physicians for musculoskeletal causes of low back pain, i.e., to treat the diagnoses of somatic dysfunctions related to the low back pain.

<table>
<thead>
<tr>
<th>Strength of evidence</th>
<th>Type of Study</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1a</td>
<td>Systematic review with homogeneity of randomized trials</td>
<td>Individual trials should be free of substantial variations in the directions and magnitudes of results</td>
</tr>
<tr>
<td>1b</td>
<td>Individual randomized controlled trial with narrow CI</td>
<td>Confidence interval should indicate a clinically important OMT effect</td>
</tr>
<tr>
<td>1c</td>
<td>Differential frequency of adverse outcomes</td>
<td>An adverse outcome was frequently observed in patients who did not receive OMT, but was infrequently observed in patients who did receive OMT (equivalent to a small number needed to treat)</td>
</tr>
<tr>
<td>2a</td>
<td>Systematic review with homogeneity of cohort studies</td>
<td>Individual studies should be free of substantial variations in the directions and magnitudes of OMT effects</td>
</tr>
<tr>
<td></td>
<td>Study Type</td>
<td>Quality Indicators</td>
</tr>
<tr>
<td>---</td>
<td>----------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>2b</td>
<td>Individual cohort study or low-quality randomized controlled trial</td>
<td>Low quality may be indicated by such factors as important differences in baseline characteristics between groups, lack of concealment of treatment allocation, and excessive losses to follow-up</td>
</tr>
<tr>
<td>3a</td>
<td>Systematic review with homogeneity of case-control studies</td>
<td>Individual studies should be free of substantial variations in the directions and magnitudes of OMT effects</td>
</tr>
<tr>
<td>3b</td>
<td>Individual case-control study</td>
<td>These should be free of substantial evidence of selection bias, information bias, or confounding variables</td>
</tr>
<tr>
<td>4</td>
<td>Case series and low quality cohort and case-control studies</td>
<td>Low quality of cohort and case control studies may be indicated by such factors as important sources of selection bias, information bias, or confounding variables</td>
</tr>
<tr>
<td>5</td>
<td>Expert opinion without explicit critical appraisal, or based on physiology, bench research, or &quot;first principles&quot;</td>
<td>These generally will have limited empirical data relevant to OMT effects in human populations</td>
</tr>
</tbody>
</table>

*Adapted from Straus SE, Richardson WS, Glasziou P, and Haynes RB, Evidence-Based Medicine. How to Practice and Teach EBM (3rd ed), 2005*

15. Potential benefits and harms: Describe anticipated benefits and potential risks associated with implementation of guideline recommendations.

Potential benefits include but are not limited to improved care for patients seeing osteopathic physicians or practitioners for somatic dysfunctions causing low back pain. Harms have not been identified in randomized clinical trials on OMT for patients with low back pain. OMT for somatic dysfunction has not demonstrated harm in any clinical trials to date.

16. Patient preferences: Describe the role of patient preferences when a recommendation involves a substantial element of personal choice or values.

Patients have a choice of provider and services when they suffer from low back pain. OMT offers another option for care for low back pain from somatic dysfunction and can be provided by osteopathic physicians. It is utilized as an adjunct or complementary to conventional or alternative methods of treatment.
17. Algorithm: Provide (when appropriate) a graphical description of the stages and decisions in clinical care described by the guideline.

Once a patient with low back pain is diagnosed with somatic dysfunction as the cause, or contributing factor, of the low back pain, OMT should be utilized by the osteopathic physician. The diagnosis of somatic dysfunction entails a focal or complete history and physical exam, including an osteopathic structural exam that provides evidence of asymmetrical anatomical landmarks, restriction or altered range of joint motion, and palpatory abnormalities of soft tissues. OMT to treat somatic dysfunction is utilized after other potential causes of low back pain are ruled out or considered improbable by the treating physician; i.e., vertebral fracture; vertebral joint dislocation; muscle tears or lacerations; spinal or vertebral joint ligament rupture; inflammation of intervertebral discs, spinal zygapophyseal facets joints, muscles or fascia; skin lacerations; sacroiliitis; ankylosing spondylitis; masses in or from the low back structures; or organic (visceral) disease referring pain to the back or causing low back muscle spasms.

Algorithm for OMT LBP decision making.

Is Somatic dysfunction the cause, or a contributing factor, in the presentation of LBP (Look for “Red Flags.”)

No

Identify cause of LBP and treat accordingly.

Yes

Contributing factor: Identify primary cause of LBP and treat accordingly. Treat contributing somatic dysfunction using the same decision making as followed if the LBP is solely the result of somatic dysfunction.

Cause:

A) Define type of dysfunctional mechanics and as appropriate, define the dysfunctional barrier.

B) Determine why the dysfunction is present (e.g., articular, muscular, myofascial, neuroreflex, membranous).

C) Determine the patient’s level of tolerance for OMT.

D) Decide upon the type of OMT to most effectively address the cause of the dysfunction with consideration for patient tolerance.

E) Apply OMT to accomplish the desired response.

F) Reassess the dysfunction and determine if and when follow-up evaluation is necessary.
Follow-up, if appropriate, and repeat steps A-F.

18. **Implementation considerations:** Describe anticipated barriers to application of the recommendations. Provide reference to any auxiliary documents for providers or patients that are intended to facilitate implementation. Suggest review criteria for measuring changes in care when the guideline is implemented.

One of the barriers to application of the recommendations cited by osteopathic physicians has been poor reimbursement for OMT. However, Medicare has reimbursed osteopathic physicians for this procedure (ICD-9 code: 98926-9), for over 30 years. Many osteopathic physicians apparently do not utilize OMT in clinical practice due to a number of barriers, including time constraints, lack of confidence, loss of skill over time from disuse, and inadequate office space. Some specialists, i.e., pathologists and radiologists, do not use OMT as it is not applicable to their duties within their specialty. The AOA believes patients with low back pain should be treated with OMT given the high level of evidence that supports its efficacy. Changes in care when this guideline is implemented will be determined by physician and patient surveys, billing and coding practice patterns amongst osteopathic physicians, data gathered from osteopathic physicians via the AOA's Clinical Assessment Program, and other registry data gathering tools currently being developed by researchers.

**REFERENCES**

DEFINITION OF TERMS USED

Glossary of Osteopathic Terminology, Revised November 2011. Reprinted with permission from the American Association of Colleges of Osteopathic Medicine. All rights reserved.

To download the complete Glossary, please go to http://www.aacom.org/news-and-events/publications/glossary-of-osteopathic-terminology

osteopathic manipulative treatment (OMT): The therapeutic application of manually guided forces by an osteopathic physician (U.S. usage) to improve physiologic function and/or support homeostasis that has been altered by somatic dysfunction. OMT employs a variety of techniques including:

active method, technique in which the person voluntarily performs an osteopathic practitioner-directed motion.

articulatory treatment, (Archaic). See osteopathic manipulative treatment, articulatory treatment system.

articulatory (ART), a low velocity/ moderate to high amplitude technique where a joint is carried through its full motion with the therapeutic goal of increased range of movement. The activating force is either a repetitive springing motion or repetitive concentric movement of the joint through the restrictive barrier.

balanced ligamentous tension (BLT), 1. According to Sutherland’s model, all the joints in the body are balanced ligamentous articular mechanisms. The ligaments provide
proprioceptive information that guides the muscle response for positioning the joint, and the ligaments themselves guide the motion of the articular components. (Foundations) 2. First described in “Osteopathic Technique of William G. Sutherland,” that was published in the 1949 Year Book of Academy of Applied Osteopathy. See also ligamentous articular strain.

Chapman reflex, See Chapman reflex.

combined method, 1. A treatment strategy where the initial movements are indirect; as the technique is completed the movements change to direct forces. 2. A manipulative sequence involving two or more different osteopathic manipulative treatment systems (e.g., Spencer technique combined with muscle energy technique). 3. A concept described by Paul Kimberly, DO.

combined treatment, (Archaic). See osteopathic manipulative treatment, combined method.

compression of the fourth ventricle (CV-4), a cranial technique in which the lateral angles of the occipital squama are manually approximated slightly exaggerating the posterior convexity of the occiput and taking the cranium into sustained extension.

counterstrain (CS), 1. A system of diagnosis and treatment that considers the dysfunction to be a continuing, inappropriate strain reflex, which is inhibited by applying a position of mild strain in the direction exactly opposite to that of the reflex; this is accomplished by specific directed positioning about the point of tenderness to achieve the desired therapeutic response. 2. Australian and French use: Jones technique, (correction spontaneous by position), spontaneous release by position. 3. Developed by Lawrence Jones, DO in 1955 (originally “Spontaneous Release by Positioning,” later termed “strain-counterstrain”).

cranial treatment (CR), See primary respiratory mechanism. See osteopathy in the cranial field.

CV-4, abbreviation for compression of the fourth ventricle. See osteopathic manipulative treatment, compression of the fourth ventricle.

Dalrymple treatment, See osteopathic manipulative treatment, pedal pump.

direct method (D/DIR), an osteopathic treatment strategy by which the restrictive barrier is engaged and a final activating force is applied to correct somatic dysfunction.

exaggeration method, an osteopathic treatment strategy by which the dysfunctional component is carried away from the restrictive barrier and beyond the range of voluntary motion to a point of palpably increased tension.

exaggeration technique, an indirect procedure that involves carrying the dysfunctional part away from the restrictive barrier, then applying a high velocity/low amplitude force in the same direction.

facilitated oscillatory release technique (FOR), 1. A technique intended to normalize neuromuscular function by applying a manual oscillatory force, which may be combined with any other ligamentous or myofascial technique. 2. A refinement of a long-standing use of oscillatory force in osteopathic diagnosis and treatment as published in early osteopathic literature. 3. A technique developed by Zachary Comeaux, DO.

facilitated positional release (FPR), a system of indirect myofascial release treatment. The component region of the body is placed into a neutral position, diminishing tissue
and joint tension in all planes, and an activating force (compression or torsion) is added.

2. A technique developed by Stanley Schiowitz, DO.

fascial release treatment, See osteopathic manipulative treatment, myofascial release.

fascial unwinding, a manual technique involving constant feedback to the osteopathic practitioner who is passively moving a portion of the patient’s body in response to the sensation of movement. Its forces are localized using the sensations of ease and bind over wider regions.

functional method, an indirect treatment approach that involves finding the dynamic balance point and one of the following: applying an indirect guiding force, holding the position or adding compression to exaggerate position and allow for spontaneous readjustment. The osteopathic practitioner guides the manipulative procedure while the dysfunctional area is being palpated in order to obtain a continuous feedback of the physiologic response to induced motion. The osteopathic practitioner guides the dysfunctional part so as to create a decreasing sense of tissue resistance (increased compliance).

Galbreath treatment, See osteopathic manipulative treatment, mandibular drainage.

hepatic pump, rhythmic compression applied over the liver for purposes of increasing blood flow through the liver and enhancing bile and lymphatic drainage from the liver.

high velocity/low amplitude technique (HVLA), an osteopathic technique employing a rapid, therapeutic force of brief duration that travels a short distance within the anatomic range of motion of a joint, and that engages the restrictive barrier in one or more planes of motion to elicit release of restriction. Also known as thrust technique.

Hoover technique, 1. A form of functional method. 2. Developed by H.V. Hoover, DO. See also osteopathic manipulative treatment, functional technique.

indirect method (I/IND), a manipulative technique where the restrictive barrier is disengaged and the dysfunctional body part is moved away from the restrictive barrier until tissue tension is equal in one or all planes and directions.

inhibitory pressure technique, the application of steady pressure to soft tissues to reduce reflex activity and produce relaxation.

integrated neuromusculoskeletal release (INR), a treatment system in which combined procedures are designed to stretch and reflexly release patterned soft tissue and joint-related restrictions. Both direct and indirect methods are used interactively.

Jones technique, See osteopathic manipulative treatment, counterstrain.

ligamentous articular strain technique (LAS), 1. A manipulative technique in which the goal of treatment is to balance the tension in opposing ligaments where there is abnormal tension present. 2. A set of myofascial release techniques described by Howard Lippincott, DO, and Rebecca Lippincott, DO. 3. Title of reference work by Conrad Speece, DO, and William Thomas Crow, DO.

liver pump, See hepatic pump.

lymphatic pump, 1. A term used to describe the impact of intrathoracic pressure changes on lymphatic flow. This was the name originally given to the thoracic pump technique before the more extensive physiologic effects of the technique were recognized. 2. A term coined by C. Earl Miller, DO.
mandibular drainage technique, soft tissue manipulative technique using passively induced jaw motion to effect increased drainage of middle ear structures via the eustachian tube and lymphatics.

mesenteric release technique (mesenteric lift), technique in which tension is taken off the attachment of the root of the mesentery to the posterior body wall. Simultaneously, the abdominal contents are compressed to enhance venous and lymphatic drainage from the bowel.

muscle energy, a form of osteopathic manipulative diagnosis and treatment in which the patient's muscles are actively used on request, from a precisely controlled position, in a specific direction, and against a distinctly executed physician counterforce. First described in 1948 by Fred Mitchell, Sr, DO.

myofascial release (MFR), a system of diagnosis and treatment first described by Andrew Taylor Still and his early students, which engages continual palpatory feedback to achieve release of myofascial tissues.

direct MFR, a myofascial tissue restrictive barrier is engaged for the myofascial tissues and the tissue is loaded with a constant force until tissue release occurs.

indirect MFR, the dysfunctional tissues are guided along the path of least resistance until free movement is achieved.

myofascial technique, any technique directed at the muscles and fascia. See also osteopathic manipulative treatment, myofascial release. See also osteopathic manipulative treatment, soft tissue technique.

myotension, a system of diagnosis and treatment that uses muscular contractions and relaxations under resistance of the osteopathic practitioner to relax, strengthen or stretch muscles, or mobilize joints.

Osteopathy in the Cranial Field (OCF), 1. A system of diagnosis and treatment by an osteopathic practitioner using the primary respiratory mechanism and balanced membranous tension. See also primary respiratory mechanism. 2. Refers to the system of diagnosis and treatment first described by William G. Sutherland, DO. 3. Title of reference work by Harold Magoun, Sr, DO.

passive method, based on techniques in which the patient refrains from voluntary muscle contraction.

pedal pump, a venous and lymphatic drainage technique applied through the lower extremities; also called the pedal fascial pump or Dalrymple treatment.

percussion vibrator technique, 1. A manipulative technique involving the specific application of mechanical vibratory force to treat somatic dysfunction. 2. An osteopathic manipulative technique developed by Robert Fulford, DO.

positional technique, a direct segmental technique in which a combination of leverage, patient ventilatory movements and a fulcrum are used to achieve mobilization of the dysfunctional segment. May be combined with springing or thrust technique.

progressive inhibition of neuromuscular structures (PINS), 1. A system of diagnosis and treatment in which the osteopathic practitioner locates two related points and sequentially applies inhibitory pressure along a series of related points. 2. Developed by Dennis Dowling, DO.
range of motion technique, active or passive movement of a body part to its physiologic or anatomic limit in any or all planes of motion.

soft tissue (ST), A system of diagnosis and treatment directed toward tissues other than skeletal or arthrodial elements.

soft tissue technique, a direct technique that usually involves lateral stretching, linear stretching, deep pressure, traction and/or separation of muscle origin and insertion while monitoring tissue response and motion changes by palpation. Also called myofascial treatment.

Spencer technique, a series of direct manipulative procedures to prevent or decrease soft tissue restrictions about the shoulder. See also osteopathic manipulative treatment (OMT), articulatory treatment (ART).

splenic pump technique, rhythmic compression applied over the spleen for the purpose of enhancing the patient’s immune response. See also osteopathic manipulative treatment (OMT), lymphatic pump.

spontaneous release by positioning, See osteopathic manipulative treatment, counterstrain.

springing technique, a low velocity/ moderate amplitude technique where the restrictive barrier is engaged repeatedly to produce an increased freedom of motion. See also osteopathic manipulative treatment, articulatory treatment system.

Still Technique, 1. Characterized as a specific, non-repetitive articulatory method that is indirect, then direct. 2. Attributed to A.T. Still. 3. A term coined by Richard Van Buskirk, DO, PhD.

Strain-Counterstrain®, 1. An osteopathic system of diagnosis and indirect treatment in which the patient’s somatic dysfunction, diagnosed by (an) associated myofascial tenderpoint(s), is treated by using a passive position, resulting in spontaneous tissue release and at least 70 percent decrease in tenderness. 2. Developed by Lawrence H. Jones, DO, in 1955. See osteopathic treatments, counterstrain.

thoracic pump, 1. A technique that consists of intermittent compression of the thoracic cage. 2. Developed by C. Earl Miller, DO.

thrust technique (HVLA), See osteopathic manipulative treatment, high velocity/low amplitude technique (HVLA).

toggle technique, short lever technique using compression and shearing forces.

traction technique, a procedure of high or low amplitude in which the parts are stretched or separated along a longitudinal axis with continuous or intermittent force.

v-spread, technique using forces transmitted across the diameter of the skull to accomplish sutural gapping.

ventral techniques, See osteopathic manipulative treatment, visceral manipulation.

visceral manipulation (VIS), a system of diagnosis and treatment directed to the viscera to improve physiologic function. Typically, the viscera are moved toward their fascial attachments to a point of fascial balance. Also called ventral techniques.

somatic dysfunction: Impaired or altered function of related components of the somatic (body framework) system: skeletal, arthrodial and myofascial structures, and their
related vascular, lymphatic, and neural elements. Somatic dysfunction is treatable using osteopathic manipulative treatment.

Appendix 2

References cited in Franke et al systematic review


Source: H325-A/20

Status: 2009; 2014 Referred; 2015 Reaffirmed as Amended; 2020 Reaffirmed as Amended
Adverse Childhood Experiences Screening

Policy Statement

The American Osteopathic Association (AOA) encourages the inclusion of Adverse Childhood Experiences (ACEs) screenings in primary care settings.

Source: H327-A/20

Status: 2020 Adopted as Amended
Inequalities in Medicaid Funding Affecting U.S. Territories

Policy Statement

The American Osteopathic Association (AOA) supports an increase in or removal of the federal funding cap on territorial Medicaid programs, thereby reducing costs and preventing the cost-reducing measures that negatively impact the quality of and access to healthcare of low-income U.S. citizens and U.S. nationals living on the U.S. territories; and, that the AOA supports changing the territorial Federal Medical Assistance Percentage formula so that it considers per capita income, thereby tailoring the federal matching rate to each population’s financial needs.

Source: H329-A/20

Status: 2020 Adopted as Amended
Use of the Term “Physician” “Doctor” and “Provider”

Policy Statement

The American Osteopathic Association (AOA) adopts as policy:

(1) that AOA members are encouraged to use the terms “physician” or “doctor” to describe themselves, leaving other terms such as “practitioner,” “clinician,” or “provider” to be used by non-physician clinicians or to categorize health care professionals as a whole;

(2) supports the appropriate use of credentials and professional degrees in advertisements;

(3) supports providing a mechanism for physicians to report advertisements related to medical care that are false or deceptive;

(4) opposes non-physician clinicians’ use of the title “physician,” as well as use of the title “doctor” without specifying the type of doctorate received, because such communication is likely to confuse the public by implying that the non-physician clinician is engaged in the unlimited practice of medicine;

(5) opposes legislation that would expand the use of the term “physician” to persons other than US-trained DOs, and MDs; and

(6) supports a policy that physicians and non-physician clinicians should identify themselves to their patients using their degree in both a verbal introduction as well as by other identification clearly visible during patient encounters.

Source: H336-A/20

Status: 2009; 2014 Reaffirmed as Amended; 2020 Reaffirmed
CDC Guideline for Prescribing Opioids for Chronic Pain — United States

Policy Statement

The American Osteopathic Association (AOA) opposes the misuse and inflexible application of the United States Centers for Disease Control and Prevention (CDC) “Guideline for Prescribing Opioids for Chronic Pain — United States, 2016, (Guidelines) by law makers and regulators; and the AOA opposes the codification of the Guidelines into law or regulation and their use as a measure of the appropriateness of physicians prescribing; and the AOA recommends physicians read and consider the use of the 2019 AMA Opioid Task Force 2019 Guidelines in patients being treated for non-malignant chronic pain conditions.

Source: H337-A/20

Status: 2020
Medication for Opioid Use Disorder (MOUD) Availability for Incarcerated Individuals and/or Individuals Under Correctional Control

Policy Statement

The American Osteopathic Association will support the administration and/or prescribing of all FDA-approved treatments for opioid use disorder (OUD) for all individuals with OUD who are incarcerated or under other forms of governmental or private correctional control.

Source: H300-A/21

Status: 2021
Availability of Modalities of Prescribing
Policy Statement

The American Osteopathic Association advocates for all methods of prescribing by physicians for schedule II through schedule V controlled substances including fax, telephone, print, EPCS (Electronic Prescriptions for Controlled Substances) and hand-written prescriptions that meet the United States Drug Enforcement Administration guidelines and applicable federal and state laws and regulations for a valid controlled substance prescription.

Source: H301-A/21

Status: 2021
Direct Acting Therapy for Hepatitis C Limitations
Policy Statement

The American Osteopathic Association supports elimination of specialty-based, physician prescribing limitations of direct acting antiviral treatments for Hepatitis C.

Source: H303-A/21
Status: 2021
Increasing Voter Access for Hospitalized Patients
Policy Statement

The American Osteopathic Association (AOA) supports access to voting for hospitalized patients.

Source: H305-A/21

Status: 2021
Support of Continued Funding for Corporation for National and Community Service (CNCS)
Policy Statement

The American Osteopathic Association (AOA) supports continued federal funding for Corporation for National and Community Service (CNCS) programs.

Source: H306-A/21
Status: 2021
Appropriate PPE Usage Provisions

Policy Statement

The American Osteopathic Association (AOA) supports evidence-based standards and national guidelines regarding the use, reuse, and proper decontamination of personal protective equipment (PPE), especially in circumstances of increased demand. The AOA will advocate for the utmost protection of all healthcare personnel, emphasizing the responsibility of the healthcare institution to provide sufficient PPE within reasonable measures.

Source: H307-A/21

Status: 2021
Intractable and/or Chronic Pain (Not Associated with End of Life Care)

Policy Statement

The American Osteopathic Association supports the enactment of legislation concerning the administration of controlled substances to persons experiencing intractable and/or chronic non-malignant pain that includes definitions and provisions substantially conforming to the following; and will advocate and promote to students, residents, fellows and practicing physicians educational resources regarding substance use disorders, diversion awareness and monitoring and appropriate referral resources, as well as the prevention and treatment of pain disorders.

Definitions:

A. Intractable pain means a pain state in which the cause of the pain cannot be removed or otherwise definitively treated and which, in the generally accepted course of medical practice, no relief or cure of the cause of the pain is possible or none has been found after reasonable efforts including, but not limited to, a face-to-face evaluation by the attending physician and/or other physicians specializing in the treatment of the area, system, or organ of the body perceived as the source of the pain. Chronic non-malignant pain may be associated with a long-term incurable or intractable medical condition or disease.1

Chronic pain means “pain that typically lasts >3 months or past the time of normal tissue healing. chronic pain can be the result of an underlying medical disease or condition, injury, medical treatment, inflammation, or an unknown cause.”2

Provisions:

A. Notwithstanding any other provision of law, a physician may prescribe or administer controlled substances to a person in the course of the physician's treatment of the person for a diagnosed condition causing intractable and/or chronic pain. This includes patients with chemical dependency and/or substance abuse history if chronic pain exists and controlled substance management is indicated. Physician hypervigilance in screening for drugs of abuse, as well as the presence of the treatment medication in these patients is necessary.

B. No physician shall be subject to adverse action (by the state medical board, employers, insurers, etc.) for appropriately prescribing or administering controlled substances in the course of treatment of a person for intractable pain and/or chronic pain.

1 See MN 152.125 Intractable Pain; TX Sec. 107.001 Intractable Pain Treatment Act; FL 458.326 Intractable Pain – Authorized Treatment.

C. No physician shall be subject to criminal prosecution (by state or federal agencies) for appropriately prescribing or administering medically necessary controlled substances in the course of treatment of a person for intractable pain and/or chronic pain.

D. This section shall not authorize a physician to prescribe or administer controlled substances to a person the physician knows to be using drugs or substances for non-therapeutic purposes.

E. This section is not intended to interfere with the power (of the state medical board) to deny, revoke, or suspend the license of any physician who fails to keep accurate records of purchases and disposal of controlled substances, writes false or fictitious prescriptions for controlled substances, or prescribes, administers, or dispenses in violation of state controlled substances acts.

Source: H308-A/21

Status: 2021
Center of Excellence for Stroke

Policy Statement

The American Osteopathic Association encourages practitioners and healthcare institutions, through certification and streamlined coordinated quality patient centered care, to develop stroke centers of excellence to improve the healthcare quality for US citizens.

Source: H313-A/21

Status: 2011, 2016 Reaffirmed; 2021 Reaffirmed as Amended
The American Osteopathic Association encourages all osteopathic physicians to adopt voting policies in their workplaces that would allow their employees time off during working hours, if necessary, to participate in voting for local, state, and national elections.

Source: H314-A/21

Status: 1991; 1996 Reaffirmed as Amended; 2001 Reaffirmed; 2006 Reaffirmed; 2011 Reaffirmed as Amended; 2016 Reaffirmed; 2021 Reaffirmed
Patient Care at Extended Long Term Care Facilities

Policy Statement

The American Osteopathic Association encourages the Centers for Medicare and Medicaid Services (CMS) and any other regulatory and non-regulatory entity to: (1) re-evaluate their payment policy to encourage appropriate and adequate care to occur at extended long term care facilities; (2) improve payment to physicians for patient care in extended long term care facilities and to reimburse time spent on phone calls and care plan oversight from extended long term care facilities to physicians; (3) encourage physicians to participate in treatment of their patients at their respective extended long term care facilities; and (4) encourage appropriate tort reform to eliminate less than meritorious claims of elder abuse and malpractice in extended long term care facilities.

Source: H315-A/21

Status: 2006; 2011 Reaffirmed as amended; 2016 Reaffirmed as Amended; 2021 Reaffirmed
Osteopathic Term Protection

Policy Statement

The American Osteopathic Association’s policy regarding the preferential terms to be used in reference to the osteopathic profession has been updated over the years. However, we are mindful that there are osteopathic physicians practicing medicine who were granted degrees in “osteopathy.” Therefore, the AOA will continue to advocate for the protection of the terms “osteopathic”, “osteopathy” and “osteopath” as referenced in state and federal laws and rules.

Source: H316-A/21

Status: 2006; 2011 Reaffirmed as Amended; 2016 Reaffirmed; 2021 Reaffirmed
Cyberbullying through Social Media

Policy Statement

The American Osteopathic Association supports increasing awareness among parents / guardians, caregivers, educators, counselors and physicians about the danger of cyberbullying through media advocacy efforts and encourages osteopathic physicians to talk to their patients and the parents / guardians of their patients about cyberbullying and the lasting emotional damage that it can cause.

Source: H317-A/21

Status: 2011; 2016 Reaffirmed; 2021 Reaffirmed
Firearms – Commission of a Crime while using a Firearm

Policy Statement

The American Osteopathic Association supports the position that persons accused of a crime involving a firearm be prosecuted to the full extent of the law.

Source: H318-A/21

Status: 1994; 1996 Reaffirmed as Amended; 2001 Reaffirmed; 2006 Reaffirmed; 2011 Reaffirmed as Amended 2011; 2016 Reaffirmed; 2021 Reaffirmed
Good Samaritan Acts (Hold Harmless Agreement) Performed on Commercial Aircraft

Policy Statement

The American Osteopathic Association strongly recommends that all counties and states recognize Good Samaritan (Hold Harmless) laws for medical care rendered on commercial aircraft and urges all airlines to provide liability coverage for such medical care; and will petition the Federal Aviation Administration and appropriate international aviation entities to adopt such standards for all commercial airlines.

Source: H319-A/21

Status: 2001; 2006 Reaffirmed; 2011 Reaffirmed as Amended; 2016 Reaffirmed; 2021 Reaffirmed
Medicaid Pharmaceutical Benefits

Policy Statement

The American Osteopathic Association should support federal and state policies that ensure Medicaid beneficiaries have access to high-quality health care at the same level of non-Medicaid beneficiaries, to include all healthcare services and products including relevant pharmaceuticals, medical devices, and therapies.

Source: H320-A/21

Status: 1996; 2001 Reaffirmed as Amended; 2006 Reaffirmed; 2016 Reaffirmed as Amended; 2021 Reaffirmed as Amended
Medical Shortages

Policy Statement

The American Osteopathic Association will work with the Federal Government, pharmaceutical and medical supply manufacturers, and hospital organizations to ensure that any interruptions of the medical supply chains are as limited in depth and breadth as possible.

Source: H321-A/21

Status: 2016; 2021 Reaffirmed as Amended
Health Insurance Availability to Osteopathic Medical Students

Policy Statement

The American Osteopathic Association will advocate for subsidized and more affordable healthcare for Osteopathic Medical Students for the duration of their education.

Source: H322-A/21

Status: 2016; 2021 Reaffirmed
Behavioral Health Services – Funding and Access

Policy Statement

The American Osteopathic Association (AOA) supports legislative and other efforts to ensure adequate funding of behavioral health services and will support actions, including federal, state or local legislation or regulation, that improve access to and continuity of behavioral health care services in local communities and that maintain stability of established patient-physician relationships.

Source: H323-A/21

Status: 2016; 2021 Reaffirmed as Amended
Physician Gag Rules – Opposition to

Policy Statement

The American Osteopathic Association (AOA) is opposed to governmental actions and policies that limit the rights of physicians and other health care practitioners to inquire of their patients whether they possess guns and how they are secured in the home or to counsel their patients about the potential dangers of guns in the home and safe practices to attempt to avoid those potential dangers. The AOA opposes any further legislation or initiatives advocating physician gag rules that limit physicians’ right to free speech or other rights.

Source: H324-A/21

Status: 2016; 2021 Reaffirmed
Congressional Budget Office Fiscal Scoring

Policy Statement

The American Osteopathic Association supports the adoption of a dynamic fiscal scoring by the Congressional Budget Office for health policy legislation.

Source: H325-A/21

Status: 2016; 2021 Reaffirmed as Amended
Pain Related Education Requirements

Policy Statement

The American Osteopathic Association will advocate for medical education for all practitioners on proper opioid prescribing practices and any state mandated pain education requirements should include proper prescribing practices for opioids relating to pain treatment, opioid addiction, and identification of prescription drug abuse, misuse and diversion.

Source: H326-A/21
Status: 2016; 2021 Reaffirmed as Amended
Non-Physician Health Care Clinician

Policy Statement

The American Osteopathic Association will request of congress and regulatory bodies that the title “health care provider” not be used in favor of the title “physician and non-physician clinician.”

Source: H327-A/21

Status: 2016; 2021 Reaffirmed
Tricare Health Insurance for our Military

Policy Statement

The American Osteopathic Association supports member participation in TRICARE plans to provide care for all armed service members, active or reserve, retirees, and their families.

Source: H329-A/21

Status: 2016; 2021 Reaffirmed
Osteopathic Manipulative Treatment (OMT) in Chronic Pain Management Guidelines
– Inclusion of
Policy Statement

The American Osteopathic Association (AOA) will educate the public and policymakers about the efficacy and cost-effectiveness of osteopathic manipulative treatment (OMT) and advocate for OMT as a clinically effective and cost-effective intervention for the treatment of chronic nonmalignant pain syndromes. The AOA will advocate for the inclusion of specific language regarding OMT in recommendations for non-pharmacological interventions for chronic nonmalignant pain syndromes.

Source: H330-A/21

Status: 2016; 2021 Reaffirmed as Amended
Support of Breastfeeding

Policy Statement

The American Osteopathic Association supports all hospitals and birth centers to provide mothers the information and skills to initiate and continue breastfeeding their babies.

Source: H331-A/21

Status: 2011; 2016 Reaffirmed; 2021 Reaffirmed as Amended
Organ and Tissue Donation and Transplantation Initiatives – Commitment to

Policy Statement

The American Osteopathic Association (AOA) affirms its support for organ and tissue donation and transplantation programs at local and national levels; will develop and continue to promote physician and public education programs to advance the cause of organ and tissue donation and transplantation; urges the Osteopathic Family to volunteer personally as organ and tissue donors, and in turn, actively encourage their patients to do the same; and encourages osteopathic divisional and specialty organizations, osteopathic medical colleges, and other members of the osteopathic family to develop organ and tissue donation programs in their states and organizations. The AOA also affirms its support for blood donation on an ongoing basis. Furthermore, the AOA is opposed to the sale of donated organs and tissues outside of the United States, and opposed to the sale of organs and tissues for profit.

Source: H332-A/21

Status: 2001; 2006 Reaffirmed; 2011 Reaffirmed; 2016 Reaffirmed as Amended; 2021 Reaffirmed
Vaccine Supply and Distribution

Policy Statement

The American Osteopathic Association shall actively advocate for federal policies that support activities and processes for monitoring the supply of vaccines and coordinating vaccine supply and preferentially direct vaccines to physicians, healthcare facilities and healthcare agencies before they are made available to retail outlets.

Source: H333-A/21

Status: 2001; 2006 Reaffirmed as Amended; 2011 Reaffirmed as Amended;
2016 Reaffirmed as Amended; 2021 Reaffirmed
Health Literacy

Policy Statement

The American Osteopathic Association strongly supports the campaign for health literacy and encourages all practitioners and medical facilities to create a shame-free environment where low-literate patients can seek help.

Source: H334-A/21

Status: 2011; 2016 Reaffirmed; 2021 Reaffirmed
Onsite Lab Work No. 1

Policy Statement

The American Osteopathic Association supports the adoption of national legislation payment and regulation that enables the physician to perform and be compensated for CLIA certified in-office laboratory tests and supports the adoption of national legislation such policies which enables the physician to perform and be appropriately compensated for medically indicated on-site diagnostic procedures.

Source: H335-A/21

Status: 1999; 2004 Reaffirmed; 2016 Reaffirmed as Amended; 2021 Reaffirmed
Managed Care Referrals

Policy Statement

The American Osteopathic Association supports and promotes legislation that enables patient access to medical specialists by direct referral from the primary care physicians without preauthorization by the managed care company.

Source: H336-A/21

Status: 2001; 2006 Reaffirmed as Amended; 2011 Reaffirmed as Amended; 2016 Reaffirmed; 2021 Reaffirmed
Medicare Physician Payment for Osteopathic Manipulative Treatment

Policy Statement

The American Osteopathic Association advocates for nationwide consistency in Medicare physician’s payment policy, as it relates to osteopathic manipulative treatment (OMT) and evaluation and management (E/M) services, leading to payment for OMT as a separately identifiable procedure from the E/M in all contract regions.

Source: H337-A/21

Status: 1991; 1996 Reaffirmed as Amended; 2001 Reaffirmed; 2006 Reaffirmed; 2011 Reaffirmed as Amended; 2016 Reaffirmed as Amended; 2021 Reaffirmed
Drug Plan Coverage Denials

Policy Statement

The American Osteopathic Association will advocate to the appropriate regulatory agencies and other health professional organizations to require drug benefit managers to fully explain any denial of medication coverage, with explanations that must include but not be limited to the following: (1) The medical reason for denial of a prescribed medication; (2) The criteria upon which a reversal of the denial will be considered; (3) A listing within the notification of denial of the approved alternatives to the prescribed medication; and (4) Listing of appeals process for denials.

Source: H338-A/21

Status: 2006; 2011 Reaffirmed as Amended; 2016 Reaffirmed; 2021 Reaffirmed
Payor Adherence to Current Procedural Terminology (CPT) and International Classification of Diseases (ICD) Coding Definitions

Policy Statement

The American Osteopathic Association will advocate for all payors to adhere to all CPT coding conventions in developing payment policies; and will support action to prevent payors from deviating from CPT definitions and promote autonomous, fair, and uniform interpretation of CPT and ICD codes to allow for non-prejudicial treatment by payors in the reimbursement arena.

Source: H339-A/21

Status: 2006; 2011 Reaffirmed as Amended; 2016 Reaffirmed as Amended; 2021 Reaffirmed
Interference – Lawful Off-Label Treatment of Patients

Policy Statement

The American Osteopathic Association (AOA) proactively support the protection of a physician’s ability to prescribe treatments and to speak freely about lawful, evidence-based, health care options, including off-label treatments or health care-related research, without fear of being sanctioned by regulatory boards, insurance companies or employers.

The AOA supports state efforts to protect patients and prevent sanctions for physicians, directly or indirectly through a subcontractor or otherwise, for making a patient aware of or educating a patient about lawful, evidence-based, health care options, including 1) off-label use of health care options; 2) health care-related research or data; and 3) for offering, providing or making available lawful, evidence-based health care options.

Source: H340-A/21

Status: 2016; 2021 Reaffirmed
Appropriate Payment Mechanisms for Physician-Led Team-Based Health Care

Policy Statement

The American Osteopathic Association (AOA) will strongly advocate for effective payment models that appropriately 1) incentivize high-quality care, and 2) ensure physicians receive payment for providing this care.

The AOA will advocate to the Centers for Medicare and Medicaid Services (CMS) that any alternative payment models (APMs) proposed for inclusion in Medicare Access and CHIP Reauthorization Act (MACRA) be reviewed through an administratively simple and transparent process, in a timely manner, and include an appeals process.

The AOA encourages public and private health insurers to develop a variety of value-based contracting options so that physician practices can select payment models that best suit their delivery of care.

Source: H341-A/21

Status: 2016; 2021 Reaffirmed as Amended
Human Immunodeficiency Virus (HIV)

Policy Statement

In accordance with the American Osteopathic Association's Code of Ethics: (1) osteopathic physicians and osteopathic medical students should provide care for those at risk and those infected with Human Immunodeficiency Virus (HIV), in an atmosphere of compassion and nondiscrimination; (2) recognize their professional and ethical obligations to care for such patients as they care for all patients; (3) osteopathic physicians and osteopathic medical students in their important role as humanitarian resources to their patients, families, and communities, provide candid, effective nonjudgmental preventive education for those at risk, and serve as effective resources for their patients' families and loved ones; and (4) osteopathic physicians and osteopathic medical students should be educational resources for those at negligible risk in an effort to promote enlightened attitudes in places of work, our schools, and communities in general; and (5) osteopathic physicians and osteopathic medical students should advocate for the removal of legal and systemic barriers to allow patients living with HIV to access care, and to allow healthcare workers living with HIV to provide care to their patients.

Source: H342-A/21

Status: 1992; 1996 Reaffirmed as Amended; 2001 Reaffirmed as Amended; 2006 Reaffirmed as Amended; 2011 Reaffirmed; 2016 Reaffirmed; 2021 Reaffirmed as Amended
White Paper – Improving Access to Physician Led Care

Policy Statement

The American Osteopathic Association adopted the white paper, Improving Access to Physician-Led Care as its position on leveraging the physician-led, team-based model of care to meet our nation’s growing health care needs in a safe and cost-effective manner.

Improving Access to Physician-led Care

Overview

This paper addresses the primary care physician workforce shortage, identifying potential solutions dispels notions that scope of practice expansions can address the issue.

Background

Numerous factors contribute to the growing physician workforce shortage in the United States, currently projected to exceed 139,000 physicians by 2030.¹ These include an aging population (including among physicians), an increase in the number of insured individuals following the enactment of the Affordable Care Act (ACA) and related state Medicaid expansions, and the arbitrarily low cap on Medicare-funded graduate medical education (GME, aka “residency”) positions for physicians that was established by Congress in 1997, as well as Medicare, Medicaid and other payor payment rates which have failed to keep pace with the increasing cost of providing care.

According to a 2020 study published by the American Association of Medical Colleges, the United States population is expected to grow by 10.4% (from about 327 million to 361 million) by 2033, while the population over age 65 is expected to grow by 45.1%.² Further, more than 2 in 5 currently practicing physicians will reach retirement age in the next decade.³ In addition, more than 20 million Americans gained insurance coverage over the past few years under the ACA. Further, if the 12 states that have not expanded Medicaid eligibility by January 2021 did so, nearly 4 million more individuals would become eligible for coverage.⁴ These factors combine to create an increasing demand for physician services, while two major factors work against a supply-side increase: (1) the freeze on Medicare funding and geographic distribution of residency slots at their 1996 levels and locations, and (2) rising educational debt that is

³ Id.
leading physicians who might otherwise choose to practice in physician shortage areas or in high need specialties to seek higher paying specialty positions in urban areas.⁵

**Legislative Proposals**

In order to address the growing physician shortage, some legislators have begun electing to circumvent evidence-based physician licensure pathways to allow non-physician clinicians (nurses, physician assistants, and even entirely new types of clinicians) to practice equivalently to physicians without completing similar education, training or testing.

There are several issues with this approach; namely, (1) that unlike physicians, the length, content and type of training (online vs. in-person, didactic vs. clinical, academic vs. practical, etc.) that these providers complete varies by state and sometimes even by provider, (2) research demonstrates that these individuals are largely drawn to the same areas where physicians are already practicing, and that (3) non-physicians tend to overprescribe/overutilize diagnostic tests, which, combined with their history of seeking pay parity with physicians legislatively once they achieve independent practice, makes it unlikely that these individuals will actually solve the cost and access issues that legislators are attempting to address.

Physician licensure requirements are largely the same across states, and require four years of medical school, a comprehensive examination series followed by supervised postgraduate (“residency”) training with progressively greater autonomy before they are allowed to independently treat patients. Medical school education is nationally standardized and includes two years of didactic study totaling upwards of 750 lecture/practice learning hours just within the first two years, plus two more years of clinical rotations done in community hospitals, major medical centers and doctors’ offices. Residency programs are also standardized by specialty, and are comprised of 12,000 to 16,000 hours of supervised training through which physicians develop advanced knowledge and clinical skills relating to a wide variety of patient conditions over the course of three to seven years.

While physician licensure requirements remain largely the same across the country – and in fact, the trend has been towards increasing physician education and training requirements over the years – some states have begun granting similar licenses to non-physician clinicians, upon completion of as little as a two-year master’s degree (which may be done largely online), a single examination and no supervised postgraduate training, as in the case of nurse practitioners (NPs).⁶ Not only do NPs complete far fewer supervised clinical hours than physicians during their educational programs, their professional organization (the American Academy of Nurse Practitioners; “AANP”) actually opposes requiring them to complete supervised residency training before becoming licensed to practice independently.⁷ Unsurprisingly based on their relatively short educational background, evidence shows that non-physician clinicians tend to overprescribe medication⁸, issue poorer quality referrals to

---

⁵ The Consolidated Appropriations Act, 2021 enacted into law on December 27, 2020, provides the Centers for Medicare & Medicaid Services funding for 1,000 new residency slots. This will support approximately 200 new Medicare-funded residency positions per year for five years.


specialists and order unnecessary diagnostic imaging compared to physicians, all of which expose patients to potentially costly, unnecessary and high-risk interventions, because their training has not prepared them to determine which cases warrant such care.

Some states have also begun allowing non-physician clinicians who complete doctorates to refer to themselves as “doctors” regardless of whether the doctorate that they completed is academic rather than clinical in nature. Use of the title “doctor” in a clinical setting can easily confuse patients into thinking that they are being seen by a physician when the individual making medical decisions has vastly different education and training.

Despite these differences in education, training and testing, history shows that once non-physician clinicians achieve independent practice they often return to state legislatures to advocate for pay parity with physicians, thereby defeating any cost savings arguments for independent practice. All health care professions have an equal right to provide stakeholder input to the Centers for Medicare & Medicaid Services (CMS), which makes centralized decisions regarding health professional payment rates after taking into account factors such as the time it takes to perform a service, the technical skill and physical effort, the required mental effort, judgment and stress due to the potential risk to the patient, as well as practice expenses and professional liability insurance costs. Nonetheless, pay parity is a stated goal of organizations like the AANP, and their success achieving it legislatively rather than through evidence-based valuation protocols may encourage other non-physician clinician associations to seek similar rate increases from state legislatures. When combined with these providers’ overutilization of costly medical procedures and prescriptions, it is unlikely that granting independent practice will have a positive impact on healthcare cost issues.

In addition to cost concerns, research demonstrates that allowing non-physician clinicians to practice independently does not solve access-to-care issues either. In fact, it shows that these individuals largely choose to practice in areas where physicians are already practicing. To avoid this, some states have attempted to place initial geographic and practice area (i.e. primary care only) limits on a provider group in order to improve access in rural areas; however, historical trends show that once independent practice is achieved, these groups return to the legislature year after year in attempts to erode any remaining restrictions on their practice. These patterns demonstrate that while the stated goal of these groups may be to address cost and access issues, their true motivation is a desire to achieve similar practice rights and reimbursement to physicians without having to complete similar training and testing requirements that help to ensure patient safety.

10 D. Hughes, M. Jiang and R. Duszak Jr. A Comparison of Diagnostic Imaging Ordering Patterns Between Advanced Practice Clinicians and Primary Care Physicians Following Office-Based Evaluation and Management Visits. JAMA Internal Medicine, January 2015.
14 See sample NP workforce maps for Wyoming, Delaware.
15 See e.g. Massachusetts - 244 CMR 4.00 of 2012 (established independent practice for certified nurse midwives) and MA House Bill 552 of 2017-18 and MA House Bill 1028 of 2019-2020 (seek payment parity).
A Better Way: the Physician-led, Team-based Model of Care

Rather than the fragmented, two-tiered healthcare system described above, studies show that the optimal way to deliver high quality, cost-effective medical care is through a team-based model that utilizes the various strengths of each member of the healthcare team with a physician at the head.

A recent study by the National Academy of Medicine (NAM) found that “multidisciplinary team-based care is associated with better performance on traditional measures of health care quality, such as emergency department utilization and hospital readmissions. In addition, several studies have concluded that optimizing team-based care is a cost-effective intervention.”

These findings are consistent across settings, including ambulatory emergency departments, intensive care units, and nursing homes, as well as other settings. Among the research cited in the NAM analysis, a 2015 review of 52 studies of team-based care for hypertension found that teams achieved controlled blood pressure in 12 percent more patients than routine care did. They also cite another study finding that a team-based care model “that works in collaboration with primary care clinicians and patient-centered medical homes to provide home-based geriatric care management was associated with 7.1 percent fewer emergency department visits, 14.8 percent fewer 30-day readmissions, 37.9 percent fewer hospital admissions, and 28.5 percent fewer total bed days of care, saving an estimated $200,000 per year after accounting for program costs.”

The best approach to improving healthcare quality while expanding system capacity is through expanding a physician and non-physician clinician workforce that is effectively trained in team-based care. Authorizing independent practice for non-physician clinicians is counterproductive to this effort, insufficiently supported by evidence, and potentially harmful to patient outcomes. There have been few randomized control trials (RCTs) assigning patients to different providers to compare cost and quality between physicians and non-physician clinician groups. Most studies have relied on analyses of claims and encounter data, and the few RCTs that have been conducted were plagued with serious methodological flaws.

A June 2019 Medicare Payment Advisory Commission (MedPAC) report to Congress noted that practices that employ both NPs or physician assistants (PAs) and physicians might systematically direct lower acuity patients to NPs or PAs. Patients may also choose among physicians, NPs, and PAs based on their preferences or the perceived severity of their illness. To the extent that systematic differences exist in the types of patients treated by physicians compared with those treated by NPs or PAs that are not observable in the data (and thus cannot be adjusted for), these studies may not effectively isolate the effects of clinician type from other confounding factors.

Additionally, the roles and responsibilities of nurses can vary in different settings, and definitions of autonomy varied between some RCTs conducted. An analysis published in 2014 found that “[i]n the evaluated studies, the assumption is that nurses possess the competence required for substituting physicians, but the level of substitution does not seem equal among studies. While the level of training may be a critical factor for an effective outcome, the studies report

---

incomplete descriptions of nurses’ roles and competencies”\textsuperscript{17} Among the few RCTs that have been conducted, long-term outcomes and condition management for complex cases are also not sufficiently accounted for.

An analysis published in the \textit{International Journal for Quality in Health Care} in 2015 describes the limitations encountered in their analysis, stating that “the physiologic outcomes addressed in current research focused on changes in parameters such as blood pressure; a more meaningful outcome would be the proportion of subjects attaining disease control over time. Future studies should also examine rates of preventable hospitalizations and appropriate preventive care, such as vaccines and disease screening. Finally, studies with longer follow-up periods will allow for assessment of rates of retention in care”\textsuperscript{18} A consistent concern among existing RCTs is the length of the follow-up period and the outcomes tracked over that period. Often, studies comparing advanced practice registered nurses and physicians have been limited to a single encounter or one month time frame.\textsuperscript{19}

The growing responsibilities that non-physician clinicians take on in our health care system, especially within collaborative care models, are critical. However, this is not sufficient to justify scope of practice expansions that can negatively impact patient care. While numerous studies highlight the quality of care provided by non-physician clinicians, it is critical to also recognize the shortcomings of the research and factors that they have been unable to account for.

Additionally, while not well-documented, it is self-evident that that there is more fragmented care where independent practice for non-physicians exists, and physicians are often called upon following an initial misdiagnosis or negative outcome resulting from care from a lesser-trained clinician.

\textbf{Evidence-based Solutions}

\textit{Targeted Funding}

The cost to produce a physician in the U.S. is staggering, and recent studies show that 76 percent of all medical school graduates graduate with student loans, averaging approximately $190,000. With interest growing over the course of a three-to-seven-year residency program, the eventual repayment total for many physicians can exceed $400,000.\textsuperscript{20} Recognizing the importance of a physician-lead medical workforce, a number of states have implemented successful graduate medical education and loan repayment programs that can serve as models for other states to help attract physicians to provide care in much-needed specialties and areas.\textsuperscript{21}

One recent example is Oregon’s Health Care Provider Incentive Fund (Fund), which was established in 2017 through an initial $16 million allocation to build health care workforce capacity in rural and medically underserved parts of Oregon and to provide resources for the


\textsuperscript{19} Id.

\textsuperscript{20} M. Runge. Public service loan forgiveness can help fix the shortage of primary care and rural physicians. \textit{STAT+}, August 11, 2017.

\textsuperscript{21} No author. Loan Repayment/Forgiveness/Scholarship and Other Programs. \textit{Association of American Medical Colleges}, no date.
Health Care Provider Incentive Program (HCPIP).\textsuperscript{22} The funding is administered by the Oregon Health Authority (OHA) in partnership with the Oregon Office of Rural Health (OORH), and utilizes loan forgiveness, loan repayment, insurance subsidies and scholarships (including one at the Pacific Northwest College of Osteopathic Medicine) to assist qualified health care providers who commit to serving the state’s Medicaid and Medicare beneficiaries for a certain period of time in rural and underserved areas of the state.

Specifically, the primary care loan forgiveness program provides loans to postgraduate trainees who agree to:

1. Practice for one to three years in an underserved Oregon community that has been federally defined as a Health Professional Shortage Area (HPSA), and

2. Serve Medicaid and Medicare members in at least the same percent as is present in the community.

If the provider still has debt upon completion of the program, they then become eligible for a loan repayment award.

In addition, the HCPIP also provides subsidies for malpractice insurance premiums for providers serving at a location that meets the OHA’s definition of a rural practice. Subsidy payments from OHA are a percentage of the provider’s malpractice premiums, with the highest subsidies awarded to providers of obstetrical care.

Lastly, the HCPIP funds scholarship awards at schools equal to the cost of a year of education, in exchange for a 1-year HPSA service obligation for each year funded.

As a result of these incentives, nine of the 16 areas identified as “target areas” for the program in 2018 have seen an increased number of full-time providers. A program evaluation identified COVID-19 as an obstacle to the growth and sustainability of the program in the last year; however, the program has adjusted to account for the increased use of telemedicine among awardees and also plans to increase targeted outreach to clinicians who are representative of those they serve to improve the program’s reach to marginalized communities.

Another example of state success – as well as the negative impact associated with cutting funding for training programs – is the state of Texas, which has provided varying levels of funding for rural and primary care training programs through its Higher Education Coordinating Board (THECB) since the 1980s. Funded programs include:

- The Statewide Primary Care Preceptorship Program, which provides funding support to preceptorship programs in family practice, general internal medicine and general pediatrics, with the goal of encouraging Texas medical students to choose primary care careers by offering direct student support for a month-long experience in one of the specialties. A comprehensive nine-year study showed that students who participated in a family medicine preceptorship were almost twice as likely to pursue a career in family medicine, and of the 238 medical students who completed the preceptorships in 2009, 93 percent said the experience made them more receptive to primary care as a career.\textsuperscript{23}

\textsuperscript{22} No author. Health Care Provider Incentive Program: Evaluation of Program Effectiveness. Oregon Health Authority, Health Policy and Analytics Division, Primary Care Office, Nov. 2020.

\textsuperscript{23} https://www.tafp.org/Media/Default/Downloads/advocacy/Support_PC_residencies.pdf
- The Physician Education Loan Repayment Program, which provides loan repayment funds for physicians who agree to provide health care services to recipients enrolled in Medicaid and the Texas Children's Health Insurance Program (CHIP), or in a Texas Juvenile Justice Department or Texas Department of Criminal Justice facility, for at least four years;

- The State Rural Training Track Grant Program, which provides funding for residency programs in rural areas, with the goal of attracting physicians to remain in those areas to practice; and

- The Family Practice Residency Program, which provides grants to the state's 31 nationally accredited family medicine residency programs, located in every region of the state, in order to help increase the number of physicians who pursue family medicine and establish their practices in rural and underserved communities in Texas.24

Although 66 percent of the physicians who completed residency training in Texas between 2008 – 2017 chose to remain in the state upon completion25 – indicating a high return on investment for the aforementioned programs – funding has been variable and over the years some programs have been forced to close permanently:26

- The Kelsey-Seybold Family Medicine Residency Program – considered a model for training new physicians in a team-based, multispecialty environment – announced its closure due to financial instability in 2009;

- The Texas Tech University Rural Program in Abilene closed its doors for financial reasons in 2008; and

- The Christus St. Elizabeth Family Medicine Residency Program in Beaumont was forced to close in 2002 due to a lack of financial support. Of the 74 graduates from the program practicing medicine in 2005, 88 percent practiced in health professional shortage areas.

According to a recent report from the Department of State Health Services, Texas will need approximately 3,400 more primary care physicians than it is on track to produce by 2030 to meet demand. Despite this, the 2021 state budget cuts the Family Practice Residency Program from $5 million a year to $4.75 million and reduces funding for family medicine residents from $14,300 per resident in 2011 to just $5,400 in 2021.27

Considering the fact that it costs the state approximately $168,000 to produce one medical school graduate, and in 2016 (the most recent year for which data was available) it produced 180 more graduates than it had first-year residency slots – representing a lost investment of $30 million in that one year alone – any cost savings to the state by reducing funding for residency programs that have been proven effective in producing Texas-based primary care physicians is

27 https://www.tafp.org/news/tpf/q1-2021/lege-update
far outweighed by the financial loss that it incurs when physicians leave the state to train (and frequently remain) elsewhere.  

It is important to note that the osteopathic profession has a longstanding commitment to providing care in rural and underserved areas, and many of the beneficiaries of the abovementioned programs are DOs. According to the 2019 Osteopathic Medical Profession Report, 57% of DOs currently practice in primary care specialties, surpassing the percentage of MDs entering primary care, which has been on the decline since 2011. Many osteopathic medical schools are located in rural and underserved areas, and nine out of the top ten medical schools with the most graduates practicing primary care are osteopathic schools. Further, in 2020, the Oklahoma State University College of Osteopathic Medicine at the Cherokee Nation became the first tribally-affiliated college of medicine in the United States.  

**Driving Specialty Decisions at the Undergraduate Medical Education Level**

The experiences of students during their first four years of medical education are critical in shaping professional interests. An analysis of the last 10 years of data from the American Association of Colleges of Osteopathic Medicine’s (AACOM) graduate survey found that mentoring by faculty may have an outsized influence in decision making on future specialty and practice setting. In 2019, students who indicated that they intended to practice in primary care or in a rural setting also tended to be more satisfied with their faculty mentoring during the undergraduate medical career. A similar survey by the Association of American Medical Colleges had similar findings, where 52.1 percent of respondents cited “role model influence” as having a strong influence on their specialty choice in 2020. The June 2019 report by MedPAC evaluated the current pipeline of primary care physicians, and it came to similar conclusions regarding the influence of the undergraduate medical education experience on practice decisions.  

This evidence suggests that specialty decisions are made well before graduation from medical school. Building training programs where students gain exposure to high-quality mentors in primary care, and even engage in community-oriented primary care education may ultimately make students more likely to go into a primary care specialty or practice in underserved settings. Several Health Resources and Services Administration (HRSA) programs seek to strengthen primary care training and steer students at the undergraduate medical education  

31 https://medicine.okstate.edu/hastings/index.html.  
34 Magzoub, Mohi Eldin M. A. MD, PhD; Schmidt, Henk G. PhD A Taxonomy of Community-based Medical Education, Academic Medicine: July 2000 - Volume 75 - Issue 7 - p 699-707
level. Expanding these programs can be a useful tool in expanding the primary workforce in underserved communities.

HRSA’s 2020 report to the HHS Secretary states that expanding the availability of longitudinal training programs, instead of 4-8 week rotations, provide meaningful education in health promotion, disease prevention, and care management for the chronically ill, while also making students more likely to ultimately specialize in primary care.35 36 While HRSA has some grant programs that can help institutions develop innovative undergraduate medical education programs to address workforce shortages, much of HRSA’s work focuses on graduate medical education. A grant program for innovation in primary care and development of longitudinal programs could help expand the pipeline of students who choose primary care upon graduation.

Data from HRSA also suggests that there is strong demand for primary care training, and additional funding for students could support more students in pursuing a medical education that emphasizes this type of practice. The National Health Service Corps (NHSC) is one program that supports students who choose to pursue a medical education and practice in primary care. The NHSC scholarship program has been highly successful, but it can only support a limited number of applicants. In 2019, the program saw nearly 1,900 applicants, but only 200 new awards were granted. Identifying more students who are interested in primary care early in their careers, encouraging commitment, and providing financial support for their education in this specialty can help produce more providers who are ready to meet the needs of rural and underserved communities across the country.

**Enhancing Payment for Medicaid**

Medicaid enrollees comprise a significant share of primary care visits and ensuring that physician practices that serve Medicaid populations receive payment at level that is needed to remain viable is critical to promoting access in rural and underserved communities. On average, state Medicaid programs pay for healthcare services at 72 percent of the Medicare rate; for primary care services, that number drops to 66 percent.37

Increasing Medicaid payment to at least an equal level with Medicare will allow more physicians to accept Medicaid patients and attract them to practice in high-need settings. An analysis by Health Affairs describes how physicians cite low reimbursement rates as a deterrent to participation. Additionally, a MACPAC and University of Minnesota analysis of National Ambulatory Medical Care Survey data found that the proportion of physicians accepting new patients varies significantly based on patient coverage type. Providers were less likely to accept new patients with Medicaid, with 70.8 percent accepting new patients, than with Medicare (85.3 percent) or private insurance (90.0 percent). MACPAC also found in their analysis that state Medicaid reimbursement was correlated with new patient acceptance. Every 1 percentage point

---


increase in the Medicaid-to-Medicare fee ratio appears to increase acceptance by 0.78 percentage points.\textsuperscript{38}

Other studies have confirmed the MACPAC finding. A recent study by the Federal Reserve Bank of Chicago analyzed the impact of the Medicaid primary care rate increase that was implemented by the ACA and expired in 2015. The study found that the increase in Medicaid payments was associated with improvements in access and health measures among Medicaid beneficiaries. The study also found a correlation between Medicaid rates and usage of health care services by beneficiaries. The researchers identified that a $10 increase in physician reimbursement is associated with a 0.29 percentage point (1.5 percent) increase in the probability that respondents covered by Medicaid went to a doctor’s office in the preceding two weeks.\textsuperscript{39} This is likely because increased availability of providers and appointment times supports patient engagement in their own care, as well as longitudinal relationships between patients and providers.

Federal policies should ensure that Medicare payment rates serve as a floor for Medicaid rates. Improving Medicaid rates will help primary care practices afford to practice in settings with a larger share of Medicaid patients.

\textbf{Conclusion}

Effectively leveraging a physician-led, team-based model of care delivery is critical to meeting our nation’s growing health care needs moving forward. Although the investment required of state and federal governments in order to adequately address these issues is significant, as the research above demonstrates, effectively training physicians in areas of high need and utilizing the physician-led team model will help us achieve cost-effective solutions without sacrificing quality of care.

Physicians remain the only category of health care professional to complete comprehensive medical education, training and competency demonstration requirements that is designed to ensure the highest, uniform standards of care nationwide. While other provider types have sought to increase their education and training in recent years, the fact remains that there is a lack of consistency, uniformity and information about the long-term outcomes of these providers, who largely resist physician involvement while continuing to seek equivalent rights and reimbursement once they achieve independent practice, which defeats the stated goals of legislatures in granting them such rights.

All patients deserve to be treated by fully trained and licensed medical professionals, regardless of location or ability to pay, and the physician-led, team-based model of care ensures that fully licensed physicians are appropriately involved in patient care while valuing the unique training and skill sets of all health care providers.

Source: H343-A/21

Status: 2021


\textsuperscript{39} Alexander and Schnell. “Closing the Gap: The Impact of the Medicaid Primary Care Rate Increase on Access and Health”
White Paper – Reforming the Health IT Landscape to Improve the Patient and Clinician Experience

Policy Statement

The American Osteopathic Association adopted the white paper, Reforming the Health IT Landscape to Improve the Patient and Clinician Experience as its position on policies to empower consumers with their personal health data while ensuring that information is seamlessly provided to physicians at the point of care.

Reforming the Health IT Landscape to Improve the Patient and Clinician Experience

Overview

This paper addresses the evolution of health information technology (HIT), recent HIT efforts and shortcomings, opportunities to improve HIT infrastructure to support patient care and clinicians and identifies potential solutions.

Introduction

Information technology in the healthcare industry has steadily advanced over the past two decades. Much of this growth can be attributed to the widespread adoption and meaningful use of electronic medical records (EHRs). However, adoption and utilization of EHRs has not been easy for physician practices or free from burden.

As the use of EHRs has increased, recent legislative activities have shifted to address longstanding barriers to interoperability and electronic exchange of healthcare information. This paper discusses the evolution of health information technology (HIT) and describes specific policy solutions to enhance interoperability of healthcare data, improve accuracy, increase efficiency, and reduce administrative burden.

The Evolution of Health Information Technology

The first major incentive for HIT started with the Health Insurance Portability and Accountability Act of 1996 (HIPAA) when the federal government mandated that health plans, healthcare clearinghouses, and certain healthcare providers comply with technical data requirements for electronic transactions. HIPAA established standards for electronic exchange of data; code set standards for diagnosis, procedures and diagnostic tests; unique identifiers for employers, providers and health plans; standards for storage of data at medical facilities, health insurance companies, and billing clearinghouses; and privacy standards to protect sensitive patient health information (PHI) from being disclosed without the patient's consent or knowledge.

In 2001, the Administrative Simplification Compliance Act required that all initial Medicare claims be submitted electronically, except in limited situations. However, it was the HIPAA provisions for simplifying administration of health insurance that encouraged the healthcare industry to computerize patients’ medical records. This specific part of the Act spawned the Health Information Technology for Economic and Clinical Health Act (HITECH).
The use of the EHR has been a consistent topic of frustration and burnout for physicians across the U.S. healthcare system. When the HITECH Act passed in 2009, its purpose was to make health data storage, sharing, and reporting more seamless and efficient, easing provider workloads, enhancing the patient experience, and improving care quality.

In 2011, the meaningful use (MU) component of HITECH was implemented to expand the adoption of HIT and facilitate the use of EHRs. The HITECH Act authorized the Centers for Medicare & Medicaid Services (CMS) to establish the Medicare and Medicaid EHR Incentive Programs. These programs paid approximately $35 billion in incentive payments to eligible professionals, hospitals, and critical access hospitals to adopt, implement, upgrade, and demonstrate the use of certified EHR technology (CEHRT). The reporting requirements involve the ability of an EHR to perform such functions as generating problem lists, exchanging patient clinical data, or e-prescribing. The MU program launched in three stages beginning in 2011. The focus of Stage 1 was data capture and sharing. In 2014, the Office of the National Coordinator for Health IT (ONC) created Stage 2, which sought to extend the requirements of Stage 1 and promote more advanced clinical processes. Stage 3 focused on improving overall outcomes. The combination of incentive payments for participation, paired with a penalty for failing to meet meaningful use criteria using the ONC certified technology, resulted in significantly expanded use of EHRs.

To qualify for federal funds, eligible healthcare professionals and hospitals not only had to adopt EHRs but also demonstrate meaningful use of CEHRT by achieving minimum core objectives in each stage of the MU program. It was also necessary to demonstrate compliance with the HIPAA security and privacy rules by conducting risk assessments. Even with the financial incentives, the requirements of the MU program were overly burdensome for physician practices and failure to meet them resulted in reduction of Medicare and Medicaid payments. While interoperability was one of the goals for the MU program, it failed in that regard. However, the financial incentive to adopt EHRs gave birth to an industry whose technology was not quite ready for its intended purpose, which is evident by the lack of uptake in the free market.

In 2016, MU was wrapped into the Merit-Based Incentive Payment System (MIPS) established under the Medicare Access and CHIP Reauthorization Act (MACRA). In 2018, CMS renamed the Medicare and Medicaid EHR Incentive Programs to the Promoting Interoperability Programs to better align with MACRA provisions for electronic exchange of healthcare information.

MACRA sought to promote “widespread interoperability” which it defined as “the ability of two or more health information systems or components to exchange clinical and other information and use the information that has been exchanged by means of common standards to provide access to longitudinal information for health care providers to facilitate coordinated care and improve patient outcomes.”

In 2009, only 12.2 percent of hospitals had adopted a basic EHR system. By 2017, the number of hospitals with an ONC certified EHR systems increased to 96 percent of hospitals and 80 percent of office-based physicians. Despite this rapid adoption of EHR technology, the vision of the HITECH Act and MACRA, an interoperable health data ecosystem that promoted efficiency and value in the healthcare system, was far from realized.

Data systems across the country became fragmented and were not interoperable. This was partially due to misaligned incentives in the HITECH Act that were heavily focused on provider requirements, with emphasis on adoption of an EHR with basic capabilities. As the program progressed, incentives were not shifted towards information exchange until MACRA, at which
point a highly siloed health data environment had formed. In 2016, a survey of healthcare providers found that “only 6% of healthcare providers report that information accessed from exchange partners on a different EMR is delivered in an effective way that facilitates improvement to patient care.” Additionally, platforms often were not designed in a usable manner, with only 8 percent of providers reporting that data could be received and located within the workflow.\textsuperscript{v} The lack of efficient technology manifests in high rates of burnout and time taken away from patients. An observational study of physician practices found that physicians spend 27 percent of their time with patients and 49.2 percent of their time on EHR and desk work. While in the examination room with patients, physicians spent approximately 53 percent of the time face-to-face with patients and 37 percent on the EHR.\textsuperscript{vi}

Recent HIT Efforts and Shortcomings

Congress addressed the fragmentation of data and lack of exchange in our healthcare system in the 21st Century Cures Act (Cures Act). Like MACRA, it mandated support for interoperable network exchange to be spearheaded by the ONC in collaboration with the National Institute of Standards and Technology and other divisions of HHS. ONC engaged in rulemaking in 2018 and 2019 to implement the interoperability and information blocking provisions of the Cures Act. This was done in tandem with the CMS Interoperability and Patient Access final rule, which developed new HIT compliance requirements for providers and certain payers to improve the electronic exchange of healthcare data and enable patients to safely and securely access their medical information through a third-party application of their choice.

The ONC rule made sweeping changes to HIT regulation to promote data sharing, empower consumers by granting them greater control over their data, and prevent healthcare entities from blocking the sharing of health data. The rule established a standard for the development of application programming interfaces (APIs), required EHR developers publish their APIs to ensure that different softwares and networks are able to effectively exchange information, and updated EHR certification criteria with a focus on interoperability. The update involves replacing the Common Clinical Data Sets required for certification with the new United States Core Data for Interoperability (USCDI).

The new data requirements are more extensive and will promote patient matching, tracking origins of data, and supports the sharing of clinical notes. Ultimately, USCDI establishes standards and formats for data to allow more seamless sharing. The rule also defines what entities are covered by information blocking, defines what constitutes information blocking, and outlines exceptions. The information blocking provisions of ONC’s Cures Act final rule took effect on April 5th, 2021, with various compliance dates staggered through 2023.\textsuperscript{vii}

These recent actions have helped level the playing field and create a regulatory framework that enables true interoperability across the U.S. healthcare ecosystem. However, much work needs to be done to ensure that the promise of true interoperability is realized, and that seamless health information exchange can be used to support population health and enhance the patient and clinician experiences.

Opportunities to Improve HIT Infrastructure to Support Patient Care and Clinicians

The next step in this process is to ensure that information is readily available to physicians and other clinicians at the point of care to improve the quality and efficiency of care, and to ensure that the health IT infrastructure is improved to better serve communities that are often left
behind in our health care system. Areas that critically need to be addressed to achieve these goals include the following:

**Effective matching of patient data**

Patient identification (patient matching) remains a persistent problem in ensuring that electronic health record (EHR) data is complete and accurate. Errors and missing information remain common in the electronic health record ecosystem, with several studies indicating that between 8 to 22 percent of all records are split or duplicate. These high-duplication and mismatched rates often translate into unnecessary resource use and poor outcomes when patient records are not up-to-date or contain inaccurate information. A 2016 report indicated that 4 percent of duplicate records result in negative clinical care and outcomes. Split and mismatched records make it difficult for physicians to have the full picture of a patient’s health and care received, and it also makes it more difficult for the patient to have access to their full record.

**Access to Data at the Point of Care**

Access to a patient’s complete medical history, including procedures, chronic conditions, and medication history, is critical to delivering high quality care. However, patients frequently misreport and or provide incomplete histories, which can result in negative outcomes due to harmful drug interactions or procedures conducted without knowledge of another comorbid condition. A study of 2,063 patients whose histories were collected during emergency department (ED) triage found that of all patients identified as taking medications, 48 percent failed to identify at least one of their medications, with a median of two drugs missed. Of the drugs missed at triage, 73 percent were prescription medications. Patients will often omit parts of their medical history for various reasons: focusing only on information the patient believes to be important, forgetting of information due to complex histories or medication lists, or intentional omission. While improved interviewing can improve this issue, access to comprehensive records at the point of care is the optimal and most efficient way to obtain a complete picture of a patient’s health. Enhanced sharing of patient data can also be used to create analytics tools built into EHR workflows.

**Streamlining Prior Authorization Processes to Eliminate Care Delays**

Prior authorization is a cumbersome process that requires physicians to obtain pre-approval for diagnostic procedures and medical treatments before they can render care to their patients. While the process is often conducted electronically, prior authorization sometimes needs to be obtained over the phone or via fax. Even when obtained electronically, payors have different processes, policies, and electronic platforms. The process for obtaining this approval is costly. The Council for Affordable Quality Healthcare (CAQH) estimated that the financial impact of prior authorization requirements to providers in 2019 was approximately $528 million, and the average transaction takes 21 minutes of provider staff time. If the healthcare industry were to fully shift to electronic prior authorizations with consistent technical standards that allow submissions from a single platform, providers could save 17 minutes per transaction and $355 million per year. However, for providers who do submit electronic prior authorizations, the process is still partially manual, as they need to log into separate portals for each payor and complete varying documentation requirements. Because prior authorization platforms do not integrate with the provider’s EHR system, the process generates significant barriers to the efficient care of patients. The current method for prior authorization is costly for providers, detracts from time spent with patients, and often forces patients to go without care or delays care. This can lead to needless increased suffering for the patient and worsening of their
condition, ultimately leading to increased cost of care. In order to have a truly effective prior authorization process, fully integrated electronic universal standards must be incorporated by all payers.

**Enhancing Health IT Regulatory Frameworks to Address Social Determinants of Health**

A quickly growing body of research indicates that social determinants of health may have a greater impact on a patient’s overall health and outcomes than treatment they receive. The HHS Healthy People 2030 initiative defines social determinants of health as the “conditions in the environments where people are born, live, learn, work, play, worship, and age that affect a wide range of health, functioning, and quality-of-life outcomes and risks.” It groups these factors into five domains, which include economic stability, education access and quality, healthcare access and quality, neighborhood and built environment, and social and community context.

A recent article published in Health Affairs compiles various studies that estimate the relative impact of various health determinants on outcomes. A study published by the University of Wisconsin-Madison found that behaviors contribute to 30 percent of outcomes, social circumstances contribute to 40 percent, environment contributes to 10 percent, and medical care contributes to 20 percent of outcomes. Overall, other studies have come to similar conclusions that 80 percent of the contributors to health outcomes are social determinants of health.

The COVID-19 pandemic particularly highlighted the impact of social determinants on outcomes and how social factors can drive disparities. Over the course of the pandemic, data has demonstrated that housing status, socioeconomic factors, and behaviors such as smoking were significant determinants of whether an individual contracted COVID-19 and the severity of their case. A study published in 2020 highlights how beyond infection, there are other downstream consequences from the pandemic. For example, children who depend on school lunches may face nutrition issues due to school closures. During the pandemic, the U.S. also saw unprecedented use of telehealth to expand access to health services and improve care. However, there are clear gaps in health IT infrastructure that prevent social determinants from being recorded and addressed.

The U.S. health system, and healthcare infrastructure, are not historically well equipped for coordinating care or capturing data outside the clinical setting. While ICD-10 codes exist for capturing information about social determinants of health in health records, many providers are not well educated on how to use them. Additionally, these codes often lack precision. At the same time, a regulatory framework for sharing health information and coordinating care with community-based organizations is relatively weak. These organizations often use different information management tools than health providers, and standards do not exist for data exchange. Even amongst certified health IT products, ONC does not have a required technical standard for sharing information related to social determinants of health. These challenges not only prevent sharing of individual level data for informed clinical decision making, but also stifle the aggregation of patient data to better understand the impact of social determinants.

Capturing and sharing social determinants of health information is critical to improving care coordination and management both within and outside of a clinic's four walls. However, the task of capturing this data should not fall solely on physicians. Ultimately, to build a health care system that is equipped to address social determinants of health, and to build an infrastructure for value-based care systems, changes to current HIT infrastructure are critical.

**Appropriate Use of Data by Third-Party Apps and Patient Protections**
Patient engagement in their own care and health maintenance is critical to overall well-being and promoting better outcomes. Patient health applications provide not only an opportunity for patient engagement in their own care, but they can also empower patients to share data with physicians and provide a clearer picture of their medical history. This is the goal of the CMS Interoperability and Patient Access final rule. However, third party apps are not properly regulated, and health data, which comprises some of the most sensitive information about an individual, can be compromised and exploited when downloaded onto third-party platforms. When patients want to use a health management application, they are often required to agree to user “terms and conditions” which often contain language permitting the developer to pass along user information to third parties. A recent study examining the 24 top-rated Android apps for health medicine management found that 19 of the 24 apps shared user data with third parties. Of these apps that shared data, 66 percent of the third parties that these apps shared data with “provided services related to the collection and analysis of user data, including analytics or advertising, suggesting heightened privacy risks.”

**Solutions**

**Effective Matching of Patient Data**

ONC should create technical standards and best practices governing how patients can monitor, update, or verify their information through applications and portals. The ONC’s final rule on interoperability gives patients unprecedented ownership over their own data, and this creates an opportunity to allow them to review demographic information that can impact the movement and matching of their record across platforms. Additionally, minor changes to data standards will help facilitate exchange of certain patient information. ONC should also standardize address formats within the USCDI and add a standard for gender identity.

**Access to Data at the Point of Care**

The CMS Interoperability and Patient Access rule finalized in 2020 requires Medicare Advantage plans, Medicaid and Children’s Health Insurance Program (CHIP) managed care plans, state agencies and Qualified Health Plans on federally facilitated exchanges to enable payor-patient exchange of claims data via FHIR API. This capability should be expanded to enable a payor-provider claims data exchange via FHIR API, and this should also apply to ACA qualified plans and Employee Retirement Income Security Act (ERISA) plans. The API should be similar to CMS’ Data at the Point of Care pilot enabled by the Blue Button 2.0 initiative. The pilot program has sought to give providers insight into patients’ claims and medication histories within their EHR workflow so they could make more informed clinical decisions during a patient encounter. A change of this nature would require legislative action to grant federal agencies authority to regulate this information sharing and qualify non-compliance as a form of information blocking. Additionally, having data on cost and coverage can prevent loss to follow-up care, particularly for patients where out-of-pocket cost is likely to result in deferred care, and also reduce administrative burden associated with prior authorization.

**Streamlining Prior Authorization Processes to Eliminate Care Delays**

Because of the growing burden created by prior authorization processes, some congressional and regulatory action has been taken to begin to address the issue. Most recently, CMS issued transaction standard for electronic prior authorization (ePA) under the Part D e-prescribing program. These ePA transaction standards would allow prescribers to use an electronic prescribing (eRX) system or an EHR with an eRX system to determine whether a patient’s Part
D plan requires prior authorization for a given medication and to receive responses in real time. While this regulation had many positive aspects, overall, given the limited scope of the Part D program, it did little to address the larger issues of standardizing prior authorization across the healthcare system. Congress has also made a legitimate effort to respond to this issue and develop policy to standardize electronic prior authorization. However, nothing has passed into law at the time of this publication, and active legislation during the 117th Congress is limited in scope to just Medicare Advantage (MA) plans.

To achieve fully standardize electronic prior authorization that integrates into a provider's workflow, legislation must be enacted that establishes technical requirements for private insurance plans regulated under the ACA and ERISA, as well as all CMS contractors that administer MA plans. This legislation must establish a universal electronic prior authorization (ePA) program and require all healthcare plans to adopt ePA capabilities that follow a single technical specification that allows payor platforms to seamlessly connect to other certified health IT. As is current practice, prior authorizations should still be reviewed by qualified medical professionals, and finally, there should be a streamlined process for reviewing prior authorization policies on routinely approved items and services. These changes are critical to ensuring that a provider's workflow is efficient, and that patient care is not delayed or impeded, resulting in worse outcomes.

**Enhancing Health IT Regulatory Frameworks to Address Social Determinants of Health**

In order to ensure that health IT can be leveraged to address social determinants of health, several changes to the current environment are needed. These changes would address the issues of data capture, interoperability and exchange, value-based care and payment.

To address improved data capture, three key changes will help ensure that health records contain more robust information on social determinants. First, ICD codes need to be made more granular to ensure appropriate information capture, and providers need to be educated on how to use relevant codes. Additionally, universal reimbursement standards should be developed to ensure consistent coding and appropriate payment for screening for social determinants and linkage to appropriate services. To address interoperability and exchange, ONC should add a data class to the USCDI to ensure that data relating to social determinants of health can be captured and shared in certified health IT. Health Level Seven (HL7) launched an initiative called the Gravity Project to create national standards for representing social determinant data in health IT. In October 2020, the Gravity Project submitted two approaches to ONC for adding a new data class for social determinants of health. Testing and adopting these standards will help ensure improved information sharing. In addition to the new USCDI data class, the AOA encouraged ONC to develop a pilot project to identify how to help community-based organizations better integrate their data systems with certified health IT.

Once health IT infrastructure is strengthened, HHS, plans, and providers can leverage newly available data to drive development of value-based initiatives. Because factors beyond the care rendered by a physician have such significant influence on a patient’s outcomes, it is critical that efforts to address social determinants are incorporated into value-based initiatives. Several efforts to achieve this are ongoing. An analysis by one managed care organization found that its efforts to meet patients’ needs for social services by referring them to resources for transportation, food programs, financial assistance for utilities, education programs, and housing services helped reduce health expenditures by as much as 10 percent for patients who had social needs met. However, action by providers at the point of care can have a greater...
impact, and models should be designed that incentivize and reward providers who help identify and address patients’ social needs.

**Appropriate Use of Data by Third-Party Apps and Patient Protection**

In 2021, the comment period closed on a proposed rule by the HHS Office for Civil Rights (OCR) to modify HIPAA. The rule fell short in advancing the security of sensitive patient data as it relates to third party apps. While the rule adds a definition for a “patient health application”, it does not consider these applications covered entities. Since the user of a third-party application agrees to the “terms and conditions”, and the applications are not covered entities, individually identifiable consumer health information collected by the apps or on personal health trackers often does not have to be stored and used in compliance with HIPAA requirements for protected health information (PHI). As such, third-party apps are allowed to transfer, sell, or share patient’s data without informing the consumer to obtain consent.

OCR should recognize applications on which patients can download PHI as a covered entity or require them to develop business associate agreements with vendors from whom they download data. Alternatively, if these approaches are not feasible, OCR should create a new class of entity that is subject to HIPAA privacy rules that captures these applications. HHS should also develop standards for authenticating patient identities to ensure that the third-party apps are held to similar standards as patient portals of HIT vendors.

While most of these solutions may be able to be address through the rule making process, some reforms will have to be codified through new federal legislation. In light of this, legislation which prevents data mining, sharing, or selling of personal health data by third-party apps must be passed into law.

There has been a willingness to work on this issue in Congress, in particular in the Senate Committee on Health, Education, Labor and Pensions (HELP), which has discussed this during public hearings, and with the introduction of legislation which seeks to address these gaps. Healthcare stakeholders must advocate for the passage of legislation which guarantees that no third-party entities are not allowed to transfer, sell or share any individually identifiable consumer health information collected regardless of the modality used to collect such data so that patients may continue to be an active participant in their own healthcare and be protected under the law without fear of losing their privacy by their use of third-party apps.

**Conclusion**

Throughout its history, HIT and EHR data entry has been a consistent topic of administrative burden and burnout for physicians across the U.S. Even when the government provided monetary incentives, it had become abundantly clear that reaching the goal of a fully interoperable EHR ecosystem that aids physician clinical decision making and lowers cost while improving quality of care is easier said than done. While the topics outlined in this document are by no means a fully comprehensive list of every concept or solution needed to fix the HIT ecosystem, it is clear that to fully realize the benefits of digital health information, we must first have truly meaningful data.

As outlined above, this includes, but is not limited to, the implementation of legislative and regulatory policies which empower consumers with their personal health data while ensuring that information is seamlessly provided to physicians at the point of care. However, to have the greatest impact, we must go beyond just access to medical data for physicians. In this new
digital world, we must also provide appropriate patient protections for any data which is acquired and used by any third-party apps. Finally, we must support and help implement future policies that improve community well-being by enhancing the HIT regulatory frameworks that influence non-medical social determinants of health factors that affect health outcomes. While much of the legislative and regulatory work is slow and tedious, if implemented correctly, effective EHR data has the possibility to improve quality of care while lowering costs, ultimately resulting in promoting healthy communities across the United States.

---


Data sharing practices of medicines related apps and the mobile ecosystem: traffic, content, and network analysis BMJ March 2019; 364:1920; Available at: https://www.bmj.com/content/364/bmj.l920 


Source: H344-A/21 

Status: 2021
Defining New Physicians in Practice

Policy Statement

The American Osteopathic Association defines a new physician in practice as a physician who is no more than 5 years past the completion of postdoctoral training.

Source: H300-A/22

Status: 2017; 2022 Reaffirmed
State Licensure of Managed Care Organizations (MCO) Medical Directors

Policy Statement

The American Osteopathic Association supports legislation or regulations that would require all Managed Care Organization (MCO) medical directors to be fully licensed physicians of the state where the care is being provided; and supports state medical boards’ rights to oversee and discipline any medical director of an MCO licensed as a physician in their state.

Source: H301-A/22

Status: 1999; 2004 Reaffirmed; 2009 Reaffirmed; 2017 Reaffirmed; 2022 Reaffirmed
Administrative Rule-Making Process

Policy Statement

The American Osteopathic Association supports closer federal and state legislative scrutiny of the administrative rule-making process effectively monitor the development of regulations and assure their conformity with expressed legislative intent.

Source: H302-A/22

Status: 1986; 1992 Reaffirmed as Amended; 1997 Reaffirmed; 2002 Reaffirmed as Amended; 2007 Reaffirmed; 2012 Reaffirmed as Amended; 2017 Reaffirmed; 2022 Reaffirmed
Advance Directives

Policy Statement

The American Osteopathic Association supports advance directives and will proactively assist in introducing this concept into federal legislation.

Source: H303-A/22

Status: 2002 Reaffirmed as Amended; 2007 Reaffirmed; 2012 Reaffirmed as Amended; 2017 Reaffirmed; 2022 Reaffirmed
Interstate Prescription Drug Monitoring Program (PDMP)

Policy Statement

The American Osteopathic Association supports an Interstate Prescription Drug Monitoring Program (PDMP) that allows prescribers, dispensers, or their designated staff in any state to access a patient's relevant prescription history, regardless of their residing state at no cost to the prescriber or dispenser.

Source: H304-A/22

Status: 2017; 2022 Reaffirmed as Amended
Improve Life-Saving Access to Epinephrine

Policy Statement

The American Osteopathic Association will advocate for states to enact comprehensive epinephrine training protocols for use during an allergic reaction for medical and non-medical professionals working in public facilities and supports increased availability of epinephrine in all forms to properly trained individuals.

Source: H305-A/22

Status: 2017; 2022 Reaffirmed as Amended
Prescription Drugs

Policy Statement

The American Osteopathic Association will: urge the FDA to strengthen its inspection and approval procedures and equivalency standards to ensure that generic drugs approved by the FDA are therapeutically equivalent to the brand drug for which they are to be substituted; oppose mandatory use of generic drugs or generic substitution programs that remove control of the treatment program from the physician; urge the development and enactment of public policy that would mandate that prescription drug plans cover name-brand medications when evidence-based treatment protocols recommend their use; act to educate healthcare insurers and managed care companies on the potential dangers of formulary substitutions; support public policy that requires a physician be available for consultation in a timely manner on pharmaceutical formulary and drug substitution decisions; oppose any attempt by federal or state governments to restrict, prohibit, or otherwise impede the prerogative of physicians to prescribe and dispense appropriate medications to their patients; urge the FDA to ensure safe and consistent drug supply that avoids shortages and ensures adequate generic pharmaceutical manufacture and supply for U.S. patients and physicians.

Source: H307-A/22

Status: 1990; 1995 Reaffirmed, 1997; 2002 Reaffirmed as Amended; 2007; 2012 Reaffirmed as Amended; 2017 Reaffirmed as Amended; 2022 Reaffirmed
Federally Funded Health Centers

Policy Statement

The American Osteopathic Association supports adequate staffing for the physicians providing medical care in federally funded health centers and opposes having a nurse practitioner or physician assistant in lieu of physicians in federally funded health centers. The AOA continues to support physician-led team healthcare delivery in all federally funded health care centers.

Source: H308-A/22

Status: 2002; 2007 Reaffirmed; 2012 Reaffirmed; 2017 Reaffirmed as Amended; 2022 Reaffirmed as Amended
Disparities Between Rural and Urban Practices

Policy Statement

The American Osteopathic Association supports federal legislation that would sustain a minimum geographic cost-of-practice index value for physicians’ services at or above 1.000.

Source: H309-A/22

Status: 2002; 2007 Reaffirmed; 2012 Reaffirmed; 2017 Reaffirmed; 2022 Reaffirmed
Preservation of Antibiotics for Medical Treatment

Policy Statement

The American Osteopathic Association supports legislation or regulatory efforts that would ban feed additive uses of antibiotics for non-therapeutic uses in animals such as for growth promotion, feed efficiency, weight gain, routine disease prevention or other routine purposes.

Source: H310-A/22

Status: 2007 Reaffirmed; 2012 Reaffirmed; 2017 Reaffirmed as Amended; 2022 Reaffirmed
Guidelines for Nutritional and Dietary Supplements

Policy Statement

The American Osteopathic Association requests: the Food and Drug Administration (FDA) to be diligent in their monitoring of all products marketed for human consumption, including nutritional supplements, and that there be close attention to reported adverse events directly caused by any of these products; and that the US Congress pass legislation requiring dietary supplements to undergo pre-market safety and efficacy evaluation by the FDA.

Source: H311-A/22

Status: 2002; 2007 Amended; 2011 Reaffirmed as Amended; 2012; 2017 Reaffirmed as Amended; 2022 Reaffirmed
Sexual Harassment

Policy Statement

The American Osteopathic Association supports state and federal legislation that prohibits sexual harassment.

Source: H312-A/22

Status: 1992; 1997 Reaffirmed, 2002 Reaffirmed as Amended; 2007; 2012 Reaffirmed as Amended; 2017 Reaffirmed; 2022 Reaffirmed as Amended
Due Process in Agency Determinations

Policy Statement

The American Osteopathic Association opposes any and all existing or proposed federal and state rules or procedures, and their underlying laws where no provision is made for a prior, fair, and formal hearing.

Source: H313-A/22

The American Osteopathic Association supports regulation in health care as follows:

1. The need for any new regulation must demonstrate that access to care, or patient safety, or the quality of health care provided, will be improved by the proposed regulatory action and that the claimed improvement can be accomplished at an acceptable cost to the public.

2. In all matters where the health profession has demonstrated its capacity for quality self-regulation, government at all levels should not impose additional or preemptive regulation.

3. Where the need for regulation has been demonstrated, it should emanate from the lowest applicable level of government.

4. Where there is a demonstrated necessity for regulation of health care, such regulation must be drawn and implemented in such a way as to promote pluralism and preserve the free enterprise system in health care.

5. Every effort should be made when formulating new regulations to harmonize them with existing regulations to prevent increasing existing regulatory burden.

Source: H315 – A/22

Status: 1997 Reaffirmed; 2002 Reaffirmed as Amended; 2007; 2012 Reaffirmed as Amended; 2017 Reaffirmed; 2022 Reaffirmed as Amended
Occupational Safety and Health Administration (OSHA) Regulations

Policy Statement

The American Osteopathic Association urges that the Occupational Safety and Health Administration (OSHA) prioritize education and training to create a safe workplace before considering assessment of fines.

Source: H316 – A/22

Status: 1992; 1997 Reaffirmed as Amended, 2002; 2007; 2012 Reaffirmed; 2017 Reaffirmed as Amended; 2022 Reaffirmed
Patient Safety

Policy Statement

The American Osteopathic Association endorses patient safety in health care that encourages payers to provide adequate payment so that physicians and hospitals can provide safe quality care.

Source: H317 – A/22

Status: 2002; 2007 Reaffirmed; 2012 Reaffirmed as Amended; 2017 Reaffirmed; 2022 Reaffirmed as Amended
Promotion of School Based Health Education

Policy Statement

The American Osteopathic Association will continue to urge the state legislatures to enact measures establishing programs that follow the Centers for Disease Control and Prevention’s Whole School Whole Community, Whole Child (WSCC) model.

Source: H318 – A/22

Status: 1992; 1997 Reaffirmed, 2002 Reaffirmed as Amended; 2007 Reaffirmed; 2012 Reaffirmed; 2017 Reaffirmed; 2022 Reaffirmed as Amended
Recoupment Laws

Policy Statement

The American Osteopathic Association supports public policy which subjects all parties to the same terms and time frame for billing, payment and appeal.

Source: H319 – A/22

Status: 2002; 2007; 2012 Reaffirmed as Amended; 2017 Reaffirmed as Amended; 2022 Reaffirmed
Right to Practice and Payment for Osteopathic Manipulative Treatment

Policy Statement

The American Osteopathic Association will pursue any and all legal and legislative recourse to protect patient access and the rights of its member physicians to deliver approved and beneficial modalities of healthcare; will work with legislators and state licensing boards to preserve the osteopathic profession’s right to establish and maintain standards of practice of osteopathic manipulative treatment; objects to any attempt by third party payers to deny or restrict payment for osteopathic manipulative treatment when appropriately rendered by a physician with appropriate training in osteopathic principles and practice; and will continue to oppose any attempt by third-party payers to interchange and/or combine osteopathic manipulative treatment codes with codes used to describe other forms of manual therapy.

Source: H320 – A/22

Equity in Medicare & Medicaid Payments

Policy Statement

The American Osteopathic Association will actively support federal legislation, rules or regulations, to include socioeconomic risk stratification in public reporting and evaluation of physician payment in all Medicare and Medicaid pay for performance value-based purchasing incentives or penalties to account for the challenges serving socioeconomically or medically underserved patient populations to ensure continued timely access to appropriate clinical services.

The AOA will support federal and state legislation, rules or regulations to improve Medicare and Medicaid payments to physicians working in socioeconomic, or medically underserved areas to ensure an adequate workforce to address the burden of care associated with complex comorbid conditions in these areas.

Source: H321 – A/22

Status: 2017; 2022 Reaffirmed as Amended
Naloxone and other Opioid Antagonists

Policy Statement

The American Osteopathic Association (AOA) will work with legislators to give statutory protection in evaluation for and prescription of Naloxone and other opioid antagonists.

Source: H322-A/22

Status: 2017; 2022 Reaffirmed as Amended
The American Osteopathic Association (AOA) endorses the “Shared Principles of Primary Care” as developed and published by the Patient-Centered Primary Care Collaborative (PCPCC).

Source: H323 – A/22

Status: 2017; 2022 Reaffirmed
Eugenic Selection with Preimplantation Genetic Diagnosis

Policy Statement

The American Osteopathic Association supports legislation in collaboration with the medical community that regulates the use of Preimplantation Genetic Diagnosis (PGD) to choose a fetus' traits unrelated to disease.

Source: H324 – A/22

Status: 2016; 2021 Referred; 2022 Reaffirmed as Amended
Interference Laws - Amendment to American Osteopathic Association Policy

Policy Statement

The American Osteopathic Association approved the following policy paper and recommendations to assist in responding to state and federal proposals and agencies that attempt to adopt interference laws.

INTERFERENCE LAWS (H358-A/19)

The American Osteopathic Association approved the following policy paper and recommendations to assist in responding to state and federal proposals and agencies that attempt to adopt interference laws (2013; 2019 Reaffirmed as Amended).

A number of states have pursued legislation that dictates how physicians treat and counsel patients during a medical exam. These laws interfere with the patient-physician relationship, and undermine physician judgment and represent a departure from evidence-based medicine. As a result, these laws are collectively referred to as “interference laws.”

Interference laws fall into one of four different classifications. The first prevents physicians from asking their patients about risk factors that may affect their health or the health of their families (PHYSICIAN “GAG LAWS”). One example of a Gag Law is a 2011 Florida law which barred physicians from asking questions about a patient’s gun ownership. The law was enjoined in 2012 on first amendments grounds, a decision which was upheld by a federal appeals court in 2017. Although 14 other states have considered similar laws, none have passed.

The second type of interference law requires physicians to discuss specific treatments that may not be appropriate or medically necessary. One example of this is New York’s Palliative Care Information Act of 2011, which requires health care providers to offer to discuss end-of-life options and palliative care services with terminally ill patients, without discretion as to how and when to raise the issues. Some argue that requiring physicians to discuss this subject with all patients is inappropriate, because physicians are not able to use their judgment to determine if or when patients should receive such sensitive information.

The third type of interference law requires physicians to provide tests or treatments which are not supported by evidence, including ones that are invasive or required without the patient’s consent. Examples of this are laws which require physicians who perform abortions to first perform a fetal ultrasound. It is argued that a fetal ultrasound is medically unnecessary and there is no legitimate medical purpose for requiring one in this circumstance.

The fourth and final type of interference law places restrictions on the content of information that physicians can disclose to patients. Examples of this include laws which limit a physician from providing information about the dangers of chemicals used in the hydraulic fracturing process, also known as “fracking.”

RECENTLY A FIFTH TYPE OF INTERFERENCE LAW HAS BEEN IDENTIFIED. THESE LAWS AND REGULATIONS INTERFERE IN THE PATIENT-PHYSICIAN RELATIONSHIP BY PROHIBITING, OR LIMITING, OR MANDATING PHYSICIANS FROM DISCUSSING,
RECOMMENDING, AND/OR PROVIDING IN THE DISCUSSION, RECOMMENDATION AND/OR PROVISION OF EVIDENCE BASED MEDICAL CARE OR TREATMENTS. AN EXAMPLE OF THIS ARE LAWS WHICH PROHIBIT OR LIMIT THE ABILITY OF PHYSICIANS TO PRESCRIBE CERTAIN MEDICATIONS BASED ON THE PHYSICIAN'S SPECIALTY.

Impact on the Osteopathic Medical Profession and the Patient-Physician Relationship
Interference laws threaten the osteopathic medical profession, in particular due to the intrusion into the patient-physician relationship, which is an essential component of the osteopathic care model's emphasis on preventive medicine and treatment of the whole patient.\(^9\) The patient-physician relationship is based on ethical principles of trust, confidentiality, respect, autonomy and open communication between the physician and patient.\(^10\)

Another critical element of osteopathic medical practice in general and the patient-physician relationship in particular is the concept of physician and patient autonomy and “patient-centered” care. The Institute of Medicine (IOM) defines patient-centered care as “providing care that is respectful of and responsive to individual patient preferences, needs and values, and ensuring that patient values guide all clinical decisions.”\(^11\) Patient-centered care is an essential element in the practice of evidence-based medicine. The American Osteopathic Association (AOA) supports the use of evidence-based medicine and the implementation of appropriate methods to optimize natural healing and to address the primary cause of disease.

The patient-physician relationship is a critical aspect of osteopathic care, due in large part to a partnership that is created between the physician and patient which relies heavily on communication. “Osteopathic physicians (DOs) consider the impact that lifestyle and community have on the health of each individual, and they work to break down barriers to good health. DOs are trained to look at the whole person, and osteopathic physicians integrate the patient into the health care delivery process as a partner.”\(^13\) Interference laws which prevent DOs from discussing certain health-related subjects such as the safe storage of firearms or the health implications of fracking undermine this partnership and violate the osteopathic principle of preventive medicine. DOs help prevent pediatric deaths by counseling caregivers on the importance of seatbelt and helmet use, but without the ability to adequately counsel a patient on the importance of safe firearm storage they may be unable to help prevent similar deaths from improperly stored firearms. “[T]he purpose of [a firearms] inquiry is so that the practitioner can determine what subject matters require further follow-up in the practice of preventive medicine.”\(^14\) The AOA rejects any censorship of professional communication, supports enactment of legislation protecting the patient-physician relationship and opposes any attempt to interfere with the patient-physician relationship.\(^15\)

Additionally, interference laws that require DOs to discuss treatments which are not medically necessary or are not supported by evidence-based guidelines violates the osteopathic principle of treating the whole patient and can undermine patient trust. In Kansas, for example, physicians are required to provide misleading information to patients regarding an unproven link between breast cancer and abortion.\(^16\) Twenty-three states currently require health care providers to refer patients to state-created “informed consent” materials, and according to a 2016 audit by Rutgers University, 31 percent of the information included in these materials was found to be medically inaccurate.\(^17\) Blanket requirements that DOs provide information on a particular treatment, or medically inaccurate information, to all patients prevents them from exercising their independent medical judgment and treating the whole patient in an objective, evidence-based manner. Similarly, interference laws which require DOs to perform certain procedures or treatments violate the osteopathic principle of providing
individualized patient-centered care. If a DO is required to perform a certain procedure or treatment for every patient, there is no individualized assessment as to what is in a particular patient’s best interests and there is no discussion with the patient because the patient has no choice. Instead of individualized care, this is a “one size fits all” approach. Ultimately, DOs are prevented from rendering individualized, evidence-based care, and patients are prevented from being involved in patient-centered care.

Legal Challenges
Two types of interference laws have been challenged in court. Florida’s controversial Firearm Owner’s Privacy Act, which restricted physicians from asking patients about firearm ownership, was enjoined in June 2012 when a Florida district court found that it violated physicians’ First Amendment rights, a decision which was upheld by a federal appeals court in 2017. In granting the injunction, the judge stated the law “chills practitioners’ speech in a way that impairs the provision of medical care and may ultimately harm the patient.”

The court also held that physician questioning did not violate patients’ Second Amendment rights stating, “[t]he law does not affect nor interfere with a patient’s right to continue to own, possess, or use firearms.”

Protecting the right to keep and bear arms is irrelevant to this law.” In addition, a similar 2012 law which prevented physicians in Pennsylvania from discussing how fracking chemicals may be affecting their patients’ health was struck down by the state supreme court in 2016.

Mandatory ultrasound laws have also been challenged on First Amendment grounds. North Carolina’s mandatory ultrasound law was struck down as a violation of physician and patient First Amendment rights. The court held that “[t]he Act goes well beyond requiring disclosure of those items traditionally a part of the informed consent process. In this case, the state compels the provider to physically speak and show the state’s non-medical message to patients unwilling to hear or see [that message].”

Conversely, a nearly identical Kentucky law was upheld by a federal appeals court, which found that the law was reasonably related to the “informed consent” process and did not violate the First Amendment rights of physicians and patients. Significantly, the circuit split between the courts sets up a probable hearing by the United States Supreme Court on the issue of mandatory ultrasound laws.

Mandatory ultrasound laws have also been challenged in court on Fourteenth Amendment Substantive Due Process grounds. A mandatory ultrasound law in Oklahoma was ruled to be unconstitutional as a violation of patients’ Fourteenth Amendment due process rights, because it placed an “undue burden” on a woman’s right to seek an abortion.

Efforts of Medical Associations
Several medical associations have developed policies or taken action in opposition to interference laws. In 2015, the American Medical Association (AMA) reaffirmed a 2011 resolution which opposes any intrusion into patient-physician relationships and supports physician judgment. In May 2018, the American Academy of Family Physicians (AAFP), the American Academy of Pediatrics, the American College of Obstetricians and Gynecologists and the American College of Physicians issued a set of joint principles based upon their organizations’ policies which oppose governmental interference with physicians’ obligations to provide comprehensive, evidence-based information to patients.

The American Bar Association (ABA) also has policy specifically opposing laws which prevent physicians from asking patients about firearm ownership. The ABA policy states that these laws
clearly violate the First Amendment rights of physicians and patients, and physician questioning does not in any way violate Second Amendment rights of patients.26

Finally, several state medical associations have adopted resolutions on the issue of interference laws. Many of these policies are very basic and simply state the association’s opposition to any interference with the patient-physician relationship. Additionally, these policies often promote the use of evidence-based medicine, seek to preserve physician judgment and support litigation which blocks the enforcement of interference laws.

Conclusion
The AOA supports the protection of the patient-physician relationship as especially paramount to the osteopathic medical profession. The osteopathic care model is based upon the treatment of the whole patient and the use of preventive medicine. The patient-physician relationship is a fundamental aspect of osteopathic care, due in large part to a partnership that is created between the physician and patient which relies heavily on communication and trust. Interference laws encroach on this relationship and undermine the osteopathic care model by preventing DOs from providing treatment in a manner that is based upon evidence they believe is best for their patients.

The AOA affirms that legislation which interferes with the patient-physician relationship impairs the autonomy of osteopathic physicians and prevents osteopathic physicians from using their independent medical judgment based on years of rigorous education and training.

The AOA asserts that physicians must be able to communicate freely with patients without fear of government intrusion in order to assure safe, comprehensive and effective medical treatment.

The AOA considers legislation that undermines physician judgment to be a barrier to evidence-based medicine.

The AOA supports the use of evidence-based medicine to ensure high quality patient care. Statutorily required medical practices interfere with evidence-based medicine by mandating a “one size fits all approach,” thereby preventing an individualized assessment of what is in a particular patient’s best interests.

The AOA affirms that legislation which interferes with the patient-physician relationship undermines patient-centered care. Patient-centered care actively involves the patient in making decisions regarding their own medical care. Statutorily required medical practices prevent patients from being involved in making medical decisions, because the patient has no choice.

The AOA believes that the ethical principle of informed consent is undermined when patients are statutorily required to undergo certain treatments or procedures, because the patient has no choice.

The AOA opposes all legislation at the state and federal level that requires physicians to discuss or perform certain treatments or procedures not supported by evidence-based guidelines, because such legislation undermines physician judgment.

The AOA opposes all legislation at the state and federal level which prevents physicians from discussing certain health-related risk factors with their patients, because such legislation violates the First Amendment rights of physicians and patients and is in conflict with evidence-based medical best practices.
The AOA believes that physicians should be free to counsel patients on end-of-life care on a case-by-case basis rather than as a result of an across-the-board mandate.

The AOA supports legal challenges to interference laws that violate First Amendment and Fourteenth Amendment rights of physicians and patients under the State and Federal Constitutions.

THE AOA OPPOSES ALL LEGISLATION AT THE STATE AND FEDERAL LEVEL WHICH PREVENTS, LIMITS, OR MANDATES PHYSICIANS FROM DISCUSSING, RECOMMENDING, OR PROVIDING AN EVIDENCE BASED TREATMENT WHICH IN THE PHYSICIAN’S CLINICAL JUDGMENT IS IN THE PATIENT’S BEST INTEREST BECAUSE SUCH LEGISLATION ERODES THE SANCTITY OF THE PATIENT-PHYSICIAN RELATIONSHIP AND UNDERMINES THE PHYSICIAN’S CLINICAL JUDGMENT.

The AOA will monitor state and federal interference laws on an ongoing basis and update this policy as needed.

Source: H325 – A/22

Status: 2022 Reaffirmed as Amended
98th ANNUAL AOA HOUSE OF DELEGATES MEETING  
As of July 23, 2018

HOUSE OF DELEGATES’  
PUBLIC AFFAIRS REFERENCE COMMITTEE

(400 series) - This reference committee reviews and considers matters relating to public and industrial health, research and physical fitness.

<table>
<thead>
<tr>
<th>Res. No.</th>
<th>Resolution Title</th>
<th>Submitted By</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>H-400</td>
<td>Blood Donors, Increasing the Number of (H400-A/13)</td>
<td>BSAPH</td>
<td>APPROVED (for sunset)</td>
</tr>
<tr>
<td>H-401</td>
<td>Gambling Disorder (H401-A/13)</td>
<td>BSAPH</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-402</td>
<td>Environmental Health (H402-A/13)</td>
<td>BSAPH</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-403</td>
<td>Airbags in Automobiles (H403-A/13)</td>
<td>BSAPH</td>
<td>REFERRED</td>
</tr>
<tr>
<td>H-404</td>
<td>Choosing Wisely Campaign (H404-A/13)</td>
<td>BOCER</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-405</td>
<td>Cervical Cancer, Screening for (H405-A/13)</td>
<td>BSAPH</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-406</td>
<td>Healthy Life Styles (H406-A/13)</td>
<td>BSAPH</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-407</td>
<td>Medication Take-Back Program (H407-A/13)</td>
<td>BSAPH</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-408</td>
<td>Fire Prevention – Teaching of (H408-A/13)</td>
<td>BSAPH</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-409</td>
<td>Healthy People 2010 (H409-A/13)</td>
<td>BSAPH</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-410</td>
<td>Distribution of Sterile Syringes and Needles to IV Drug Abusers – Approval of (H410-A/13)</td>
<td>BSAPH</td>
<td>APPROVED (for sunset)</td>
</tr>
<tr>
<td>H-411</td>
<td>Immunizations (H411-A/13)</td>
<td>BSAPH</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-412</td>
<td>Patient Education (H412-A/13)</td>
<td>BSAPH</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-413</td>
<td>Pediatric Drug Testing (H413-A/13)</td>
<td>BFHP</td>
<td>APPROVED (for sunset)</td>
</tr>
<tr>
<td>H-414</td>
<td>Substance Abuse (H414-A/13)</td>
<td>BSAPH</td>
<td>APPROVED as AMENDED</td>
</tr>
<tr>
<td>H-415</td>
<td>Tuberculosis Medical Training (H415-A/13)</td>
<td>BSAPH</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-416</td>
<td>Pediatric Medical Imaging (H416-A/13)</td>
<td>BSAPH</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-417</td>
<td>Disaster Preparedness Planning (H417-A/13)</td>
<td>BSAPH</td>
<td>APPROVED as AMENDED</td>
</tr>
<tr>
<td>H-418</td>
<td>Distracted Driver Awareness (H418-A/13)</td>
<td>BSGA</td>
<td>APPROVED as AMENDED</td>
</tr>
<tr>
<td>H-419</td>
<td>Pediatric Obesity (H419-A/13)</td>
<td>BSAPH</td>
<td>APPROVED</td>
</tr>
<tr>
<td>Res. No.</td>
<td>Resolution Title</td>
<td>Submitted By</td>
<td>Reference Committee</td>
</tr>
<tr>
<td>---------</td>
<td>-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>--------------</td>
<td>---------------------------------</td>
</tr>
<tr>
<td>H-420</td>
<td>Osteopathic Manipulative Treatment of Somatic Dysfunction of the Head, Safety in (H426-A/13)</td>
<td>BOCER</td>
<td>APPROVED as AMENDED</td>
</tr>
<tr>
<td>H-421</td>
<td>Physician-Patient Relationship as Related to Proposed Gun Control Laws, Protection of the (H427-A/13)</td>
<td>BSAPH</td>
<td>REFERRED</td>
</tr>
<tr>
<td>H-422</td>
<td>Energy Drinks (H428-A/13)</td>
<td>BSAPH</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-423</td>
<td>“Opioid Overdose” Deaths in America – Epidemic (H429-A/13)</td>
<td>BSAPH</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-424</td>
<td>Human Immunodeficiency Virus (HIV) Testing – Clinical and Public Health Application of (H430-A/13)</td>
<td>BSAPH</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-425</td>
<td>Breastfeeding Exclusivity (H433-A/12)</td>
<td>BSAPH</td>
<td>APPROVED as AMENDED</td>
</tr>
<tr>
<td>H-426</td>
<td>Breastfeeding – Protecting (H600-A/13)</td>
<td>BFHP</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-427</td>
<td>American Osteopathic Association Makes Public Statement and Develops Protocols to Prevent Sexual Abuse of Patients</td>
<td>MOA</td>
<td>APPROVED as AMENDED</td>
</tr>
<tr>
<td>H-428</td>
<td>Concerns in Homeless Population</td>
<td>MOA</td>
<td>APPROVED as AMENDED</td>
</tr>
<tr>
<td>H-429</td>
<td>Patient Discrimination of Osteopathic Physicians</td>
<td>IOMA</td>
<td>REFERRED</td>
</tr>
<tr>
<td>H-430</td>
<td>Physician Assisted Death (Response to RES. NO. H-341 - A/2017 TASK FORCE TO STUDY PHYSICIAN AID IN DYING)</td>
<td>ELPTF</td>
<td>DISAPPROVED</td>
</tr>
</tbody>
</table>
HOUSE OF DELEGATES’ REFERENCE COMMITTEE DESCRIPTIONS:

- Committee on Public Affairs (400 series)
  This reference committee reviews and considers matters relating to public and industrial health, research and physical fitness.

<table>
<thead>
<tr>
<th>Res. No.</th>
<th>Resolution Title</th>
<th>Submitted By</th>
<th>Reference Committee</th>
</tr>
</thead>
<tbody>
<tr>
<td>H-400</td>
<td>Patient Safety and use for Patients with Pain Conditions (H400-A/14)</td>
<td>BOCER</td>
<td>Public</td>
</tr>
<tr>
<td>H-401</td>
<td>Human Trafficking – Awareness as a Global Health Problem (H401-A/14)</td>
<td>BSAPPH</td>
<td>Public</td>
</tr>
<tr>
<td>H-402</td>
<td>Same-Sex Relationships and Healthy Families (H403-A/14)</td>
<td>BSAPPH</td>
<td>Public</td>
</tr>
<tr>
<td>H-403</td>
<td>Public Information – Correction of, About the Osteopathic Profession (H404-A/14)</td>
<td>BIOM</td>
<td>Public</td>
</tr>
<tr>
<td>H-404</td>
<td>Alert Network – Silver and Gold (H405-A/14)</td>
<td>BSAPPH</td>
<td>Public</td>
</tr>
<tr>
<td>H-405</td>
<td>Alcohol Abuse (H407-A/14)</td>
<td>BSAPPH</td>
<td>Public</td>
</tr>
<tr>
<td>H-406</td>
<td>Discrimination in Healthcare (H408-A/14)</td>
<td>BFHP</td>
<td>Public</td>
</tr>
<tr>
<td>H-407</td>
<td>Sudden Infant Death Syndrome (H409-A/14)</td>
<td>BSAPPH</td>
<td>Public</td>
</tr>
<tr>
<td>H-408</td>
<td>Pharmaceuticals – Support Efforts to Encourage the Proper Disposal of Unused and Expired (H410-A/14)</td>
<td>BSAPPH</td>
<td>Public</td>
</tr>
<tr>
<td>H-409</td>
<td>Advertising - Inflammatory and Unethical by Attorneys (H411-A/14)</td>
<td>BSGA</td>
<td>Public</td>
</tr>
<tr>
<td>H-410</td>
<td>Comparative Effectiveness Research (H412-A/14)</td>
<td>BOCER</td>
<td>Public</td>
</tr>
<tr>
<td>H-411</td>
<td>Epidemic Terrorist Attack Victims, Government Responsibility of Health Care (H413-A/14)</td>
<td>BFHP</td>
<td>Public</td>
</tr>
<tr>
<td>H-412</td>
<td>Fluoridation (H414-A/14)</td>
<td>BSAPPH</td>
<td>Public</td>
</tr>
<tr>
<td>H-413</td>
<td>Maternal and Child Healthcare Block Grants (H415-A/14)</td>
<td>BSA</td>
<td>Public</td>
</tr>
<tr>
<td>H-415</td>
<td>Breastfeeding While On Methadone Maintenance (H417-A/14)</td>
<td>BSAPPH</td>
<td>Public</td>
</tr>
<tr>
<td>H-416</td>
<td>Raw Milk – Health Risks (H418-A/14)</td>
<td>BSAPPH</td>
<td>Public</td>
</tr>
<tr>
<td>H-417</td>
<td>Vaccines (H419-A/14)</td>
<td>BSAPPH</td>
<td>Public</td>
</tr>
<tr>
<td>H-418</td>
<td>Domestic and Intimate Partner Violence – Development of Programs to Prevent (H424-A/14)</td>
<td>BSAPPH</td>
<td>Public</td>
</tr>
<tr>
<td>H-419</td>
<td>Health Care Fraud (H425-A/14)</td>
<td>BSA</td>
<td>Public</td>
</tr>
<tr>
<td>H-420</td>
<td>Automated External Defibrillator Availability (H426-A/14)</td>
<td>BSGA</td>
<td>Public</td>
</tr>
<tr>
<td>Res. No.</td>
<td>Resolution Title</td>
<td>Submitted By</td>
<td>Reference Committee</td>
</tr>
<tr>
<td>---------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>--------------</td>
<td>---------------------</td>
</tr>
<tr>
<td>H-421</td>
<td>Minorities, Underrepresented – Increasing Numbers of Applicants, Graduates And Faculty At Colleges of Osteopathic Medicine (H429-A/14)</td>
<td>BOE</td>
<td>Public</td>
</tr>
<tr>
<td>H-422</td>
<td>Lead Exposure In Children – Prevention, Detection, and Management (H431-A/14)</td>
<td>BSAPH</td>
<td>Public</td>
</tr>
<tr>
<td>H-423</td>
<td>Hepatitis C Screening (H432-A/14)</td>
<td>BSA</td>
<td>Public</td>
</tr>
<tr>
<td>H-424</td>
<td>Regulation of E-Cigarettes and Nicotine Vaping (H435-A/14)</td>
<td>BSGA</td>
<td>Public</td>
</tr>
<tr>
<td>H-425</td>
<td>Firearm Safety (H406-A/14)</td>
<td>BSAPH</td>
<td>Public</td>
</tr>
<tr>
<td>H-426</td>
<td>Protecting Patients with Private Insurance from Balance Billing</td>
<td>BFHP</td>
<td>Public</td>
</tr>
<tr>
<td>H-429</td>
<td>CMS Rules on Psychotropic Medications in Nursing Facilities</td>
<td>IOMA</td>
<td>Public</td>
</tr>
<tr>
<td>H-430</td>
<td>Opposition to Patient Discrimination of Osteopathic Physicians Because of Race, Color, Religion, Gender, Sexual Orientation, Gender Identity or National Origin</td>
<td>IOMA</td>
<td>Public</td>
</tr>
<tr>
<td>H-431</td>
<td>Recognition of Health Care as a Human Right</td>
<td>MOA</td>
<td>Public</td>
</tr>
<tr>
<td>H-432</td>
<td>Osteopathic Physicians and the Availability of Naloxone</td>
<td>OOA</td>
<td>Public</td>
</tr>
<tr>
<td>H-433</td>
<td>Physician Awareness of Firearm Safety in Older Persons</td>
<td>POMA</td>
<td>Public</td>
</tr>
<tr>
<td>H-434</td>
<td>Opposing Zero-Tolerance Immigration Policies and the Separation of Families at the Border</td>
<td>SOMA</td>
<td>Public</td>
</tr>
<tr>
<td>H-435</td>
<td>Recognizing Food Insecurity as a Public Health Issue</td>
<td>SOMA</td>
<td>Public</td>
</tr>
<tr>
<td>H-436</td>
<td>Community Pharmacies; Required Notification of Primary Care Providers Regarding Vaccination Administration</td>
<td>IOMS</td>
<td>Public</td>
</tr>
<tr>
<td>H-437</td>
<td>Firearm Violence</td>
<td>IOMA</td>
<td>Public</td>
</tr>
</tbody>
</table>
HOUSE OF DELEGATES’ REFERENCE COMMITTEE DESCRIPTION:

- Committee on Public Affairs (400 series)
  This reference committee reviews and considers matters relating to public and industrial health, research and physical fitness.

<table>
<thead>
<tr>
<th>Res. No.</th>
<th>Resolution Title</th>
<th>Submitted By</th>
<th>Reference Committee</th>
</tr>
</thead>
<tbody>
<tr>
<td>H400</td>
<td>Interference in the Physician-Patient Relationship by Personal Injury Attorneys and Insurance Carrier Agents (H400-15)</td>
<td>BSAPH / BSA</td>
<td>Public</td>
</tr>
<tr>
<td>H401</td>
<td>Osteopathic Name and Identity (H401-A/15)</td>
<td>BOE</td>
<td>Public</td>
</tr>
<tr>
<td>H402</td>
<td>Public Education Regarding the Importance and Safety of Vaccines for Infants, Children, and Adults (H402-A/15)</td>
<td>BSAPH</td>
<td>Public</td>
</tr>
<tr>
<td>H403</td>
<td>Support for the Advisory Committee on Immunization Practices (ACIP) Recommendations (H403-A/15)</td>
<td>BSAPH</td>
<td>Public</td>
</tr>
<tr>
<td>H404</td>
<td>Vaccination Rates – Daycare Notification to Parents (H404-A/15)</td>
<td>BSGA</td>
<td>Public</td>
</tr>
<tr>
<td>H405</td>
<td>Protection of Safe Water Supply (H405-A/15)</td>
<td>BFHP / BSAPH</td>
<td>Public</td>
</tr>
<tr>
<td>H406</td>
<td>Antibiotic Stewardship (H407-A/15)</td>
<td>BSAPH</td>
<td>Public</td>
</tr>
<tr>
<td>H407</td>
<td>Vaccines for Children Program (H408-A/15)</td>
<td>BSAPH</td>
<td>Public</td>
</tr>
<tr>
<td>H408</td>
<td>Seat Belt Laws – Primary Enforcement (H409-A/15)</td>
<td>BSGA</td>
<td>Public</td>
</tr>
<tr>
<td>H409</td>
<td>Intrauterine Fetal Demise Awareness (H410-A/15)</td>
<td>BSAPH</td>
<td>Public</td>
</tr>
<tr>
<td>H410</td>
<td>Antifreeze Poisoning (H411-A/15)</td>
<td>BSAPH</td>
<td>Public</td>
</tr>
<tr>
<td>H411</td>
<td>Aircraft Emergency Medical Supplies (H412-A/15)</td>
<td>BFHP</td>
<td>Public</td>
</tr>
<tr>
<td>H412</td>
<td>Animals in Medical Research (H413-A/15)</td>
<td>BSAPH</td>
<td>Public</td>
</tr>
<tr>
<td>H413</td>
<td>Cancer (H415-A/15)</td>
<td>BSAPH</td>
<td>Public</td>
</tr>
<tr>
<td>H414</td>
<td>Cardiopulmonary Resuscitation, Training (H416-A/15)</td>
<td>BSAPH</td>
<td>Public</td>
</tr>
<tr>
<td>H415</td>
<td>Children’s Safety Seats (H417-A/15)</td>
<td>BSAPH</td>
<td>Public</td>
</tr>
<tr>
<td>H416</td>
<td>Death – Right to Die (H419-A/15)</td>
<td>BSGA</td>
<td>Public</td>
</tr>
<tr>
<td>H417</td>
<td>Environmental Responsibility--Waste Materials (H420-A/15)</td>
<td>BSAPH</td>
<td>Public</td>
</tr>
<tr>
<td>H418</td>
<td>Firearms and Non-Powdered Guns - Education for Users (H421-A/15)</td>
<td>BFHP</td>
<td>Public</td>
</tr>
<tr>
<td>H419</td>
<td>Genetic Manipulation of Food Products – Consumers Right to Know (H422-A/15)</td>
<td>BSAPH</td>
<td>Public</td>
</tr>
<tr>
<td>H420</td>
<td>Condom Usage – Health Education (H423-A/15)</td>
<td>BSAPH</td>
<td>Public</td>
</tr>
</tbody>
</table>
## SPECIAL MEETING OF THE AOA HOUSE OF DELEGATES

### OCTOBER 2020 MEETING

#### PUBLIC AFFAIRS - RESOLUTION ROSTER

As of September 28, 2020

<table>
<thead>
<tr>
<th>Res. No.</th>
<th>Resolution Title</th>
<th>Submitted By</th>
<th>Reference Committee</th>
</tr>
</thead>
<tbody>
<tr>
<td>H421</td>
<td>Support of Literacy Programs <em>(H424-A/15)</em></td>
<td>BSAPH</td>
<td>Public</td>
</tr>
<tr>
<td>H422</td>
<td>Tanning Devices <em>(H425-A/15)</em></td>
<td>BSGA</td>
<td>Public</td>
</tr>
<tr>
<td>H423</td>
<td>Tobacco Settlement Funds <em>(H426-A/15)</em></td>
<td>BSGA</td>
<td>Public</td>
</tr>
<tr>
<td>H424</td>
<td>Healthy Family, Support of <em>(H428-A/15)</em></td>
<td>BSAPH</td>
<td>Public</td>
</tr>
<tr>
<td>H425</td>
<td>Immunization of 9 to 26 Year Old Male and Females with Human Papilloma Virus Vaccine <em>(H429-A/15)</em></td>
<td>BSAPH</td>
<td>Public</td>
</tr>
<tr>
<td>H426</td>
<td>Drugs, Curbing Counterfeit <em>(H430-A/15)</em></td>
<td>BFHP</td>
<td>Public</td>
</tr>
<tr>
<td>H427</td>
<td>Sleep Disorders – Promoting the Understanding and Prevention of <em>(H432-A/15)</em></td>
<td>BSAPH</td>
<td>Public</td>
</tr>
<tr>
<td>H428</td>
<td>Minority Health Disparities <em>(H433-A/15)</em></td>
<td>BSAPH</td>
<td>Public</td>
</tr>
<tr>
<td>H429</td>
<td>Infant Walker (Mobile) – Ban on the Manufacture, Sale and Use of <em>(H434-A/15)</em></td>
<td>BSAPH</td>
<td>Public</td>
</tr>
<tr>
<td>H430</td>
<td>Develop In-Vitro Fertilization Standards of Care <em>(H435-A/15)</em></td>
<td>BSAPH</td>
<td>Public</td>
</tr>
<tr>
<td>H431</td>
<td>Complementary and Alternative Medicine by Non-Physicians <em>(H436-A/15)</em></td>
<td>BSGA</td>
<td>Public</td>
</tr>
<tr>
<td>H432</td>
<td>Continued Support OF Combating Bio-Terrorism Activities <em>(H437-A/15)</em></td>
<td>BFHP</td>
<td>Public</td>
</tr>
<tr>
<td>H433</td>
<td>Childhood Obesity – Worsening Epidemic in the American Society <em>(H438-A/15)</em></td>
<td>BSAPH</td>
<td>Public</td>
</tr>
<tr>
<td>H434</td>
<td>Immunizations – Mainstay of Preventive Medical Practice <em>(H439-A/15)</em></td>
<td>BSAPH</td>
<td>Public</td>
</tr>
<tr>
<td>H435</td>
<td>Texting While Driving <em>(H440-A/15)</em></td>
<td>BSAPH</td>
<td>Public</td>
</tr>
<tr>
<td>H436</td>
<td>Silver Alert System <em>(H442-A/15)</em></td>
<td>BFHP</td>
<td>Public</td>
</tr>
<tr>
<td>H437</td>
<td>National Institutes of Health Grants <em>(H443-A/15)</em></td>
<td>BFHP</td>
<td>Public</td>
</tr>
<tr>
<td>H438</td>
<td>Screening for Breast Cancer <em>(H444-A/15)</em></td>
<td>BSAPH</td>
<td>Public</td>
</tr>
<tr>
<td>H439</td>
<td>Gender Identity Non-Discrimination <em>(H445-A/15)</em></td>
<td>BSAPH</td>
<td>Public</td>
</tr>
<tr>
<td>H440</td>
<td>Traumatic Brain Injury Awareness <em>(H446-A/15)</em></td>
<td>BSAPH</td>
<td>Public</td>
</tr>
<tr>
<td>H441</td>
<td>Support for Family Caregivers <em>(H448-A/15)</em></td>
<td>BSAPH</td>
<td>Public</td>
</tr>
<tr>
<td>H442</td>
<td>Firearm Violence <em>(H450-A/15)</em></td>
<td>BFHP</td>
<td>Public</td>
</tr>
<tr>
<td>H443</td>
<td>Addressing Police Use of Disproportionate Force…</td>
<td>SOMA</td>
<td>Public</td>
</tr>
<tr>
<td>H444</td>
<td>Adopting and Promoting Non-Stigmatizing Language for Substance Use Disorders</td>
<td>SOMA</td>
<td>Public</td>
</tr>
<tr>
<td>H445</td>
<td>AOA Response to Novel Public Health Threats</td>
<td>MOA</td>
<td>Public</td>
</tr>
</tbody>
</table>
### SPECIAL MEETING OF THE AOA HOUSE OF DELEGATES
### OCTOBER 2020 MEETING
### PUBLIC AFFAIRS - RESOLUTION ROSTER
### As of September 28, 2020

<table>
<thead>
<tr>
<th>Res. No.</th>
<th>Resolution Title</th>
<th>Submitted By</th>
<th>Reference Committee</th>
</tr>
</thead>
<tbody>
<tr>
<td>H446</td>
<td>Background Checks and Firearms Safety Training as a Condition of Firearms Purchase</td>
<td>BFHP</td>
<td>Public</td>
</tr>
<tr>
<td>H447</td>
<td>Fentanyl Testing Strips</td>
<td>AOAAM</td>
<td>Public</td>
</tr>
<tr>
<td>H448</td>
<td>Firearms Policy</td>
<td>BFHP</td>
<td>Public</td>
</tr>
<tr>
<td>H449</td>
<td>Homeless Support</td>
<td>OPSC</td>
<td>Public</td>
</tr>
<tr>
<td>H450</td>
<td>Medical Amnesty for Underage Consumption of Alcohol</td>
<td>AOAAM</td>
<td>Public</td>
</tr>
<tr>
<td>H451</td>
<td>Opposition to Abstinence-Only Sex Education</td>
<td>SOMA</td>
<td>Public</td>
</tr>
<tr>
<td>H452</td>
<td>REFERRED RESOLUTION: Breastfeeding While on Medication Assisted Treatment (MAT)</td>
<td>BSAPH</td>
<td>Public</td>
</tr>
<tr>
<td>H454</td>
<td>REFERRED SUNSET RESOLUTION: H429 A/14 Minorities, Underrepresented (URM) – Increasing Numbers of Applicants…</td>
<td>BSAPH</td>
<td>Public</td>
</tr>
<tr>
<td>H455</td>
<td>REFERRED RESOLUTION: Regulation of E-Cigarettes and Nicotine Vaping</td>
<td>BSAPH</td>
<td>Public</td>
</tr>
<tr>
<td>H456</td>
<td>Recognizing Health Care as a Human Right</td>
<td>MOA</td>
<td>Public</td>
</tr>
<tr>
<td>H457</td>
<td>Support a Culture of Patient Safety and Speaking Up from Medical Students and Preceptors in Healthcare Settings</td>
<td>SOMA</td>
<td>Public</td>
</tr>
<tr>
<td>H458</td>
<td>WITHDRAWN</td>
<td>IOMA</td>
<td>Public</td>
</tr>
</tbody>
</table>
**House of Delegates’ Reference Committee Description:**
Committee on Public Affairs (400 series)
This reference committee reviews and considers matters relating to public and industrial health, research, and physical fitness.

<table>
<thead>
<tr>
<th>Res. No.</th>
<th>Resolution Title</th>
<th>Submitted By</th>
<th>Reference Committee</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>H-400</td>
<td>Endorse Nutritionally Balanced, Low Cost or Free Meals for Children in Schools</td>
<td>ACOFP</td>
<td>Public Affairs</td>
<td>ADOPTED as AMENDED</td>
</tr>
<tr>
<td>H-401</td>
<td>Supporting Public Policy to Encourage Wholesome Food Donations to Those in Need in America</td>
<td>MOA</td>
<td>Public Affairs</td>
<td>ADOPTED</td>
</tr>
<tr>
<td>H-402</td>
<td>Collection of Public Health Data Concerning Firearm Fatalities</td>
<td>MOA</td>
<td>Public Affairs</td>
<td>ADOPTED as AMENDED</td>
</tr>
<tr>
<td>H-403</td>
<td>Patient Centered Treatment for Pain Management and Appropriate use of Opioids</td>
<td>MOA</td>
<td>Public Affairs</td>
<td>ADOPTED</td>
</tr>
<tr>
<td>H-404</td>
<td>Physician Communication to Patients Regarding COVID-19 Prevention PUBLIC HEALTH CRISIS</td>
<td>NYSOMS</td>
<td>Public Affairs</td>
<td>ADOPTED as AMENDED</td>
</tr>
<tr>
<td>H-405</td>
<td>Addressing Dermatologic Health Disparities in People of Color</td>
<td>SOMA</td>
<td>Public Affairs</td>
<td>NOT ADOPTED</td>
</tr>
<tr>
<td>H-406</td>
<td>Addressing Law Enforcement Disproportionate use of Force During Interactions with Marginalized Groups as a Public Health Issue</td>
<td>SOMA</td>
<td>Public Affairs</td>
<td>NOT ADOPTED</td>
</tr>
<tr>
<td>H-407</td>
<td>Addressing The Change in Climate Effects on National Health</td>
<td>SOMA</td>
<td>Public Affairs</td>
<td>ADOPTED as AMENDED</td>
</tr>
<tr>
<td>H-408</td>
<td>Increased Law Enforcement Resources and Training for Response in Mental Health Crises</td>
<td>SOMA</td>
<td>Public Affairs</td>
<td>REFERRED</td>
</tr>
<tr>
<td>H-409</td>
<td>Referred Resolution H437-A/19 – AOA Firearm Policy</td>
<td>BFHP</td>
<td>Public Affairs</td>
<td>ADOPTED</td>
</tr>
<tr>
<td>H-410</td>
<td>Improving Outcomes in Behavioral Health Care in the Emergency Department</td>
<td>BFHP</td>
<td>Public Affairs</td>
<td>ADOPTED as AMENDED</td>
</tr>
<tr>
<td>H-411</td>
<td>COVID-19 Anti-Asian Discrimination and Abuse</td>
<td>MOA</td>
<td>Public Affairs</td>
<td>NOT ADOPTED</td>
</tr>
<tr>
<td>H-412</td>
<td>Drug Samples (SR-Source: H327-A/16)</td>
<td>BFHP</td>
<td>Public Affairs</td>
<td>ADOPTED</td>
</tr>
<tr>
<td>Res. No.</td>
<td>Resolution Title</td>
<td>Submitted By</td>
<td>Reference Committee</td>
<td>Action</td>
</tr>
<tr>
<td>---------</td>
<td>----------------------------------------------------------------------------------</td>
<td>--------------</td>
<td>----------------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>H-413</td>
<td>Concussion, Return-to-Play and Return-to-Learn (SR-Source: H352-A/16)</td>
<td>CSHA</td>
<td>Public Affairs</td>
<td>ADOPTED</td>
</tr>
<tr>
<td>H-414</td>
<td>Osteopathic Medicine -- Autonomy of (SR-Source: H401-A/16)</td>
<td>BOT</td>
<td>Public Affairs</td>
<td>ADOPTED</td>
</tr>
<tr>
<td>H-415</td>
<td>Chelation Therapy (SR-Source: H406-A/16)</td>
<td>BORPH</td>
<td>Public Affairs</td>
<td>ADOPTED</td>
</tr>
<tr>
<td>H-416</td>
<td>Minority Health and Osteopathic Medical Education (SR-Source: H409-A/16)</td>
<td>BORPH</td>
<td>Public Affairs</td>
<td>ADOPTED as AMENDED</td>
</tr>
<tr>
<td>H-417</td>
<td>Obesity in Children (SR-Source: H410-A/16)</td>
<td>BORPH</td>
<td>Public Affairs</td>
<td>ADOPTED</td>
</tr>
<tr>
<td>H-418</td>
<td>Fitness, Sports, FITNESS and Nutrition (SR-Source: H412-A/16)</td>
<td>BORPH</td>
<td>Public Affairs</td>
<td>ADOPTED</td>
</tr>
<tr>
<td>H-419</td>
<td>Plastic Beverage and Food Container Recycling Act (SR-Source: H413-A/16)</td>
<td>BORPH</td>
<td>Public Affairs</td>
<td>ADOPTED</td>
</tr>
<tr>
<td>H-420</td>
<td>Childhood And Teenage Sexual Exposure (SR-Source: H414-A/16)</td>
<td>BORPH</td>
<td>Public Affairs</td>
<td>ADOPTED as AMENDED</td>
</tr>
<tr>
<td>H-422</td>
<td>Damage to Hearing from use of Headphones (SR-Source: H417-A/16)</td>
<td>BORPH</td>
<td>Public Affairs</td>
<td>ADOPTED</td>
</tr>
<tr>
<td>H-423</td>
<td>Dangers of the “Choking Game” (SR-Source: H418-A/16)</td>
<td>BORPH</td>
<td>Public Affairs</td>
<td>ADOPTED</td>
</tr>
<tr>
<td>H-424</td>
<td>Medical USE OF Cannabis – Research On (SR-Source: H419-A/16)</td>
<td>BORPH</td>
<td>Public Affairs</td>
<td>ADOPTED</td>
</tr>
<tr>
<td>Res. No.</td>
<td>Resolution Title</td>
<td>Submitted By</td>
<td>Reference Committee</td>
<td>Action</td>
</tr>
<tr>
<td>----------</td>
<td>----------------------------------------------------------------------------------</td>
<td>--------------</td>
<td>----------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>H-426</td>
<td>Blood Donors, Protection from Depletion of Iron (SR-Source: H423-A/16)</td>
<td>BORPH</td>
<td>Public Affairs</td>
<td>ADOPTED</td>
</tr>
<tr>
<td>H-427</td>
<td>5-2-1-0+10 Campaign for America’s Children (SR-Source: H424-A/16)</td>
<td>BORPH</td>
<td>Public Affairs</td>
<td>ADOPTED as AMENDED</td>
</tr>
<tr>
<td>H-428</td>
<td>Healthy, Hunger-Free Kids Act (SR-Source: H425-A/16)</td>
<td>BORPH</td>
<td>Public Affairs</td>
<td>ADOPTED for sunset</td>
</tr>
<tr>
<td>H-429</td>
<td>Obesity Epidemic – Addressing the American (SR-Source: H427-A/16)</td>
<td>BORPH</td>
<td>Public Affairs</td>
<td>ADOPTED</td>
</tr>
<tr>
<td>H-430</td>
<td>Mandatory Influenza Vaccine of Healthcare Personnel (SR-Source: H429-A/16)</td>
<td>BORPH</td>
<td>Public Affairs</td>
<td>ADOPTED</td>
</tr>
<tr>
<td>H-431</td>
<td>Title X Funded Family Planning Services – Support for (SR-Source: H433-A/16)</td>
<td>BORPH</td>
<td>Public Affairs</td>
<td>ADOPTED</td>
</tr>
<tr>
<td>H-432</td>
<td>Shackling Of Pregnant Inmates (SR-Source: H435-A/16)</td>
<td>BORPH</td>
<td>Public Affairs</td>
<td>ADOPTED</td>
</tr>
<tr>
<td>H-433</td>
<td>Cancer Clinical Trials – Explore Incentives to Increase Patient Involvement In (SR-Source: H438-A/16)</td>
<td>BORPH</td>
<td>Public Affairs</td>
<td>REFERRED</td>
</tr>
<tr>
<td>H-434</td>
<td>Lesbian, Gay, Bisexual, Transgender, Queer / Questioning INTERSEX, ASEXUAL Protection Laws (SR-Source: H439-A/16)</td>
<td>BFHP/CSHA</td>
<td>Public Affairs</td>
<td>ADOPTED as AMENDED</td>
</tr>
<tr>
<td>H-435</td>
<td>Substance Use Disorders (SUD) – Evidence Based Treatment Programs for (SR-Source: H440-A/16)</td>
<td>BORPH</td>
<td>Public Affairs</td>
<td>REFERRED</td>
</tr>
<tr>
<td>H-436</td>
<td>Osteopathic Manipulative Medicine (OMM) and Osteopathic Manipulative Treatment (OMT) – Affirming the Scientific and Medical Foundation of (SR-Source: H605-A/16)</td>
<td>BORPH</td>
<td>Public Affairs</td>
<td>ADOPTED</td>
</tr>
<tr>
<td>H-438</td>
<td>Physician Comparative Utilization &amp; Profiling (SR-Source: H610-A/16)</td>
<td>CERA</td>
<td>Public Affairs</td>
<td>ADOPTED as AMENDED</td>
</tr>
<tr>
<td>Res. No.</td>
<td>Resolution Title</td>
<td>Submitted By</td>
<td>Reference Committee</td>
<td>Action</td>
</tr>
<tr>
<td>---------</td>
<td>----------------------------------------------------------------------------------</td>
<td>--------------</td>
<td>----------------------</td>
<td>----------</td>
</tr>
<tr>
<td>H-439</td>
<td>Physician Supply in Rural, Underserved United States – Recommendations for Improving (SR-Source: H613-A/16)</td>
<td>BFHP/CSHA</td>
<td>Public Affairs</td>
<td>ADOPTED</td>
</tr>
<tr>
<td>H-441</td>
<td>Health Insurance Coverage for Medical and Surgical Treatments for Good Oral Health (SR-Source: H619-A/16)</td>
<td>CERA</td>
<td>Public Affairs</td>
<td>ADOPTED</td>
</tr>
<tr>
<td>H-442</td>
<td>Physician Profiles (SR-Source: H623-A/16)</td>
<td>CSHA</td>
<td>Public Affairs</td>
<td>ADOPTED</td>
</tr>
</tbody>
</table>
### HOUSE OF DELEGATES’ REFERENCE COMMITTEE DESCRIPTIONS:

Committee on Public Affairs (400 series)

This reference committee reviews and considers matters relating to public and industrial health, research and physical fitness.

<table>
<thead>
<tr>
<th>Res. No.</th>
<th>Resolution Title</th>
<th>Submitted By</th>
<th>Reference Committee</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>H-400</td>
<td>Drugs-Prescription Discounts (SR - Source: H400-A/17)</td>
<td>BFHP</td>
<td>Public Affairs</td>
<td>Adopted</td>
</tr>
<tr>
<td>H-402</td>
<td>Counseling Female Patients on Reproductive Issues (SR - Source: H407-A/17)</td>
<td>CSHA</td>
<td>Public Affairs</td>
<td>Adopted as Amended</td>
</tr>
<tr>
<td>H-403</td>
<td>Genetic Testing (SR - Source: H412-A/17)</td>
<td>BFHP</td>
<td>Public Affairs</td>
<td>Adopted</td>
</tr>
<tr>
<td>H-404</td>
<td>Substance Impaired and Distracted Driving (SR - Source: H413-A/17)</td>
<td>CSHA</td>
<td>Public Affairs</td>
<td>Adopted</td>
</tr>
<tr>
<td>H-405</td>
<td>Accessibility to Breast Cancer Prevention, Detection, Diagnosis and Treatment (SR – Source: H408-A/17)</td>
<td>BORPH</td>
<td>Public Affairs</td>
<td>Adopted</td>
</tr>
<tr>
<td>H-406</td>
<td>Support For Prenatal and Pediatric Hospice and Palliative Care (SR - Source: H409-A/17)</td>
<td>BORPH</td>
<td>Public Affairs</td>
<td>Adopted</td>
</tr>
<tr>
<td>H-407</td>
<td>AOA Support for Hospice Care Programs (SR - Source: H411-A/17)</td>
<td>BORPH</td>
<td>Public Affairs</td>
<td>Adopted as Amended</td>
</tr>
<tr>
<td>H-408</td>
<td>Treatment of Obesity (SR - Source: H414-A/17)</td>
<td>BORPH</td>
<td>Public Affairs</td>
<td>Adopted as Amended</td>
</tr>
<tr>
<td>H-409</td>
<td>Women's Contraceptive Coverage Legislation (SR - Source: H416-A/17)</td>
<td>BORPH</td>
<td>Public Affairs</td>
<td>Adopted as Amended</td>
</tr>
<tr>
<td>H-410</td>
<td>Promotion for the Requirement of All Sporting Events to Have Access to an Automated External Defibrillator (AED) To Treat Commotio Cordis (SR - Source: H418-A/17)</td>
<td>BORPH</td>
<td>Public Affairs</td>
<td>Adopted as Amended</td>
</tr>
<tr>
<td>H-411</td>
<td>Meningococcal Vaccine Recommendations (SR - Source: H419-A/17)</td>
<td>BORPH</td>
<td>Public Affairs</td>
<td>Adopted</td>
</tr>
<tr>
<td>H-412</td>
<td>PSA-Based Screening for Prostate Cancer (SR - Source: H422-A/17)</td>
<td>BORPH</td>
<td>Public Affairs</td>
<td>Adopted</td>
</tr>
<tr>
<td>H-413</td>
<td>Mandates on School Lunches (SR - Source: H423-A/17)</td>
<td>BORPH</td>
<td>Public Affairs</td>
<td>Adopted</td>
</tr>
<tr>
<td>H-414</td>
<td>Judicious Use of Antimicrobial (SR - Source: H425-A/17)</td>
<td>BORPH</td>
<td>Public Affairs</td>
<td>Adopted as Amended</td>
</tr>
<tr>
<td>Resolution Number</td>
<td>Description</td>
<td>Sponsor</td>
<td>Committee</td>
<td>Status</td>
</tr>
<tr>
<td>-------------------</td>
<td>------------------------------------------------------------------------------</td>
<td>---------</td>
<td>-----------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>H-415</td>
<td>Anti-Bullying Law (SR- Source: H426-A/17)</td>
<td>BORPH</td>
<td>Public Affairs</td>
<td>Adopted as Amended</td>
</tr>
<tr>
<td>H-416</td>
<td>Promotion, Protection and Support of Breastfeeding (SR - Source: H428-A/17)</td>
<td>BORPH</td>
<td>Public Affairs</td>
<td>Adopted as Amended</td>
</tr>
<tr>
<td>H-417</td>
<td>Protocol and Guidelines for Emergency Medical Identification (SR- Source: H429-A/17)</td>
<td>BORPH</td>
<td>Public Affairs</td>
<td>Adopted as Amended</td>
</tr>
<tr>
<td>H-418</td>
<td>Organ Donation – Opposition to Financial Incentives for Organ Donors (SR - Source: H430-A/17)</td>
<td>BORPH</td>
<td>Public Affairs</td>
<td>Adopted as Amended</td>
</tr>
<tr>
<td>H-419</td>
<td>Violence in the Entertainment Media (SR - Source: H432-A/17)</td>
<td>BORPH</td>
<td>Public Affairs</td>
<td>Adopted</td>
</tr>
<tr>
<td>H-420</td>
<td>Stem Cell Research (SR - Source: H433-A/17)</td>
<td>BORPH</td>
<td>Public Affairs</td>
<td>Adopted</td>
</tr>
<tr>
<td>H-421</td>
<td>Education on Human Papillomavirus Vaccination (SR- Source: H434-A/17)</td>
<td>BORPH</td>
<td>Public Affairs</td>
<td>Adopted</td>
</tr>
<tr>
<td>H-423</td>
<td>Use of Tobacco Products (SR- Source: H436-A/17)</td>
<td>BORPH</td>
<td>Public Affairs</td>
<td>Adopted as Amended</td>
</tr>
<tr>
<td>H-424</td>
<td>Policy Statement on End of Life Care (SR- Source: H438-A/17)</td>
<td>BORPH</td>
<td>Public Affairs</td>
<td>Referred</td>
</tr>
<tr>
<td>H-425</td>
<td>Powdered Caffeine (SR - Source: H439-A/17)</td>
<td>BORPH</td>
<td>Public Affairs</td>
<td>Adopted</td>
</tr>
<tr>
<td>H-426</td>
<td>Health Insurance Coverage for Residential Treatment and Inpatient Treatment of Eating Disorders (SR- Source: H440-A/17)</td>
<td>BORPH</td>
<td>Public Affairs</td>
<td>Adopted</td>
</tr>
<tr>
<td>H-427</td>
<td>Violence and Abuse Prevention and Education (SR- Source: H441-A/17)</td>
<td>BORPH</td>
<td>Public Affairs</td>
<td>Adopted</td>
</tr>
<tr>
<td>H-428</td>
<td>Recreational Marijuana Use by Physicians, Students and Patients – White Paper (SR- Source: H442-A/17)</td>
<td>BORPH</td>
<td>Public Affairs</td>
<td>Adopted as Amended</td>
</tr>
<tr>
<td>H-430</td>
<td>Medication For Indigent Patients (SR- Source: H444-A/17)</td>
<td>BORPH</td>
<td>Public Affairs</td>
<td>Adopted</td>
</tr>
<tr>
<td>H-431</td>
<td>AOA Policies on Opioids and Substance Use – White Paper</td>
<td>BORPH</td>
<td>Public Affairs</td>
<td>Adopted as Amended</td>
</tr>
<tr>
<td>H-432</td>
<td>Addressing Diversity, Equity and Inclusion as a Profession</td>
<td>POMA</td>
<td>Public Affairs</td>
<td>Referred</td>
</tr>
<tr>
<td>H-433</td>
<td>Support Interpretation of Medical Information among the General Public</td>
<td>OOA</td>
<td>Public Affairs</td>
<td>Referred</td>
</tr>
</tbody>
</table>
### RESOLUTION ROSTER (400 SERIES)

<table>
<thead>
<tr>
<th>Resolution</th>
<th>Description</th>
<th>Committee</th>
<th>Department</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>H-434</td>
<td>Recognizing the Disproportionate Prevalence of Cardiovascular Disease in the African American Population as a Public Health Issue</td>
<td>SOMA</td>
<td>Public Affairs</td>
<td>Adopted as Amended</td>
</tr>
<tr>
<td>H-435</td>
<td>Standardized Screening for Intimate Partner Violence for all Individuals</td>
<td>SOMA</td>
<td>Public Affairs</td>
<td>Referred</td>
</tr>
<tr>
<td>H-436</td>
<td>Support for Increased Crisis Intervention Team Training for Law Enforcement</td>
<td>SOMA</td>
<td>Public Affairs</td>
<td>Adopted as Amended</td>
</tr>
<tr>
<td>H-437</td>
<td>Increased Research on the Public Health Impacts of Decriminalizing Possession of all Illicit Drugs</td>
<td>SOMA</td>
<td>Public Affairs</td>
<td>Adopted</td>
</tr>
</tbody>
</table>
Gambling Disorder

Policy Statement

The American Osteopathic Association supports research on gambling disorder.

Source: H401-A/18

Status: 1998; 2003 Reaffirmed as Amended; 2008 Reaffirmed; 2013 Reaffirmed as Amended; 2018 Reaffirmed
The American Osteopathic Association strongly encourages the federal government to increase its efforts to promote standards which will prevent human suffering and death from environmental threats and hazards; and reaffirms its commitment to support governmental agencies' efforts in eradicating environmentally related health risks.

Source: H402-A/18

Choosing Wisely Campaign

Policy Statement

The American Osteopathic Association (AOA) endorses the spirit of the “Choosing Wisely Campaign” to help disseminate information and education to patients and health care providers to make prudent decisions in the evaluation and management of medical conditions. The AOA also supports a higher level of commitment to increasing the evidence base for the effectiveness of osteopathic manipulative treatment with the ultimate goal of submitting it to be included in the campaign.

Source: H404-A/18

Status: 2013; 2018 Reaffirmed
Cervical Cancer, Screening for

Policy Statement

The American Osteopathic Association encourages all osteopathic physicians and students to continue to educate themselves and their patients on current guidelines related to cervical cancer screening using the Pap and HPV testing.

Source: H405-A/18

Status: 2013; 2018 Reaffirmed
Healthy Life Styles
Policy Statement

The American Osteopathic Association promotes guidelines for healthy life styles and will continue to work with Congress and related state and federal health care agencies to develop those guidelines. A healthy life style includes healthy eating, regular exercise and maintaining a healthy weight. Healthy eating is based on a diet rich in fruits and vegetables, with limited intake of fat, sugar and salt. A healthy life style eliminates the use of tobacco and illicit drugs, and limits alcohol intake. A healthy life style also includes proper care for mental health and encourages connection with one’s community.

Source: H406-A/18

Status: 1992; 1997 Reaffirmed as Amended, 2002; 2007; 2013 Reaffirmed as Amended; 2018 Reaffirmed
Medication Take-Back Program

Policy Statement

The American Osteopathic Association supports the national prescription drug take-back day that aims to provide a safe, convenient and responsible means of disposing of prescription drugs, while also educating the general public about the potential for abuse of medications; and encourages its state associations and local agencies to sponsor take-back medication days on a frequent basis but at least annually.

Source: H407-A/18

Status: 2013; 2018 Reaffirmed
Fire Prevention – Teaching of

Policy Statement

The American Osteopathic Association supports fire prevention education.

Source: H408-A/18

Healthy People 2020

Policy Statement

The American Osteopathic Association supports "Healthy People 2020".

Source: H409-A/18

Status: 1998, 2003 Reaffirmed as Amended; 2008; 2013 Referred for review and comment; 2018 Reaffirmed
Immunizations

Policy Statement

The American Osteopathic Association supports the Centers for Disease Control and Prevention in its efforts to achieve a high compliance rate among infants, children and adults by encouraging osteopathic physicians to immunize patients of all ages when appropriate; supports the HHS National Vaccine Implementation Plan; and encourages third-party payers to pay for vaccines and their administration.

Source: H411-A/18

Status: 1993; 1998 Reaffirmed as Amended, 2003; 2008; 2013 Reaffirmed as Amended; 2018 Reaffirmed
Patient Education

Policy Statement

The American Osteopathic Association reaffirms its commitment to the advancement of patient education to promote a better understanding of personal health and wellness.

Source: H412-A/18

Substance Use Disorder

Policy Statement

The American Osteopathic Association encourages its members, to maintain current knowledge of addictive substances with a high potential for abuse, and of appropriate treatment techniques, and supports health care and community support agencies in their efforts to eliminate substance abuse use disorder, and urges all members of the osteopathic profession to participate in the prevention and rehabilitation of persons suffering from substance use disorder and the disease of addiction.

Source: H414-A/18

Tuberculosis Medical Training

Policy Statement

The American Osteopathic Association supports tuberculosis prevention programs carried out by the Centers for Disease Control and Prevention (CDC), The National Institutes of Health (NIH) and other organizations and encourages the use of the CDC's core curriculum on tuberculosis by osteopathic physicians who treat patients diagnosed with tuberculosis or who are at high risk for tuberculosis disease or infection.

Source: H415-A/18

Status: 1993; 1998 Reaffirmed as Amended; 2003 Reaffirmed; 2008; 2013 Reaffirmed as Amended; 2018 Reaffirmed
Pediatric Medical Imaging

Policy Statement

The American Osteopathic Association supports the reduction of excess ionizing radiation exposure of the pediatric population and urges its members involved in medical imaging of pediatric patients to review the latest research and educational materials from the National Cancer Institute and other organizations and pledge to do their part to “child-size” the radiation dose used in children’s imaging.

Source: H416-A/18

Status: 2008; 2013 Reaffirmed as Amended; 2018 Reaffirmed
Disaster Preparedness Planning

Policy Statement

The American Osteopathic Association supports the Centers for Disease Control and Prevention’s (CDC) Centers for Public Health Preparedness programs established to strengthen terrorism and emergency preparedness by linking academic expertise to state and local health agency needs, including programs that focus on vulnerable populations such as, but not limited to, pregnant women, new mothers, infants, and the elderly.

Source: H417-A/18

Status: 2008; 2013 Reaffirmed as Amended; 2018 Reaffirmed as Amended
Distracted Driving
Policy Statement

The American Osteopathic Association supports appropriate legislation to ensure safe driving without distractions.

Source: H418-A/18

Status: 2008; 2013 Reaffirmed; 2018 Reaffirmed as Amended
Pediatric Obesity

Policy Statement

The American Osteopathic Association (AOA) encourages dissemination of research related to pediatric obesity and continuing medical education (CME) activities; encourages primary care physicians to teach and use body mass index (BMI) measurements; and encourages physicians providing health care to children to.

Source: H419-A/18

Status: 2008; 2013 Reaffirmed as Amended; 2018 Reaffirmed
Osteopathic Manipulative Treatment of Somatic Dysfunction of the Head, Safety in

Policy Statement

The American Osteopathic Association promotes public awareness of the complexity and vulnerability of the human central nervous system; promotes public awareness for the safe intervention of physical forces to the head by the educated hands of a trained osteopathic physician; advocates full disclosure to patients of all requirements for accredited education, qualifying training and licensure of AOA recognized medical treatments including osteopathic manipulative treatment of the head; promotes health care laws which supports the teaching of medical interventions to fully qualified professionals; hold the position that medical licensure is the most appropriate foundation for the practice of osteopathic medicine and surgery including osteopathic manipulative treatment of somatic dysfunction of the head including osteopathic cranial manipulative medicine; and believes that the practice of OMT of somatic dysfunction of the head and osteopathic cranial manipulative medicine requires a professional clinical diagnosis, complete medical treatment plan, professional ethics and appropriate follow-up care.

Source: H420-A-18

Status: 2013; 2018 Reaffirmed as Amended
Energy Drinks

Policy Statement

The American Osteopathic Association supports community awareness and education regarding the effects and potential dangers of consuming energy drinks, and encourages physicians to screen for the use of energy drinks.

Source: H422-A/18

Status: 2013; 2018 Reaffirmed
“Opioid Overdose” Deaths in America – Epidemic

Policy Statement

The American Osteopathic Association recommends systematic evaluation of all available interventions to prevent opioid overdose deaths including patient education and the normalization of take-home Naloxone.

Source: H423-A/18

Status: 2013; 2018 Reaffirmed
Human Immunodeficiency Virus (HIV) Testing – Clinical and Public Health Application of

Policy Statement

The American Osteopathic Association supports widespread application of HIV testing in the clinical setting particularly for those at risk for HIV infection as determined by physician evaluation; supports continued anonymous testing and counseling programs in public health facilities to maximize individual participation; supports mandatory HIV testing only for source patients, in cases of rape or incest, or in cases of an accidental exposure in patients who are at risk for HIV/AIDS; and supports the following recommendation of the American College of Osteopathic Obstetricians and Gynecologists.

Source: H424-A/18

Breastfeeding Exclusivity

Policy Statement

The American Osteopathic Association supports dissemination of information by practicing physician about the health benefits associated with the duration and exclusivity of breastfeeding for six months. Additionally, in harmony with the centers for disease control and prevention, American Academy of Pediatrics, and American Academy of Family Physicians, the encouragement of breastfeeding should continue while adding complementary solid foods for at least one year.

Source: H425-A/18

Status: 2002; 2007 Reaffirmed; 2012; 2018 Reaffirmed as Amended
Breastfeeding Mothers – Protecting

Policy Statement

The American Osteopathic Association supports legislation protecting the rights of breastfeeding mothers.

Source: H426-A/18

Status: 2003; 2008 Amended; 2013 Reaffirmed; 2018 Reaffirmed
American Osteopathic Association Makes Public Statement and Develops Protocols to Prevent Sexual Abuse of Patients

Policy Statement

The American Osteopathic Association support development of a toolkit with templates of comprehensive uniform protocols for adoption by osteopathic institutions and organizations to protect patients from abuse; and to be implemented so that suspected violations are investigated and appropriately referred to legal authorities for prosecution when appropriate.

Source: H427-A/18

Status: 2018
Concerns in Homeless Population

Policy Statement

The American Osteopathic Association (AOA) encourage all physicians to partner with their communities to understand barriers to health, and advocate to improve access to healthcare for people experiencing homelessness; and the AOA support, through education and advocacy, dissemination of social and health related resources and programs that serve individuals and families experiencing a homeless situation and their care providers; and AOA advocate, promote, and support programs that ensure delivery of primary and preventive healthcare to all underserved populations, including those experiencing homelessness.

Source: H428-A/18

Status: 2018
Patient Safety and use for Patients with Pain Conditions

Policy Statement

The American Osteopathic Association affirms that OMT is a safe intervention and should be considered as first-line treatment for patients with pain associated with Somatic Dysfunction and other appropriate conditions.

Source: H400-A/19

Status: 2014; 2019 Reaffirmed
Human Trafficking – Awareness as a Global Health Problem

Policy Statement

The American Osteopathic Association acknowledges human trafficking as a violation of human rights and a global public health problem; encourages osteopathic physicians to be aware of the signs of human trafficking and the resources available to aid them in identifying and addressing the needs of victims of human trafficking, including appropriate medical assessment, and reporting to law enforcement.

Source: H401-A/19

Status: 2014; 2019 Reaffirmed
Same-Sex Relationships and Healthy Families

Policy Statement

The American Osteopathic Association (AOA) recognizes the need of same-sex households to have the same access to health insurance and health care as opposite-sex households and supports measures to eliminate discrimination against same-sex households in health insurance and health care. The AOA supports children’s access to a nurturing home environment, including through adoption or foster parenting without regard to the sexual orientation or the gender identity of the parent(s). The AOA recognizes and promotes healthy families by lessening disparities and increasing access to healthcare for same-sex marriages and civil unions and the children of those families.

Source: H402-A/19

Status: 2014; 2019 Reaffirmed
Public Information – Correction of, About the Osteopathic Profession

Policy Statement

The American Osteopathic Association (AOA) will work with online and public information sites to ensure that content is accurate and unbiased and encourage osteopathic physicians to notify the AOA Division of Media Relations to address misinformation regarding osteopathic medicine.

Source: H403-A/19

Status: 2014; 2019 Reaffirmed as Amended
Alert Network – Silver and Gold

Policy Statement

The American Osteopathic Association endorses the wide-spread state adoption of emergency response systems for missing mentally impaired adults throughout the United States, via “Silver Alert” and “Gold Alert” networks which are also known as “Endangered Person Advisory Networks.”

Source: H404-A/19

Status: 2014; 2019 Reaffirmed
Alcohol Abuse

Policy Statement

The American Osteopathic Association endorses local, state, and federal legislation that would control the consumption and purchase of alcohol by individuals under the age of twenty-one; and urges that alcohol abuse prevention and treatment programs be given a high national priority.

Source: H405-A/19

Discrimination in Healthcare

Policy Statement

The American Osteopathic Association adopts a zero tolerance policy for all forms of patient discrimination; and in concert with other healthcare organizations, and the federal, state and local governments will continue to monitor, correct and prevent any future negative bias towards one or more patient groups.

Source: H406-A/19

Status: 1999, 2004 Reaffirmed; 2009 Reaffirmed as Amended; 2014 Reaffirmed; 2019 Reaffirmed
Sudden Infant Death Syndrome

Policy Statement

The American Osteopathic Association urges: continued research into the causes and prevention of sudden infant death syndrome (SIDS); that information based on current medical literature be made available to the public on the nature of sudden infant death syndrome and proper counseling be available to families who lose infants to this disease; and supports the US Department of Health and Human Services and Centers for Disease Control and prevention campaigns by encouraging its members to educate the parents and care-givers of infants on strategies to reduce the risk of SIDS.

Source: H407-A/19

Pharmaceuticals – Support Efforts to Encourage the Proper Disposal of Unused and Expired

Policy Statement

The American Osteopathic Association supports the development of educational materials for the public by the appropriate regulatory/environmental and public health agencies on the dangers of keeping unused and expired pharmaceuticals in their possession; and will supports that such materials also include education on the proper disposal of unused and expired pharmaceuticals.

Source: H408-A/19

Status: 2004; 2009 Reaffirmed; 2014 Reaffirmed; 2019 Reaffirmed as Amended
Comparative Effectiveness Research

Policy Statement

The American Osteopathic Association (AOA) will continue to engage the osteopathic medical profession in Comparative Effectiveness Research (CER) projects and studies across private organizations and government agencies. The AOA will continue to disseminate CER findings to the osteopathic medical profession, consumers of medical information, patients, family members, and caregivers. The AOA adopts the following principles regarding comparative effectiveness research:

Physicians and Patients

• Comparative effectiveness research should enhance the ability of osteopathic physicians (DOs) to provide the highest quality care to patients utilizing the best proven and widely accepted evidence based medical information at the time of treatment.

• Comparative effectiveness research should not be used to control medical decision-making authority, professional autonomy and should not be used to deny coverage or payment.

• Comparative effectiveness research should enhance, complement, and promote quality patient care, not impede it.

• Guidelines developed as a result of comparative effectiveness research studies should be advisory and not mandatory.

• Comparative effectiveness research should be viewed as a positive development for patients and physicians and a useful tool in the physician’s armamentarium, working in concert with patients.

• Physicians in practice should be included in any discussions and decisions regarding comparative effectiveness research.

• Comparative effectiveness research should focus on clinical effectiveness, not cost effectiveness.

• The physician/patient relationship must be protected, and the needs of the patients should be paramount.

Source: H410-A/19

Status: 2009; 2014 Reaffirmed as Amended; 2019 Reaffirmed as Amended
Fluoridation

Policy Statement

The American Osteopathic Association supports the fluoridation of fluoride-deficient public water supply.

Source: H412-A/19

Status: 2004; 2009 Reaffirmed; 2014 Reaffirmed; 2019 Reaffirmed
Maternal and Child Healthcare Block Grants

Policy Statement

The American Osteopathic Association (AOA) supports government expenditures for the Title V Maternal and Child Healthcare Block Grant Program and the efficient use of its resources. The AOA supports ensuring sufficient funding for this program.

Source: H413-A/19

Employee Retirement Income Security Act of 1974

Policy Statement

The American Osteopathic Association supports federal legislation to reform the Employee Retirement Income Security Act (ERISA) of 1974 to ensure the ability of states to guarantee that clinical decisions be made by physicians and that patients have legal remedies in state court. The American Osteopathic Association also supports legislation that extends these protections to clinical decisions impacting patient access to prescription drugs.

Source: H414-A/19

Status: 2004; 2009 Reaffirmed; 2014 Reaffirmed; 2019 Reaffirmed
Raw Milk – Health Risks

Policy Statement

The American Osteopathic Association believes that all milk sold for human consumption should be required to be pasteurized; and encourages osteopathic physicians to educate their patients on the safety concerns and the health risks of consuming raw milk.

Source: H416-A/19

Status: 2009; 2014 Reaffirmed; 2019 Reaffirmed as Amended
Vaccines

Policy Statement

The American Osteopathic Association will continue to promote evidence-based information on vaccination compliance and safety.

Source: H417-A/19

Status: 2009; 2014 Reaffirmed; 2019 Reaffirmed
Domestic and Intimate Partner Violence – Development of Programs to Prevent

Policy Statement

The American Osteopathic Association will continue to support the efforts of the United States Department of Health and Human Services to develop and foster programs that prevent domestic and intimate partner violence.

Source: H418-A/19

Health Care Fraud

Policy Statement

The American Osteopathic Association urges the Center for Medicare and Medicaid Services (CMS) to:

(1) disclose to the public and the medical community the actual amount of "fraud" in dollars, based on the reasonable definition of “fraud" omitting all denied and resubmitted claims and all honest mistakes by physicians and the Medicare carriers; and

(2) strongly opposes the use of law enforcement agencies and auditors to enter physicians’ offices without prior request, warning or due process under the law for the purpose of confiscating records.

Source: H419-A/19

Status: 1999; 2004 Reaffirmed; 2009 Reaffirmed as Amended; 2014 Reaffirmed as Amended; 2019 Reaffirmed
Automated External Defibrillator Availability

Policy Statement

The American Osteopathic Association recommends an automated external defibrillator (AED) be placed in as many public places as possible and supports legislation that will limit the liability for installing an AED for use by the public.

Source: H420-A/19

Status: 2009; 2014 Reaffirmed; 2019 Reaffirmed
Lead Exposure in Children – Prevention, Detection, and Management

Policy Statement

The American Osteopathic Association (AOA) encourages physicians and public health departments to screen children for lead based upon current recommendations and guidelines established by the US Centers for Disease Control and Prevention’s Childhood Lead Poisoning Prevention PROGRAM and, encourages the reporting of all children with elevated blood lead levels to the appropriate health department in their state or community in order to fully assess the burden of lead exposure in children and, encourages public health policy initiatives that identify exposure pathways for children and develop effective and innovative strategies to reduce overall childhood lead exposure.

Source: H422-A/19

Status: 2014; 2019 Reaffirmed
Hepatitis C Screening

Policy Statement

The American Osteopathic Association (AOA) publicly supports universal screening of baby boomers (those born 1945-1964) in addition to testing those at risk for hepatitis C virus (HCV) and promote public educational programs that educate their members about HCV, testing strategies, and treatment. The AOA will work with public health entities to educate the public about the need for testing and treatment.

Source: H423-A/19

Status: 2014; 2019 Reaffirmed as Amended
Firearm Safety

Policy Statement

The American Osteopathic Association (AOA) recommends that physicians ask patients and/or caregivers about the presence of firearms in the home and counsel patients who own firearms about the potential dangers inherent in gun ownership, especially if vulnerable individuals’ children and adolescents are present. The AOA recommends strategies such as secure storage and the use of safety locks to eliminate the inappropriate access to firearms by vulnerable individuals’ children and adolescents and recommends all physicians to educate families in the safe use and storage of firearms.

Source: H425-A/19

Status: 1994; 1999 Reaffirmed; 2004 Reaffirmed; 2009 Reaffirmed; 2014 Reaffirmed; 2019 Reaffirmed as Amended
Protecting Patients with Private Insurance from Balance Billing

Policy Statement

The American Osteopathic Association (AOA) supports patients’ right to access emergency medical care at a reasonable cost; and, that the AOA, in emergency medical care, supports a system in which patients are removed from the process of resolving outstanding medical expenses that is beyond their cost sharing responsibilities for in-network care; and, that disputes over the reasonable cost for out of network emergency care be determined by an independent, third party or arbitration.

Source: H426-A/19

Status: 2019
Airbags in Automobiles – White Paper

Policy Statement

Today, almost every vehicle on the road has safety features that help drivers to be safer, either through protecting drivers and passengers involved in a crash or to preventing passenger vehicle crashes. This white paper will provide information on all vehicle safety features and whether or not the feature is federally mandated, as well as recommend associated policy for adoption by the American Osteopathic Association.

White Paper - Occupant Protection in Passenger Vehicles

INTRODUCTION
Today, almost every vehicle on the road has safety features that help drivers to be safer, either through protecting drivers and passengers involved in a crash or to preventing passenger vehicle crashes. This paper will provide information on all vehicle safety features and whether or not the feature is federally mandated, as well as recommend associated policy for adoption by the AOA.

OCCUPANT PROTECTION IN PASSENGER VEHICLES
Occupant protection includes safety belts, lower anchor and tethers for children (LATCH), airbags, and active head restraints. These features were designed to protect both drivers and passengers.

In 2016, National Highway Traffic Safety Administration (NHTSA) developed a fact sheet with information on passenger vehicle occupant protection, which included the use of restraints and benefits of safety belts, frontal airbags, and child restraints. According to the fact sheet, safety belts saved an estimated 14,668 lives of passenger vehicle occupants 5 years old and older in 2016, frontal air bags saved an estimated 2,756 lives, and car seats saved an estimated 328 lives of children under the age of 5 years. NHTSA estimated that lap/shoulder safety belts, when used, reduce the risk of fatal injury among front-seat passenger vehicle occupants by 45%; moderate to critical injury to front-seat passenger vehicle occupants by 50%; fatal injury in front-seat light truck occupants by 60%, and moderate to critical injury to front-seat light truck occupants by 65%.

Frontal airbags, combined with lap/shoulder bags offer effective safety protection for passenger vehicle occupants. NHTSA estimated that the use of frontal airbags without safety belts reduced the fatality risk by 11%, and when using safety belts, fatality drops further by 14%. In 2016, frontal airbags saved an estimated 2,756 lives. From 1987, when airbags first began to be installed in passenger vehicles, through 2016, 47,648 lives were saved.

NHTSA estimated that car seat use in passenger vehicles reduce the risk of fatal injury by 71% for infants younger than 1 year of age and 54% for toddlers age 1 to 4 years. For infants and toddlers, the risk of fatal injury in light trucks is 58% for infants younger than 1 year, and 59% for toddlers ages 1 to 4 years. In 2016, car seat restraints saved an estimated 328 lives of children age 4 years and younger (313 associated with the use of car seats and 15 with the use of adult safety belts). NHTSA estimated that an additional 42 lives could have been saved (a total of 370 children age 4 and younger). Since 1975, the lives of 11,274 children 4 years old and younger involved in automobile accidents were saved because of child restraint use.

There is an abundance of technology available to protect occupants of passenger vehicles.
Most of the advancements have been in place for many years. As technology progressed, many of the features improved, resulting in more saved lives.

**Safety-Belt Features**
While the seat belt is the most important piece of automotive safety equipment, enhanced features have helped the seat belt do its job more efficiently.2

On March 1, 1967, the first Federal Motor Vehicle Safety Standard (FMVSS) mandate required that all passenger vehicles have safety belts. FMVSSs are United States federal regulations specifying the design, construction, performance, and durability requirements for passenger vehicles safety-related components, systems, and design features. FMVSSs are developed and enforced by the National Highway Traffic Safety Administration (NHTSA), pursuant to the National Traffic and Motor Vehicle Safety Act of 1966.

Safety belts now have belt tensioners; a device designed to pull a seat belt tight in an accident. This feature helps position passengers properly to take full advantage of a deploying airbag.2

Force limiters, companions to belt tensioners, reduce the force of the seat belt above a certain threshold and, in conjunction with belt tensioners and airbags, lessen the risk of upper body injuries to front seat passengers.2

Other seatbelt enhancements include inflatable seatbelts and adjustable shoulder anchors. Some car models have inflatable safety belts in the rear seat that reduces the force of the seat belt on passengers involved in an accident. Inflatable safety belts help protect the elderly and children who are the primary rear seat occupants.2

Safety belts also have adjustable shoulder anchors that help position the belt across the chest instead of the neck, which helps prevent neck injuries.2

**Latch (Lower Anchors and Tethers for Children)**
All passenger vehicles are now required to have the LATCH system. This system not only encourages the use of child safety seats but also integrates lower anchors and top tether attachment points. These anchors and attachment points allow the installation of the car safety seat to be effortless and eliminate the challenges and incompatibilities of installing a car safety seat. However, in some cars and trucks, the LATCH system is challenging to use correctly.2

NHTSA developed a traffic fact sheet that contains information on the fatal motor vehicle crashes and facilities, based on the Fatality Analysis Reporting System (FARS). Assuming that all passenger vehicle crashes have the LATCH system, in 2017, there were 23,351 passenger vehicle occupants killed in fatal crashes, 794 (3.3%) were infants (less than 1 year) to age 14. Of the 794 children killed, 244 (31%) were in a child restraint seat, 202 (25%) were in a lap belt only or shoulder, and lap belt and 103 (13%) were unknown. Of the 39,822 passenger vehicle occupants who survived in fatal crashes, 4,700 (11.8%) were infants (less than 1 year) to age 14 and 509 (11%) was unrestrained. Of the 63,373 passenger vehicle occupants involved in fatal crashes, 5,494 (8.7%) were infants (less than 1 year) to age 14, and 776 (15%) was unrestrained.3

**Airbags**
Since 1998, front airbags have been standard on all new cars, and since 1999, airbags have been standard on light trucks. The on-board computer-connected crash sensors detect a frontal collision and trigger the bags. In a few milliseconds, the bag inflates, then immediately deflates.2

Airbags have saved thousands of lives, but they also have the potential to cause children or occupants who do not use a seat belt to suffer injury or even death.2 “From 1987 to 2015, frontal air bags saved 44,869 lives. That is enough people to fill a major league ballpark.”4
2016, the estimated number of lives saved by frontal airbags were 2,756. According to a Special Crash Investigations Report released in January 2009, from 1990 through January 1, 2009, there have been 296 airbag-related fatalities, (191 children, 92 adult drivers, and 13 adult passengers). Also, the Takata airbag defection has caused 16 deaths in the U.S.; and 24 deaths and 300 injuries worldwide.

Adaptive or dual-stage front airbags were introduced in 2003 and became the standard by 2007. Most airbag systems now have sensors that detect weight and the seat position of the driver and front passenger. The airbag system will deactivate if it senses that the driver is positioned too close to the wheel or the front passenger or child is out of position. This system minimizes injury from an accident.

**Side Airbags.** Side-impact airbags protect the torso of front seat passengers. (Consumer Reports 2016) Depending on the passenger vehicle model, side airbags are offered as standard or optional equipment on many new passenger vehicles.

**Side Curtain Airbags.** Side curtain airbags are designed to prevent occupants from hitting their heads and shielding them from flying debris. They remain inflated longer than other airbags to keep people from being ejected during a rollover or a high-speed side crash.

A standard enacted late in 2007 and effective September 1, 2009, NHTSA mandated that all automakers phase in additional side-impact protection as a standard feature for their cars, trucks, and SUVs by 2013.

**Active Head Restraints**
In a rear crash, active head restraints move up and forward to cradle the head and absorb energy to diminish whiplash injury.

**ACCIDENT AVOIDANCE SYSTEMS**
The automotive industry is continually developing traffic safety technologies that will help drivers avoid crashes. Some of these technologies have a warning system and rely on the driver to take corrective action, while others are designed to automatically brake or steer, thus taking an active action approach to accident prevention. These features are expected to contribute to an overall improvement in traffic safety.

AAA Foundation for Traffic Safety developed a research brief that presented the probable safety benefits of various advanced driver assistance systems and provided estimates regarding the numbers of crashes, injuries, and deaths that such systems could have potentially helped to prevent based on the characteristics of the crashes that occurred on U.S. roads in 2016.

According to the brief, the Forward Collision Warning (FCW) could theoretically have prevented an estimated 69-81% of all rear-end crashes, 76-81% of angle crashes, and 23-24% of single-vehicle crashes, totaling approximately 2.3 million crashes and 7,166 fatal crashes per year between 2002 and 2006. In 2016, there were an estimated 1,994,000 crashes, 884,000 injuries and 4,738 deaths that could have been prevented or mitigated by the FCW system if it were a standard feature in all vehicles.

The brief estimated that Lane Departure Warning (LDW) and Lane Keeping Assistance (LKA) technology equipped in passenger vehicles could have theoretically addressed 179,000 crashes and 7,529 fatal crashes annually between 2004 and 2008. In 2016, there were an estimated 519,000 crashes, 187,000 injuries, and 4,654 deaths that could have been prevented or mitigated by LDW or LKA systems.

The brief estimated that blind spot warning systems (BSW) could have prevented approximately 24% of all lane-changing crashes between 2004 and 2008. In 2016, there were an estimated...
318,000 crashes, 89,000 injuries, and 274 deaths that could have been prevented by the BSW system.  

There is also an abundance of advanced driver assistance technology available. This technology is designed to prevent crashes. The features are relatively new; thus, they will have varying levels of NHTSA recognition.

**Forward Collision Prevention/Warning (FCW)**

**Adaptive Headlights.** Adaptive headlights are primarily intended to move side-to-side to help illuminate curves and corners. “These headlights use electronic sensors that can detect your steering angle to swivel based on the direction your car is heading.”

**Bicycle Detection.** The bicycle detection feature alerts the driver to a potential collision with a bicyclist ahead. NHTSA has not set any performance specifications for this feature.

**Forward-Collision Warning (FCW).** Forward-collision warning utilizes cameras, radar or laser to scan for autos ahead and alert the driver that they are moving toward a vehicle in their path excessively quick and an accident is inescapable. Most Forward-Collision warning systems alert the driver with a visual and/or audible signal to a potential accident, allowing time for a reaction.

This system meets NHTSA performance specifications but is an option on many new cars, SUVs, and trucks.

**Left Turn Crash Avoidance.** Left turn car avoidance feature monitors traffic when the driver turns left at low speeds. The sensor automatically activates warning sounds, dash lights, and brakes when a driver turns left into another car’s path. NHTSA has not set any performance specifications for this feature.

**Obstacle Detection.** Obstacle detection uses sensors mounted on the front and/or rear bumpers to determine the distance between the car and a nearby object. If an object is detected, the sensor automatically slows down the passenger vehicle. NHTSA has not set any performance specifications for this feature.

**Pedestrian Detection.** This system utilizes the features of the Forward-Collision Warning system and automatically initiates the car’s braking system to protect pedestrians from being hit. The car’s camera or radar looks for a pedestrian in the path of the vehicle. Some systems will alert the driver with an audible or visual alert, and some systems will automatically initialize the emergency braking system if the collision is deemed high. NHTSA has not set any performance specifications for this feature but recognized that this is a promising technology. This system is currently an option on many new cars, SUVs, and trucks.

**Breaking, Tire Pressure, and Anti-Rollover**

**Brake Assist.** Brake Assist helps detect when a driver is braking to maximum strength. In conjunction with anti-lock brakes, the system allows braking without locking the wheels. Studies have shown that most drivers are not braking as hard as they can, so Brake Assist intervenes to reach the shortest stop distance possible.

**Traction Control.** Traction control electronically controls the wheels spinning motion during acceleration to obtain the maximum traction. This system is useful in wet, icy, or snowy conditions.

**Electronic Stability Control (ESC).** Electronic stability control (ESC) is a step beyond traction control. In order to avoid sliding or skidding, this system helps keep the vehicle on its intended path during a turn. ESC uses a series of sensors connected to a computer to detect wheel
speed, steering angle, side movement, and yaw (rotation). If the car drifts outside the intended path, the stability control system momentarily brakes one or more wheels and reduces the power of the engine to pull the car back on track depending on the system.  

ESC is particularly useful for tall, heavy-duty vehicles such as sports equipment pickups; helping to keep the vehicle from rollover.  

The federal government required stability control on all vehicles by the 2012 model.  

**Anti-Lock Braking System (ABS).** Before the invention of the anti-lock braking system (ABS), car wheels easily locked during hard braking which caused the front tires to slide and made steering impossible; which is dangerous on slippery surfaces. ABS prevents this from occurring. ABS uses sensors that are controlled by a computer on each wheel. The system maximizes the breaking action on each wheel to avoid locking the wheel which results in the driver maintaining control of the car to avoid hitting obstacles.  

“Over the past 10 years, most car manufacturers have made ABS standard in their vehicles. The federal government required all new cars to have ABS by September 1, 2011.” 

**Automatic Emergency Braking (AEB).** AEB adds to the advantages of forward-crash cautioning. AEB will detect a potential crash, and if the response time is moderate, the vehicle will start braking.  

This system engages Dynamic Brake Support and Crash Imminent Braking technology.  

**Dynamic Brake Support (DBS) and Crash Imminent Braking (CIB).** If the driver does not brake hard enough to evade a crash, the DBS system will automatically supplement the driver’s breaking to avoid the collision. If the driver does not take any action to prevent the accident, the CIB system will automatically apply the car’s brakes to slow or stop the vehicle. (National Highway Traffic Safety Administration n.d.) This system has been available on some car models since 2006 but is typically an optional feature on many new cars, SUVs, and trucks.  

**Temperature Warning.** Temperature warning alerts the driver when the outside temperature is detected to be at or below freezing, which can affect road conditions. NHTSA has not set any performance specifications for this feature. 

**Hill Descent Assist.** Hill descent assist works with the passenger vehicle’s existing braking systems to block the driver from going past a certain speed while traveling downhill or on treacherous terrain. If the vehicle begins accelerating past a safe downhill speed, this feature further applies the brakes. NHTSA has not set any performance specifications for this feature. 

**Hill Start Assist.** Hill start assist uses sensors in the vehicle to detect when a vehicle is on an incline. For a set time, the system maintains the brake pressure as the driver switches from the brakes to the gas pedal. Once the driver presses the accelerator, it releases the brake. In cars with a manual transmission, the Hill Start Assist also maintains brake pressure until the driver lets up on the clutch. NHTSA has not set any performance specifications for this feature. 

**Driver State Monitoring**  

**Tire-Pressure Monitor System.** Tire pressure monitoring systems (TPMS) warn drivers of under or overinflated tires. The system helps to increase the car’s fuel economy and potentially prevent a tire blowout which can be dangerous at high speeds and lead to a car accident. The federal government required all new vehicles to include this system starting in late 2007. 

**Curve Speed Warning.** Curb speed warning uses Global Positioning System (GPS) to alert the driver of upcoming sharp turns. This feature tracks the passenger vehicle speed and location and warns the driver to slow down when approaching curves and exits. NHTSA has
not set any performance specifications for this feature.  

High-Speed Alert.  High-speed Alert uses a built-in speed sensor and GPS to compare a database of known road speed limit against the driver's actual speed and alerts the driver if they are speeding. Some versions may track school and work zones. Future versions may be able to read limits through a camera. NHTSA has not set any performance specifications for this feature.  

Adaptive Cruise Control (ACC). ACC utilizes lasers, radar, cameras, or a blend of these to keep a steady distance between the driver and the vehicle ahead. If the traffic slows, some systems automatically stop the car and automatically accelerate to full speed when the traffic returns to normal. The system allows the driver to lose their focus on driving, which is a hazard.  

Push Button Start. Push Button Start simplifies turning the passenger vehicle on and off using a key fob unique to the vehicle. NHTSA has not set any performance specifications for this feature.  

Drowsiness Alert. Drowsiness alert borrows some of the sensors from lane departure warning systems to track lane markings and the automobile’s lane position. Many versions of this feature will track how often the driver departs from the lane over a short period to determine if the driver may be drowsy. This feature may alert the driver using a coffee cup or other symbol on the dash suggesting that the driver take a break and when it will be safe to pull over. NHTSA has not set any performance specifications for this feature.  

Automatic High Beams. Automatic high beam lights switch from high to low and back again to improve nighttime visibility and as conditions warrant.  

Parking and Backing Assistance 
Backup Camera. The backup camera assistance system is activated when the driver of a passenger places the gear in reverse. The monitor is in the center console of the passenger vehicle and displays items behind the car. This system is primarily used as a parking aid or spotting a child or pedestrian concealed in the blind zone.  

NHTSA required this life-saving technology on all new vehicles in May 2018. 

Back-up Warning. Back-up warning uses sensors mounted to the rear bumper. These sensors detect objects in the path of the vehicle. The system may beep or vibrate if an object is in the way.  

At this time, this is not a new car standard. As stated above, NHTSA required this life-saving technology on all new vehicles in May 2018. In the future, manufacturers are expected to pair the back-up warning and the back-up camera systems in new cars. 

Parking Assist System. Parking assist incorporates sensors in the car's front, rear, or both bumpers. The system alerts the driver that light poles, walls, shrubbery, and other obstacles are close when the passenger vehicle is moving at a slow speed (parking speed).  

Automatic Parallel Parking. Automatic parallel parking can detect objects in front and back of a car while parking. It provides audible warnings when detecting one or more objects. Advanced sensors read the gaps between vehicles in the area where the driver chooses to park. The feature will not activate if there is insufficient room to parallel park, which helps ensure that the car does not bump into any nearby vehicles. When initiated, this feature takes over some of the vehicle's steering and acceleration functions needed to park.
Rear Cross-Traffic Alert. Rear cross-traffic alerts sense traffic crossing the path of a passenger vehicle as the driver backs out of a parking space or driveway. Some systems automatically brake to prevent an accident.  

The Rear cross-traffic alert system is not a standard feature for passenger vehicles, but the federal government does mandate the feature for such vehicles as buses and trucks. However, manufacturers often pair rear cross traffic alert with back-up cameras; so the mandate may increase the popularity of rear cross traffic alert features soon. 

Lane and Side Assistance

Lane-Departure Warning (LDW). Lane-departure warning alerts the driver when the car drifts out of its lane without activating the turn signal. The system uses a camera or lasers to monitor lane markers. The system will chime, the dashboard will blink, or the steering wheel or seat will vibrate to warn the driver that they are drifting into another lane. This system meets NHTSA’s performance specifications and is an option on many new cars, SUVs, and trucks. 

Lane-Keeping Assist (LKA). Lane-keeping assist will generate mild steering to put the driver back in their lane. This system also senses when the driver leaves their lane.

NHTSA has not set performance specifications for this technology, but this technology may be available on new cars, SUVs, and trucks. 

Blind-Spot Warning (BSW) or Blind Spot Detection (BSD). BSW utilizes radars or cameras and shines a light or symbol in or adjacent to the outside mirrors to warn the driver that another vehicle is driving in the parallel lane in an area that the drivers outside mirrors cannot detect. This system will sound an audible warning if the driver attempts to change lanes or uses their turn signal to indicate that they plan to change lanes. There are additional advanced systems that can initiate the braking system or the steering system in order to move the vehicle back towards the center of the lane.

NHTSA has not set performance specifications for BSW, but NHTSA recognizes this as a promising technology. On many new cars, SUVs, and trucks, this system is an option and can help avoid a crash.

Side View Camera. Side view cameras improve visibility on the passenger side, and in some cases provide the driver with a circuit view of the surrounding area of the car. The driver can use this feature to protect bumpers, side mirrors, trim, and wheel rims from damage at low speeds. This camera also provides an expanded view of a lane beside the driver when the driver uses their turn signal or when the driver manually activates this feature. This feature is similar to the blind spot monitor.

Communication

911 Notification - Automatic Crash Notification (ACN). ACN is technology designed to notify emergency responders that an accident has occurred and provide the location. This system uses sensors to detect a deployed airbag or detect a dramatic and sudden deceleration. Once this is detected, the system will automatically connect to an operator who will be able to talk with the accident victims.

This system has the potential to reduce death and disability by reducing the time it takes for emergency medical services to reach an accident scene and transport victims to a hospital.

NHTSA has not set performance specifications for this technology. This system is available as an option on many new cars, SUVs, and trucks. 

Telematics. Telematics is the use of cellular, Global Positioning Satellite (GPS), and other technology (e.g., GM OnStar, BMW Assist, Hyundai BlueLink, Kia UVO, Lexus Safety Connect, Mercedes-Benz’s mBrace, and Toyota Safety Connect) to gather and transmit data.
system allows the driver to communicate with a central dispatch center at the touch of a button. This center knows the location of the vehicle and can provide route directions of emergency aid on request.\(^2\)

**CONCLUSION**

There are many safety features to prevent automobile accidents and protect drivers. Because some do carry the potential risk of harm, these features continue to evolve. Research is regularly conducted to ensure that passenger vehicles are able to lessen the impact of crashes, reduce injuries and help drivers prevent crashes. However, consumer education is needed on the proper use of existing safety features. NHTSA, for example, not only conducts research and establish standards, but insurance companies and not-for-profit agencies such as AAA Foundation for Traffic Safety conduct research.

Although some crashes are unavoidable, the probability that passenger vehicle crashes, **INJURIES, AND DEATH** will continue to decrease is high because of the ongoing research, available educational opportunities, and existing and future advanced technologies.

After review of the existing literature on automotive safety, including airbags, the American Osteopathic Association (AOA) adopts the following policies: The American Osteopathic Association:

1. supports the ongoing efforts of the National Safety Council (NSC), the National Highway Traffic and Safety Administration (NHTSA), the National Transportation Safety Board (NTSB) and other responsible safety organizations to educate the public regarding the proper use of all occupant protection devices in passenger vehicles, including safety belts, child safety seats, and airbags;
2. urges continued corporate development and research into safer airbags and monitoring of adult and child fatalities resulting from airbag deployment; and
3. encourages the National Safety Council, the National Highway Traffic and Safety Administration, the National Transportation Safety Board, and other responsible safety organizations to educate the public regarding the benefits and potential dangers of all occupant protection equipment and accident avoidance systems.

**REFERENCES**


Source: H427-A/19

Status: 2019
Physician-Patient Relationship as Related to Proposed Gun Control Laws - Protection of the

Policy Statement

While the American Osteopathic Association (AOA) supports measures that save the community at large from gun violence, the AOA opposes public policy that mandates reporting of information regarding patients and gun ownership or use of guns except in those cases where there is duty to protect, as established by the Tarasoff ruling, for fear of degrading the valuable trust established in the physician-patient relationship.

Source: H428-A/19

Status: 2013; 2019 Reaffirmed
The American Osteopathic Association (AOA) petition the Centers for Medicare and Medicaid Services (CMS) to exclude hospice patients from the CMS rules for use of psychotropic and antipsychotic medication in NFs; and, that the AOA work with CMS to refine the rules governing the PRN use of antipsychotic and other psychotropic medications for any nursing facility patient to improve the continuity of patient care, decrease costs, and ease physician burden, based on scientific evidence and valid clinical studies.

Source: H429-A/19

Status: 2019
Recognizing Food Insecurity as a Public Health Issue

Policy Statement

The American Osteopathic Association recognizes food insecurity as a public health issue.

Source: H435-A/19

Status: 2019
Community Pharmacies; Required Notification of Primary Care Providers Regarding Vaccination Administration

Policy Statement

The American Osteopathic Association support measures that would require pharmacists to provide documentation of immunizations, administered in the community-based pharmacy setting, to the patient’s primary care physician in appropriate registries.

Source: H436-A/19
Status: 2019
Interference in the Physician-Patient Relationship by Personal Injury Attorneys and Insurance Carrier Agents

Policy Statement

The American Osteopathic Association (AOA) opposes any interference in the physician-patient relationship by persons with financial and business interests regarding a personal injury incident.

Source: H400-A/20

Status: 2015; 2020 Reaffirmed
Public Education Regarding the Importance and Safety of Vaccines for Infants, Children, and Adults

Policy Statement

The American Osteopathic Association (AOA) supports the widespread use and high compliance rate of the Health and Human Services National Vaccine Implementation Plan for infants, children, and adults through education of the public using media and marketing tools available to its organization.

Source: H402-A/20

Status: 2015; 2020 Reaffirmed
Support for the Advisory Committee on Immunization Practices (ACIP) Recommendations

Policy Statement

The American Osteopathic Association (AOA) encourages osteopathic physicians consider the vaccination history as an integral part of their patient’s health record and should counsel their patients on appropriate vaccinations for their age and health conditions. Osteopathic physicians should take all reasonable steps to ensure their patients of all ages are fully immunized against vaccine preventable illnesses and make vaccine recommendations to their patients according to the recommendations of the Advisory Committee on Immunization Practices (ACIP) and published in the Morbidity and Mortality Weekly Report (MMWR) and should not advocate alternative schedules.

Source: H403-A/20

Status: 2015; 2020 Reaffirmed
Vaccination Rates – Daycare Notification to Parents

Policy Statement

The American Osteopathic Association (AOA) supports legislation at the state level that requires daycare facilities to notify parents (in compliance with Health Insurance Portability and Accountability Act (HIPAA) regulations and state regulations where applicable) that their facility has in its care unvaccinated children who may pose a health risk to high-risk populations.

Source: H404-A/20

Status: 2015; 2020 Reaffirmed
Protection of Safe Water Supply

Policy Statement

The American Osteopathic Association (AOA) encourages the oil industry and the Environmental Protection Agency (EPA) to seek out new technologies for safer disposal of waste well water and the protection of our water supply.

Source: H405-A/20

Status: 2015; 2020 Reaffirmed
Antibiotic Stewardship

Policy Statement

The American Osteopathic Association (AOA), supports the five core actions outlined in the National Strategy for Combating Antibiotic-Resistant Bacteria and calls upon osteopathic physicians to adopt the principles of responsible antibiotic use, or antibiotic stewardship, which is a commitment to use antibiotics only when they are medically necessary.

Source: H406-A/20

Status: 2015; 2020 Reaffirmed
The American Osteopathic Association (AOA) supports the expansion of the Vaccines for Children (VFC) Program to include all Advisory Committee on Immunizations Practices (ACIP) age-appropriate vaccines for all underinsured children, in keeping with the original goals of the program.

Source: H407-A/20

Status: 2005; 2010 Reaffirmed as Amended; 2015 Reaffirmed; 2020 Reaffirmed
Seat Belt Laws – Primary Enforcement

Policy Statement

The American Osteopathic Association (AOA) supports the primary enforcement seat belt laws in every state.

Source: H408-A/20

Status: 2005; 2010 Reaffirmed; 2015 Reaffirmed; 2020 Reaffirmed
Intrauterine Fetal Demise Awareness

Policy Statement

The American Osteopathic Association (AOA) supports increasing public awareness of the risk for intrauterine fetal demise and encourages the director of the National Institutes of Health to allocate more resources to intrauterine fetal demise research.

Source: H409-A/20

Status: 2010; 2015 Reaffirmed as Amended; 2020 Reaffirmed
Aircraft Emergency Medical Supplies

Policy Statement

The American Osteopathic Association (AOA) supports the concept that airlines, under the control of the Federal Aviation Administration, maintain a policy for adequately equipping commercial aircraft of greater than 19 seats with at least minimal diagnostic and emergency medical supplies and supports legislation and regulation that any physician providing emergency service while on board aircraft be immune from any liability or legal action.

Source: H411-A/20

Status: 1984; 1989 Reaffirmed as Amended; 1995 Reaffirmed; 2000 Reaffirmed, 2005 Reaffirmed as Amended; 2010 Reaffirmed; 2015 Reaffirmed as Amended; 2020 Reaffirmed
Animals in Medical Research

Policy Statement

The American Osteopathic Association (AOA) supports the use of animals for valid medical research projects and the humane handling and treatment of such animals, and their ready availability from legitimate sources. The AOA supports eventual elimination of the use of animals in medical research as better techniques become available.

Source: H412-A/20

Status: 1990; 1995 Reaffirmed; 2000 Reaffirmed as Amended; 2005 Reaffirmed as Amended; 2010 Reaffirmed; 2015 Reaffirmed as Amended; 2020 Reaffirmed
Cancer

Policy Statement

The American Osteopathic Association (AOA) recognizes, endorses, and approves the continuing efforts of the National Cancer Institute to develop means to significantly reduce the incidence of cancer and the suffering and death resulting from cancer. The AOA will disseminate to the medical community and the public information gained from osteopathic and other research activities on the applications of the latest advances in cancer prevention, detection, early diagnosis and treatment.

Source: H413-A/20

Cardiopulmonary Resuscitation - Training

Policy Statement

The American Osteopathic Association (AOA) strongly supports instruction in Cardiopulmonary Resuscitation (CPR) and Automated External Defibrillator (AED) training to the general public; and encourages member physicians to qualify as instructors in basic life support so as to enable them to teach Cardiopulmonary Resuscitation and AED courses on a voluntary basis.

Source: H414-A/20

Children’s Safety Seats

Policy Statement

The American Osteopathic Association (AOA) supports the adoption and enforcement of child safety seat statutes in accordance with the National Highway Traffic Safety Administration Guidelines.

Source: H415-A/20

Status: 1985; 1990 Reaffirmed as Amended; 1995 Reaffirmed; 2000 Reaffirmed as Amended; 2005 Reaffirmed; 2010 Reaffirmed as Amended; 2015 Reaffirmed; 2020 Reaffirmed
The American Osteopathic Association (AOA) believes that the decision to withhold or withdraw treatment from a patient whose prognosis is terminal, or when death is imminent, shall be based upon the wishes of the patient or their family or legal representative if the patient lacks capacity to act on their own behalf as mandated by applicable law.

Source: H416-A/20

Status: 1979; 1984 Reaffirmed as Amended; 1989 Reaffirmed; 1995 Reaffirmed; 2000 Reaffirmed; 2005 Reaffirmed; 2010 Reaffirmed as Amended; 2015 Reaffirmed; 2020 Reaffirmed
Environmental Responsibility--Waste Materials

Policy Statement

The American Osteopathic Association (AOA) supports recycling.

Source: H417-A/20

Status: 1995; 2000 Reaffirmed as Amended; 2005 Reaffirmed as Amended; 2010 Reaffirmed as Amended; 2015 Reaffirmed; 2020 Reaffirmed
Firearms and Non-Powdered Guns - Education for Users

Policy Statement

The American Osteopathic Association (AOA) supports education involving firearm and non-powdered guns safety and the inherent risk, benefits and responsibility of ownership. [Editor’s Note: Non-Powdered Guns are defined as: BB, air and pellet guns, expelling a projectile (usually made of metal or hard plastic) through the force of compressed air or gas, electricity, or spring action. Non-powder guns are distinguished from firearms, which use gunpowder to generate energy to launch a projectile.

Source: H418-A/20

Status: 1990; 1995 Reaffirmed; 2000 Reaffirmed; 2005 Reaffirmed; 2010 Reaffirmed as Amended; 2015 Reaffirmed as Amended; 2020 Reaffirmed as Amended
Genetic Manipulation of Food Products – Consumers Right to Know

Policy Statement

The American Osteopathic Association (AOA) supports efforts that require clear identification of any genetically manipulated food products so that consumers may be properly informed as they make food choices.

Source: H419-A/20

Status: 2000, 2005 Reaffirmed as Amended, 2010 Reaffirmed; 2015 Reaffirmed; 2020 Reaffirmed
Condom Usage – Health Education

Policy Statement

The American Osteopathic Association (AOA) supports full disclosure of the risks and benefits of condom usage and the data on condom failure rates and causes of failure, whenever condom usage is taught.

Source: H420-A/20

Support of Literacy Programs

Policy Statement

The American Osteopathic Association (AOA) supports programs that promote literacy in the United States.

Source: H421-A/20

Status: 1990; 1995 Reaffirmed as Amended; 2000 Reaffirmed, 2005 Revised; 2010 Reaffirmed; 2015; 2020 Reaffirmed
Tanning Devices

Policy Statement

The American Osteopathic Association (AOA) supports programs that promote literacy in the United States.

Source: H422-A/20

Tobacco Settlement Funds

Policy Statement

The American Osteopathic Association (AOA) supports the use of the tobacco settlement fund exclusively for health care services, education and research.

Source: H423-A/20

Status: 2000, 2005 Revised; 2010 Reaffirmed; 2015; 2020 Reaffirmed
Healthy Family - Support of

Policy Statement

The American Osteopathic Association (AOA) recommends that their members support healthy families by encouraging families to do the following:

(1) Try to eat at least one meal per day together, using healthful nutritional guidelines;
(2) A set time be spent together as a family to help with schoolwork and include reading to and with children;
(3) Encouraging media-free time;
(4) Limiting exposure to violence; and
(5) Engaging in a healthy lifestyle that includes exercise.

Source: H424-A/20

Status: 2005; 2010 Revised; 2015 Reaffirmed; 2020 Reaffirmed
Immunization of 9 to 26 Year Old Male and Females with Human Papilloma Virus Vaccine

Policy Statement

The American Osteopathic Association (AOA) supports education and immunization for Human Papilloma Virus (HPV).

Source: H425-A/20

Status: 2010; 2015 Reaffirmed; 2020 Reaffirmed as Amended
Drugs, Curbing Counterfeit

Policy Statement

The American Osteopathic Association (AOA) supports the Food and Drug Administration’s (FDA) efforts to educate osteopathic physicians on how to identify counterfeit drugs.

Source: H426-A/20

Status: 2005; 2010 Revised; 2015 Reaffirmed; 2020 Reaffirmed
Sleep Disorders - Promoting the Understanding and Prevention of

Policy Statement

The American Osteopathic Association (AOA) supports the Food and Drug Administration’s (FDA) efforts to educate osteopathic physicians on how to identify counterfeit drugs.

Source: H427-A/20

Status: 2005; 2010 Revised; 2015 Reaffirmed; 2020 Reaffirmed
Minority Health Disparities

Policy Statement

The American Osteopathic Association (AOA) adopts the following Position Statement on Minority Health Disparities.

POSITION STATEMENT ON MINORITY HEALTH DISPARITIES

The minority healthcare crisis in America stems from a multitude of factors. In particular, healthcare disparities most greatly affect underrepresented minorities, which include African-Americans, Hispanic-Americans, Asian-Americans, Native Americans and Pacific Islanders. In order to effectively create positive change, certain questions must be addressed. These include, but are not limited to: Which minorities are most affected by disease-specific illness? Why do these disparities exist? What can be done to eliminate them? Will a concerted effort to increase awareness and education about health-care disparities result in improved delivery of quality healthcare?

There is a need for the osteopathic profession and all of organized medicine to develop strategies which address health care disparities among minorities and prepare culturally competent physicians. Guidance should be offered to educate practicing physicians and trainees to better resolve known disparities and serve diverse populations. Efforts must be made to assure cultural competency and to identify and overcome language and other barriers to delivering health care to minorities.

Healthcare disparities include differences in health coverage, health access and quality of care. Health disparities result in morbidity and mortality experienced by one population group in relation to another.

Cultural competency is a set of academic and personal skills that allow one to understand and appreciate cultural differences among groups. The better a healthcare professional understands a patient’s behavior, values and other personal factors, the more likely that patient will receive effective, high quality care.

Racial and ethnic healthcare disparities caused by problems with access to, and utilization of, quality care may be alleviated through improvements in the cultural competency skills of physicians. Healthcare disparities may also be alleviated through effective recruitment of underrepresented minorities into health professions schools.

The Centers for Disease Control, in conjunction with the U.S. Department of Health and Human Services, created an Office of Minority Health in 1985. Through this collaboration, the Racial and Ethnic Approaches to Community Health Act (REACH) was designed to identify and eliminate disparities in a number of major areas. Disparities in access to care as well as quality of care in these areas result in poorer outcomes for racial and ethnic minorities.

The identified areas of disparity include: 1) infant mortality; 2) breast and cervical cancer screening and malignancy; 3) cardiovascular and cerebrovascular disease; 4) diabetes; 5) infectious diseases (i.e., Covid-19, influenza, HIV/Aids); and 6) child and adult
immunizations. In addition, serious disparities exist in the provision of care for mental health problems, substance abuse and suicide prevention.

The American Osteopathic Association calls for the following actions to be taken to address minority health disparities and to improve cultural competency of its physician members:

1. The education of physicians regarding racial and ethnic healthcare needs, including disparities in the areas listed above;
2. The promotion of education regarding implicit or explicit biases among healthcare professionals that may play a role in clinical decision-making;
3. The evaluation and analysis of medical information which would permit the targeting of populations who are at greatest risk;
4. The identification of new methods to involve physician members in the communities in which they serve;
5. The identification and integration of available resources to better serve minority communities, including houses of worship, schools and local government;
6. The inclusion of cultural competency training throughout the continuum of osteopathic education;
7. The development of strategies to actively recruit underrepresented minority physicians into the profession in both primary care and subspecialties;
8. The development of approaches to encourage all physicians to provide care to underserved minority populations.

The adoption of strategies to assist physicians to effectively communicate with their patients, addressing translation and other barriers to patient understanding

Source: H428-A/20

Status: 2005; 2010 Reaffirmed; 2015; 2020 Reaffirmed as Amended
Infant Walker (Mobile) – Ban on the Manufacture, Sale and Use of

Policy Statement

The American Osteopathic Association (AOA) supports the ban on the manufacture, sale and use of mobile infant walkers; and urges osteopathic physicians to educate parents and other caregivers on the risks associated with the use of these devices.

Source: H429-A/20

Status: 2003; 2010 Revised; 2015 Reaffirmed; 2020 Reaffirmed
Develop In-Vitro Fertilization Standards of Care

Policy Statement

The American Osteopathic Association (AOA) supports the appropriate and evidenced based use of in-vitro fertilization in a manner that promotes the health and safety of both the mother and embryo; and supports the ethical guidelines for the practice of in-vitro fertilization that include, but are not limited to, the appropriate number of embryos implanted per patient.

Source: H430-A/20

Status: 2010; 2015 Reaffirmed; 2020 Reaffirmed as Amended
Continued Support of Combating Bio-Terrorism Activities

Policy Statement

The American Osteopathic Association (AOA) supports the appropriate and evidenced based use of in-vitro fertilization in a manner that promotes the health and safety of both the mother and embryo; and supports the ethical guidelines for the practice of in-vitro fertilization that include, but are not limited to, the appropriate number of embryos implanted per patient.

Source: H432-A/20

Status: 2010; 2015 Reaffirmed; 2020 Reaffirmed as Amended
Childhood Obesity – Worsening Epidemic in the American Society

Policy Statement

The American Osteopathic Association (AOA) encourages schools and vending machine suppliers to include healthy choice snacks in vending machines; and supports the limited use of vending machines in schools to avoid unnecessary caloric intake.

Source: H433-A/20

Status: 2010; 2015 Reaffirmed; 2020 Reaffirmed
Texting While Driving

Policy Statement

The American Osteopathic Association (AOA) supports efforts to educate all drivers concerning the dangers of texting and driving and supports efforts to ban the use of texting while driving.

Source: H435-A/20

Status: 2010; 2015 Reaffirmed; 2020 Reaffirmed
Silver Alert System

Policy Statement

The American Osteopathic Association (AOA) supports the formation of a “Silver Alert” System on a national level to notify communities of missing persons with mental disabilities, particularly seniors with cognitive or developmental impairments.

Source: H436-A/20

Status: 2010; 2015 Reaffirmed; 2020 Reaffirmed
National Institutes of Health Grants

Policy Statement

The American Osteopathic Association (AOA) encourages osteopathic physicians, osteopathic medical schools, and their affiliated institutions to pursue NIH funding for biomedical research; and requests that the NIH include osteopathic medical schools in the overall United States medical school funding reports and also to include a category specific to Osteopathic Manipulative Treatment (OMT) in the estimates of funding for various Research, Condition, And Disease Categories (RCDC) reported each year to Congress and the American public.

Source: H437-A/20

Status: 2010; 2015 Reaffirmed; 2020 Reaffirmed as Amended
Screening for Breast Cancer

Policy Statement

The American Osteopathic Association (AOA) recognizes and promotes the importance of the integrity of the patient-physician relationship and recommends that breast cancer clinical preventive screenings and coverage be individualized to the extent possible for every patient.

Source: H438-A/20

Status: 2010; 2015 Reaffirmed as Amended; 2020 Reaffirmed
Gender Identity Non-Discrimination

Policy Statement

The American Osteopathic Association (AOA) supports the provision of adequate and medically necessary treatment for transgender and gender-variant people and opposes discrimination on the basis of gender identity.

Source: H439-A/20

Status: 2010; 2015 Reaffirmed; 2020 Reaffirmed
Traumatic Brain Injury Awareness

Policy Statement

The American Osteopathic Association (AOA) believes that osteopathic physicians should be aware of and utilize “best practices” when caring for victims of civil or military conflicts, or natural or man-made disasters, including civilians, returning veterans and their families, particularly those with Traumatic Brain Injury (TBI); and the AOA will work in conjunction with state, specialty and regional societies to provide educational programs to advance this goal.

Source: H440-A/20

Status: 2010; 2015 Reaffirmed; 2020 Reaffirmed as Amended
Support for Family Caregivers

Policy Statement

The American Osteopathic Association (AOA), recognizing a growing number of family caregivers have unaddressed needs related to personal health and wellbeing, supports caregivers by participating in the developing public debate regarding health care policy to include family caregivers and encourages its members to gain education in caregiver illnesses, resources in their area and treat and/ refer when appropriate.

Source: H441-A/20

Status: 2010; 2015 Reaffirmed; 2020 Reaffirmed
Firearm Violence

Policy Statement

The American Osteopathic Association (AOA):

(1) Supports the federal government’s January 2013 clarification, “that no federal law in any way prohibits doctors or other health care providers from reporting their patients’ threats of violence to the authorities, and issuing guidance making clear that the Affordable Care Act does not prevent doctors from talking to patients about gun safety;”

(2) Supports funding for the Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH) and other research entities to conduct research on firearm violence and to provide recommendations on reducing firearm violence;

(3) Supports promotion of policies that will increase access to mental health services and for the appropriate coverage of mental health services by public and private health care programs; and

(4) Encourages enhanced education of gun safety and safe handling of firearms; and

(5) Approves the attached Policy Statement on Firearm Violence.

AOA Policy Statement – Firearm Violence

The American Osteopathic Association (AOA) is dedicated to preventing violence in our communities, especially the increased prevalence of firearm violence. As physicians, we see first-hand the devastating consequences of violence to victims and their families. The AOA recognizes that laws, regulations, and policies have the potential to decrease the occurrence of violence, especially firearm violence, in our communities. The AOA supports:

Preserving the Ability of Physicians to Educate and Counsel their Patients on Firearm Violence
Preserving the rights of physicians and other health care professionals to counsel patients on prevention, including the prevention of injury or death as a result of firearms is critical. Physicians play an important role in preventing firearm injuries through health screenings, patient counseling, and referral to mental health services. The AOA supports the Administration's January 2013 clarification, “that no federal law in any way prohibits doctors or other health care providers from reporting their patients’ threats of violence to the authorities, and issuing guidance making clear that the Affordable Care Act does not prevent doctors from talking to patients about gun safety.” We must ensure that no federal or state law hinders, restricts, or criminalizes the patient-physician relationship.

Advancing Research to Reduce Firearm Violence
Advancing research to reduce firearm violence is a public health issue that deserves the allocation of appropriate resources. The AOA supports funding for the Centers for Disease
Control (CDC) and Prevention, the National Institutes of Health (NIH), and other research entities to conduct research on firearm violence and to provide recommendations on reducing firearm violence.

**Improving Access to Mental Health Services and Resources**

Improving access to mental health services and resources is essential to reducing firearm violence. The AOA supports promotion of policies that will increase access to mental health services and for the appropriate coverage of mental health services by public and private health care programs. Access to mental health services and resources for young adults should be a priority. The early identification of diagnosable mental health issues and subsequent treatment is vital to reducing firearm violence.

Source: H442-A/20

Status: 2013; 2015 Revised; 2020 Reaffirmed as Amended
Adopting and Promoting Non-Stigmatizing Language for Substance Use Disorders

Policy Statement

The American Osteopathic Association (AOA) commit to the use of clinically-accurate, non-stigmatizing, person-first language (“substance use disorder,” “recovery,” “substance misuse,” “positive or negative urine screen,” and “person with a substance use disorder”) and discourage the use of stigmatizing terminology (“substance abuse,” “substance abuser,” “addict,” “alcoholic,” and “clean/dirty”) in future publications, resolutions, and educational materials both in print and online; and, that the AOA encourages its members and organizational partners to incorporate clinically-accurate, non-stigmatizing, person first language into their clinical practice.

Source: H444-A/20

Status: 2020
AOA Response to Novel Public Health Threats

Policy Statement

The American Osteopathic Association (AOA) will continue to serve as a trusted source of information and education for physicians, health professionals and the public relative to urgent, emergent and novel public health threats; and, that the AOA will advocate for and support those responding to urgent, emergent and novel public health threats, including all healthcare workers and volunteers; and, that the AOA will advocate for proactive planning, improved public health infrastructure, disease threat surveillance and evidence-based responses to novel public health threats affecting the U.S. population.

Source: H445-A/20

Status: 2020
Background Checks and Firearms Safety Training as a Condition of Firearms Purchase

Policy Statement

The American Osteopathic Association (AOA) recognizes public health data demonstrating the impact of firearms on mortality and wellness in the United States and will support federal legislation requiring comprehensive background checks for all firearm purchases, including sales by gun dealers, sales at gun shows, and online sales for purchase, which does not extend to firearms transfers between family members or firearms attained through inheritance; and, that the AOA will support efforts to require firearms safety training, including military or law enforcement training, as a condition to purchase any class of firearms; and that H421-A/15 is superseded by this resolution.

Source: H446-A/20

Status: 2020
The American Osteopathic Association (AOA) reaffirm support for state and federal efforts, including efforts by private organizations, as well as those enumerated in the 2018 House of Delegates resolution number H-428 – A/2018, and that those efforts include addressing social determinants affecting health, substance abuse programs, mental health resources, clinical care programs and provision of stable housing for all homeless individuals that are seeking temporary or permanent shelter.

Source: H449-A/20

Status: 2020 Reaffirmed as Amended
Referral Resolution: Breastfeeding While on Medication Assisted Treatment (MAT)

Policy Statement

The attached White paper, titled, “Breastfeeding While on Medication Assisted Treatment (MAT)”, and the recommendations within be adopted as policy.

Breastfeeding While on Medication Assisted Therapy

Introduction

Opioid use among pregnant women is a growing public health concern. In 2014, the Centers for Disease Control and Prevention (CDC) recorded a 333% national increase in opioid use disorder (OUD) among pregnant women, with 6.5 cases of opioid abuse per 1,000 hospital deliveries, compared to 1.5 cases in 1999.1 Opioid use during pregnancy is not uncommon; as many as 1 in 5 pregnant women enrolled in Medicaid filled an opioid prescription during their pregnancy.2 Prenatal opioid exposure has been directly linked to adverse health outcomes for mothers and babies across the nation. These adverse health outcomes include increased maternal mortality and morbidity, poor fetal development, preterm births, still births, birth defects, and increased incidence of Neonatal Abstinence Syndrome (NAS).3

Studies have found that breastfeeding among women being treated for OUD offers many benefits that can mitigate the impacts of OUD for the mother and infant. Benefits include, but are not limited to, reduced hospital stays and decreased need for morphine treatment in infants born with NAS.4

Opioid Use Disorder Treatment

Medication Assisted Treatment, or MAT, is defined as the use of medications in combination with counseling and behavioral therapies to treat OUD and aid patients in sustaining their recovery.5 MAT may be utilized with pregnant women to treat opioid use disorder and avoid the severe consequences associated with untreated opioid use disorder or stopping opioid usage too quickly. The U.S. Food and Drug Administration has approved three medications, buprenorphine, methadone, and naltrexone for OUD treatment.5

Naltrexone is the newest therapy approved by the U.S. Food and Drug Administration to treat opioid use disorder in pregnant women. Since it is also the least studied therapy, there is a research gap regarding the safety and effectiveness of naltrexone during pregnancy.6 As a result, MAT for pregnant women commonly entails the use of methadone or buprenorphine with naloxone, in conjunction with coordinated care among behavioral therapists, OB-GYNs, and addiction specialists.7 Both methadone and buprenorphine treatment are endorsed by the American College of Obstetricians and Gynecologists and the American Society of Addiction Medicine as best practices for addressing opioid use during pregnancy.4

Methadone, a long-acting opioid agonist that decreases the desire to take opioids, was established as the standard of care in 1998 for treating OUD in pregnant women. The Substance Abuse and Mental Health Service Administration (SAMHSA) identified methadone as a safe drug to take while pregnant or preparing for pregnancy, along with counseling and participation in social support programs.6
Recently, The American Society of Addiction Medicine (ASAM) recognized Buprenorphine combined with Naloxone as the standard of care for the treatment of women who are pregnant or breastfeeding with OUD. The American Osteopathic Academy of Addiction Medicine (AOAAM) supports ASAM consensus that the combination of Buprenorphine and Naloxone is regularly used, safe, and effective. Buprenorphine is the first medication to treat opioid use disorder that was authorized to be administered in physician offices, resulting in improved access to treatment. Studies indicate that buprenorphine reduces fluctuations in fetal levels of opioids, minimizes repeated prenatal withdrawal, decreases overdoses, and limits drug interactions.

Neonatal withdrawal, also called neonatal abstinence syndrome (NAS), is an anticipated and treatable condition caused by perinatal exposure to opioids, including methadone and the combination of buprenorphine with naloxone. Although NAS may still occur in infants whose mothers receive MAT, the symptoms are milder than they would be without treatment. Neonatal withdrawal, also called neonatal abstinence syndrome (NAS), is an anticipated and treatable condition caused by perinatal exposure to opioids, including methadone and the combination of buprenorphine with naloxone. Although NAS may still occur in infants whose mothers receive MAT, the symptoms are milder than they would be without treatment.

Postpartum, both infants and women on maintenance therapies can experience greater benefits through breast feeding. Although trace amounts of both methadone and buprenorphine have been found to seep into breast milk, research has shown that the benefits of breastfeeding outweigh the negligible risk associated with the medication that enters breast milk.

Breastfeeding
Because of the associated benefits, exclusive breastfeeding, without other supplementation, is recommended for healthy women by both the American Academy of Pediatrics and the World Health Organization for the first 6 months of life. Breastfeeding contributes to attachment between a woman and her infant, encourages skin-to-skin contact. The antibodies and hormones found in breast milk defend the infant’s immune system against illness and lower the risk of asthma, leukemia, childhood obesity, lower respiratory infections, eczema, diarrhea, vomiting, and Sudden Infant Death Syndrome. Breastfeeding also improves the health of mothers post-delivery, simultaneously, lowering potential risk for diabetes, breast cancer, and ovarian cancer. Breast milk is also easier for infants to digest and cost efficient for parents.

The American Academy of Pediatrics (AAP) recommendation applies to women who take methadone or buprenorphine as well, without regard for dosage. Breastfeeding among women who are opioid dependent is also encouraged by both, the American College of Obstetricians and Gynecologists (ACOG) and the American College of Osteopathic Obstetricians and Gynecologists (ACOOG), as long as the women are taking methadone or buprenorphine consistently, abstaining from illicit drugs, and have no underlying complexities or conditions, such as human immunodeficiency virus (HIV) and or Hepatitis C with open/bleeding and cracked nipples. Additionally, The ACOOG supports the ACOG committee review that women in the post-partum period who return to using street drugs and are not on stable OUD therapy should restrain from breastfeeding. After 6 months, the AAP recommends continuation of breastfeeding, alongside introduction of complementary foods during the first year of life.

In spite of these endorsements, less than 25% of mothers exclusively breastfeed for 6 months in the United States. Formula supplementation of breast milk is commonly utilized. Supplementation is reportedly associated with many side effects that can lead to adverse infant and maternal outcomes. Formula supplements can negatively impact the "maternal milk supply, the duration of exclusive breastfeeding, and the infant’s gut microbiome; alteration of the neonatal gut environment can be responsible for mucosal inflammation and disease, autoimmunity disorders, and allergic conditions in both childhood and adulthood".

The Centers for Disease Control and Prevention established the breastfeeding report card, which provides national data on breastfeeding rates, breastfeeding support indicators, and
breastfeeding practices. The breastfeeding report card indicates that, in 2015, 83.2% of infants were breastfed starting at birth, 57.6% were still breastfed at some level at 6 months, and 35.9% at 12 months. This data suggests that “the early postpartum period is a critical time for establishing breastfeeding, but mothers may not be getting the support they need from health care providers, family members, and employers to meet their breastfeeding goals”.

Uptake of breastfeeding is likely even lower among women with OUD. National Institute on Drug Abuse (NIDA) states that the rate of breastfeeding is normally “low” among mothers with OUD. Increased formal breastfeeding education, direct support for mothers, health care providers training on breastfeeding techniques, and peer support are all effective interventions that promote the start and sustainability of breastfeeding among mothers.

Conclusion
Increasing rates of maternal opioid use during pregnancy and NAS are public health concerns. The utilization of MAT with methadone or buprenorphine has been approved as a safe mechanism for combatting opioid use during pregnancy and while breastfeeding.

Breastfeeding improves maternal and infant morbidity and mortality and decreases the impact of adverse health conditions. Breastfeeding infants who were exposed to opioids prenatally have the added advantage of lessening the impact of other conditions, such as NAS. Encouraging breastfeeding among mothers with exposure to opioids, who are undergoing MAT, is a significant step toward addressing OUD and NAS and improving maternal and child health. It shall be noted that the ACOOG and AOAM supports the content of this paper and the policy recommendations outlined to encourage exclusive breastfeeding among mothers with a history of OUD.

American Osteopathic Association Policy
Given the research surrounding the positive impact of breastfeeding, the American Osteopathic Association adopts the following policy statements as its official position on breastfeeding among mothers with exposure to opioid use disorder in the United States:

1. The American Osteopathic Association (AOA) acknowledges that exclusive breastfeeding significantly improves maternal and infant health outcomes.
2. The American Osteopathic Association supports methadone and buprenorphine/naloxone assisted treatment as standards of care for addressing opioid use disorder during pregnancy and in the postpartum period.
3. The American Osteopathic Association (AOA) encourages exclusive breastfeeding among mothers with a history of Opioid Use Disorder (OUD), who are under physician care, actively engaged in a recovery program, on appropriate opioid agonists (methadone or buprenorphine), abstaining from illicit drugs, and who have no other contraindications, such as human immunodeficiency virus (HIV) infection and or Hepatitis C with open/bleeding and cracked nipples.
4. The American Osteopathic Association (AOA) recommends the use of counseling, coordination of care, and social support for mothers during pregnancy and breastfeeding in the postpartum period.

References:


5. U.S. Food and Drug Administration. Information about Medication Assisted Treatment – MAT. (2020); Retrieved from [https://www.fda.gov/drugs/information-drug-class/information-about-medication-assisted-treatment-mat](https://www.fda.gov/drugs/information-drug-class/information-about-medication-assisted-treatment-mat)


8. Substance Abuse and Mental Health Services Administration. Methadone. (2020); Retrieved From [https://www.samhsa.gov/medication-assisted-treatment/treatment/methadone](https://www.samhsa.gov/medication-assisted-treatment/treatment/methadone)


10. Substance Abuse and Mental Health Services Administration. Buprenorphine. (2019); Retrieved From [https://www.samhsa.gov/medication-assisted-treatment/treatment/buprenorphine](https://www.samhsa.gov/medication-assisted-treatment/treatment/buprenorphine)


Source: H452-A/20

Status: 2020 Adopted
Policy Statement

The American Osteopathic Association supports all healthcare personnel and first responders and victims of domestic or foreign terrorist attacks in the United States being eligible for healthcare treatment stemming from the act to be covered by the United States Government.

Source: H453-A/20

Status: 2004; 2009 Reaffirmed as Amended; 2014 Reaffirmed; 2020 Adopted as Amended
The American Osteopathic Association encourages an increase in the total number of URM graduates from colleges of osteopathic medicine by the year 2020 and encourages an increase in the total number of URM faculty by the year 2025.

Source: H454-A/20

Status: 2014; 2020 Adopted as Amended
The following policy paper and the recommendations provided within be adopted as the amended policy of the AOA.

REGULATION OF E-CIGARETTES AND NICOTINE VAPING

BACKGROUND
The adverse health effects associated with tobacco use are well documented public health concerns. Smoking can damage every human organ, and it can lead to death from heart disease, cancers or strokes. According to the World Health Organization (WHO), 1 in 10 deaths each year, or nearly 8 million deaths around the world, are caused by tobacco use. More than 7 million of those deaths are the result of direct tobacco use, while around 1.2 million are the result of non-smokers being exposed to second-hand smoke. In the United States, this translates to 480,000 deaths per year from cigarette smoking and second-hand smoke exposure.

In response to the negative health effects of tobacco products and cigarettes in particular, a natural market for smoking cessation and reduction products has emerged over the past 4 decades. The use of electronic nicotine delivery systems (ENDS), such as electronic cigarettes (e-cigarettes), has reached a rapidly expanding consumer base. E-cigarettes are often used or promoted to reduce consumption of tobacco products. Alternative strategies for reaching smoking cessation goals include switching to low or light cigarettes or using nicotine-infused chewing gum, lozenges, lollipops, dermal patches or hypnosis.

In the US, e-cigarettes are the most frequently utilized tobacco product among youth, who are also more likely than adults to use them. In 2019, over 5 million US middle and high school students had used e-cigarettes in the past 30 days. In 2018, 3.2% of US adults were current e-cigarette users.

The name e-cigarette is an umbrella term that includes any battery-powered device that vaporizes liquid nicotine for delivery via inhalation. These devices are most commonly referred to as electronic cigarettes, e-cigarettes, e-cigs, vaping, vape pens, vape pipes, hookah pens, e-hookahs, but could potentially be referred to by other terms. Since its 2007 introduction in the United States, the e-cigarette market has grown to include more than 460 brands. E-cigarettes are a 2.5 billion dollar business in the United States. The attraction to e-cigarettes crosses many segments of the population, appealing to tobacco cigarette smokers trying to quit as well as non-smokers who want to try nicotine without the harmful additives. Though some states and municipalities have started to ban e-cigarettes, tobacco cigarette smokers can use e-cigarettes as a source of nicotine in some venues where conventional cigarettes are banned.

Costs associated with smoking-related illnesses continue to escalate. In 2014, smoking-related illness costs in the United States were more than $300 billion each year, including approximately $170 billion for direct medical care for adults, and more than $156 billion in lost
productivity. Nearly $5.6 billion of the lost productivity cost was due to secondhand smoke exposure.\textsuperscript{13}

Overall, e-cigarettes may be less harmful for heavy or moderate smokers because they may reduce exposure to carcinogens and other toxic chemicals that cause serious disease and death.\textsuperscript{14} However, the effect of long term consumption of nicotine and associated aerosols remains unclear. Studies have shown that e-cigarette vapors may be harmful, particularly in places with limited ventilation and for people with compromised health. Furthermore, e-juice liquids have been found to increase accidental poisonings in children. The full scale of health and safety hazards of vaping for users and secondhand users is undetermined.\textsuperscript{15}

\textbf{ANALYSIS}

Regulation of e-cigarettes by the Food and Drug Administration (FDA) only began in earnest in 2016. The Family Smoking Prevention and Tobacco Control Act (Tobacco Control Act) provided the FDA authority to regulate the manufacture, marketing and distribution of tobacco products.\textsuperscript{16} However, e-cigarettes were not initially included in the FDA's regulation of tobacco products. Unlike tobacco cigarettes, e-cigarettes have enjoyed the ability to advertise on television and radio.\textsuperscript{17} This allows e-cigarette companies to market their product in a more liberal fashion in response to market demands, including the use of celebrity endorsements.\textsuperscript{18} However, some manufacturers have voluntarily begun to limit their advertising in an attempt to avoid federally imposed restrictions on advertising.

\textbf{The Composition of E-Cigarettes}

The e-cigarette is a smokeless, battery-powered device that vaporizes liquid nicotine for delivery via inhalation.\textsuperscript{19} Using an e-cigarette may also be referred to as "vaping", or as "juuling", the branded form of flavored e-cigarettes popular among younger consumers. The e-cigarette contains nicotine derived from tobacco plant and several secondary chemical ingredients.\textsuperscript{20} It is primarily composed of a nicotine cartridge, atomizer, and a battery.\textsuperscript{21} The atomizer, which converts the nicotine liquid into a fine mist, consists of a metal wick and heating element.\textsuperscript{22} When screwed onto the cartridge, the nicotine liquid from the cartridge, which could also include flavoring, comes into contact with the atomizer unit and is carried to the metal coil heating element.\textsuperscript{23} A single cartridge can hold the nicotine equivalent of an entire pack of traditional cigarettes.\textsuperscript{24} E-cigarettes can also be used to deliver marijuana and other drugs.\textsuperscript{25}

While the typical e-cigarette is sold in the shape of a cigarette, many products are sold in the shape of discreet objects such as pipes, pens, lipsticks, and other everyday items.\textsuperscript{26} Often, they can be legally used where traditional tobacco products are banned.

\textbf{Federal Efforts to Regulate}

In 2016, the FDA finalized a rule extending regulatory authority to cover all tobacco products, including electronic nicotine delivery systems (ENDS) that meet the definition of a tobacco product.\textsuperscript{27} The FDA now regulates the manufacture, import, packaging, labeling, advertising, promotion, sale, and distribution of ENDS. Prior to this rule, the FDA could regulate e-cigarettes only if the manufacturer made a therapeutic claim, such as the product was being marketed as a cessation device.\textsuperscript{28}

The rule established restrictions on youth access to newly regulated tobacco products by: (1) banning their sale to individuals younger than 18 years of age (federal legislation raised this to 21 years in 2019) and requiring age verification via photo ID; and (2) prohibiting the sale of tobacco products in vending machines (unless in an adult-only facility).\textsuperscript{29}
The Federal Food, Drug, and Cosmetic Act was signed into law on December 20, 2019, and raised the federal minimum age of sale for tobacco products from 18 to 21 years. Retailers are now prohibited from selling tobacco products to anyone under the age of 21.

Further, in January 2020, the FDA banned all mint- and fruit-flavored e-cigarettes, but exempted menthol- and tobacco-flavored products, in an effort to target products widely used by minors while preserving an “off-ramp” for adults who are trying to quit smoking.

Tobacco is a major threat to public health, and one of the goals of the FDA is to protect Americans from tobacco-related diseases and death. This rule allows the FDA to protect youth by restricting their access to tobacco products, helps consumers better understand the risks of using these products, prohibits false and misleading product claims, and prevents new tobacco products from being marketed unless a manufacturer demonstrates that the product meets relevant public health standards.

State Efforts to Regulate
Various states and municipalities have also enacted laws restricting the sale of e-cigarettes. Twenty-seven states, along with the District of Columbia, Puerto Rico, and the U.S. Virgin Islands, and 1,107 municipalities have passed laws that ban smoking in all non-hospitality workplaces, restaurants, and bars; of these, 22 states and 929 municipalities also restrict e-cigarette use in 100% smoke-free venues.

In November 2019, Massachusetts became the first state to restrict the sale of all flavored tobacco products, including e-cigarettes and menthol cigarettes. New Jersey prohibited the use of e-cigarettes in all enclosed indoor places of public access as well as in working places, and in January 2020, the state enacted legislation banning the sale of all flavored e-cigarettes. In March 2020, Rhode Island also announced a permanent ban on the sale of flavored e-cigarettes. Six other states (Michigan, Montana, New York, Oregon, Utah and Washington) temporarily banned the sale of flavored e-cigarettes in 2019, but of those, only Montana’s and Washington’s bans are currently in effect while the others are facing various legal challenges.

As of 2019, twenty-three (23) states and the District of Columbia have enacted statutes which require licenses for retail sales of e-cigarettes.

Arguments for E-Cigarettes
Proponents of e-cigarettes consider e-cigarettes to be less harmful than traditional tobacco products and believe they increase adult smoking cessation. While it has been established that e-cigarettes contain fewer carcinogenic elements than traditional tobacco cigarettes, the long-term health effects of e-cigarette use are unknown. According to the American Lung Association there are approximately 600 ingredients in cigarettes. When burned, they create more than 7,000 chemicals. At least 69 of these chemicals are known to cause cancer, and many are poisonous. While e-cigarettes may have fewer component chemicals, a study found that the usage of e-cigarettes contributes to indoor air contamination. A 2016 report from the WHO determined that second-hand aerosols from e-cigarettes are a new source of pollution for hazardous particulate matter (PM). The levels of nickel, chromium, and other metals found in second-hand aerosols are higher than ambient air and higher than second-hand tobacco smoke.

The greatest appeal of e-cigarettes for smoking cessation is that they deliver nicotine to alleviate nicotine withdrawal symptoms. E-cigarettes evoke the psychological response to
cigarette smoking because of its shape and the familiar behavior aspect of smoking.\textsuperscript{47} A 2011 survey of 104 e-cigarette users revealed that 66\% started using them with the intention to quit smoking and almost all felt that the e-cigarette had helped them to succeed in quitting smoking.\textsuperscript{48} Another survey of 3,037 e-cigarette users revealed that 77\% of respondents used e-cigarettes to quit smoking or to avoid relapse.\textsuperscript{49} None said they used them to reduce consumption of tobacco with no intent to quit smoking.\textsuperscript{50} However, the overall effectiveness of e-cigarettes is still in question. In a randomized study, participants given e-cigarettes, nicotine patches and placebo e-cigarettes that lacked nicotine were able to quit smoking at roughly the same rates, with insufficient statistical power to conclude superiority of nicotine e-cigarettes.\textsuperscript{51}

\textbf{Consequences of E-Cigarettes}

Advocates of e-cigarettes contend that e-cigarettes are less risky than traditional tobacco products and can serve as a mode of harm reduction by reducing smoking or serving as a smoking cessation strategy.\textsuperscript{52} While there is limited evidence that suggests that adult smokers could benefit from e-cigarette use instead of combustible tobacco products, smokers would need to fully switch to e-cigarettes and stop smoking cigarettes and other tobacco products completely to achieve any meaningful health benefits from e-cigarettes. Experts who serve on the US Preventive Services Task Force have resolved that there is insufficient evidence to recommend e-cigarettes for smoking cessation in adults, including pregnant women. Thus, e-cigarettes are not currently approved by the FDA as an aid to quit smoking.\textsuperscript{53}

Another major concern is that e-cigarettes appeal to youth by being flavorful, trendy and a convenient accessory.\textsuperscript{54} The flavorings being used, such as candy and other sweet flavorings are particularly attractive to younger populations. For this reason, these flavorings are banned in traditional cigarettes.\textsuperscript{55} Despite a downturn prior to 2017, e-cigarette use among youth has drastically increased. From 2017 to 2018, the percent of middle school students who used e-cigarettes increased 48\%, resulting in 570,000 middle school students, or 4.9\%, who were current e-cigarette users. Among high school students during the same period, current e-cigarette use, defined as use at least one day in the past 30 days, increased by 78\%, from 11.7\% to 20.8\%, the equivalent of 3.05 million high school students using e-cigarettes in 2018. Current e-cigarette users in high school who reported use on 20 days or more in the past 30-day period increased from 20\% to 27.7\%. During the same timeframe, use of flavored e-cigarettes increased among high school students who currently used e-cigarettes as well. Use of any flavored e-cigarette went up among current users from 60.9\% to 67.8\%, and menthol use increased from 42.3\% to 51.2\% among all current e-cigarette users, including consumers of multiple products, and from 21.4\% to 38.1\% among those using only e-cigarettes. From 2018 to 2019, the number of middle school and high school students who reportedly used e-cigarettes in the past 30 days increased from a total of 3.6 million to 5.4 million youth.\textsuperscript{56}

In addition to exposure to the carcinogenic and toxic effects of tobacco, smokers become addicted to the nicotine.\textsuperscript{57} Nicotine addiction is characterized as a form of drug dependence recognized in the Diagnostic and Statistical Manual of Mental Disorders (DSM-V).\textsuperscript{58} E-cigarette cartridges can contain up to 20 times the nicotine of a single cigarette, and the process of vaping lacks the normal cues associated with cigarette completion, such as the butt of the cigarette ending a dose.\textsuperscript{59}

Conditioning has a secondary role in nicotine addiction. Smokers associate particular cues with the high of smoking, often causing relapse when those seeking to quit smoking are confronted with those cues.\textsuperscript{60} E-cigarettes allow quitting smokers to respond to those cues. This poses a risk of overconsumption. The lack of finality to an e-cigarette is determined only by the battery or
nicotine cartridge. Distinguishable from tobacco cigarettes, smokers who have turned to the e-cigarette no longer have the butt of the cigarette as a cue to stop smoking.61

E-cigarettes can cause other inadvertent injuries as well. The CDC, the US Food and Drug Administration (FDA), state and local health departments, and other clinical and public health organizations have investigated a national outbreak of e-cigarette, or vaping, product use-associated lung injury (EVALI).62 EVALI is an inflammatory response in the lungs triggered by inhaled substances. EVALI has been found to vary due to the substantial variety of products and ingredients used. It may present as pneumonia or an inflammatory condition known as fibrinous pneumonitis.63 As of February 2020, 2,807 hospitalized EVALI cases or deaths were reported to CDC from all 50 states, the District of Columbia, Puerto Rico and U.S. Virgin Islands. Sixty-eight (68) deaths were confirmed in 29 states and the District of Columbia. Vitamin E acetate, an additive in some THC-containing e-cigarette products, was found to be strongly associated with the EVALI outbreak.64

Additionally, e-cigarettes are manufactured from metal and ion components that introduce concerns about faulty products and malfunctions.65 Defective e-cigarette batteries have caused fires and explosions, some of which have resulted in serious injuries. Lithium-ion batteries have reportedly overheated, caught fire or exploded, an event known as thermal runaway. From 2015 to 2017, an estimated 2,035 e-cigarette explosions and burn injuries presented to hospital emergency departments. Although the explosions are relatively rare, they can cause severe injuries.66

**CONCLUSION**
The AOA supports FDA and state regulation of the ingredients in all electronic cigarette cartridges, requiring ingredient labels and warnings, and eliminating the use of flavors that are banned in traditional cigarettes.

The AOA supports FDA and state regulation prohibiting sales and advertisements of electronic cigarettes to persons under the age of 21. Advertisements for electronic cigarettes should be subject to the same rules and regulations that are enforced on traditional cigarettes.

The AOA further encourages federal, state and local government action to ban the use of electronic cigarette devices in all spaces where traditional cigarettes are currently barred from use.

The AOA promotes tobacco and nicotine cessation treatment, and the use of any such treatment that has been proven safe and effective by the FDA.

The AOA supports research by the FDA and other organizations into the health and safety impact of e-cigarettes and liquid nicotine.

The AOA encourages physicians to educate patients about the risks of e-cigarette use, and to counsel patients to submit voluntary reports to the US Department of Health and Human Services Safety Reporting Portal (www.safetyreporting.hhs.gov) if they sustain adverse reactions to e-cigarettes.

**REFERENCES**
3. Available at https://www.cdc.gov/tobacco/data_statistics/fact_sheets/fast_facts/index.htm#diseases
5. Id. at 330.
7. Id.
12. Id. at 331.
20. Id. at 353.
23. Id.
32. Jordan Paradise at 374.
36. Bach, Laura supra.
37. Id.
38. Id.


41. Dan Radel, supra quoting Robert Lahita, Chair of Medicine at New Beth Israel Medical Center.


43. Id.

44. Id.

45. Schober et al, Use of Electronic Cigarettes (E-Cigarettes) Impairs Indoor Air Quality and Increases FeNO Levels of E-Cigarette Consumers, International Journal of Hygiene Environment and Health.


47. Michael B. Siegal et. al., Electronic Cigarettes as a Smoking-Cessation Tool: Results from an online Study, 40 Am. J. Preventive Med. 472, 474 (2011).


49. Id.

50. Id.


52. Jordan Paradise at 329.


54. Jordan Paradise at 329.

55. Bridget M. Kuehn, supra.

56. Available at https://www.cdc.gov/tobacco/basic_information/e-cigarettes/about-e-cigarettes.html#what-are-e-cigarettes


59. Jordan Paradise at 335.

60. Neal L. Benowitz, supra.

61. Jordan Paradise at 359.

62. Available at https://www.cdc.gov/tobacco/basic_information/e-cigarettes/severe-lung-disease.html#overview

63. EVALI: New information on vaping-induced lung injury; Available at https://www.health.harvard.edu/blog/evali-new-information-on-vaping-induced-lung-injury-2020040319359

64. Available at https://www.cdc.gov/tobacco/basic_information/e-cigarettes/severe-lung-disease.html#overview

65. Id. at 335.


Source: H455-A/20

Status: 2020 Adopted as Amended
Support Nutritionally Balanced, Low Cost or Free Meals for Children in Schools

Policy Statement

The American Osteopathic Association (AOA) advocates for legislative efforts in support of widely accessible, nutritionally-balanced, low-cost or free meals for all children in the U.S. Pre-K through 12 schools.

Source: H400-A/21

Status: 2021
Supporting Public Policy to Encourage Wholesome Food Donations to those in Need in America

Policy Statement

The American Osteopathic Association (AOA) stands in support of our current public policy that increases access to food for all Americans. The AOA supports increasing access to donations of wholesome food through the use of qualified food banks.

Source: H401-A/21

Status: 2021
Collection of Public Health Data Concerning Firearm Fatalities

Policy Statement

The American Osteopathic Association (AOA) supports the collection of public health data concerning firearm fatalities. The data points to be collected should be separated into the following categories: homicides, including the number of domestic violence homicides; suicides and accidents; and non-fatal firearm related injuries. Within each category, the ages of the victims to be noted.

Additional data to be collected is the hospitalizations that occurred as a result of a firearm that did not result in death and include the caliber of the firearm used.

The AOA will advocate to make this data publicly available and develop healthcare guidance and inform public policy.

Source: H402-A/21

Status: 2021
Patient Centered Treatment for Pain Management and Appropriate Use of Opioids

Policy Statement

The American Osteopathic Association (AOA) support increased access to evidence-based pharmacotherapy for treatment of chronic pain, with a lens that places value on the functional status of the patient rather than the Milligram Morphine Equivalent (MME) of the prescription. The AOA will continue to support risk management in terms of toxicology monitoring, volume prescribed, and the use of the Prescription Monitoring Program (PMP) and the AOA will continue to promote referral for patient centered treatment when a SUD is diagnosed.

Source: H403-A/21

Status: 2021
Improving Outcomes in Behavioral Health Care in the Emergency Department

Policy Statement

The American Osteopathic Association (AOA) supports innovative models that increase availability of emergency behavioral health care for crisis stabilization.

Source: H410-A/21

Status: 2021
Introduction
The American Osteopathic Association (AOA) is dedicated to reducing the impact of violence on health and wellness in our communities, including injury and death that result from firearm violence. As physicians, we see firsthand the consequences of violence to victims and their families. The AOA recognizes that laws, regulations, and policies have the potential to decrease the occurrence of violence, especially firearm violence, in our communities.

The 2019 AOA House of Delegates (HOD) adopted a resolution, H437-A/19, Firearm Violence, which states that the AOA “will develop a comprehensive policy which consolidates all current firearm violence policies into a single unified policy and present it for consideration by the 2020 AOA House of Delegates.” In response to the adoption of this policy, the Bureau on Federal Health Programs (BFHP) concluded that having a broad array of policies on a given topic allows AOA staff to accurately respond to federal and regulatory concerns. With nuanced policy to reference, the bureau determined that the best approach to implementing this policy is to develop a comprehensive document that includes all current AOA policies relating to firearm violence. This approach is also intended to preserve any relevant background and history of individual resolutions and avoid any potential impediments to future policy changes.

The BFHP submitted a white paper to the 2020 HOD in response to the direction provided in H437-A/19 that included an overview of AOA firearm policy through 2019. Questions were raised by delegates at the 2020 HOD regarding the scope of the document submitted and whether more current data was available, and it subsequently was referred back to the BFHP. In response to this referral, the BFHP has updated its research; firearms resolutions adopted by the 2020 HOD along with updated federal statistics and citations are included in this compendium.

Background
Much of the AOA’s policy is predicated on an understanding of the role of firearms on public health in the United States. According to the Centers for Disease Control and Prevention (CDC), firearm-related deaths in the U.S. reached a twenty year high in 2017\(^1\). In 2018, there were 39,740 firearms-related deaths in the U.S., with 109 people dying from firearm-related injury each day\(^2\). The CDC estimates that 6 in 10 of these are suicide and 3 in 10 are homicide\(^3\). Additionally, in 2018, more U.S. deaths were attributed to firearms than motor vehicle accidents\(^4\).

An analysis of 2010 data showed that the U.S. had the highest rate of firearm-related violence, suicides, and accidents among industrialized countries\(^5\). Beyond the impact on the health and well-being of Americans, there is an economic impact, with gun violence in the U.S. costing $229 billion in 2015\(^6\).
Policies Preserving the Ability of Physicians to Educate and Counsel their Patients on Firearm Violence

Preserving the rights of physicians and other health care professionals to counsel patients on prevention, including the prevention of injury or death, as a result of firearms is critical. Physicians play an important role in preventing firearm injuries through health screenings, patient counseling, and referral to mental health services.

Current Resolutions on Firearm Education:

- **H425-A/19 FIREARM SAFETY**
  The American Osteopathic Association (AOA) recommends that when appropriate, physicians ask patients and/or caregivers about the presence of firearms in the home and counsel patients who own firearms about the potential dangers inherent in gun ownership, especially if vulnerable individuals, children and adolescents are present. The AOA recommends strategies such as secure storage and the use of safety locks to eliminate the inappropriate access to firearms by vulnerable individuals, children and adolescents and recommends all physicians educate families on the safe use and storage of firearms. 1994; revised 1999, 2004; reaffirmed 2009; 2014; reaffirmed as amended 2019

- **H418-A/20 FIREARMS AND NON-POWDERED GUNS – EDUCATION FOR USERS**
  The American Osteopathic Association supports education involving firearm and non-powdered guns safety and the inherent risk, benefits and responsibility of ownership. 1990; reaffirmed 1995, 2000, 2005; revised 2010; revised 2015; adopted as amended 2020
  
  [Editor’s Note: Non-powdered guns are defined as: BB, air and pellet guns, expelling a projectile (usually made of metal or hard plastic) through the force of air pressure, CO2 pressure, or spring action. Non-powder guns are distinguished from firearms, which use gunpowder to generate energy to launch a projectile.]

- **H340-A/16 PHYSICIAN GAG RULES – OPPOSITION TO**
  The American Osteopathic Association (AOA) is opposed to governmental actions and policies that limit the rights of physicians and other health care practitioners to inquire of their patients whether they possess guns and how they are secured in the home or to counsel their patients about the potential dangers of guns in the home and safe practices to attempt to avoid those potential dangers. The AOA opposes any further legislation or initiatives advocating physician gag rules that limit physicians’ right to free speech or other rights. 2016

- **H428-A/19 PHYSICIAN-PATIENT RELATIONSHIP AS RELATED TO PROPOSED GUN CONTROL LAWS, PROTECTION OF THE**
  While the American Osteopathic Association supports measures that save the community at large from gun violence, the AOA opposes public policy that mandates reporting of information regarding patients and gun ownership or use of guns except in those cases where there is duty to protect, as established by the Tarasoff ruling, for fear of degrading the valuable trust established in the physician-patient relationship. 2013; reaffirmed 2019
Policies on Advancing Research to Reduce Firearm Violence

Advancing research to reduce firearm violence is a public health issue that deserves the allocation of appropriate resources. The AOA supports funding for the Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), and other research entities, to conduct research on firearm violence and to provide recommendations on reducing firearm violence.

Current Resolutions on Firearm Research:

- **H442-A/20 FIREARM VIOLENCE**
  The American Osteopathic Association (AOA) (1) supports the federal government's January 2013 clarification, "that no federal law in any way prohibits doctors or other health care providers from reporting their patients' threats of violence to the authorities, and issuing guidance making clear that the Affordable Care Act does not prevent doctors from talking to patients about gun safety"; (2) supports funding for the Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH) and other research entities to conduct research on firearm violence and to provide recommendations on reducing firearm violence; (3) supports promotion of policies that will increase access to mental health services and for the appropriate coverage of mental health services by public and private health care programs; and (4) encourages enhanced education of gun safety and safe handling of firearms; and (5) approves the attached Policy Statement on Firearm Violence. 2013; revised 2015; adopted as amended 2020

AOA Policy Statement – Firearm Violence

The American Osteopathic Association (AOA) is dedicated to preventing violence in our communities, especially the increased prevalence of firearm violence. As physicians, we see first-hand the devastating consequences of violence to victims and their families. The AOA recognizes that laws, regulations, and policies have the potential to decrease the occurrence of violence, especially firearm violence, in our communities. The AOA supports:

**Preserving the Ability of Physicians to Educate and Counsel their Patients on Firearm Violence**

Preserving the rights of physicians and other health care professionals to counsel patients on prevention, including the prevention of injury or death as a result of firearms, is critical. Physicians play an important role in preventing firearm injuries through health screenings, patient counseling, and referral to mental health services. The AOA supports the administration's January 2013 clarification, "that no federal law in any way prohibits doctors or other health care providers from reporting their patients' threats of violence to the authorities, and issuing guidance making clear that the Affordable Care Act does not prevent doctors from talking to patients about gun safety." We must ensure that no federal or state law hinders, restricts, or criminalizes the patient-physician relationship.
Advancing Research to Reduce Firearm Violence

Advancing research to reduce firearm violence is a public health issue that deserves the allocation of appropriate resources. The AOA supports funding for the Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), and other research entities to conduct research on firearm violence and to provide recommendations on reducing firearm violence.

Improving Access to Mental Health Services and Resources

Improving access to mental health services and resources is essential to reducing firearm violence. The AOA supports promotion of policies that will increase access to mental health services and for the appropriate coverage of mental health services by public and private health care programs. Access to mental health services and resources for young adults should be a priority. The early identification of diagnosable mental health issues and subsequent treatment is vital to reducing firearm violence.

- **H630-A/18 COMPREHENSIVE GUN VIOLENCE REFORM**
  The American Osteopathic Association joins like-minded organizations in the call for Congressional legislation that:

  1. Labels gun violence as a national public health issue.
  2. Funds appropriate research on gun violence as part of future federal budgets.
  3. Establishes constitutionally appropriate restrictions on the manufacturing and sale, for civilian use, of large-capacity magazines and firearms with features designed to increase their rapid and extended killing capacity. 2018

Additional Policies Supporting Reduced Firearm Injury

- **H318-A/16 FIREARMS – COMMISSION OF A CRIME WHILE USING A FIREARM**
  The American Osteopathic Association supports the position that persons accused of a crime involving a firearm be prosecuted to the full extent of the law. 1994; revised 1996, 2001; reaffirmed 2006; reaffirmed as amended 2011; reaffirmed 2016

- **H446-A/20 BACKGROUND CHECKS AND FIREARMS SAFETY TRAINING AS A CONDITION OF FIREARMS PURCHASE**
  The American Osteopathic Association (AOA) recognizes public health data demonstrating the impact of firearms on mortality and wellness in the United States and will support federal legislation requiring comprehensive background checks for all firearm purchases, including sales by gun dealers, sales at gun shows, and online sales for purchase, which does not extend to firearms transfers between family members or firearms attained through inheritance; and the AOA will support efforts to require firearms safety training, including military or law enforcement training, as a condition to purchase any class of firearms. H421-A/15 is superseded by this resolution. adopted 2020
Conclusion
As noted above, the AOA House of Delegates adopted a policy in 2019 that calls for the identification of all current firearm violence policies in a single document. This compendium reflects that policy and highlights the wide range of issues addressed in AOA firearm policies which includes eight individual policies. At least two resolutions (H425-A/19 and H418-A/20) support education and recommend safety precautions for gun owners. One (H340-A/16) opposes any governmental action that would limit the right of physicians to discuss with their patients the topic of responsible gun ownership and safe storage. Another (H428-A/19) opposes any mandated reporting of patient gun ownership. Two policies (H442-A/20 and H630-A/18) support federal funding for research on firearm violence. H630-A/18 also labels gun violence as a national public health issue and supports federal legislation that would establish constitutionally appropriate restrictions on the manufacturing and sale of certain classes of firearms. Lastly, H446-A/20 supports federal legislation requiring comprehensive background checks for firearms as well as efforts to require firearm safety training.

There is a separate and distinct focus in most of these policies, with covered issues ranging from education, to protecting the rights of physicians, support for research, and support for certain restrictions on sales. As such, these policies, as well as any future firearm-related policies, should be maintained and taken up for review and reconsideration by the House of Delegates on an individual basis.

---

iii Id.
Drug Samples

Policy Statement

The American Osteopathic Association (1) encourages the pharmaceutical industry to continue the distribution of drug samples, and/or vouchers to physicians, including those drugs whose patents have expired, (2) will petition the Food and Drug Administration to not limit the manufacturers’ distribution of drug samples and/or vouchers; and (3) will continue to defend and support policies that allow osteopathic physicians to provide drug samples (including stock bottles or vouchers when appropriate) free-of-charge to patients.

Source: H412-A/21

Concussion, Return-to-Play and Return-to-Learn

Policy Statement

The American Osteopathic Association (AOA) approves the Youth Concussion and Return-to-Play white paper and its position on concussion, return-to-play and return-to-learn.

Source: H413-A/21

Status: 2016; 2021 Reaffirmed as Amended
Youth Concussion and Return-To-Play White Paper

Since 2009, every state has passed some form of legislation to address concussion safety in youth athletics. Most states' laws address the following five common areas:

1. Parent and student education,
2. Parent and student signature requirements,
3. Coach training, removal and return-to-play [RTP],
4. Return-to-learn [RTL] and
5. Clearing provider types

State laws vary, however, in the precise degree of detail and rigor of their respective requirements. The American Osteopathic Association (AOA) is committed to helping states work to address this public health risk by providing evidence-based guidance on concussion as a part of the spectrum of Traumatic Brain Injuries (TBIs), as well as RTP and RTL protocols for youth athletes. We support policies that are backed by current scientific evidence, with appropriate clarification regarding the definitions of terms and protocols. The AOA believes that allopathic and osteopathic physicians (MDs and DOs) possess the complete medical knowledge and training needed to recognize and diagnose the subtle, varying and evolving symptoms of concussion, but that coordination across all levels of the physician-led team is imperative for timely evaluation and intervention, and appropriate follow-up care. In order to ensure the appropriate level of care, team physicians should possess up-to-date documentation of knowledge, skills and experience in this area of medicine. The goal of this paper is to encourage greater consistency among the terminology used by health care organizations, and to utilize current evidence to help states create a standardized approach to concussion, RTP and RTL.

Background

In recent years, a consensus has emerged among the scientific community that head injuries resulting from contact sports, including football, soccer, boxing, ice hockey and others, can have devastating long-term effects. Among the consequences of repeated head injuries are headache, dizziness, difficulty concentrating or completing tasks, and in some cases, increased risk of depression and suicide. Children and teenagers are especially susceptible to concussion-related injuries, because their brains lack the coating and insulation of adult brains and their heads are relatively heavy, and necks weak, compared to adults. Thus, children are at risk of sustaining more serious brain injuries than adults when exposed to the same amount of force. According to the CDC, the number of TBI-


related emergency department visits among youth doubled from 2002 to 2010, from approximately 500 to 1,000 per 100,000 people. Further, female athletes appear to be more susceptible to sustaining concussions than males.

To address this issue, all states have now implemented some form of concussion and RTP legislation. The National Center for Injury Prevention and Control (NCIPC) conducted a case study on two states that were early implementers of these laws, Washington and Massachusetts, to evaluate differences in their laws and approaches to addressing youth sports-related injuries.

Washington became the first state to implement a concussion law with the passage of the “Zackery Lystedt Law” in May 2009. This law mandates that youths suspected of having sustained a head injury or concussion should be removed from competition, and returned to play only after an evaluation and written medical clearance from a “licensed health care provider* trained in the evaluation and management of concussion.” The law requires individual school districts to develop information to educate youth athletes, their parents and coaches about the nature and risk of concussions, but it does not provide any specific requirements for the content of those guidelines. The law does not require any coach training, and students are not required to complete concussion history forms.

Massachusetts' law, by contrast, requires stakeholder groups including parents, coaches, trainers, school athletic directors and school-employed physicians and nurses to participate in an athletic head injury safety training program developed by the Department of Public Health. It directs the Department to utilize materials from the Centers for Disease Control and Prevention to create the program, which shall include (1) current training in recognizing the symptoms of concussions and (2) providing students who participate in athletic activities a summary of the medical protocol for recognizing concussion symptoms, a protocol for post-concussion participation in athletics, and the short- and long-term consequences of concussions. It requires schools to implement an RTP protocol containing 17 specific items including procedures for medical review of all concussion history forms and plans for gradual RTP following injury. It also mandates that schools establish their own RTP protocol implementation teams. The law requires students to provide information about their concussion and head injury history at the start of each sports season on a form that must be signed by the student and their parent or guardian and forwarded to their coach(es). A student who becomes unconscious or is suspected of having suffered a concussion must be

---


removed from practice or competition and not returned to the practice or competition during which the concussion or suspected concussion occurred. The student may only return to subsequent athletic activities with the written clearance of a physician, neuropsychologist, certified athletic trainer or other “appropriately trained or licensed health care professional as determined by the Department of Public Health.”

Numerous state laws in addition to Massachusetts’ include athletic trainers and nurses among the “clearing provider types” who may allow a youth to return to athletic activity following a concussion. Forty-nine states (with the exception of California) license and regulate athletic trainers, and all require that certified athletic trainers work within their state practice act under the direction of a physician. All forty-nine states recognize certification by the National Athletic Trainers’ Association, which will soon increase the minimum education required for certification from a bachelor’s degree to a master’s degree from an accredited professional athletic training education program.10 Graduates must then pass a comprehensive examination, and meet ongoing continuing education requirements. Education programs include training in the identification of signs, symptoms, interventions and RTP criteria for brain injury including concussion, but continuing education requirements vary widely (some states require concussion management as a part of these continuing education requirements, while others do not).11, 12, 13

While all states license and regulate nurses, nursing education varies more widely and concussion education is not mandatory. The National Association of School Nurses (NASN) recommends a four-year bachelor’s degree and registered nurse (RN) certification as the minimum standard for a school nurse.14 The NASN has issued a position statement on the importance of the school nurse on the concussion management team; however, the RN examination does not include concussion among the list of topics and not all states require continuing education for nurses.15, 16 As athletic trainers and school nurses are frequently on the front lines of youth concussion evaluation and management, more robust state education and training requirements are needed to ensure that these health care professionals receive current, evidence-based training in this area, particularly when these providers are listed among the state’s “clearing provider types.”

Washington and Massachusetts’ laws illustrate the wide variation in approaches that states have taken to attempt to address concussion among student athletes, and while all 50 states now possess similar laws, these laws differ significantly in their provisions. Several physician specialty organizations have examined this issue, and published position statements which include evidence-based guidance for states.

10 No author. “After 2.5 Years of Diligent Analysis, Leaders of the Key Athletic Training Organizations Have Decided to Change the AT Degree Level to a Master’s.” AT Strategic Alliance, May 20, 2015. Available at: http://atstrategicalliance.org/statements/strategic-alliance-degree-statement.
The American Osteopathic Academy of Sports Medicine (AOASM), as a contributing author on the 2013 paper *Concussion and the Team Physician: A Consensus Statement (TPCC)*, which is still current, advocated for on-field and sideline protocols such as neurological assessments and a plan for post-injury follow-up, as well as post-game-day evaluation and treatment. The TPCC urged guidelines that encourage individualized RTP decisions not based on a rigid timeline, with the physician ultimately bearing responsibility for making the decision. The paper also advocates that treating physicians should understand the complications of concussion, including that cumulative concussions may increase subsequent risk for concussion, and other neurological and physical symptoms. Physicians should also understand prevention principles, including helmet use and the utility of educating athletes, parents and coaches about concussion risks in advance.

The Centers for Disease Control and prevention (CDC) published guidelines on the diagnosis and management of mild traumatic brain injury among children in 2018. *Recommendations from the CDC pediatric TBI guidelines include:*

1. Do not routinely image patients to diagnose TBI.
2. Use validated, age-appropriate symptom scales to diagnose TBI.
3. Assess evidence-based risk factors for prolonged recovery.
4. Provide patients with instructions on return to activity customized to their symptoms.
5. Counsel patients to return gradually to non-sports activities after no more than 2-3 days of rest.

The CDC has also developed an educational program called “heads up: concussion in youth sports.”

The American Academy of Neurology (AAN) has a position statement on sports concussion (2020) called concussion policy for youth and high school sports. The AAN supports
educational resources such as the CDC'S heads up: concussion in youth sports online training course for coaches and parents and processes to confirm that the education is understood by parents and athletes. The AAN supports removal from participation for any athlete who is exhibiting symptoms or signs of a concussion until they are evaluated by a qualified healthcare provider properly trained in the assessment and management of concussion, such as a neurologist and as defined by state law. AAN recommends that student athletes should not return to athletic competition until the signs and symptoms of concussion have resolved and have been cleared by a qualified healthcare professional trained in the management of concussion, such as a neurologist. Student athletes should return to full academic participation before returning to competition.


The American Medical Society for Sports Medicine (AMSSM) recently published an update to their 2013 position statement on concussion in sport in 2019. AMSSM recommends that any athlete suspected of having a concussion be removed from the activity and assessed by a licensed healthcare provider trained in the evaluation and management of concussions “reasons for immediate removal and prompt evaluation include loss of consciousness (LOC), impact seizure, tonic posturing, gross motor instability, confusion, or amnesia. Any of these reported or observed signs should result in removal from practice or competition for at least the rest of the day.” Since concussions can cause changes in attention, learning, and short-term memory that make learning difficult, return to learn should be coordinated with school personnel to quickly implement a school support plan without delay. AMSSM recommends that “concussion-related symptoms and signs should be resolved before returning to sport. A return-to-play progression involves a gradual, stepwise increase in physical demands and sport-specific activities without return of symptoms before the final introduction of exposure to contact.”

The American Academy of Pediatrics (AAP) updated their clinical report on sport-related concussion in children and adolescents in 2018. AAP recommends that “testing after a sport-related concussion should be performed and conducted by providers who have been trained in the proper administration and interpretation of the tests.” All athletes with a suspected concussion should be immediately removed from play. They should not return to full sports participation until they have completed a return-to-sport progression without a return of
concussion symptoms. Health care providers should be aware of their state’s laws regarding return to play after a concussion.


22 HALSTEAD ME, WALTER KD, MOFFATT K. SPORT-RELATED CONCUSSION IN CHILDREN AND ADOLESCENTS. PEDIATRICS. 2018; 142(6):e20183074.

As the above position statements demonstrate, there is a need for a stronger, unified voice from the medical community in order to provide state legislatures with the best tools and up-to-date guidance as they work to combat this public health concern. The AOA believes that emphasizing the physician-led, team-based model of care, where licensed health care providers at all levels possess current education and training in concussion management, will ensure that medical professionals with comprehensive knowledge of scientific evidence and advancements are appropriately involved in patient care.

AOA Policy Development

Strong evidence of the serious, negative long-term health effects of concussions underscores the need to create policy in this AREA to help guide osteopathic advocacy in response to current and proposed state legislation. Unified, evidence-based advocacy from medical groups, including the AOA, will benefit states as they update their concussion and RTP laws, which currently vary widely. The AOA adopts the following policy statements as its official position on concussion, RTP and RTL and encourages states, as well as schools, sports clubs and professional leagues to develop official rules that promote education and prevention of TBIS by incorporating these tenets:

1. **Parent and Student Education.** The AOA believes that educating students, parents and guardians about the nature, symptoms, risks and short- and long-term health effects of concussions and traumatic brain injuries will improve student safety by increasing awareness of concussion warning signs and allowing for early treatment. This has been shown to decrease the risk of subsequent injuries during recovery and improve long-term outcomes. Education should also include clarification of the RTP and RTL processes. The AOA believes that all schools and youth athletic organizations should disseminate evidence-based teaching tools such as those issued by the Centers for Disease Control (CDC), Sports Safety International (SSI), certain state members of the Brain Injury Alliance (BIA) or other nationally recognized health or medical organizations to students, parents and guardians prior to the start of every school year or athletic season.23

2. **Parent and Student Signature.** The AOA supports requiring signatures from parents/guardians and students on an information sheet acknowledging that they have received the aforementioned education and been made aware of the risks of concussion inherent in athletic activities, and understand appropriate steps for concussion evaluation and management, prior to every school year or athletic season.
Coach/Official Training. The AOA encourages states to adopt mandatory annual training for coaches, athletic directors, school nurses and other school and youth sports officials based upon materials published by the CDC, SSI, BIA or other nationally recognized health or medical organizations. Training should emphasize prevention as well as the need for early identification of concussions and improve treatment and management strategies, with an emphasis on prohibiting same-day return-to-play for concussed athletes in all circumstances and requiring clearance from a physician (as defined elsewhere in AOA policy) prior to allowing a concussed athlete to return to athletic activity.

24 NO AUTHOR. “HEADS UP TO SCHOOLS: TEACHERS, COUNSELORS, AND SCHOOL PROFESSIONALS.” CENTERS FOR DISEASE CONTROL AND PREVENTION, NO DATE. AVAILABLE AT HTTPS://WWW.CDC.GOV/HEADSUP/SCHOOLS/TEACHERS.HTML.
4. **Removal and Return-to-Play.** The AOA believes that it is vital that youth suspected of having sustained a concussion be removed from practice or competition immediately, and examined by a member of the physician-led team who is a licensed health care provider (LHCP) with documentation reflecting current concussion training, whose scope of practice includes the evaluation and management of concussions. The AOA supports the use of baseline testing conducted by a trained health care professional prior to the start of each athletic season or school year to assess a youth’s balance and cognitive function as well as the presence of any concussion symptoms. At the time of a suspected concussion, results from this baseline testing can be compared to results from post-concussive testing again assessing balance and cognition. If the provider suspects a possible concussion, the athlete should be evaluated by a physician immediately. There should be no same-day return-to-play for athletes diagnosed with a concussion, and no subsequent return-to-play without written clearance by a physician with documented current concussion training. For students diagnosed with a concussion, examining physicians should work with parents/guardians, coaches, athletic trainers and other stakeholders on ongoing concussion management and gradual RTP and RTL for the student athlete. The examining physician should also coordinate with a multi-disciplinary team that may include physical therapists, occupational therapists, neuropsychologists, cognitive rehabilitation specialists and certified athletic trainers, among others, as the patient recovers from suffering from a concussion.

5. **Clearing Provider Type.** The AOA believes a LHCP member of the physician-led team who is trained in the evaluation and management of concussions, such as a certified athletic trainer or school nurse, may conduct a sideline assessment. If a youth’s sideline assessment indicates a possible concussion, the youth must be evaluated by an allopathic or osteopathic physician with expertise in concussion management, who shall establish a clinical diagnosis. Proof of this expertise may include concussion training in sports medicine fellowship, or documentation of course completion in a recognized concussion course such as one from the CDC or SSI. Physicians possess the most comprehensive education and training of any health care provider, which enables them to recognize the variable and often subtle signs of concussion. The evaluating physician shall create a treatment plan and work with other members of the physician-led team to implement it, and the youth may only return to athletic activity with written clearance from the evaluating physician.

6. **Return-to-Learn.** The AOA recommends that the evaluating physician work with school officials to implement an RTL protocol for students following a concussion. The physician may adjust the protocol with school officials as the patient's symptoms evolve and gradually improve, usually within one to three weeks after the injury. Each concussion is an individualized entity, however, and as such should be treated by the physician on an individualized basis with the physician making the deciding determination regarding RTL. The physician should communicate the importance of cognitive rest following a concussion to parents and school officials, emphasizing that a student may require a lighter workload, exemption from classes that appear to exacerbate concussion symptoms, and/or testing extensions until symptoms improve or disappear.
Osteopathic Medicine -- Autonomy of

Policy Statement

Policy of the American Osteopathic Association states that the osteopathic profession, in the interest of providing the best possible healthcare to the public, shall maintain its status as a complete and distinct philosophy of medicine.

Source: H414-A/21

Chelation Therapy

Policy Statement

The American Osteopathic Association does not endorse chelation therapy as useful treatment for other than its current Food and Drug Administration approved use, and as medical evidence supports.

Source: H415-A/21

Status: 1985; 1990 Reaffirmed as Amended; 1995 Reaffirmed; 2000 Reaffirmed as Amended; 2005 Referred; 2006 Reaffirmed as Amended; 2011 Reaffirmed; 2016 Reaffirmed as Amended; 2021 Reaffirmed as Amended
Minority Health and Osteopathic Medical Education

Policy Statement

The American Osteopathic Association encourages the development of internal programs to address the disproportionate incidence of preventable diseases in minority populations, the impaired access to quality healthcare in minority communities, and the under representation of minority populations in osteopathic medicine; and will work with the American Association of Colleges of Osteopathic Medicine (AACOM), and towards eliminating such disparities within its osteopathic medical educational processes, and collaborate with federal/state governments, academia, and the healthcare industry to develop programs to eliminate medical and academic disparities between minority and non-minority groups in the US.

Source: H416-A/21

Status: 1996; 2001 Reaffirmed; 2006 Reaffirmed as Amended; 2011 Reaffirmed; 2016 Reaffirmed; 2021 Reaffirmed as Amended
Obesity in Children

Policy Statement

The American Osteopathic Association supports programs which advocate physical fitness and good nutrition for children and families.

Source: H417-A/21

Status: 2001; 2006 Reaffirmed as Amended; 2011 Reaffirmed as Amended; 2016 Reaffirmed; 2021 Reaffirmed
Sports, Fitness and Nutrition

Policy Statement

The American Osteopathic Association supports the President's Council on Sports, Fitness and Nutrition.

Source: H418-A/21

Status: 1991; 1996 Reaffirmed as Amended; 2001 Reaffirmed; 2006 Reaffirmed; 2011 Reaffirmed as Amended; 2016 Reaffirmed; 2021 Reaffirmed as Amended
Plastic Beverage and Food Container Recycling Act

Policy Statement

The American Osteopathic Association supports conservational recycling and encourages that materials are made from recycled products.

Source: H419-A/21

Childhood and Teenage Sexual Exposure

Policy Statement

The American Osteopathic Association: (1) encourages osteopathic physicians to provide anticipatory guidance to minor children about the risks of sexual exposure and sexually-transmitted diseases, and provide this same guidance to their parents and/or caregivers; (2) encourages osteopathic physicians to support the development of curriculum by local, state and national educational organizations that will lead to the prevention of unwanted pregnancy and transmission of disease, using medically appropriate measures, preferably abstinence and avoidance of high risk sexual behavior; and (3) support public education efforts to prevent unwanted pregnancy and sexually transmitted infections.

Source: H420-A/21

Status: 2005; 2006 Reaffirmed; 2011 Reaffirmed as Amended; 2016 Reaffirmed; 2021 Reaffirmed as Amended
Tobacco Control – The Framework Convention on

Policy Statement

The American Osteopathic Association support the efforts of international health agencies in eliminating the use of tobacco products, smokeless tobacco products, and vaporizing products from their societies, and encourage the United States to use its experience in tobacco products control, smokeless tobacco products control, and vaporizing products control to help developing countries with this health issue and support the public health initiatives of the World Health Organization for tobacco products control, smokeless tobacco products control, and vaporizing products control by promoting the Framework Convention on Tobacco Control (FCTC) and urge the President of the United States to submit the framework convention on tobacco products control, smokeless tobacco products control, and vaporizing products control to the United States Senate for ratification.

Source: H421-A/21

Status: 2001; 2006 Reaffirmed as Amended; 2011 Reaffirmed as Amended; 2016 Reaffirmed Amended; 2021 Reaffirmed
Damage to Hearing from use of Headphones

Policy Statement

The American Osteopathic Association (1) supports public education campaigns to increase awareness among children and their parents of the potential risk of noise-induced hearing loss that can occur from listening to headphones at high volumes for extended periods of time; (2) encourages manufacturers to include information about the hazards of unsafe volume levels on or within product packaging and to recommend implementation of built-in mechanisms that can be enabled to limit a product's decibel output; and (3) encourages osteopathic physicians to actively educate young people and parents about the safety concerns of using headphones and the necessary safeguards to prevent hearing damage.

Source: H422-A/21

Status: 2011; 2016 Reaffirmed; 2021 Reaffirmed as Amended
Dangers of the “Choking Game”

Policy Statement

The American Osteopathic Association supports increasing awareness among parents, educators, counselors and physicians of the risks and warning signs associated with the choking game and of the resources available for educating teens about the dangers of the choking game; and supports the inclusion of information about the dangers of the “choking game” in classroom education and other school-sponsored discussions about drugs and risky behaviors.

Source: H423-A/21

Status: 2011; 2016 Reaffirmed; 2021 Reaffirmed
Medical Cannabis – Research on

Policy Statement

The American Osteopathic Association supports well-controlled clinical studies on the use of cannabis, commonly referred to as marijuana, and related cannabinoids for patients who have significant medical conditions for which current evidence suggests possible efficacy; and encourages the National Institutes of Health (NIH) to facilitate the development of well-designed clinical research studies into the medical use of cannabis.

Source: H424-A/21

Status: 2011; 2016 Reaffirmed as Amended; 2021 Reaffirmed
Blood Donors, Protection from Depletion of Iron

Policy Statement

The American Osteopathic Association encourages blood collection facilities to establish guidelines to identify frequent blood donors, and institute the necessary testing to monitor their iron stores.

Source: H426-A/21

Status: 2006; 2011 Reaffirmed; 2016 Reaffirmed; 2021 Reaffirmed
5-2-1-0+10 Campaign for America’s Children

Policy Statement

The American Osteopathic Association recommends the continued support of the 5-2-1-0+10 campaign for America’s children. 5-2-1-0+10 stands for 5 servings of fruits and vegetables each day, 2 hours or less of recreational screen time per day, 1 hour of physical activity per day, 0 sweetened or sugary drinks, and 10 hours of sleep every night for children.

Source: H427-A/21

Status: 2011; 2016 Reaffirmed as Amended; 2021 Reaffirmed as Amended
Obesity Epidemic – Addressing the American
Policy Statement

The American Osteopathic Association, in conjunction with its specialty and divisional affiliates, the American Association of Colleges of Osteopathic Medicine, the National Board of Osteopathic Medical Examiners and the certifying boards, will initiate a profession-wide program to provide leadership in addressing the American obesity epidemic; encourages each osteopathic physician and medical student to measure the body mass index (BMI) and waist circumference in every patient and address with them their obesity-related issues, and also encourages each osteopathic physician and student to address any obesity-related issues in their own health as an example to their patients.

Source: H429-A/21

Status: 2011; 2016 Reaffirmed; 2021 Reaffirmed
Mandatory Influenza Vaccine of Healthcare Personnel

Policy Statement

The American Osteopathic Association recommends mandatory seasonal Influenza vaccination of all healthcare personnel and that medical exemptions to required influenza immunization (e.g., life threatening allergic reaction after receiving an influenza vaccine or severe allergy to a vaccine component) should be kept at a minimum to ensure high coverage rates and granted only on an individual basis.

Source: H430-A/21

Status: 2016; 2021 Reaffirmed
Title X Funded Family Planning Services – Support for

Policy Statement

The American Osteopathic Association believes that Title X funded family planning services are critical components of public health and primary health care and shall advocate for Title X funded family planning services.

Source: H431-A/21

Status: 2016; 2021 Reaffirm
Shackling of Pregnant Inmates

Policy Statement

The American Osteopathic Association acknowledges the potential harm shackling can cause harm to both the mother and fetus, including miscarriage, and premature birth; and supports restricting the use of any form of shackling on an inmate who is pregnant or in labor unless the woman is an immediate and serious threat to herself or others or if the woman is a substantial flight risk.

Source: H432-A/21

Status: 2016; 2021 Reaffirmed
Lesbian, Gay, Bisexual, Transgender, Queer / Questioning, Intersex, Asexual Protection Laws

Policy Statement

The American Osteopathic Association (AOA) supports the protection of Lesbian, Gay, Bisexual, Transgender, Queer/Questioning, Intersex, Asexual (LGBTQIA+) individuals from discriminating practices and harassment and reaffirms equal rights and protections for all patient populations as stated in the AOA Rules and Guidelines on Professional Conduct.

Source: H434-A/21

Status: 2016; 2021 Reaffirmed as Amended
Osteopathic Manipulative Medicine (OMM) and Osteopathic Manipulative Treatment (OMT) –
Affirming the Scientific and Medical Foundation of

Policy Statement

The American Osteopathic Association continues to affirm its position that the scientific and medical foundation of osteopathic manipulative medicine (OMM) and osteopathic manipulative treatment (OMT) is integral to this distinctive practice; and advocates for proper recognition of the scientific and medical foundation of osteopathic manipulative medicine (OMM) and osteopathic manipulative treatment (OMT) to all political bodies, research groups, third party payers, and any other entity that formulates policy on OMM and OMT.

Source: H436-A/21

Status: 2011; 2016 Reaffirmed; 2021 Reaffirmed
Third Party Payors Changing Classes of Medications

Policy Statement

The American Osteopathic Association supports all efforts to end the practice of requiring a change in class of medication, thereby decreasing the administrative burden and improving access to care.

Source: H437-A/21

Status: 2006; 2011 Reaffirmed; 2016 Reaffirmed; 2021 Reaffirmed
The American Osteopathic Association (AOA) adopts the following principles on physician comparative utilization and physician profiling.

The physician comparative utilization, rating, and profiling programs should exclusively use metrics that are developed with physician involvement. Where possible, measure sets and/or data points should be evidenced-based and vetted by relevant physician specialty or professional societies. The measure constructs should be evaluated on a timely basis to reflect validity, reliability and impact on patient care. Additionally, all evidenced-based measures should be reviewed in light of evolving evidence to maintain the clinical relevance of all measures.

Comparative utilization, profiling, and rating should only occur once data has been acquired from a statistically significant sample of a physician’s patient population which has been risk adjusted.

Comparisons between physicians should be based on geographic/demographic (rural, urban, suburban) comparisons of similar practice specialty.

Anonymous patient satisfaction data, whether in a formal profiling program or through an informal consumer website, should be excluded.

Physicians should have the opportunity to review any data or rating for accuracy and be afforded the right to request changes to inaccurate information in advance of the publication of that data. All methodologies, including those used to determine case identification and measure definitions, should be transparent and readily available to physicians.

If comparative utilization or physician profiling data were to be made public, only measures that are deemed sensitive and specific to the care being delivered are used and appropriate context and methodology are shared with the public.

The physician rating and profiling program(s) should not adversely impact the physician-patient relationship or unduly intrude upon physicians’ medical judgment.

Source: H438-A/21

Status: 2016; 2021 Reaffirmed as Amended
Policy Statement

The American Osteopathic Association will work toward improving rural physician supply and monitor the potential for nationwide implementation of the following recommendations:

Recommendations for Improving Physician Supply in Rural Underserved America

1. Support Practice Incentive / Benefit and Other Recruitment Programs
   - Federal and state rural practice incentive/benefit programs should be sufficiently funded to be successful in recruiting and retaining physicians in rural, underserved communities.
   - Physicians, medical students and residents should have easy access to information about rural practice incentive programs. Further, the programs should be widely publicized by state authorities, and application forms readily accessible and user-friendly.
   - Area Health Education Centers need to be adequately funded through federal and state funding sources to: a) provide recruitment and retention services in rural areas; b) assist in locating reasonable housing for student and resident preceptorships; and c) provide practice support services to providers and communities, as referenced in other principles listed herein.
   - Incentives should be developed by state authorities to encourage physicians to add a secondary, part-time practice in rural, underserved communities located within a reasonable distance of their primary practice site. Physicians are encouraged to consider hiring and supervising mid-level practitioners, as appropriate, to augment their secondary practices.
   - Physicians are urged to adopt telemedicine services in their practices as outreach to patients in underserved communities, within the scope of their licensure and receive appropriate payment, when applicable and purposeful in meeting health care needs.
   - Physicians should be informed of the potential impact of the employed-practice model on their scope of practice before signing hospital employment contracts, including resources provided.

2. Support Promotion of Rural Practice
   - Information on rural physician shortage areas should be readily available through coordinated websites of state agencies, area health education centers, practicing physicians, medical students, and residents seeking rural practice opportunities, as well as to underserved communities. To assist physicians in selecting practice opportunities, comprehensive community profiles should be compiled to identify characteristics and statistics such as: population demographics (percentage child-bearing (for obstetrical needs), aged (for adult medicine-needs), etc.), insurance status, supply of physicians and other health professionals, degree of physician shortage, socioeconomic status, as well as educational and recreational opportunities.
   - Physicians who locate to rural areas, as well as medical students and residents interested in locating to rural areas, should be informed by state and/or local authorities of benefits and incentives available to strengthen the financial viability of their practice, including Medicare bonus payments, recruitment assistance, publicly funded locum tenens programs, tax credits, loan repayment opportunities, etc. Further, they should be
informed of the health care infrastructure in their area, including systems of care such as federally qualified health centers, indigent care clinics, rural health clinics, hospitals (including Critical Access Hospitals), long term care facilities, emergency medical services, and hospice. They should also be informed about the availability of other health providers and services such as nursing, pharmacies, therapists, medical equipment, etc.

- County medical societies, hospitals, and other health facilities (when available) should facilitate communication between new physicians and physicians with established practices in the community to help new physicians be better prepared for entering practice in an underserved community.
- Physicians who receive benefits through state loan repayment programs should also be informed by state authorities of specialized practice support services, including practice start-up, billing, locum tenens, professional development and CME, staff recruitment and training, telemedicine, etc.
- Physician practice re-entry programs should be widely publicized and monitored to assess their ability to meet demands by state authorities. Further, when physicians allow their medical license to lapse, they should be informed by the relevant state licensing authority of the potential obstacles to re-licensure should they decide to re-enter practice following an extended absence from practice.
- Outreach should be provided by state authorities, to physicians without a full-time medical practice to promote volunteer work or part-time practice at clinics in underserved communities.
- Federal and state policies that impact rural medicine, e.g., payment policies, should be monitored for their potential impact on the viability of rural practices. The American Osteopathic Association should continue to advocate for payment parity between Medicaid and Medicare.
- Physicians in practice and those in training programs should be informed by state authorities, of special state medical licensing provisions applicable for practice in rural, underserved areas.

3. Support for Preparing Physicians for Rural Practice

- Medical schools and residency programs should be incentivized by state authorities to develop and adequately support rural education and training tracks. Examples:
  a. Bonuses for medical students or residents who participate in rural training tracks; and
  b. Additional state formula funding for medical student and residents in rural training tracks.
- Appropriate criteria should be used by Post-Doctoral training programs for identifying student-applicants and residents most likely to be successful in rural practice.
- To measure outcomes, assessments should be conducted to identify whether students and residents who participate in rural educational or training tracks are retained in the state for practice after completion of training.
- Area health education centers should offer opportunities for community physicians who volunteer as preceptors to access information and knowledge of practices that contribute to a positive clinical learning experience. Further, educational institutions should provide adequate support and incentives to recruit and retain physician preceptors, including appropriate levels of recognition and benefits for their teaching efforts. This will become increasingly important as community physicians face continuing pressures to increase productivity.
• Medicare GME policies should allow for residency program-specific support rather than institutional support for resident training to allow GME funding to follow the resident throughout their training.

• The Accreditation Council for Graduate Medical Education should consider allowing more flexibility for residents to travel away from their core programs to rural areas in order to achieve established training goals for minimum numbers of procedures or encounters.

• The impact of changes in resident duty-hour restrictions should be monitored for the impact on rural training programs and health care delivery in comparison to institution-based residency programs.

4. Support for Rural Access to Care
  • Develop solutions for providing after-hours care for patients of federally-funded health clinics requiring urgent or emergent care to prevent undue burdens on community physicians.

Source: H439-A/21

Status: 2011; 2016 Reaffirmed as Amended; 2021 Reaffirmed as Amended
Alternative Payment Models – Ensuring Do Opportunities and Patient Access In

Policy Statement

The American Osteopathic Association (AOA) will advance federal and state policies to ensure alternative payment models (APM) that: (1) offer high quality healthcare to all patients; (2) empower physicians to engage patients in making decisions involving their healthcare, including both economic and clinical decisions; (3) permit freedom of choice of hospital and doctors within the scope of the care model; (4) allow participation of osteopathic physicians including as part of the leadership, board, or other administrative body of the APM; permit the patient to make economic decisions involving his healthcare; (5) will not exclude DOs on the basis of degree or AOA certification or training; (6) will provide providers with information about the costs, risk, and payments associated with practicing in the APM; (7) apprise participating physicians of the progress of the APM; (8) do not exclude physicians and hospitals who are not part of the APM from honest competition for any segment of the marketplace; (9) afford all physicians appropriate hearing and appeal processes.

Source: H440-A/21

Status: 1988; 1993 Reaffirmed as Amended, 1994 Reaffirmed, 1999 Reaffirmed; 2004 Referred; 2006 Reaffirmed; 2016 Reaffirmed as Amended; 2021 Reaffirmed
Health Insurance Coverage for Medical and Surgical Treatments for Good Oral Health

Policy Statement

The American Osteopathic Association supports the concept that medical insurance coverage should include medical and surgical treatments as needed to support good oral health, especially for patients with comorbid conditions.

Source: H441-A/21

Status: 2001; 2006 Reaffirmed; 2011 Reaffirmed; 2016 Reaffirmed as Amended; 2021 Reaffirmed
Physician Profiles

Policy Statement

It is the American Osteopathic Association’s position that state medical or osteopathic boards, as the licensing and regulatory authorities for physicians, are the appropriate entities to collect, maintain, and disseminate physician profile information to the public; supports the position that any legislation or regulations which mandate the release of physician profile information provide funding for the creation and maintenance of the profiling system without added expense to the physician; supports the position that only physician profiles that incorporate all of the following five principles (fairness, relevancy, timeliness, accuracy, and reliability) should be released to the public; opposes the inclusion of medical malpractice histories within physician profiles due to their susceptibility to misinterpretation and inherently prejudicial effect; supports the position that before physician profiles are released to the public, every physician has the opportunity to verify the accuracy of the information and to contest any incorrect information before it is disseminated to the public; and believes that the state licensing boards must include an appeal mechanism in their regulations that a physician may pursue if any information in his or her profile is inaccurate, and institute appropriate corrections.

Source: H442-A/21

Status: 2001; 2006 Reaffirmed; 2016 Reaffirmed; 2021 Reaffirmed
AOA Support of Public Health Service

Policy Statement

The American Osteopathic Association recognizes the contribution of the US Public Health Service (PHS) Commissioned Corps to the healthcare of the United States and supports the continued existence of the United States Public Health Service Commissioned Corps.

Source: H401 – A/22

Genetic Testing

Policy Statement

The American Osteopathic Association supports the public interest in prohibiting discrimination in employment, insurance coverage, and access to care on the basis of genetic information.

Source: H403 – A/22

Status: 1997; 2002 Reaffirmed as Amended; 2007 Reaffirmed; 2012 Reaffirmed; 2017 Reaffirmed; 2022 Reaffirmed
Substance Impaired and Distracted Driving

Policy Statement

The American Osteopathic Association pledges its support to law enforcement agencies in their efforts to enforce substance impaired and distracted driving statutes; encourages agencies in government and in the private sector to promote greater public awareness of the problem; and encourages its members, through discussions with their patients and their communities, to actively assist in the effort by making the problem and its prevention more visible to the public.

Source: H404 – A/22

Status: 1997; 2002 Reaffirmed as Amended; 2007 Reaffirmed; 2012 Reaffirmed; 2017 Reaffirmed; 2022 Reaffirmed
Accessibility to Breast Cancer Prevention, Detection, Diagnosis and Treatment

Policy Statement

The American Osteopathic Association supports development and application of the latest advances in breast cancer prevention, detection, diagnosis, and treatment, with dissemination as rapidly as possible to the medical community and the public it serves; and urges adoption of measures and programs to improve access to breast cancer screening for all appropriate patient populations.

Source: H405 – A/22

Status: 2007; 2012 Reaffirmed as Amended; 2017 Reaffirmed; 2022 Reaffirmed
Support For Prenatal and Pediatric Hospice and Palliative Care

Policy Statement

The American Osteopathic Association endorses the practice of hospice and palliative medicine in prenatal and pediatric patient populations; urges that osteopathic physicians providing prenatal care or consultation be knowledgeable about the existence and availability of prenatal hospice and palliative care, and offer it as an option to parents of a baby with a likely fatal fetal anomaly; and supports organizations dedicated to the promotion, education and provision of prenatal and pediatric hospice and palliative care.

Source: H406 – A/22

Status: 2007; 2012 Reaffirmed; 2017 Reaffirmed as Amended; 2022 Reaffirmed
Prevention and Treatment of Obesity

Policy Statement

The American Osteopathic Association recognizes obesity as a disease which requires a chronic care model to address prevention and treatment. The AOA encourages research at colleges of osteopathic medicine; endorses continued curriculum enhancement for osteopathic students, interns, and residents to receive specific training in obesity education and supports continuing medical education for physicians with established practices. The AOA supports efforts to close the gap between current and desirable practice patterns, by soliciting grants to collect and study the extent to which obesity treatment and prevention services are covered by third party insurers and will advocate for adequate coverage for obesity treatment and prevention. The AOA supports comprehensive efforts, commensurate with available funding, to disseminate knowledge to the treating community, media, legislature and employer groups directed at controlling the obesity epidemic by improving treatment access and encouraging physical activity.

Source: H408 – A/22

Status: 2002; 2007 Reaffirmed; 2012 Reaffirmed as Amended; 2017 Reaffirmed; 2022 Reaffirmed as Amended
Contraceptive Coverage Legislation

Policy Statement

The American Osteopathic Association supports health insurance coverage for federal Food and Drug Administration (FDA) approved contraceptive services and supports language which would maintain co-payment for contraceptive services at a cost no higher than the set level of co-payment for any other prescription.

Source: H409 – A/22

Status: 1999; 2004 Reaffirmed as Amended; 2009 Reaffirmed; 2017 Reaffirmed; 2022 Reaffirmed as Amended
Promotion for the Requirement of All Sporting Events to Have Access to an Automated External Defibrillator (AED)

Policy Statement

The American Osteopathic Association requests: the Food and Drug Administration (FDA) to be diligent in their monitoring of all products marketed for human consumption, including nutritional supplements, and that there be close attention to reported adverse events directly caused by any of these products; and that the US Congress pass legislation requiring dietary supplements to undergo pre-market safety and efficacy evaluation by the FDA.

Source: H410-A/22

Status: 2012; 2017 Reaffirmed; 2022 Reaffirmed as Amended
Meningococcal Vaccine Recommendations

Policy Statement

The American Osteopathic Association supports the administration of meningococcal vaccines as recommended by the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP); and urges adequate public and private insurance coverage for vaccines in patient populations as recommended by the ACIP.

Source: H411-A/22

Status: 2012; 2017 Reaffirmed as Amended; 2022 Reaffirmed
PSA-Based Screening for Prostate Cancer

Policy Statement

The American Osteopathic Association recognizes and promotes the importance of the integrity of the patient-physician relationship and recommends that prostate cancer clinical preventive screenings be individualized.

Source: H412-A/22

Status: 2012; 2017 Reaffirmed; 2022 Adopted
Mandates on School Lunches

Policy Statement

The American Osteopathic Association advocates for a holistic approach with respect to childhood nutrition and wellness without mandates that force children to purchase school lunches.

Source: H413-A/22

Status: 2012; 2017 Reaffirmed as Amended; 2022 Reaffirmed
Antimicrobial Stewardship

Policy Statement

The American Osteopathic Association supports antimicrobial stewardship education in order to decrease drug-resistant organisms.

Source: H414-A/22

Status: 2002; 2007 Reaffirmed as Amended; 2012 Reaffirmed; 2017 Reaffirmed; 2022 Reaffirmed as Amended
Anti-Bullying Policy

Policy Statement

The American Osteopathic Association supports anti-bullying policies enabling students to go to school in a peaceful manner without fear of being tormented or intimidated and supports a policy to prevent bullying in schools and provide treatment for those involved.

The AOA acknowledges that successful antibullying interventions recognize the nature of bullying behavior as complex and related to mental health and societal influences, and that all those involved can suffer detrimental physical and mental health effects.

Source: H415-A/22

Status: 2002; 2007 Reaffirmed; 2012 Reaffirmed; 2017 Reaffirmed as Amended; 2022 Reaffirmed as Amended
Promotion, Protection and Support of Breastfeeding

Policy Statement

The American Osteopathic Association encourages its membership to take a role to protect, promote and support breastfeeding and encourages the provision of breastfeeding friendly environments in their places of study and work, including but not limited to colleges, hospitals, and other healthcare facilities.

Source: H416-A/22

Status: 2002; 2007 Reaffirmed; 2012 Reaffirmed; 2017 Reaffirmed as Amended; 2022 Reaffirmed as Amended
Promoting Emergency Medical Identification Programs

Policy Statement

The American Osteopathic Association supports the concept of medical identification systems, and urges that osteopathic physicians encourage their patients to participate in an emergency medical identification program.

Source: H417-A/22

Organ Donation – Opposition to Incentives for Organ Donors

Policy Statement

The American Osteopathic Association opposes direct payment or other financial inducement in exchange for donation of human organs and tissue and urges the investigation of other, more ethical alternatives to raising organ donor identification rates while protecting patient.

Source: H418-A/22

Status: 2002; 2007 Reaffirmed, 2012 Reaffirmed; 2017 Reaffirmed as Amended; 2022 Reaffirmed as Amended
Violence in the Entertainment Media

Policy Statement

The American Osteopathic Association opposes the presentation of gratuitous violence in the entertainment media.

Source: H419-A/22

Stem Cell Research

Policy Statement

Insert Policy: The American Osteopathic Association supports biomedical research on stem cells and will continue to monitor developments in stem cell research and sources of stem cell funding.

Source: H420-A/22

Status: 2007; 2012 Reaffirmed; 2017 Reaffirmed; 2022 Reaffirmed
Education on Human Papillomavirus Vaccination

Policy Statement

The American Osteopathic Association supports efforts to educate the general public regarding the Human Papilloma Virus (HPV) and its relationship to certain cancers and genital warts; urges osteopathic physicians to educate themselves and their patients regarding the availability and benefits of administering HPV vaccine to patients as recommended by the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP); and urges adequate public and private insurance coverage for HPV vaccines in patient populations as recommended by the Advisory Committee on Immunization Practices (ACIP); and supports ongoing research to determine whether HPV vaccine is beneficial to other groups in the general population.

Source: H421-A/22

Status: 2007; 2012 Reaffirmed as Amended; 2017 Reaffirmed; 2022 Reaffirmed
Daily Physical Education for Grades K-12

Policy Statement

The American Osteopathic Association supports daily physical education for all US students in grades K-12.

Source: H422-A/22

Use of Tobacco Products

Policy Statement

The American Osteopathic Association supports education on the hazards of tobacco products beginning at the elementary school level; encourages physicians to inquire into tobacco use and exposure as part of both prenatal visits and every appropriate health encounter; strongly recommends that all federal and state health agencies continue to take positive action to discourage the American public from using cigarettes and other tobacco products; encourages its members to discuss the hazards of tobacco use with their patients; encourages the elimination of federal subsidies and encourages increased taxation of tobacco products at both federal and state levels suggesting that monies from the additional taxation could be earmarked for smoking-reduction programs and research for prevention of tobacco-related diseases; and that municipal, state and federal executive agencies and lawmakers enact clean-indoor air acts, a total ban on tobacco product advertising, opposes cigarette vending machines in general and supports the elimination of free distribution of cigarettes or tobacco products in the United States; and that grades K-12 should be encouraged to incorporate a curricular component that has been proven effective in preventing tobacco usage in its health education curriculum; urge the development of anti-tobacco educational programs targeted to all members of society, with the ultimate goal of achieving a tobacco-free nation.

Source: H423-A/22

Status: 1990; 1995 Reaffirmed as Amended; 1997 Reaffirmed; 2002 Reaffirmed as Amended; 2007 Reaffirmed; 2012 Reaffirmed as Amended; 2017 Reaffirmed as Amended; 2022 Reaffirmed as Amended
Powdered Caffeine

Policy Statement

The American Osteopathic Association opposes the use of concentrated powdered caffeine for non-medical uses.

Source: H425-A/22

Status: 2017; 2022 Reaffirmed
Health Insurance Coverage for Residential Treatment and Inpatient Treatment of Eating Disorders

Policy Statement

The American Osteopathic Association supports improved access to treatment in residential and inpatient facilities and efforts to reduce the financial barriers of intensive treatment for patients suffering from eating disorders; encourages residential and inpatient treatment facilities caring for patients suffering from eating disorders, to manage care in consideration of the patient's overall medical and mental health needs, and to continue treatment until goals of weight restoration and physiologic status are obtained; and supports continued care for individuals suffering from eating disorders staying in residential and inpatient facilities, regardless of insurance criteria requiring termination of treatment.

Source: H426-A/22

Status: 2017; 2022 Reaffirmed
Purpose

This policy paper addresses the potential risks and benefits of recreational cannabis, the potential risks and benefits of medical cannabis, and policy guidelines for the use of these substances by osteopathic medical students, physicians, and patients. The policy paper provides the following:

1. Summary of current literature regarding risks and benefits of cannabis as a foundation for policy development around cannabis for both medicinal and recreational use.

2. Discussion of the driving forces in the legalization/decriminalization of cannabis use at the state level.

3. Policy recommendations around risk/benefit of cannabis use and its potential impact on osteopathic physicians and students as well as patients.

Background

In 2020, 17.9% of people aged 12 and older used cannabis. The percentage of people who used cannabis in the past year was highest among young adults aged 18 to 25 (34.5%) compared with 16.3% of adults aged 26 or older and 10.1% of adolescents aged 12 to 17.\(^1\) As of January 2022, 36 states, the District of Columbia, Guam, Puerto Rico and the U.S. Virgin Islands have approved comprehensive, publicly available cannabis for medicinal and recreational use.\(^2\)

The trend of legalizing cannabis illuminates two, often competing, forces which are: (1) a greater public acceptance of cannabis for medicinal and recreational use; and (2) a concern for the impact of existing laws governing cannabis possession and use on the societal as well as personal level. As states continue to legalize medicinal and recreational cannabis use, it is important to take into consideration the potential public health threat cannabis use represents. Similar to alcohol consumption and tobacco use, osteopathic physicians must guide the care of patients as cannabis use moves from a criminal act to an acceptable behavior, albeit a behavior that may pose a public health threat.\(^2\)

Risks and Benefits of Cannabis

A systematic review of cannabis was commissioned by the National Academy of Science, Engineering and Medicine (the Academies) in April 2016 and published on January 17, 2017, the most up to date, comprehensive report.\(^3\)
The commissioned report is the first comprehensive review of published literature since the 1999 Institute of Medicine (IOM) Report, Marijuana and Medicine: Assessing the Science Base. The Academies’ report is entitled, The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. This publication represents the best current knowledge regarding the risks and benefits of cannabis synthesized by leading national researchers. In addition, the report describes gaps in the literature, identifies future research opportunities, and summarizes policy issues regarding the laws and uses of cannabis across the various states that have decriminalized cannabis. The report also discusses current federal activities such as the enforcement of the Controlled Substance Act.

The committee commissioned by the Academies conducted an extensive search of relevant databases which included Medline, Embase, the Cochrane Database of Systematic Reviews, and PsycINFO. The committee identified more than 24,000 abstracts of articles published since the 1999 IOM report. Only articles published in English were eligible for the study. Case reports, editorials, studies by “anonymous” authors, conference abstracts, and commentaries were excluded. Ultimately, the committee conducted an in-depth review of more than 10,700 abstracts in determining their relevance to the final report.

Summary of Major Findings

Therapeutic Benefits. Research has demonstrated that cannabis use has therapeutic effects for patients. Oral cannabinoids are an effective antiemetic in treating nausea and vomiting resulting from chemotherapy treatment. With respect to chronic pain, cannabis and/or cannabinoids can significantly reduce pain symptoms for chronic pain (e.g., fibromyalgia) patients. For multiple sclerosis patients, short-term use of oral cannabinoids improves patient-reported spasticity symptoms. Other therapeutic benefits of cannabis may be seen in patients that suffer from Tourette syndrome, Posttraumatic Stress Disorders (PTSD) and social anxiety disorders. More research, however, is needed for the effects of cannabinoids on other conditions such as epilepsy, Parkinson’s disease, and schizophrenia.

Cancer Risks. Cannabis use poses health risks for various diseases and conditions as well as injury and death. There is modest evidence that cannabis use is associated with an increased incidence of a specific type of testicular cancer. There is insufficient evidence that cannabis use increases the risk of other cancers (e.g., esophageal, prostate, cervical, leukemia, or cancer in children whose mother used cannabis during her pregnancy), and there is no evidence that smoking cannabis increases the risk of such cancers as lung cancer or head and neck cancer.

Pulmonary & Cardiometabolic Concerns. Cannabis use and its growing popularity raise questions regarding pulmonary and cardiometabolic issues. Evidence has shown that regular use of cannabis is associated with chronic cough and phlegm production. More research, however, is needed to determine whether smoking cannabis is associated with Chronic Obstructive Pulmonary Disease (COPD), asthma, and/or a decline in lung function. More research is also needed to determine the exact association of cannabis use with heart attack, stroke and diabetes.

Effect on Infectious Diseases. There is a lack of evidence regarding the effects of cannabis on the human immune system. There has been some belief that cannabis use has adverse effects on the immune system of HIV patients. More research is needed to determine a statistical association. According to the limited evidence that does exist, smoking cannabis on a regular basis may have anti-inflammatory benefits. However, more research is needed.

Effect on Cognitive Impairment. Cannabis use is associated with cognitive impairment which affects a person’s performance. This altered state of mind can lead to injury that may, ultimately,
result in death. Studies have found that cannabis use immediately prior to operating a vehicle increases the risk of getting into a motor vehicle accident.

Cognitive performance (i.e., learning, memory and attention) can be impaired up to 24 hours after the use of cannabis. A few studies have found that impairments in cognitive domains may continue even after a person has stopped smoking cannabis. The lingering effects of cannabis are especially concerning for adolescents. The evidence purports that the use of cannabis during adolescence can have lasting effects on a young person’s academic achievement, future employment, and social interactions and productivity.³

Additional Concerns Regarding Children. In states where recreational cannabis has been legalized, the evidence indicates that children have an increased risk of unintentional adverse effects (e.g., respiratory distress). There are other concerns such as low birth weight. Studies have found that maternal recreational cannabis use during pregnancy is associated with low birthweight babies. More research is necessary to determine the association of cannabis use and other pregnancy and childhood outcomes.³

Mental Health Issues. Studies have found that the use of cannabis increases the risk of developing schizophrenia and other psychoses. The risk of developing a mental health issue increases with the dosage. Conversely, individuals with schizophrenia and other psychoses prior to using cannabis may experience better performance on learning and memory tasks when they use cannabis. Studies have found bipolar disorder is an exception to this observation. Individuals diagnosed with bipolar disorder who use cannabis daily may experience intensified symptoms as compared to those diagnosed with bipolar disorder who do not use cannabis.³

Other mental health illness studies include depression, anxiety, suicide and posttraumatic stress disorder (PTSD). There is evidence that heavy cannabis users are more likely to report thoughts of suicide than non-users, and individuals that use cannabis regularly have an increased risk of developing social anxiety disorder. There is a lack of evidence that cannabis use increases the likelihood of developing other types of anxiety disorders, depression, or PTSD.³

Cannabis Addiction and Abuse of Other Substances. As individuals increase their frequency of cannabis consumption, there is a corresponding increased risk of becoming addicted to the substance. Additionally, it has been found that individuals who begin using cannabis at a young age are at an increased risk of developing an addiction to cannabis. Cannabis use has also been linked to an increased risk of an individual abusing other substances.³

Clinical Features of Cannabis Intoxication

Regardless of the positive and negative aspects of cannabis use, it is important to understand and recognize the clinical manifestations of cannabis intoxication. Similar to alcohol intoxication, cannabis intoxication can influence an individual’s behaviors, perceptions and interaction with others. For example, a person experiencing cannabis intoxication may have a heightened sociability and sensitivity to certain stimuli (e.g., colors, music), altered perception of time, and an intensified appetite for sweet and fatty foods. Some users report feeling relaxed or experiencing a sensation described as a “rush” or “buzz” after smoking cannabis.³ Such effects may be accompanied by decreased short-term memory, dry mouth, and impaired perception and motor skills. Other concerns regarding cannabis use focus on public safety. In light of the current trend in legalizing cannabis for medicinal and recreational use, the potential for impaired driving due to acute intoxication is a genuine threat to public safety.

Acute cannabis intoxication has several major contributors. One of the key contributors is tetrahydrocannabinol (THC), a compound found in the cannabis plant that stimulates cells in the
Brain and cause psychological effects. In incidents where a person using cannabis may have high blood levels of THC, the person may experience panic attacks, paranoid thoughts and hallucinations. In addition to the dosage of THC in a person’s system, two other key factors that impact the intensity and duration of intoxication due to cannabis use are (1) individual differences in the rate of absorption and metabolism of THC, and (2) the loss of sensitivity to THC’s effects. Studies as synthesized in the Academies’ report have found that “prolonged CB1 receptor occupation as a consequence of the sustained use of cannabis can trigger a process of desensitization, rendering subjects tolerant to the central and peripheral effects of THC and other cannabinoid agonists.” In studies conducted with animals, recurrent exposure to THC resulted in decreased CB1 receptor levels and connections between CB1 and its transducing G-proteins were compromised. Similar results were found in humans. In one study, researchers used imaging to study the brain of humans who were considered chronic cannabis users and found a down-regulation of CB1 receptors in the cortical regions of the brain.

Decriminalization of Cannabis Use

There has been a recent trend in states legalizing cannabis use for medical as well as recreational purposes. What once was criminalized is now becoming legal and acceptable in society. Public opinion appears to be the primary influence for many of the policy changes.

A new survey, conducted by Pew Research Center from April 5-11, 2021 shows an overwhelming share of U.S. adults (91%) say either that cannabis should be legal for medical and recreational use (60%) or that it should be legal for medical use only (31%). Fewer than one-in-ten (8%) say cannabis should not be legal for use by adults.

More than two in three Americans (68%) support legalizing cannabis. Gallup has documented increasing support for legalizing cannabis over more than five decades, with particularly sharp increases occurring in the 2000s and 2010s.

State and National Policies

Currently, states are the main players in changing policy regarding cannabis for medicinal and recreational use. As of January 2022, 36 states, the District of Columbia, Guam, Puerto Rico and the U.S. Virgin Islands have approved comprehensive, publicly available cannabis for medicinal and recreational use. Some states have broad laws regarding medicinal use, others have stricter laws that limit access, and then there are those states that still criminalize cannabis use, but may allow for a legal defense under specific circumstances.

State Broad Policies. In states with broad policies, access to cannabis for medicinal and recreational use is restricted to a specific population or condition/illness. Patients may access medical cannabis as their physician deems necessary. Many people may view this approach as de facto legalization of cannabis for recreational use.

State Restrictive Policies. States that have implemented restrictions to access typically require patients to meet certain qualifying criteria before permitting them access. The states may also restrict the types of medical products available to patients. Such states like New York do not allow patients to smoke cannabis, but they may have access to tinctures, oils, concentrates, and other similar products.

Other states may have non-THC (tetrahydrocannabinol) policies which require products to have no-THC or low-THC/high-CBD (cannabidiol) such as CBD oil. Oftentimes, the states that have no-THC policies have exceptions to the law that can be used as a legal defense.
State Policies – Production & Distribution. Not only do states have different policies on the recommendation/certification of cannabis products, but also, different policies on the production and distribution of products. For example, some states regulate the establishment and operation of dispensaries (storefronts). Patients with physician recommendation/certification may visit these dispensaries to obtain a wide array of cannabis products. Some dispensaries are allowed to advertise their products and services to patients, while others may promote their services to the broader general public. In other states, only patients and caregivers may cultivate cannabis solely for the purpose of using it as prescribed within their homes. Yet, there are other states that strictly prohibit the supply and distribution of any cannabis products.²

Federal Law. Unlike the states, the federal government has not implemented any national laws legalizing cannabis use nor have they challenged any laws implemented by the states. Congress failed to pass federal legislation legalizing cannabis in 2021, including the Cannabis Administration and Opportunity Act and The Marijuana Opportunity Reinvestment and Expungement Act. However, a “compromise” bill, the States Reform Act, introduced in November 2021, would give individual states the full authority to regulate or prohibit cannabis. As a result, cannabis would be descheduled under the Controlled Substances Act.⁸

Existing AOA Policy and Previous Considerations

The American Osteopathic Association (AOA) has adopted a policy supporting well-controlled clinical studies on the use of cannabis and related cannabinoids for patients who have significant medical conditions for which current evidence suggests possible efficacy; and encouraging the National Institutes of Health (NIH) to facilitate the development of well-designed clinical research studies into the medical use of cannabis. (H424-A/2021).

The AOA also has policies governing the impaired behaviors of practicing physicians. These policies, listed below, broadly apply to physicians and non-physicians who are experiencing impairment resulting from use of any mind-altering substance, including cannabis.

H407-A/16 OPERATOR INTOXICATION/ IMPAIRMENT
H331-A/18 PHYSICIAN HEALTH ASSISTANCE
H424-A/21 MEDICAL CANNABIS – RESEARCH ON POLICY STATEMENT
H628-A/18 CANNABIS RECLASSIFICATION: EFFECT ON RESEARCH

AOA Policy

As cannabis decriminalization moves forward, there is a greater need to educate health professionals about the evidence-based benefits and risks of cannabis use for both medicinal and recreational purposes. All policies should focus on assuring that the public health threat of cannabis is minimized and that the benefit of the drug, where indicated by evidence, is available to patients in need.

Physicians and students using cannabis for medicinal and recreational use will suffer cognitive impairment. Critical thinking, key to the ability to diagnose and treat patients, will be affected and patient safety will be jeopardized. Furthermore, though studies suggest cognitive dysfunction associated with cannabis use continues even after cessation of cannabis use, the duration of the impairment cannot be known. More empirical research is needed to clarify and quantify the overall impact of cannabis use and develop recommendations for use.

The American Osteopathic Association (AOA) adopts the following policies:
1. The AOA does not recommend any use of cannabis by physicians and medical students because of patient safety concerns.

2. The AOA does not support recreational use of cannabis by patients due to uncertainties in properties, dosing, and potential for impairment. Recreational cannabis use is legal only as determined by specific state law.

3. The AOA recognizes that the use of cannabis is an evolving field of research, and thus, encourages the NIH and other research entities to conduct research on the effects of cannabis use on cognition as well as the public health implications of cannabis use.

4. The AOA shall review its policy in light of any new evidence that will be generated by research entities and update this policy as necessary.

References


Source: H428-A/22

Status: 2017; 2022 Reaffirmed as Amended
Harm Reduction Modalities for People Who Inject Drugs
White Paper
Policy Statement

H429-A2022 Harm Reduction Modalities for People Who Inject Drugs (PWID)
White Paper

INTRODUCTION

In 2019, 36,801 people received an HIV diagnosis in the United States (US) and dependent areas. From 2015 to 2019, HIV diagnoses decreased 9% overall in the US and dependent areas. In 2019, people who inject drugs (PWID) accounted for 7% (2,508) of the 36,801 new HIV diagnoses.¹

The recent epidemic of prescription opioid abuse has led to increased numbers of PWID. In 2019, nearly 50,000 people in the US died from opioid-involved overdoses. The misuse of and addiction to opioids, including prescription pain relievers, heroin, and synthetic opioids such as fentanyl, is a serious national crisis that affects public health as well as social and economic welfare.²

Behaviors such as sharing needles, syringes, and other injection equipment cause PWID to be at high risk for contracting and transmitting HIV, viral hepatitis, and other infections. To mitigate the impact of injection drug use and its associated consequences, communities across the US and abroad are considering harm reduction approaches, such as needle exchange programs and safe injection facilities. The goal of this paper is to discuss the benefits and risks of implementing such interventions, and to present the American Osteopathic Association’s (AOA’s) position on harm reduction as an approach for impacting the consequences of substance abuse among PWID.

PUBLIC HEALTH SIGNIFICANCE

According to the CDC, 1.2 million people in the US are living with HIV at the end of 2019. Of those people, about 87% knew they had HIV.³

PWID represent a significant percentage (13.8%) of persons living with HIV (PLWH) as well as those newly diagnosed with HIV (7%). HIV-negative persons who inject drugs have a 1 in 160 chance of contracting HIV each time they share a needle with an HIV-positive person.⁴

In addition to being at risk for HIV and viral hepatitis, PWID can have other serious health problems, like skin infections and heart infections. People can also overdose and get very sick or even die from having too many drugs or too much of one drug in their body or from products that may be mixed with the drugs without their knowledge (for example, fentanyl).⁴

Addressing the burden of HIV and hepatitis C virus (HCV) requires facilitation of multiple public health strategies aimed at interrupting disease transmission and reducing risk of acquiring and transmitting HIV, hepatitis B virus (HBV), HCV, and other blood-borne infections.⁵
Strategies to interrupt disease transmission for PWID include evidence-based practices of promoting the use of sterile needles or syringes for every injection, as well as ensuring access to medical treatment, behavior-change counseling, and addiction treatment services.\(^6\)

Injection drug use carries the consequence of inflicting considerable harm on PWID themselves and to society. As communities develop methods of reversing increasing mortality trends, public health officials, as well as federal, state, and local organizations are exploring harm reduction interventions aimed at preventing overdose deaths, interrupting disease transmission, and alleviating harm to people misusing drugs and their families.

**HARM REDUCTION PHILOSOPHY AND APPROACHES**

With respect to illicit drug use, harm reduction refers to a public health approach consisting of policies, programs, and practices directed at reducing the harms associated with the use of mind-altering drugs. The defining element is prevention of harm, rather than abstinence or prevention of drug use, and its targets are people who continue to use drugs and are at elevated risk for contracting and spreading diseases.\(^7\)

Though components of it can be traced back to the early 1930’s, the term ‘harm reduction’ gained popularity in the mid-1980s. As awareness grew about high incidences of HIV among PWID in many countries, European cities began pioneering interventions such as needle and syringe programs. During the 90’s, harm reduction strategies gained acceptance around the world, and by 2000 they were vital components of drug policy guidance from the European Union. By 2009, 31 European countries provided needle/syringe programs (NEP, NSP) and opioid substitution therapy (OST), or at least supported them by policy. Harm reduction in prisons was also established during this period with six countries offering needle and syringe exchange programs, and 23 providing OST. Europe was also a pioneer in establishing drug consumption rooms (DCR), opening nearly all of the DCRs in the world. Due in part to the efforts of Europe, harm reduction is now official policy of the United Nations.\(^8\)

Rooted in the concept of harm reduction is the principle that drug use for some people is inevitable because they are either unable or unwilling to abstain. In the 2019 National Survey on Drug Use and Health, for example, 40% of illicit drug users who had not entered treatment responded that they simply were not ready to commit to stopping their drug use.\(^9\)

To effectively serve people in different phases of addiction and abuse, harm reduction ideally involves multiple simultaneous interventions customized for locality and need. For example, a harm reduction package may be comprised of opioid substitution therapy, needle and syringe programs, drug consumption rooms and counseling services. They may also include peer interventions and advocacy for funding or policy change. Needle and syringe programs are generally at the center of harm reduction interventions targeting PWID.\(^10\)

**NEEDLE-SYRINGE SERVICE PROGRAMS**

The Centers for Disease Control and Prevention define Syringe Service Programs (SSPs), also referred to as syringe exchange programs (SEPs), needle exchange programs (NEPs) and needle-syringe programs (NSPs), as “…community-based programs that provide access to sterile needles and syringes free of cost and facilitate safe disposal of used needles and syringes.”\(^11\)

The first NEP was established in Amsterdam in 1983 in an attempt to quell a hepatitis B outbreak. Other European countries followed suit after the presentation of HIV/AIDS.\(^12\) The first SSP in the US was in New Haven, Connecticut in 1987. The program operated underground because of laws which made possession of drug paraphernalia illegal. In many
states this is still the case. The first SSP to receive public funds opened in 1988 in Tacoma, Washington. Just 2 years later, in Hawaii, the first state approved SSP was signed into law. Throughout the world, harm reduction implementation has not improved since 2018. The number of countries where NSPs are available remained at 86.

In addition to providing sterile needles, syringes, other drug preparation equipment, and disposal services, SSPs offer clients a range of other services. Many programs provide health education and counseling, immunizations, access to substance abuse and mental health treatment, screening for tuberculosis, hepatitis, HIV and other sexually transmitted infections (STIs), and condom distribution, as well as referrals for social services and medical programs. Programs may also be equipped with naloxone to reverse opioid overdoses.

The US has experienced an increase in drug injection. Of particular concern are persons who escalated to injecting prescription opioids and heroin after using oral analgesics. Much of this activity has been identified in suburban and rural areas. HCV and HIV infection in these nonurban areas correlate with noted injection patterns and trends.

**History of the Ban on Funding Needle Exchange Programs**

With the advent of the “War on Drugs” in 1988, the US Congress implemented a ban on the use of federal funds to support syringe exchange. During the 1990s, however, an Institute of Medicine panel recommended that the federal prohibition of NSPs be revoked. The idea was supported by findings that NSPs contributed to lowered HIV incidence and did not amplify injection drug use. The Centers for Disease Control and Prevention also assessed NSPs and concluded that they were effective in halting the spread of HIV among PWID. Based on these endorsements, it was anticipated that the ban would be repealed, but President Clinton chose not to pursue changes to the federal law.

In December 2009, President Obama signed the Consolidated Appropriations Act of 2010. Though this act gave states permission to fund SSPs with federal dollars, there was no money specifically earmarked. One year later, however, in December of 2011, Congress restored the ban, reversing the 2009 decision.

Precipitated by the HIV outbreak in Indiana, along with sharp increases in rates of injection drug use across the country, Kentucky and West Virginia legislators championed the addition of language into an omnibus spending bill to revoke the ban. The bill was passed by Congress at the end of December 2015. The modified law is theoretically a partial repeal. Through the Consolidated Appropriations Act of 2016, states were given the ability to use federal dollars to finance SSP operations, including staffing, automobiles, gas, leases, and other operating expenses. The purchase of sterile needles and syringes is still prohibited, but funds may be used to support comprehensive services for PWID.

The Consolidated Appropriations Act of 2018 permits the use of funds from the Department of Health and Human Services (HHS), under certain circumstances, to support SSPs. However, HHS funds may not be used to purchase needles or syringes.

**Perceived Risks of Needle-Syringe Exchange Programs**

Antagonists of NSPs in the US have primarily focused on three ideological and moral arguments for justifying prohibition. The first argument is that federal funding of NSPs would signal governmental acceptance of illegal drug use, conflicting with law enforcement efforts. The second argument is that federal funding of NSPs could encourage drug abuse and jeopardize public health and safety by facilitating Injection Drug Use (IDU), increasing the circulation of contaminated
needles, and increasing crime. The third argument is that federal approval of needle and syringe exchange programs could cause children to believe that drug use is acceptable.\textsuperscript{15} However, studies have shown these concerns to be largely unfounded.

The US government authorized several reports to evaluate outcomes of NSPs. Key report authors were: 1) the National Commission on AIDS; 2) the US General Accounting Office; 3) the Centers for Disease Control/University of California; and 4) the National Academy of Sciences. The reports reinforced the advantages of NSPs and did not indicate any negative outcomes. The studies affirmed that when barriers such as criminalization laws regarding the purchase and possession of IDU equipment are eliminated, PWID are less likely to share needles. The reports further concluded that NSPs do not increase drug use among program participants, nor do they lead to the recruitment of new drug users.\textsuperscript{17}

As a potential threat to public safety, the concern of improper disposal of needles has been widely studied. This perspective assumes that PWID will not return needles to distribution sites, and will, therefore, potentially endanger the health of the surrounding community by exposing residents to contaminated needles. However, successful rates of return of used needles have been documented. In her meta-analysis, study author Kate Ksobiech reviewed needle return data from 8 studies, comprised of 26 articles. Ksobiech calculated an overall worldwide return rate of 90%, though there was great variability at individual sites. Return rates for U.S. NSPs were comparable to those of international programs. One limitation noted in the study, however, is that researchers could not confirm where the needles originated, nor could they ascertain if people returned their own needles or those of their social network.\textsuperscript{18}

Additionally, the World Health Organization has concluded that there is no evidence that NSPs negatively impact PWID, their communities, or society at large. “Studies have searched for and found no convincing evidence of the following unintended complications associated with needle and syringe exchange programs: greater injection frequency, increased illicit drug use, a rise in syringe lending to other IDUs, recruitment of new IDUs, social network formation, greater numbers of discarded used needles, less motivation to change, i.e., reduce, drug use and increased transition from non-injecting drug use to IDU.”\textsuperscript{19}

Needle and syringe exchange sites are not always accessible to people when they need them. As a result, some PWID collect and exchange high volumes of used needles and then sell the clean ones to their peers. This black market has been identified as an unintended consequence of NSPs in some rural and scarcely resourced areas and underscores the need for more substance abuse services and IDU resources in these communities.\textsuperscript{20} Little if any research has been conducted on the effects of black-market needles on injection drug use and HIV transmission.

Also of note, while NSPs are found to be effective in reducing HIV transmission and injecting risk behaviors among PWID, evidence regarding their impact on reducing HCV infection has been inconclusive.\textsuperscript{21}

\textbf{Benefits of Needle-Syringe Exchange Programs}

The most notable benefit of NSPs is that they lead to a reduction of morbidity and disease transmission, which translates to a reduction in associated health care costs. However, there are many other documented benefits. NSPs also promote public health and safety, connect PWID to substance abuse treatment programs, and provide an entry point into other health services, such as HIV and STI testing and care and treatment programs.\textsuperscript{14}

\begin{itemize}
  \item Interruption of Disease transmission
\end{itemize}
In their systematic review, Bramson, Des Jarlais et al found positive associations between publicly funded NSPs, low HIV incidence, low absolute numbers of new HIV diagnoses, and greater service provision. The study concluded that the distribution of large numbers of needles and syringes was causal, indicating that public funding of NSPs leads to lower HIV incidence. When NSPs and over the counter sales of syringes are consistently funded, they are impactful in reducing HIV transmission.\(^\text{22}\)

According to the CDC, “Nearly 30 years of research has shown that comprehensive SSPs are safe, effective, and cost-saving, do not increase illegal drug use or crime, and play an important role in reducing the transmission of viral hepatitis, HIV and other infections.”\(^\text{13}\)

- **Linkage to Care and Services**

Many SSPs link PWID to key services and programs, such as HIV care and treatment, pre-exposure prophylaxis (PrEP), and post-exposure prophylaxis (PEP) services; hepatitis C treatment, hepatitis A and B vaccinations; screening for STI’s and tuberculosis; partner services; prevention of mother-to-child HIV transmission; and other medical, social, and mental health services.\(^\text{3}\) Given the availability of new treatments that effectively cure HCV, linking PWID to HCV and HIV testing and referring those diagnosed to care and treatment may be the most significant services offered.\(^\text{14}\)

The majority of SSPs offer referrals to medication-assisted treatment. New SSPs users are five times more likely to enter drug treatment and three times more likely to stop using drugs than those who don’t use the programs.\(^\text{14}\)

- **Reduction in Health Care Costs**

According to the CDC, “SSPs reduce health care costs by preventing HIV, viral hepatitis, and other infections, including endocarditis, a life-threatening heart valve infection. The estimated lifetime cost of treating one person living with HIV is more than $450,000. Hospitalizations in the U.S. for substance-use-related infections cost over $700 million each year. SSPs reduce these costs and help link people to treatment to stop using drugs.”\(^\text{23}\)

- **Promotion of Public Health and Safety**

In communities where IDU is prevalent, residents are understandably concerned about unsafe disposal and circulation of potentially contaminated needles and syringes because inadvertent contact could lead to infection. SSPs address this issue by removing used needles from circulation and educating their clients about safe disposal of used syringes.\(^\text{13}\)

Evidence demonstrates that SSPs do not increase illegal drug use or crime. Studies in Baltimore and New York City have found no difference in crime rates between areas with and areas without SSPs. In Baltimore, trends in arrests were examined before and after a SSP was opened and found that there was not a significant increase in crime rates. The study in New York City assessed whether proximity to a SSP was associated with experiencing violence in an inner-city neighborhood and found no association.\(^\text{13}\)

- **Protection of Law Enforcement Personnel from Needle Stick Injuries**

In the course of duty, police officers are in danger of needle stick injuries, placing them at risk of becoming infected with hepatitis B, hepatitis C and HIV. Risk factors include working evening shifts, performing pat-down searches, being on patrol duties, and being a less experienced officer.
Studies show that SSPs provide safe needle disposal and reduce the number of needles in the community which protects first responders and the public. Data from CDC’s 2015 National HIV Behavioral Surveillance System showed that the more syringes distributed at SSPs per PWID in a geographic region, the more likely PWID in that region were to report safe disposal of used syringes.\textsuperscript{13}

\textbf{SAFE INJECTING FACILITIES}

Safe injection facilities (SIF) are known by many names, including Safe(r) injection Sites (SIS), drug consumption facilities (DCF), Medically Supervised Injection Centers (MSIC), and Safer or Supervised Injection Facilities (SIF). They are part of a harm reduction approach to IDU. At these sites, users of illicit drugs have access to disinfecting agents and clean needles, as well as medical professionals. These legally sanctioned facilities provide a safe environment without the threat of arrest, and it provides them with access to professionals that can offer advice and refer them for rehabilitation services.\textsuperscript{10} SIFs are not “shooting galleries”, which are illegal injecting facilities run by drug dealers.\textsuperscript{24} SIFs are managed by medical professionals, such as nurses and social workers, and drug sales are prohibited.\textsuperscript{25}

Government sanctioned SIFs came into operation in Europe in the mid-1980s; the first of these facilities was established in Switzerland in 1984. Other SIFs existed in the Netherlands prior to this era, but they were not government sanctioned. In Germany, government sanctioned SIFs came into operation in the early 1990s, but government funding and approval was not obtained until later in 2000. Australia has attempted to open three non-government sanctioned SIFs in the late 1990s; one facility was legally approved in 2001.\textsuperscript{24}

In December 2021, New York City opened the nation’s first overdose prevention center pilots. The Drug Policy Alliance and its allies advocated for many years to reach this milestone.\textsuperscript{25}

In July 2021, Rhode Island authorized a two-year pilot program to establish "harm reduction centers" where people can consume pre-obtained substances under the supervision of trained staff, becoming the first state to do so.\textsuperscript{25}

There are various models of SIFs, however, the core services are generally the same:
- Provision of sterile injecting equipment;
- Medical supervision of injections, including emergency response to drug overdoses;
- Injection-related first aid (such as wound and abscess care); and
- Assessment and referral to primary health care, drug treatment and social services.\textsuperscript{23}

\textbf{ADVANTAGES OF SAFE INJECTING FACILITIES}

There are many benefits associated with this kind of intervention. These benefits include allowing PWID to inject in a clean environment without having to rush, allowing PWID to have access to medical staff that are able to respond to overdoses and prevent deaths, and easy access to clean IDU equipment. The success rate of reduction of overdose deaths in safe injecting facilities is very high. SIFs aid public health by controlling the spread of disease and improving the quality of life for PWID.\textsuperscript{24}

A systematic literature review performed via PubMed, ScienceDirect, and Web of Science databases found seventy-five articles whose study results converged to find that SIFs were most effective in attracting marginalized PWID, providing access to primary health care, reducing the frequency of overdoses, and providing safer conditions for injection. There was no evidence indicating an increase in drug trafficking, drug use, nor crime in the areas surrounding the SIFs. There was a positive correlation between the presence of SIFs, reduced amounts of abandoned
syringes, and reduced levels of public drug injections. The majority of referenced articles originated in Vancouver and Sydney.  

**OPPOSITION TO SAFE INJECTING FACILITIES**

Common objections to the establishment of facilities such as SIFs, SISs, drug consumption rooms (DCRs), and other harm reduction programs include the fear that these facilities would attract more drug users to that area, encourage youths to use drugs, and increase drug use rates. Even though the evidence previously presented along with other evidence has not supported these beliefs, these views still have a large influence on the public’s beliefs about the effects of these facilities on their communities.

**CONCLUSION**

As of 2018, there are approximately 3,864 new HIV infections among PWID per year in the US. HIV, HCV, overdose, STIs, soft tissue infections, tuberculosis, and substance use disorders are among the many health problems facing PWID. Harm reduction interventions such as NSPs, opioid substitution therapy, and SIFs have demonstrated potential to reduce morbidity, mortality, and disparities among vulnerable individuals, decrease costs associated with injection drug use, and diminish harm sustained by PWID and their communities. However, public funding is necessary to provide effective, comprehensive services for this population.

State and local funding is only possible in areas with favorable syringe exchange policies. Fully repealing the ban on the use of federal funds for harm reduction interventions would provide additional funding to programs and enhance overall impact. IDU has been an important factor of HIV transmission in the US. Public funding of NSPs is strongly associated with both reducing HIV transmission among PWID in states that experienced high HIV incidence, and with maintaining low HIV in other states. Increased, consistent state and local public funding of NSPs and other harm reduction strategies, in addition to federal funding, would be a significant step forward.

**AOA POLICY**

Given the research demonstrating the effectiveness of harm reduction strategies, such as syringe service programs (SSPs) and supervised injection facilities, in reducing HIV transmission, along with endorsements of the World Health Organization (WHO), US Centers for Disease Control and Prevention (CDC), and the Institute of Medicine (IOM), the American Osteopathic Association (AOA) adopts the following policy statements as its official position on the use of harm reduction strategies to combat the consequences of injection drug use:

1. The AOA supports the decriminalization of harm reduction strategies, such as syringe service programs (SSPs) and supervised injection facilities. Such services should be legally provided and paired with more comprehensive services, such as substance abuse and mental health counseling and treatment.

2. The AOA shall advocate for the increased availability of harm reduction modalities including safe injecting facilities and supervised injection facilities at the local, state, and federal level.

3. The AOA strongly encourages state medical associations to initiate state legislation that decriminalizes drug paraphernalia possession and procurement so that injection drug users can obtain needles and syringes without a prescription and needle exchange program employees are protected from prosecution for disseminating syringes.
4. The AOA is in favor of complete repeal of the ban on federal funding for syringe exchange programs.

5. The AOA is in favor of syringe service programs and encourages physicians to provide patients with education on such programs.

REFERENCES


Source: H429-A22

Status: 2017; 2022 Reaffirmed as Amended
Medication For Indigent Patients

Policy Statement

The American Osteopathic Association supports the donation of non-expired medications for distribution to indigent patients on the basis of financial need.

Source: H430-A22

Status: 2001; 2006 Reaffirmed as Amended; 2011 Reaffirmed; 2017 Reaffirmed as Amended; 2022 Reaffirmed
Opioid addiction and abuse continues to be an urgent public health crisis. Based on 2019 data, an average of 38 people died each day from overdoses involving prescription opioids, totaling more than 14,000 deaths. For the 12-month period ending in December 2020, provisional data from the Centers for Disease Control and Prevention (CDC) indicates that the number of overdose deaths rose to 93,331. This number is the highest ever recorded for overdose deaths in a 12-month period. Opioids were involved in approximately 75% of these deaths.\(^1\)

Over the last few years, drug overdose deaths involving synthetic opioids and methamphetamine have shifted geographically.\(^2\)

- From 2018 to 2019, the largest increase in death rates involving synthetic opioids occurred in the West (67.9%). Previously, the highest increases in deaths involving synthetic opioids occurred in the East.

- The largest increase in death rates involving psychostimulants occurred in the Northeast (43.8%) compared to the Midwest which had the highest increases in the past.

- No state had a significant decrease from 2018-2019.

In July 2021, the AOA House of Delegates directed the AOA Bureau of Osteopathic Research and Public Health to combine all AOA policies on opioids and substance use disorders into a comprehensive white paper. The following paper includes AOA policy statements on opioids and substance use disorders. Policies are divided into the following categories: Education on Substance Use Disorders, Education on Opioid Use and Abuse, Access to Treatment, and Diversion.

**Education on Substance Use Disorders**

1. The American Osteopathic Association (AOA) will advance knowledge and understanding of appropriate use of prescription drugs and TREATMENT OF substance use disorders through the education of the public and osteopathic medical education at all levels.
2. The AOA encourages its members to maintain current knowledge of addictive substances with a high potential for abuse and appropriate treatment techniques. The AOA urges all
members of the osteopathic profession to participate in the prevention and rehabilitation of persons suffering from substance use disorder and the disease of addiction.

3. The AOA will work with other associations representing health care professionals to educate on the indicators of potential prescription drug abuse, misuse, and diversion.

4. The American Osteopathic Association (AOA) encourages communities to work collaboratively with law enforcement agencies to implement evidence-based referral resources and advocate for Medication Assisted Treatment (MAT) programs as the most clinically effective and cost-effective intervention for sustained recovery, and reduction of criminal activity and mortality.

Education on Opioid Use and Abuse

1. The AOA will advocate for medical education for all practitioners on proper opioid prescribing practices and any state mandated pain education requirements should include proper prescribing practices for opioids relating to pain treatment, opioid addiction, and identification of prescription drug abuse, misuse, and diversion.

2. The AOA encourages osteopathic physicians whose practice includes the prescribing of Extended Release-Long Acting (ER/LA) Opioids to complete ER/LA Opioid Risk Evaluation and Mitigation Strategy (REMS) training to ensure that ER/LA opioids are prescribed, when indicated, in a manner that enhances patient well-being and does not contribute to individual or public harm.

Access to Treatment

1. The AOA will not support any program which limits access to prescription drugs for patients with legitimate need and will not support any program which reduces the provider’s ability to inform the patient’s care. In addition, it is in the best interest of all patients not to confine, or seek to regulate medications, including opioid/opiate, by limiting their use to a small number of selected specialties of medicine. This would also extend to modalities now developed, or yet to be developed, such as long-acting opioid/opiate preparations. These exclusionary strategies will limit access for patients with medical indications for therapy, complicate delivery of care, and add to pain and suffering of patients.

2. The AOA supports policies that do not hinder patient access to and coverage of appropriate pharmacologic and non-pharmacologic treatments. It is a right of all patients to have access to medically appropriate intervention and/or treatment for conditions, including acute and chronic pain. It is the right of all physicians, to provide medically appropriate intervention and treatment modalities that will achieve safe and effective treatment, including pain control, for all their patients.

3. The AOA opposes the imposition of administrative or financial deterrents that decrease access to and coverage of prescription drugs with abuse-deterrent properties.

4. The AOA will advocate to states to not lower opioid addiction treatment numbers below the 275 maximum patient load allowed under the Comprehensive Addiction Recovery Act.
5. The AOA will support the administration and/or prescribing of all FDA-approved treatments for opioid use disorder (OUD) for all individuals with OUD who are incarcerated or under other forms of governmental or private correctional control.

**Diversion**

1. The AOA will advocate for evidence-informed use of state prescription monitoring programs, tamper resistant drug formulas and support efforts to assist state osteopathic medical associations in developing physician drug abuse, misuse and diversion awareness and prevention education programs.
2. The AOA supports an integrated national opioid database that allows prescribers, dispensers, or their designated staff in any state to access a patient's prescription history, regardless of their residing state at no cost to the prescriber or dispenser.
3. The AOA will continue to cooperate with the pharmaceutical industry, law enforcement, and government agencies to stop prescription drug abuse, misuse and diversion as a threat to the health and well-being of the American public.
4. The AOA will encourage the Institute of Medicine and other private and public organizations/agencies to conduct further research into development of reliable outcome indicators for assessing the effectiveness of measures proposed to reduce prescription drug abuse, misuse, and diversion.

**References:**


**Background Information:** Provided by AOA Staff

**Current AOA Policy:**

The white paper is based on the following current AOA policies. If this white paper is approved, it is recommended that these policies be deleted.

- H203-A/18 Substance Use Disorders Education
- H300-A/19 Training – Extended Release-Long Acting (Er/La) Opioid Risk Evaluation And Mitigation Strategy (Rems)
- H300-A/21 Medication For Opioid Use Disorder (Moud) Availability For Incarcerated Individuals and/or Individuals Under Correctional Control Policy Statement
- H322-A/20 Prescription Drug Diversion And Abuse – Education, Research, And Advocacy
- H326-A/21 Pain Related Education Requirements Policy Statement
- H330-A/17 Patient Load Restrictions To Increase Pharmacological Opioid Addiction Treatment Access – Abolishment Of
H331-A/17 Interstate Opioid Database
H414-A/18 Substance Use Disorder
H440-A/16 Substance Use Disorders (Sud) – Evidence Based Treatment Programs For

Source: H431-A22

Status: 2022 Reaffirmed as Amended
Recognizing the Disproportionate Mortality from Cardiovascular Disease in the African American Population as a Public Health Issue

Policy Statement

The American Osteopathic Association (AOA) recognize the disproportionate mortality from cardiovascular disease in the African American population as a public health issue, for which greater awareness and research is needed.

Source: H434-A22

Status: 2022 Reaffirmed as Amended
Support for Increased Crisis Intervention Team Training for Law Enforcement

Policy Statement

The American Osteopathic Association (AOA) encourages increased resources and training initiatives, such as the crisis intervention team (CIT) and other continued best practices, for law enforcement to improve patient safety and reduce negative outcomes for patients.

Source: H436-A/22

Status: 2017; 2022 Reaffirmed as Amended
Increased Research on the Public Health Impacts of Decriminalizing Possession of all Illicit Drugs

Policy Statement

The American Osteopathic Association (AOA) encourages increased research and data collection on the public health outcomes associated with decriminalizing the possession of all illicit drugs.

Source: H437-A/22

Status: 2017; 2022 Reaffirmed
HOUSE OF DELEGATES’
AD HOC REFERENCE COMMITTEE

(600 series) - This reference committee reviews and considers materials relating to physician practice issues, affiliate dynamics, insurance and communications activities.

<table>
<thead>
<tr>
<th>Res. No.</th>
<th>Resolution Title</th>
<th>Submitted By</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>H-600</td>
<td>Centers for Medicare and Medicaid Services Policies (H601-A/13)</td>
<td>BFHP</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-601</td>
<td>Centers for Medicare and Medicaid – Regulatory Reform (H602-A/13)</td>
<td>BSA</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-602</td>
<td>Centers for Medicare and Medicaid Services’ Method in Calculation Patient Services -- A Change in (H603-A/13)</td>
<td>BSA</td>
<td>APPROVED (for sunset)</td>
</tr>
<tr>
<td>H-603</td>
<td>Colorectal Cancer Screening -- Reimbursement for (H604-A/13)</td>
<td>BSA</td>
<td>APPROVED as AMENDED</td>
</tr>
<tr>
<td>H-604</td>
<td>Physician – Co-Management of a Patient (H605-A/13)</td>
<td>BSA</td>
<td>APPROVED as AMENDED</td>
</tr>
<tr>
<td>H-605</td>
<td>Criminal Litigation for Clinical Decisions (H606-A/13)</td>
<td>BSGA</td>
<td>APPROVED as AMENDED</td>
</tr>
<tr>
<td>H-606</td>
<td>Recovery Audit Contractors (RACs) – Payment of (H607-A/13)</td>
<td>BSA</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-607</td>
<td>Opposing Policies by Third Party Payors (Health Insurers) that May Negatively Impact the Provision of Healthcare (H609-A/13)</td>
<td>BSA</td>
<td>APPROVED as AMENDED</td>
</tr>
<tr>
<td>H-608</td>
<td>Current Procedural Terminology Codes 98925-98929, Qualifications for the Practice of Osteopathic Manipulative Treatment and the Coding and Billing for (H610-A/13)</td>
<td>BSA</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-609</td>
<td>Geriatrics --Lack of Liability Insurance Coverage for Practitioners of (H612-A/13)</td>
<td>BFHP</td>
<td>APPROVED (for sunset)</td>
</tr>
<tr>
<td>H-610</td>
<td>ICD-9 Codes for Laboratory Tests -- Assignment of Appropriate (H613-A/13)</td>
<td>BSA</td>
<td>APPROVED as AMENDED</td>
</tr>
<tr>
<td>H-611</td>
<td>Osteopathic Graduate Medical Education (H614-A/13)</td>
<td>COGMED</td>
<td>APPROVED as AMENDED</td>
</tr>
<tr>
<td>H-612</td>
<td>Postpartum Depression (H615-A/13)</td>
<td>BSAPH</td>
<td>REFERRED</td>
</tr>
<tr>
<td>Res. No.</td>
<td>Resolution Title</td>
<td>Submitted By</td>
<td>Action</td>
</tr>
<tr>
<td>---------</td>
<td>----------------------------------------------------------------------------------------------------------</td>
<td>--------------</td>
<td>---------------------------------------</td>
</tr>
<tr>
<td>H-613</td>
<td>Tobacco Use in Entertainment Media (H616-A/13)</td>
<td>BSAPH</td>
<td>APPROVED as AMENDED</td>
</tr>
<tr>
<td>H-614</td>
<td>Veterans – Health Care for US (H617-A/13)</td>
<td>BFHP</td>
<td>APPROVED as AMENDED</td>
</tr>
<tr>
<td>H-615</td>
<td>Taser Safety (H618-A/13)</td>
<td>BSAPH</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-616</td>
<td>Centers for Medicare and Medicaid Services’ – Burdensome Requirements for Diabetic Supplies (H619-A/13)</td>
<td>BSA</td>
<td>APPROVED as AMENDED</td>
</tr>
<tr>
<td>H-617</td>
<td>Tenets of Osteopathic Medicine (H622-A/13)</td>
<td>BOE</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-618</td>
<td>AOA Accreditation of Sponsors Providing Osteopathic Continuing Medical Education (AOA Category 1-A)</td>
<td>POMA /et al</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-619</td>
<td>Demographics to be Shared with Affiliates</td>
<td>IOMA</td>
<td>DISAPPROVED</td>
</tr>
<tr>
<td>H-620</td>
<td>Electronic Availability of AOA House of Delegates</td>
<td>NYSOMS</td>
<td>DISAPPROVED</td>
</tr>
<tr>
<td>H-621</td>
<td>Group Purchasing Organizations – Effect on Healthcare Costs</td>
<td>MAOPS</td>
<td>DISAPPROVED</td>
</tr>
<tr>
<td>H-622</td>
<td>Inclusion of Osteopathic Language and Structural Exam in Electronic Health Record Systems</td>
<td>IOMA</td>
<td>APPROVED as AMENDED</td>
</tr>
<tr>
<td>H-623</td>
<td>H613-A/15 Non-Physician Clinicians</td>
<td>BSGA</td>
<td>APPROVED as AMENDED</td>
</tr>
<tr>
<td>H-624</td>
<td>WITHDRAWN</td>
<td></td>
<td></td>
</tr>
<tr>
<td>H-625</td>
<td>Access to Health Care/Health Insurance</td>
<td>SOMA</td>
<td>REFERRED</td>
</tr>
<tr>
<td>H-626</td>
<td>Adoption of Expedited Partner Therapy (EPT) Policy and Advocacy for National Legalization of Interstate Opioid Database</td>
<td>SOMA</td>
<td>APPROVED as AMENDED</td>
</tr>
<tr>
<td>H-627</td>
<td>Advocating for the Repeal of the Dickey Amendment, and Public Health Research on Firearm Violence</td>
<td>SOMA</td>
<td>DISAPPROVED</td>
</tr>
<tr>
<td>H-628</td>
<td>Cannabis Reclassification: Effect on Research</td>
<td>SOMA</td>
<td>APPROVED</td>
</tr>
<tr>
<td>H-629</td>
<td>Combating Pharmaceutical Evergreening to Decrease Healthcare Costs and Increase Quality, Competition</td>
<td>SOMA</td>
<td>APPROVED</td>
</tr>
<tr>
<td>Res. No.</td>
<td>Resolution Title</td>
<td>Submitted By</td>
<td>Action</td>
</tr>
<tr>
<td>---------</td>
<td>----------------------------------------------------------------------------------</td>
<td>--------------</td>
<td>-----------------------------</td>
</tr>
<tr>
<td>H-630</td>
<td>Comprehensive Gun Violence Reform</td>
<td>SOMA</td>
<td>APPROVED as AMENDED</td>
</tr>
<tr>
<td>H-631</td>
<td>Increased Resources and Accessibility for LGBTQ Persons in Federally Funded</td>
<td>SOMA</td>
<td>DISAPPROVED</td>
</tr>
<tr>
<td></td>
<td>Halfway Houses</td>
<td></td>
<td></td>
</tr>
<tr>
<td>H-632</td>
<td>Increasing the Education and Preventative Prescribing of Naloxone use for Opioid</td>
<td>SOMA</td>
<td>APPROVED as AMENDED</td>
</tr>
<tr>
<td></td>
<td>Overdose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>H-633</td>
<td>Opposing Immigration and Customs Enforcement at Sensitive Locations</td>
<td>SOMA</td>
<td>DISAPPROVED</td>
</tr>
<tr>
<td>H-634</td>
<td>Recognizing Sexual Assault Survivors’ Rights</td>
<td>SOMA</td>
<td>APPROVED as AMENDED</td>
</tr>
<tr>
<td>H-635</td>
<td>Religious Freedom and Ethical Medical Practice</td>
<td>SOMA</td>
<td>DISAPPROVED</td>
</tr>
<tr>
<td>H-636</td>
<td>Standing Against Restrictive Housing and Solitary Confinement for Juvenile</td>
<td>SOMA</td>
<td>REFERRED</td>
</tr>
<tr>
<td></td>
<td>Inmates of Prison Systems in the US</td>
<td></td>
<td></td>
</tr>
<tr>
<td>H-637</td>
<td>Urge Congress to Retain DACA Protections</td>
<td>SOMA</td>
<td>APPROVED as AMENDED</td>
</tr>
</tbody>
</table>
HOUSE OF DELEGATES’ REFERENCE COMMITTEE DESCRIPTIONS:

- Ad Hoc Committee (600 series)
  This reference committee reviews and considers materials relating to physician practice issues, affiliate dynamics, insurance and communications activities.

<table>
<thead>
<tr>
<th>Res. No.</th>
<th>Resolution Title</th>
<th>Submitted By</th>
<th>Reference Committee</th>
</tr>
</thead>
<tbody>
<tr>
<td>H-600</td>
<td>Hospice – Federal Reimbursement for Required Face-to-Face Visits (H600-A/14)</td>
<td>BSA</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H-601</td>
<td>Palliative Care – Federal Funding for Support Services (H601-A/14)</td>
<td>BSA</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H-602</td>
<td>Medicare Transition Care Codes (H602-A/14)</td>
<td>BSA</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H-603</td>
<td>Regulation of Health Information Technology Software (H605-A/14)</td>
<td>BSA</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H-604</td>
<td>Emerging States – Assistance By Other States and the AOA (H606-A/14)</td>
<td>BSGA</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H-605</td>
<td>Osteopathic Terminology - Glossary of (H607-A/12)</td>
<td>BOM</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H-606</td>
<td>Government Intervention in Private Practice (H607-A/14)</td>
<td>BSA</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H-607</td>
<td>Drug Therapy Surveyor Guidelines for Nursing Homes (H608-A/14)</td>
<td>BOCER</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H-608</td>
<td>Centers For Medicare and Medicaid Communications with Physicians (H609-A/14)</td>
<td>BSA</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H-609</td>
<td>Mandated Patient Care – Assignment of (H610-A/14)</td>
<td>BSA</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H-610</td>
<td>Investment Tax (H611-A/14)</td>
<td>BFHP</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H-611</td>
<td>OMT – Osteopathic Manipulative Treatment (H613-A/14)</td>
<td>BOCER</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H-612</td>
<td>Third-Party Payers and Utilization Review Firms – Accountability (H614-A/14)</td>
<td>BSA</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H-613</td>
<td>Mail Order Pharmacy (H615-A/14)</td>
<td>BSGA</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H-614</td>
<td>Medicare Physician Payment (H617-A/14)</td>
<td>BSA</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H-615</td>
<td>Mergers and Buy-Outs of Third Party Payers (H618-A/14)</td>
<td>BSA</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H-616</td>
<td>Federal Health Information Technology Incentives – AOA Support (H619-A/14)</td>
<td>BSA</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H-617</td>
<td>Local Coverage Determination (H622-A/14)</td>
<td>BSA</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H-618</td>
<td>Latex Allergy (H623-A/14)</td>
<td>BSAPH</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H-619</td>
<td>Managed Care Plans – Service, Access and Costs in (H624-A/14)</td>
<td>BSA</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H-620</td>
<td>Family Medical Leave Act Employee Relationship Modification (H625-A/14)</td>
<td>BFHP</td>
<td>Ad Hoc</td>
</tr>
</tbody>
</table>
### 99th ANNUAL AOA HOUSE OF DELEGATES MEETING

#### 2019 MEETING

#### RESOLUTION ROSTER

*As of June 27, 2019*

<table>
<thead>
<tr>
<th>Res. No.</th>
<th>Resolution Title</th>
<th>Submitted By</th>
<th>Reference Committee</th>
</tr>
</thead>
<tbody>
<tr>
<td>H-621</td>
<td>Pharmaceutical Packaging/ Environmental Responsibility (H626-A/14)</td>
<td>BSAPH</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H-622</td>
<td>Industry Transparency Standards (H627-A/14)</td>
<td>BFHP</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H-623</td>
<td>Electronic Health Records Software – Reporting Errors to Physicians (H630-A/14)</td>
<td>BSA</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H-624</td>
<td>Electronic Medical Record/Professional Credentials – Signature for (H631-A/14)</td>
<td>BSA</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H-625</td>
<td>Beer's Criteria For Potentially Inappropriate Medication Use In Older Adults-Use Of (H635-A/14)</td>
<td>BOCER</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H-626</td>
<td>Physician Testing Process for Unlimited Licensure – Collaboration to Protect the Integrity of the (H637-A/14)</td>
<td>BSGA</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H-627</td>
<td>Maintenance of Licensure (H638-A/14)</td>
<td>BSGA</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H-629</td>
<td>Clinical Data Registries and Qualified Clinical Data Registries</td>
<td>BSA</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H-630</td>
<td>Communication Technology-Based and Remote Evaluation Services</td>
<td>BSA</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H-631</td>
<td>Incident to Billing by Physician Assistants and Advance Practice Registered Nurses</td>
<td>BSA</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H-632</td>
<td>Patient Matching of Electronic Health Record Data</td>
<td>BSA</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H-633</td>
<td>Post-Partum Depression</td>
<td>BSA</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H-634</td>
<td>Cooperation of the Veterans Administration and Non-VA Clinicians</td>
<td>FOMA</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H-635</td>
<td>Prior Authorization – Patient Authorization</td>
<td>IOMA</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H-636</td>
<td>Obesity Treatment Reimbursement in Primary Care</td>
<td>MOA</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H-637</td>
<td>Prior Authorization and Utilization Management Reform</td>
<td>MOA</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H-638</td>
<td>Addressing the Gender Pay Gap in the Medical Profession</td>
<td>SOMA</td>
<td>Ad Hoc</td>
</tr>
</tbody>
</table>
HOUSE OF DELEGATES’ REFERENCE COMMITTEE DESCRIPTION:

- Ad Hoc Committee (600 series)
  This reference committee reviews and considers materials relating to physician practice issues, affiliate dynamics, insurance and communications activities.

<table>
<thead>
<tr>
<th>Res. No.</th>
<th>Resolution Title</th>
<th>Submitted By</th>
<th>Reference Committee</th>
</tr>
</thead>
<tbody>
<tr>
<td>H600</td>
<td>Dissemination of Publications in Osteopathic Research (H600-A/15)</td>
<td>BOCER</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H601</td>
<td>Reduction of Osteopathic Training Positions in Post-Graduate Medical Education (H601-A/15)</td>
<td>BOE</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H602</td>
<td>Reimbursement for Physician Time Spent Obtaining Pre-Certification and Pre-Authorization (H602-A/15)</td>
<td>BSA</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H603</td>
<td>Pay for Performance (H604-A/15)</td>
<td>BSA</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H604</td>
<td>Proper Badge Identification of Employees in a Hospital Setting (H606-A/15)</td>
<td>BSAPH</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H605</td>
<td>Interoperability of Health Information Technology (H607-A/15)</td>
<td>BSA</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H606</td>
<td>Gifts to Physicians from Industry (H612-A/15)</td>
<td>Ethics</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H607</td>
<td>Physician Competency Retesting (H614-A/15)</td>
<td>BOS</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H608</td>
<td>Health Plan Coverage of Tobacco Cessation Treatment (H615-A/15)</td>
<td>BSA</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H609</td>
<td>Encouraging Patient Participation in Their Health Care (H616-A/15)</td>
<td>BSAPH</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H610</td>
<td>Frivolous Liability Lawsuits (H617-A/15)</td>
<td>BFHP</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H611</td>
<td>Provider Tax (H618-A/15)</td>
<td>BSGA</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H612</td>
<td>Medicaid Payment (H619-A/15)</td>
<td>BSGA</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H613</td>
<td>Lay Midwives (H620-A/15)</td>
<td>BSGA</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H614</td>
<td>Medical Malpractice Judgments Requiring Reimbursement of Medicare Payments (H621-A/15)</td>
<td>BSA</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H615</td>
<td>Electronic Health Records – Physician Assistance Programs for Transition to (H622-A/15)</td>
<td>BSA</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H616</td>
<td>Prescription Medications -- Overrides for (H624-A/15)</td>
<td>BSGA</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H617</td>
<td>Pediatric Psychiatric Care Health Records (H625-A/15)</td>
<td>BSA / BSAPH</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H618</td>
<td>Attention Deficit Disorder / Attention Deficit Hyperactivity Disorder (H626-A/15)</td>
<td>BSA</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H619</td>
<td>Medicare Recovery Audit Contractors (H628-A/15)</td>
<td>BSA</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>Res. No.</td>
<td>Resolution Title</td>
<td>Submitted By</td>
<td>Reference Committee</td>
</tr>
<tr>
<td>---------</td>
<td>---------------------------------------------------------------------------------</td>
<td>--------------</td>
<td>---------------------</td>
</tr>
<tr>
<td>H620</td>
<td>Medicare Law and Rules (H629-A/15)</td>
<td>BFHP</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H621</td>
<td>Veterans Administration Credentialing of Non-Physician Providers Health Records (H630-A/15)</td>
<td>BFHP</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H622</td>
<td>Tax Credits for Health Profession Shortage Areas (H631-A/15)</td>
<td>BFHP</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H623</td>
<td>Osteopathic Manipulative Treatment (OMT) in a Pre-Paid Environment--Payment Policies for (H632-A/15)</td>
<td>BSA</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H624</td>
<td>Prescription of Drugs for Off Label Uses (H633-A/15)</td>
<td>BFHP</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H625</td>
<td>Newborn and Infant Hearing Screens (H635-A/15)</td>
<td>BSAPH</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H626</td>
<td>Medicare Preventive Medical Screening (H636-A/15)</td>
<td>BFHP</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H627</td>
<td>Confidentiality of Patient Records (H637-A/15)</td>
<td>Ethics</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H628</td>
<td>Diabetics Confined to Correctional Institutions (H638-A/15)</td>
<td>BSAPH</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H629</td>
<td>Discrimination by Insurers (H639-A/15)</td>
<td>BSA</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H630</td>
<td>Executions in Capital Crimes Criminal Cases (H640-A/15)</td>
<td>Ethics</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H631</td>
<td>Managed Care – All Products Clauses (H642-A/15)</td>
<td>BSGA</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H632</td>
<td>Medical Procedure Patents (H643-A/15)</td>
<td>BFHP</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H633</td>
<td>Medicare Contractor Denial Letters (H644-A/15)</td>
<td>BSA</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H634</td>
<td>Osteopathic Medical Student, Resident, and Physician Mental Health (H646-A/15)</td>
<td>BEL</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H635</td>
<td>American Osteopathic Association (AOA) Osteopathic Manipulative Treatment (OMT) Coverage Determination Guidance (H647-A/15)</td>
<td>BSA</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H636</td>
<td>Access to Care – Network Adequacy and Coverage</td>
<td>BSGA</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H637</td>
<td>Addressing Fears and Barriers to Telemedicine Implementation and Alignment</td>
<td>MOA</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H638</td>
<td>Addressing Social Determinants of Health Through Data Collection and Improved Access to Social Services</td>
<td>SOMA</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H639</td>
<td>Elimination of Prior Authorization and Step Therapy</td>
<td>MOA</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H640</td>
<td>H623-A/18 Non-Physician Clinicians</td>
<td>BSGA</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H641</td>
<td>Marketing AOA Board Certification</td>
<td>AOCOPM</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H642</td>
<td>Prior Authorization</td>
<td>BSA</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H643</td>
<td>Professional Liability Insurance Reform</td>
<td>BSGA</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H644</td>
<td>Re-Establishment of the Bureau of Osteopathic Specialty Societies (BOSS)</td>
<td>AOCOPM</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>Res. No.</td>
<td>Resolution Title</td>
<td>Submitted By</td>
<td>Reference Committee</td>
</tr>
<tr>
<td>---------</td>
<td>----------------------------------------------------------------------------------</td>
<td>--------------</td>
<td>---------------------</td>
</tr>
<tr>
<td>H645</td>
<td>REFERRED RESOLUTION: H636-A/2019 Obesity Treatment Reimbursement in Primary Care</td>
<td>BSA</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H646</td>
<td>REFERRED RESOLUTION: H-615: Postpartum Depression</td>
<td>BSAPH</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SOMA</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H649</td>
<td>Support the Bolstering of Veteran Health Administration Resources Through Provider Pay Reform</td>
<td>SOMA</td>
<td>Ad Hoc</td>
</tr>
<tr>
<td>H650</td>
<td>Telemedicine; Reimbursement for</td>
<td>NYSOMS</td>
<td>Ad Hoc</td>
</tr>
</tbody>
</table>
House of Delegates’ Reference Committee Description:
Ad Hoc Committee (600 series)
This reference committee reviews and considers materials relating to physician practice issues, affiliate
dynamics, insurance and communications activities.

<table>
<thead>
<tr>
<th>Res. No.</th>
<th>Resolution Title</th>
<th>Submitted By</th>
<th>Reference Committee</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>H-600</td>
<td>Decreasing the Limitations on Prescribing Calcitonin Gene-Related Peptide (CGRP) Inhibitors in Primary Care</td>
<td>OOA</td>
<td>Ad Hoc</td>
<td>REFERRED</td>
</tr>
<tr>
<td>H-601</td>
<td>ADVOCATING FOR Requiring the Coverage of Elemental Formula in State, Federal, And Private Insurance Programs</td>
<td>BFHP</td>
<td>Ad Hoc</td>
<td>ADOPTED as AMENDED</td>
</tr>
<tr>
<td>H-602</td>
<td>Prior Authorization</td>
<td>CERA</td>
<td>Ad Hoc</td>
<td>ADOPTED</td>
</tr>
<tr>
<td>H-603</td>
<td>AOA Policy on Telehealth - H601-A/17</td>
<td>CERA</td>
<td>Ad Hoc</td>
<td>ADOPTED as AMENDED</td>
</tr>
<tr>
<td>H-604</td>
<td>Patient Access to Home Health Services</td>
<td>CERA</td>
<td>Ad Hoc</td>
<td>ADOPTED as AMENDED</td>
</tr>
<tr>
<td>H-605</td>
<td>Disaster Relief Volunteers (SR-Source: H313-A/16)</td>
<td>CSHA/BFHP</td>
<td>Ad Hoc</td>
<td>ADOPTED as AMENDED</td>
</tr>
<tr>
<td>H-606</td>
<td>Electronic Medical/Health Record Exemption Without Penalty (SR-Source: H326-A/16)</td>
<td>CERA</td>
<td>Ad Hoc</td>
<td>ADOPTED</td>
</tr>
<tr>
<td>H-607</td>
<td>Physician Administered OMT (SR-Source: H601-A/16)</td>
<td>CERA</td>
<td>Ad Hoc</td>
<td>ADOPTED</td>
</tr>
<tr>
<td>H-608</td>
<td>Mandatory Participation in Insurance Plans (SR-Source: H617-A/16)</td>
<td>CERA</td>
<td>Ad Hoc</td>
<td>ADOPTED</td>
</tr>
<tr>
<td>H-609</td>
<td>Medicare Claims Coding – Centers for Medicare and Medicaid Services Communications with Physicians (SR-Source: H620-A/16)</td>
<td>CERA</td>
<td>Ad Hoc</td>
<td>ADOPTED</td>
</tr>
<tr>
<td>H-610</td>
<td>Physician Negotiation Rights (SR-Source: H622-A/16)</td>
<td>CERA</td>
<td>Ad Hoc</td>
<td>ADOPTED as AMENDED</td>
</tr>
<tr>
<td>Res. No.</td>
<td>Resolution Title</td>
<td>Submitted By</td>
<td>Reference Committee</td>
<td>Action</td>
</tr>
<tr>
<td>---------</td>
<td>----------------------------------------------------------------------------------</td>
<td>--------------</td>
<td>---------------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>H-611</td>
<td>Readmission Rates by the Centers for Medicare and Medicaid Services as a</td>
<td>CERA</td>
<td>Ad Hoc</td>
<td>ADOPTED</td>
</tr>
<tr>
<td></td>
<td>Criterion for Ranking – Opposition to use of (SR-Source: H626-A/16)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>H-613</td>
<td>Health Insurance Exchanges (SR-Source: H633-A/16)</td>
<td>CERA</td>
<td>Ad Hoc</td>
<td>ADOPTED</td>
</tr>
<tr>
<td>H-614</td>
<td>Access To Care – Network Adequacy and Coverage (SR-Source: H635-A/16)</td>
<td>CERA/CSHA</td>
<td>Ad Hoc</td>
<td>ADOPTED</td>
</tr>
<tr>
<td>H-615</td>
<td>Third Party Payor-INSURER Coverage Process Reform (SR-Source: H637-A/16)</td>
<td>CERA</td>
<td>Ad Hoc</td>
<td>ADOPTED as AMENDED</td>
</tr>
<tr>
<td>H-616</td>
<td>Merit-Based Incentive Payment System (MIPS) &amp; Alternative Payment Models (APMS) (SR-Source: H638-A/16)</td>
<td>BFHP</td>
<td>Ad Hoc</td>
<td>ADOPTED</td>
</tr>
<tr>
<td>H-617</td>
<td>Health Insurer Consolidation (SR-Source: H643-A/16)</td>
<td>CERA/CSHA</td>
<td>Ad Hoc</td>
<td>ADOPTED as AMENDED</td>
</tr>
<tr>
<td>H-618</td>
<td>Medicare Medical Necessity Certification Requirements (SR-Source: H645-A/16)</td>
<td>BFHP</td>
<td>Ad Hoc</td>
<td>ADOPTED as AMENDED</td>
</tr>
<tr>
<td>H-619</td>
<td>Expanding Gender Identity Options on Physician Intake Forms (SR-Source: H647-A/16)</td>
<td>BORPH</td>
<td>Ad Hoc</td>
<td>ADOPTED as AMENDED</td>
</tr>
</tbody>
</table>
HOUSE OF DELEGATES' REFERENCE COMMITTEE DESCRIPTIONS:
Ad Hoc Committee (600 series)
This reference committee reviews and considers materials relating to physician practice issues, affiliate dynamics, insurance and communications activities.

<table>
<thead>
<tr>
<th>Res. No.</th>
<th>Resolution Title</th>
<th>Submitted By</th>
<th>Reference Committee</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>H-600</td>
<td>Osteopathic Neurologic and Psychiatric Standard of Care</td>
<td>BORPH/CSHA</td>
<td>Ad Hoc</td>
<td>Adopted</td>
</tr>
<tr>
<td>H-601</td>
<td>Physician / Patient Educational Materials Received from Pharmaceutical Companies that Produce and/or Market Generic Medications</td>
<td>BORPH</td>
<td>Ad Hoc</td>
<td>Adopted</td>
</tr>
<tr>
<td>H-602</td>
<td>Osteopathic Musculoskeletal Evaluation</td>
<td>BORPH</td>
<td>Ad Hoc</td>
<td>Adopted</td>
</tr>
<tr>
<td>H-603</td>
<td>Adjustment to Primary Care Incentive Program</td>
<td>BFHP</td>
<td>Ad Hoc</td>
<td>Adopted as Amended</td>
</tr>
<tr>
<td>H-604</td>
<td>Physician Depositions</td>
<td>CSHA</td>
<td>Ad Hoc</td>
<td>Adopted</td>
</tr>
<tr>
<td>H-605</td>
<td>The Practice of Osteopathic Medicine Discrimination</td>
<td>CSHA</td>
<td>Ad Hoc</td>
<td>Adopted</td>
</tr>
<tr>
<td>H-606</td>
<td>Drug Prescribing, Including Elderly Patients</td>
<td>CSHA</td>
<td>Ad Hoc</td>
<td>Adopted as Amended</td>
</tr>
<tr>
<td>H-607</td>
<td>Human Immunodeficiency Virus (HIV) – Positive Status as a Disability for Physicians</td>
<td>CSHA</td>
<td>Ad Hoc</td>
<td>Adopted</td>
</tr>
<tr>
<td>H-608</td>
<td>Health Care Fraud and Abuse</td>
<td>CSHA</td>
<td>Ad Hoc</td>
<td>Adopted</td>
</tr>
<tr>
<td>H-609</td>
<td>Military Medical Readiness</td>
<td>BFHP</td>
<td>Ad Hoc</td>
<td>Adopted</td>
</tr>
<tr>
<td>H-610</td>
<td>Payment For Psychiatric Diagnoses and Treatment by Primary Care Physicians</td>
<td>CSHA</td>
<td>Ad Hoc</td>
<td>Adopted</td>
</tr>
<tr>
<td>H-611</td>
<td>Physician Fines Imposed by Third Party Payors</td>
<td>BFHP</td>
<td>Ad Hoc</td>
<td>Adopted</td>
</tr>
<tr>
<td>H-612</td>
<td>Health Care Insurance Options</td>
<td>CSHA</td>
<td>Ad Hoc</td>
<td>Adopted</td>
</tr>
<tr>
<td>H-613</td>
<td>Physician Payment in Federal Programs</td>
<td>BFHP</td>
<td>Ad Hoc</td>
<td>Adopted as Amended</td>
</tr>
<tr>
<td>H-614</td>
<td>Human Immunodeficiency Virus (HIV) Consent Form Elimination</td>
<td>BFHP</td>
<td>Ad Hoc</td>
<td>Adopted</td>
</tr>
</tbody>
</table>
## RESOLUTION ROSTER (600 SERIES)

<table>
<thead>
<tr>
<th>Resolution Number</th>
<th>Resolution Title</th>
<th>Source</th>
<th>Committee</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>H-615</td>
<td>Direct Primary Care</td>
<td>BFHP</td>
<td>Ad Hoc</td>
<td>Adopted as Amended</td>
</tr>
<tr>
<td>H-616</td>
<td>Opposition to the Practice of LGBTQIA+ Conversion Therapy or Reparative Therapy</td>
<td>CSHA</td>
<td>Ad Hoc</td>
<td>Adopted as Amended</td>
</tr>
<tr>
<td>H-617</td>
<td>Standing Against Sexual Orientation Change Efforts (SOCE)</td>
<td>BFHP</td>
<td>Ad Hoc</td>
<td>Adopted for Sunset</td>
</tr>
<tr>
<td>H-618</td>
<td>Patient Interpreters</td>
<td>BFHP</td>
<td>Ad Hoc</td>
<td>Adopted</td>
</tr>
<tr>
<td>H-619</td>
<td>AOA Opposition to Merging of State Osteopathic Licensing Boards with State Medical Licensing Boards</td>
<td>CSHA</td>
<td>Ad Hoc</td>
<td>Adopted as Amended</td>
</tr>
<tr>
<td>H-620</td>
<td>Prescription Drug Pricing</td>
<td>CSJA</td>
<td>Ad Hoc</td>
<td>Adopted as Amended</td>
</tr>
<tr>
<td>H-621</td>
<td>WITHDRAWN BY AUTHOR</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>H-622</td>
<td>Addressing Insurance Denials</td>
<td>MAOPS</td>
<td>Ad Hoc</td>
<td>Referred</td>
</tr>
<tr>
<td>H-623</td>
<td>WITHDRAWN BY AUTHOR</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>H-624</td>
<td>Reducing the Waiting Period for Credentialing, Re-Credentialing and Enrollment of Health Care Professionals by Health Plans</td>
<td>MOA</td>
<td>Ad Hoc</td>
<td>Adopted as Amended</td>
</tr>
<tr>
<td>H-625</td>
<td>Expanding Seven Core Competencies to Include Diverse Patient Populations Including but not limited to LGBTQ+ within Standardized Patient Education</td>
<td>OPSC</td>
<td>Ad Hoc</td>
<td>Referred</td>
</tr>
<tr>
<td>H-626</td>
<td>Expanding Scheduled Dialysis Services to all Patients with End Stage Kidney Disease</td>
<td>SOMA</td>
<td>Ad Hoc</td>
<td>Disapproved</td>
</tr>
</tbody>
</table>
Centers for Medicare and Medicaid Services Policies

Policy Statement

The American Osteopathic Association will continue to inform state associations and their members on policies and rules being considered by the Centers for Medicare and Medicaid Services and/or other federal agencies on major patient/physician issues and encourages the state associations to provide their members with the information and take an active role in responding to CMS on policies and rules pertinent to their members, their practices and patients.

Source: H600-A/18

Status: 1998; 2003 Reaffirmed as Amended; 2008 Reaffirmed; 2013; 2018 Reaffirmed
Cancer Screening – Payment for

Policy Statement

The American Osteopathic Association supports cancer screening payment by all payers according to the current evidence-based guidelines.

Source: H603-A/18

Status: 1998, 2003 Reaffirmed as Amended; 2008 Amended and Reaffirmed; 2013 Reaffirmed as Amended; 2018 Reaffirmed as Amended
Physician – Co-Management of a Patient

Policy Statement

The American Osteopathic Association’s supports co-management of a patient, requiring the patient to have an examination by the physician who will be performing the procedure; the physician providing the procedure be available for the follow-up care of the patient; and if for any reason the physician providing the procedure cannot provide the pre- and post-procedural care to the patient, that he/she arrange for an osteopathic or allopathic physician to provide for the pre-procedural and post-procedural care. In cases where a physician is unavailable, non-physician clinicians should be under physician supervision, in accordance with the state law.

Source: H604-A/18

Status: 2002, 2003 Reaffirmed as Amended; 2008 Reaffirmed; 2013 Reaffirmed as Amended; 2018 Reaffirmed as Amended
Criminal Liability for Clinical Decisions

Policy Statement

The American Osteopathic Association opposes criminal of liability for a physician whose clinical decisions were made without malice and in good faith.

Source: H605-A/18

Status: 1998, 2003 Reaffirmed as Amended; 2008 Reaffirmed; 2013 Reaffirmed as Amended; 2018 Reaffirmed as Amended
Recovery Audit Contractors (RACs) – Payment of

Policy Statement

The American Osteopathic Association supports removing the contingency payment of Recovery Audit Contractors (RACs) replacing with a flat-rate compensation.

Source: H606-A/18

Status: 2013; 2018 Reaffirmed
Opposing Policies by Third Party Payors that may negatively impact the provision of Healthcare

Policy Statement

The American Osteopathic Association to preserve the physician-patient relationship and physician clinical judgement as the basis for formulating an individual plan of care, supports policy requiring that third party payors should assist physicians by publishing their guidelines and rationales for exceptions to expedite care; opposes policies and any practice of third party payors that replace physician clinical judgment with a fixed protocol or potentially less effective medications for required trial of treatment; and opposes policies and any practice of third party payors that replace physician clinical judgment with a fixed protocol of prerequisite of diagnostic procedures.

Source: H607-A/18

Status: 2013; 2018 Reaffirmed as Amended
ICD-10 Codes for Laboratory Tests -- Assignment of Appropriate

Policy Statement

The American Osteopathic Association supports the use of appropriate single ICD codes should suffice to justify the ordering of laboratory tests, if those tests are ordered as part of the evaluation of a disease process or in the context of an already known disease; and the AOA will communicate this policy to the Centers for Medicare and Medicaid Services, the Department of Health and Human Services, health insurance companies, and to the US Congress.

Source: H610-A/18

Status: 1998, 2003 Reaffirmed as Amended; 2008; 2013 Reaffirmed as Amended; 2018 Reaffirmed as Amended
Osteopathic Graduate Medical Education

Policy Statement

The American Osteopathic Association urges its member physicians to support hospitals that provide osteopathic postdoctoral training programs, including those with osteopathic recognition through ACGME, which are an integral part of osteopathic medical education.

Source: H611-A/18

Status: 1998; 2003 Reaffirmed as Amended; 2008; 2013 Reaffirmed; 2018 Reaffirmed as Amended
Tobacco Use in Entertainment Media

Policy Statement

The American Osteopathic Association encourages media producers to eliminate the use of tobacco products in entertainment media.

Source: H613-A/18

Status: 2003; 2008; 2013 Reaffirmed as Amended; 2018 Reaffirmed as Amended
Veterans – Health Care for US

Policy Statement

The American Osteopathic Association supports adequate health care funding by the federal government to provide health care for all US Veterans at Veterans Health Administration facilities and supports federal funding for veterans to utilize community physicians for care when Veterans’ Health Administration facilities cannot provide adequate or timely access.

Source: H614-A/18

Status: 2003; 2008; 2013 Reaffirmed; 2018 Reaffirmed as Amended
Tenets of Osteopathic Medicine

Policy Statement

The American Osteopathic Association approves the following consensus statement on the tenets of osteopathic medicine:

(1) The body is a unit; the person is a unity of body, mind and spirit.

(2) The body is capable of self-regulation, self-healing and health maintenance.

(3) Structure and function are reciprocally interrelated.

(4) Rational treatment is based upon an understanding of the basic principles of body unity, self-regulation and the interrelationship of structure and function.

Source: H617-A/18

Status: 2008; 2013 Reaffirmed; 2018 Reaffirmed
AOA Accreditation of Sponsors Providing Osteopathic Continuing Medical Education
(AOA Category 1-A)

Policy Statement

The American Osteopathic Association (AOA) be barred from divesting itself of, through merger, sale or other action, the responsibility of accrediting osteopathic continuing medical education sponsors to any entity other than an AOA recognized osteopathic affiliated organization.

Source: H618-A/18

Status: 2018 Reaffirmed
Non-Physician Clinicians

Policy Statement

The American Osteopathic Association has adopted the policy paper as its position on non-physician clinicians including appropriate onsite supervision.

Source: H623-A-18

Status: 2000, 2005 Reaffirmed as Amended, 2010 Reaffirmed; 2018 Reaffirmed as Amended
Combating Pharmaceutical Evergreening to Decrease Healthcare Costs and Increase Quality, Competition

Policy Statement

The American Osteopathic Association (AOA) advocate for and support all efforts to combat evergreening defined as the practice of extending the patent on a drug by filing a new patent for a marginal modification in shape, dose, or color in such a way that no efficacious benefit is made, in the pharmaceutical sector.

Source: H629-A-18

Status: 2018
Comprehensive Gun Violence Reform

Policy Statement

The American Osteopathic Association join physician like-minded organizations in the call for Congressional legislation that:

1. Labels gun violence as a national public health issue.
2. Funds appropriate research on gun violence as part of future federal budgets.
3. Establishes constitutionally appropriate restrictions on the manufacturing and sale, for civilian use, of large-capacity magazines and firearms with features designed to increase their rapid and extended killing capacity.

Source: H630-A-18

Status: 2018
Increasing the Education and Preventative Prescribing of Naloxone use for Opioid Overdose

Policy Statement

The American Osteopathic Association supports preventative prescribing of Naloxone and the education and training of its use for patients at risk of overdose, family members, and caregivers, in order to prevent opioid / opiate related deaths.

Source: H632-A-18

Status: 2018
Recognizing Sexual Assault Survivors’ Rights

Policy Statement

The American Osteopathic Association (AOA) advocate for the legal protection of sexual assault survivors' rights as defined by the Survivors' Bill of Rights Act of 2016.

Source: H634-A-18

Status: 2018
Urge Congress to Retain DACA Protections

Policy Statement

The American Osteopathic Association (AOA) supports Deferred Action for Childhood Arrivals (DACA) medical students, residents and physicians; and the AOA support and urge Congress to pass comprehensive immigration legislation that accommodates and resolve DACA status.

Source: H637-A-18

Status: 2018
Hospice – Federal Reimbursement for Required Face-to-Face Visits

Policy Statement

The American Osteopathic Association supports reasonable federal payment to hospice organizations for federally required face-to-face visits for patients enrolled in hospice.

Source: H600-A/19

Status: 2014; 2019 Reaffirmed as Amended
Palliative Care – Federal Funding for Support Services

Policy Statement

The American Osteopathic Association supports federal funding for chaplain, social work, and home health aide provider services for palliative care patients.

Source: H601-A/19

Status: 2014; 2019 Reaffirmed
Regulation of Health Information Technology Software

Policy Statement

The American Osteopathic Association (AOA) supports a new risk-based oversight framework for clinical software, developed through a multi-stakeholder consensus-based process. The framework should take into account risk relative to intended use, cost/benefit of proposed oversight, and the principle of shared responsibility. Patient safety and appropriate improvements in quality, effectiveness, and efficiency of care delivery should be paramount. This framework should not conflict with or duplicate the medical device regulation framework.

The AOA does not support data treated as a medical device regardless of the category of health information technology associated with the data. The AOA supports a national network for reporting patient safety events, where data can be accessed, analyzed, and communicated in a timely manner. Existing programs should be leveraged and utilized. The AOA supports a common data structure that will enable interoperability; setting a clear course of action, supporting an exchange infrastructure, and adopting standards that will make it easier to share information so that physicians and patients can make informed decisions.

Source: H603-A/19

Status: 2014; 2019 Reaffirmed
Emerging States – Assistance by Other States and the AOA

Policy Statement

The American Osteopathic Association encourages liaison between state affiliate organizations whether formal or informal and supports assistance to state affiliate organizations in need.

Source: H604-A/19

Osteopathic Terminology - Glossary of

Policy Statement

The American Osteopathic Association designates the entries in the Glossary of Osteopathic Terminology as the AOA’s official terms and definitions; whenever terms or definitions in the Glossary of Osteopathic Terminology conflict substantively with AOA policy, AOA branding guidelines or AOA publications’ style guidelines, the AOA will seek to resolve the conflict through the Glossary of Osteopathic Terminology’s standard process for revision and external input; and the JAOA-The Journal of the American Osteopathic Association’s “Instructions for Authors” will advise authors to use the terms and definitions in the Glossary of Osteopathic Terminology.

Source: H605-A/19

Status: 2012; 2019 Reaffirmed
Government Intervention in Private Practice

Policy Statement

The American Osteopathic Association strongly recommends that any intervention by federal, state or private third-party payers shall not impose a financial penalty on any physician without proper peer review and opportunity for appeal, and encourages the continued availability of judicial review of claims.

Source: H606-A/19

Status: 1985; 1990 Reaffirmed; 1994 Reaffirmed; 1999 Reaffirmed; 2004 Reaffirmed; 2009 Reaffirmed; 2014 Reaffirmed; 2019 Reaffirmed as Amended
Drug Therapy Surveyor Guidelines for Nursing Homes

Policy Statement

The American Osteopathic Association supports drug therapy surveyor guidelines regarding inappropriate drug use in nursing facilities be developed in collaboration with professional organizations possessing clinical expertise in geriatrics and long-term care medicine.

Source: H607-A/19

Status: 1999; 2004 Reaffirmed as Amended; 2009 Reaffirmed; 2014 Reaffirmed as Amended; 2019 Reaffirmed
Centers for Medicare and Medicaid Communications with Physicians

Policy Statement

The American Osteopathic Association supports the distribution of thorough and current written information by all Medicare administrative contractors on the correct preparation and coding of Medicare claims to all physicians and supports communication to the physician of the complete justification for the denial of any Medicare claims.

Source: H608-A/19

Status: 1999; 2004 Reaffirmed; 2009 Reaffirmed as Amended; 2014 Reaffirmed; 2019 Reaffirmed
Mandated Patient Care – Assignment of

Policy Statement

The American Osteopathic Association strongly opposes any attempt by a third-party payer, business, institution or government to mandate a patient be seen and managed by any individual, including a hospitalist, or anyone other than the patient and their physician in any setting without the concurrence of the patient’s physician.

Source: H609-A/19

Status: 1999; 2004 Reaffirmed; 2009 Reaffirmed; 2014 Reaffirmed; 2019 Reaffirmed as Amended
Investment Tax

Policy Statement

The American Osteopathic Association notes that it is the responsibility of all osteopathic associations with 501(c)(6) tax status to urge their state legislators, U.S. senators and representatives, to defeat any proposed expansion of the tax on unrelated business income to include dividends, capital gains and/or interest income on reserves and current operational funds, under the 501(c)(6) tax status.

Source: H610-A/19

Status: 1999; 2004 Reaffirmed; 2009 Reaffirmed as Amended; 2014 Reaffirmed; 2019 Reaffirmed
The American Osteopathic Association urges that in all forms of communication the term OMT shall always be “Osteopathic Manipulative Treatment”.

Source: H611-A/19

Status: 1999; 2004 Reaffirmed; 2009 Reaffirmed; 2014 Reaffirmed; 2019 Reaffirmed
Third-Party Payers and Utilization Review Firms – Accountability

Policy Statement

The American Osteopathic Association supports the disclosure of the origin of utilization review criteria used by third-party payers.

Source: H612-A/19

Status: 1994; 1999 Reaffirmed; 2004 Reaffirmed; 2009 Reaffirmed; 2014 Reaffirmed; 2019 Reaffirmed
Mail Order Pharmacy

Policy Statement

The American Osteopathic Association opposes pharmaceutical programs that require all medications be delivered to the patient's residence as failing to act in the best interests of the patient. Maintenance medication prescriptions should be obtainable by the means preferred by the patient.

Source: H613-A/19

Status: 2004; 2009 Reaffirmed; 2014 Reaffirmed; 2019 Reaffirmed as Amended
Mergers and Buy-Outs of Third-Party Payers

Policy Statement

The American Osteopathic Association advocates that all third-party payers automatically enrolling physicians in all products of an acquiring company should notify the physician of the products offered and permit physicians to reject one or all of the products of the acquiring company.

Source: H615-A/19

Status: 2004; 2009 Reaffirmed; 2014 Reaffirmed as Amended; 2019 Reaffirmed
Federal Health Information Technology Incentives – AOA Support

Policy Statement

The American Osteopathic Association supports the federal Health Information Technology (HIT) initiatives by assisting its members through education and other services necessary for them to adopt the appropriate technology which would be cost effective for their practices.

Source: H616-A/19

Status: 2009; 2014 Reaffirmed as Amended; 2019 Reaffirmed
Local Coverage Determination

Policy Statement

The American Osteopathic Association encourages public and private insurance carriers, as well as the Centers for Medicare and Medicaid Services to utilize the local coverage determination (LCD) adopted in the State of Florida as a guide when determining coverage requirements for osteopathic manipulative treatment.

Source: H617-A/19

Status: 2009; 2014 Reaffirmed; 2019 Reaffirmed
Latex Allergy

Policy Statement

The American Osteopathic Association strongly encourages hospitals and other healthcare facilities to provide non-latex alternatives.

Source: H618-A/19

Status: 1999; 2004 Reaffirmed; 2009 Reaffirmed; 2014 Reaffirmed as Amended; 2019 Reaffirmed
Family Medical Leave Act Employee Relationship Modification

Policy Statement

The American Osteopathic Association supports legislation amending the Family Medical Leave Act (FMLA) Basic Leave Entitlement ‘To care for the employee’s spouse, son or daughter, or parent, who has a serious health condition’ to include responsible designee; and requests the Department of Labor to include these changes at the federal level.

Source: H620-A/19

Status: 2009; 2014 Reaffirmed; 2019 Reaffirmed
Pharmaceutical Packaging/ Environmental Responsibility

Policy Statement

The American Osteopathic Association supports environmentally responsible packaging of pharmaceutical samples.

Source: H621-A/19

Industry Transparency Standards

Policy Statement

The American Osteopathic Association (AOA):

(1) acknowledges the contributions made by pharmaceuticals, biologics, and medical devices to the improved health, management of disease, and enhanced life function for millions of patients cared for by physicians as distinguished in H-346-A/16 and as outlined in H-623-A/18;

(2) acknowledges concerns regarding the perception that pharmaceutical and device companies have undue influence over physicians;

(3) affirms its commitment to providing all osteopathic physicians, their patients, and the public timely, accurate, and relevant information on advances in medical science, treatment of disease, prevention, wellness, and other information that advances mental and physical health; (4) continues its commitment to life-long learning for all osteopathic physicians;

(5) supports transparency in its industry partnerships by disclosing all industry partnerships entered into to advance life-long learning;

(6) will further advance transparency by encouraging all partners to disclose fully their relationship with the AOA and other organizations;

(7) directs the Council on Continuing Medical Education to adopt and implement transparency standards;

(8) discourages business practices that interfere with the patient-physician relationship, attempt to unduly influence the practice of medicine, or attempt to inappropriately persuade patients to seek services or products; and

(10) stands resolute that our commitment to advancing medical science, quality health care, the treatment of disease, and transparency in our actions, along with the ethical code by which our members serve, are the principles by which we engage industry partners.

Source: H622-A/19

Status: 2009; 2014 Reaffirmed as Amended; 2019 Reaffirmed as Amended
Electronic Health Records Software – Reporting Errors to Physicians

Policy Statement

The American Osteopathic Association supports prompt notification by Electronic Health Record (EHR) vendors to physician clients of reported software errors and provisions of software updates that correct these errors, in a systematic, cost-effective and timely fashion at no cost to the EHR user.

Source: H623-A/19

Status: 2014; 2019 Reaffirmed as Amended
Beer's Criteria for Potentially Inappropriate Medication Use in Older Adults—Use of
Policy Statement

The American Osteopathic Association recognizes the limitations of the Beer's Criteria as published by the American Geriatrics Society, as guidelines and not mandates to limit or prohibit access to medications deemed appropriate by the patient’s physician.

Source: H625-A/19

Status: 2014; 2019 Reaffirmed as Amended
Maintenance of Licensure

Policy Statement

The American Osteopathic Association (AOA):

(1) supports the development of state level maintenance of licensure (MOL) programs to demonstrate that all physicians are competent to provide quality care that incorporates relevant technological and scientific advancements over the course of their career. Flexible pathways for achieving MOL should be maintained. The requirements for MOL should balance transparency with privacy protection and not be overly burdensome or costly to physicians or state licensing boards.

(2) Continues to address and promote physician competency through the teaching of core competencies at the predoctoral and postdoctoral levels as well as ongoing physician assessment through Osteopathic Continuous Certification (OCC).

(3) Continues to work with State Osteopathic Affiliates, the American Association of Osteopathic Examiners and other stakeholders to establish and implement MOL policies that promote patient safety and the delivery of high quality of care.

(4) Through its bureaus, councils and committees, will continue to ensure that OCC is recognized by the federal government, state governments and other regulatory agencies and credentialing bodies as equivalent to other national certifying bodies' "maintenance" or "continuous" certification programs.

(5) While supporting the use of board certification as a recognition of quality and excellence, signifying the highest physician achievement in a particular specialty; opposes any efforts to require OCC as a condition of medical licensure;

(6) Collaborates with entities properly qualified for and tasked with decision-making regarding insurance payment, hospital privileges, network participation, malpractice insurance coverage, physician employment, to determine the role of physician board certification and OCC or other "maintenance of certification" programs in such decisions.

(7) Continues to innovate and improve the OCC process.

Source: H627-A/19

Status: 2010; 2015 Reaffirmed; 2017 Reaffirmed; 2019 Reaffirmed as Amended
Standing Against Restrictive Housing and Solitary Confinement for Juvenile Inmates of Prison Systems in the US

Policy Statement

White Paper

Opposing Restrictive Housing and Solitary Confinement for Juvenile Inmates of Prison Systems in the U.S.

Introduction
Every day approximately 53,000 youth under the age of 18 are sent to correctional facilities as a result of juvenile or criminal justice involvement. Correctional facilities generally offer limited medical and mental health care, resulting in harmful health outcomes, such as increased violence, mental illness, cognitive impairment, and increased risk of disease. It is not uncommon for incarcerated youth to be housed in solitary confinement or restrictive housing while in these facilities. The use of solitary confinement further compromises the quality of the health care detainees receive, and results in long-lasting, adverse physical, psychological, and social effects. Thus, the use of such housing has become a major public health concern in the U.S.

For many individuals who are committed to improving health outcomes for juvenile youth, there has been an urgent need for interventions and reformation programs that encourage humane alternatives and movement towards the abolishment of juvenile solitary confinement in the U.S. In fact, several professional and human rights organizations have taken positions in favor of limiting or eliminating solitary confinement.

The purpose of this paper is to discuss the frequency and impact of solitary confinement (isolation) on juvenile well-being and to present the AOA’s position opposing restrictive housing and solitary confinement for juvenile inmates in the U.S.

Solitary Confinement
The term, solitary confinement, is often used interchangeably with the terms segregation, isolation, and restrictive housing. The National Commission on Correctional Health Care refers to solitary confinement, or isolation, as the housing of an adult or juvenile with minimal to rare meaningful contact with other individuals. Additionally, the United States Department of Justice defines restrictive housing as any type of detention that involves one of the following:

1. Removal from the general inmate population, whether voluntary or involuntary.
2. Placement in a locked room or cell, whether alone or with another inmate.
3. Inability to leave the room or cell for the vast majority of the day, typically 22 hours or more.

There are several forms of restrictive housing. High security facilities that contain solitary confinement units are called supermaximum ("supermax") facilities. These facilities house inmates who have engaged in violent behavior aimed at other inmates or staff in another institution or those who were not compliant at lower-security prisons. Some supermax facilities also house inmates in protective custody or those considered to be a “special population”, such as prisoners on death row. In addition to these facilities, there are facilities that contain solitary...
confinement cells, known as segregated housing or secured housing units, in institutions that are not considered supermax facilities.³

By design, solitary confinement restricts human contact and environmental simulation. The facilities commonly have minimal natural light, leaving detainees exposed to constant artificial light, and inmates experience punitively distasteful meals, have limited personal items, and are denied opportunities to communicate with others.³

Public Health Implications
Though data on the frequency and duration of solitary confinement is scant, the Office of Juvenile Justice and Delinquency Prevention reports that half of the individuals in the juvenile penal system were isolated for more than four hours at a time.⁴ Exact statistics are not readily available, since the federal government does not require prisons to report the number of juveniles in solitary confinement, the frequency, or the amount of time they are isolated.³

In some jurisdictions, youth may be detained in solitary confinement for several weeks or months. In addition to the harms associated with adults in solitary confinement, youth may also lack educational options or interaction with their families, and they may experience the beginning of mental illnesses that commonly occur during late adolescence.⁵

Many studies have underscored the troubling realities of physical and mental health outcomes directly related to the increase of solitary confinement. While incarceration alone yields unintentional but inevitable consequences on wellness, especially mental health issues, solitary confinement amplifies the risk of anxiety, depression, psychosis and self-harm, as supported by both the American Psychological Association and American Academy of Child and Adolescent Psychiatry.⁶

The practice of placing youth in solitary confinement is especially troubling since children and young adults are still developing physically, mentally, and socially and are more vulnerable to the noted long-lasting negative effects of solitary confinement. Accordingly, mental health problems are more prevalent among youth inmates compared to adult inmates, with 95% of youth in the juvenile penal system having at least one mental health problem, and 80% of youth developing more than one mental health illness.⁷

Furthermore, the Centers for Disease Control and Prevention reports that suicide is the 3rd leading cause of death for youth, resulting in approximately 4,600 deaths per year.⁸ However, young people in prisons are 18 times more likely to commit suicide than their counterparts in the community.⁷ Thus, isolation of juveniles increases the risk of both mental illness and suicide for adolescents and young adults. Thus, concerns about the use of solitary confinement have mounted.

In a July 14, 2015, speech at the NAACP National Convention, President Barack Obama announced that he had asked Attorney General Loretta Lynch to conduct a review of “the overuse of solitary confinement across American prisons.” The President directed that the focus not only on understanding how, when, and why correctional facilities isolate certain prisoners from the general inmate population, but also that it includes strategies for reducing the use of this practice throughout our nation’s criminal justice system.

Among other findings, the study report summary noted that implementation of solitary confinement and the length of time an inmate is isolated is the discretion of correctional officers, not decided by a court or jury. The report also recommended that the Bureau end the practice of placing juveniles in restrictive housing, pursuant to the standards proposed in the Sentencing Reform and Corrections Act of 2015.²
The United Nations has also taken a stance against solitary confinement and considers isolation within juvenile facilities a form of torture. The U.N. has encouraged the U.S. to create federal and state legislature ratifying the Convention on the Rights of the Child, an international agreement set forth by the U.N. to protect children from abuse. To date, only seven U.S. states have placed any prohibition on juvenile solitary confinement.3

The American Academy of Child and Adolescent Psychiatry highlights the code of ethics surrounding the psychiatrist's responsibility to not only reduce the harmful impacts of the behavior of others but the community and social effects as well.7 Often, correctional facilities have a culture of their own that produce a different code of ethics for the survival and safety of juvenile inmates; this can create a dilemma for clinicians as it relates to providing quality care to inmates.

Racial and Gender Disparities
Within the issue of solitary confinement in juvenile detention facilities, there is a concern that certain races/ethnicities are disproportionally exposed to these practices than youth from other races/ethnicities. Across the nation, the youth rate of incarceration is 152 per 100,000. However, the Black youth placement rate is nearly three times higher than the national rate at 433 per 100,000. Comparatively, the White youth placement rate is 86 per 100,000, nationally. According to the Department of Justice, Black youth are five times more likely to be detained compared to Whites. When examining the system further, Black males and Native American females are an over-represented population in the U.S. juvenile prison system. Currently, in the U.S., Black males under the age of 18 make up 14% of the total population; however, 43% of Black males under 18 years of age are in juvenile facilities. Nationally, Native Americans make up less than 1% of all youth, but 3% of Indian females are in juvenile facilities.7

Over the last decade, the racial disparity in youth placed in the juvenile penal system has increased by nearly 22%.9 As a result of disparities in the number of justice-involved juveniles, minority youth detainees are more likely to suffer severe psychological/mental health issues and live in restrictive facilities away from home. Black juveniles, specifically, are experiencing worse health outcomes, especially mental health outcomes, due to disparities in the juvenile penal system.9

Social and Societal Impact
Family support and love are essential for the development of juveniles social identity.9 However, visits, phone calls, and sometimes even letters are prohibited during solitary confinement, creating additional separation between inmates, their families, and the outside world in general. Isolation due to incarceration creates separation from society that makes it very difficult to form a social identity. Solitary confinement exacerbates the social complexities and behaviors of re-entering into society by aggravating preexisting depression or anxiety due to separation from home or the community. Consequently, isolation hinders the development of juveniles making it extremely difficult for them to reintegrate into the community easily or productively.3

Additionally, author, Jessica Lee, highlights that solitary confinement also negatively impacts the physical growth of juveniles by restricting much needed exercise and nutrition.3

Reformation Efforts
The impact of juvenile solitary confinement has led to a call for reform by legislators and scientific scholars.3 Although some states have been successful in abolishing or reducing solitary confinement, it is still practiced within the juvenile penal system.4 This call for reform regarding solitary confinement has the potential to shift the juvenile justice system toward a more ethical and just model.

- Federal Reformation Efforts
U.S. Representative Cedric Richmond presented a bill calling for a study across the nation on
the impacts that solitary confinement has on mental health. The intent of this bill, known as the
Solitary Confinement Study and Reform Act of 2014, was to reduce the use of solitary
confinement.\(^3\) The bill died and was reintroduced to the House in 2015.

In 2015 Senator Cory Booker introduced, Maintaining Dignity and Eliminating Unnecessary
Restrictive Confinement of Youth, commonly known as the Mercy Act. The Mercy Act entails the
following:

1. Prohibits the use of solitary confinement of juveniles in federal custody, except for a
   maximum of three hours, if the juvenile harms any individual.
2. Requires that facilities first use less restrictive measures to control behavior before
   placing the juvenile into solitary.
3. If, after the maximum three hours of solitary have ended, the juvenile still poses a risk of
   physical harm to themselves or anyone else, then the juvenile can be transferred to a
different juvenile facility or “internal location” where he or she can be treated without the
use of solitary.

The Mercy Act was introduced to the Senate in 2017, but no further action has been taken.\(^3\)

- **State & Local Reformation Efforts**
  In the state of New York, legislators agreed to ban solitary confinement for inmates younger
  than 21 at Riker’s Island and implement a practice where inmates between the ages of 18-21
  undergo counseling and classes in a different facility as an alternative.\(^3\) The reason for this
  reform was to combat the psychological effects that solitary confinement has on young adults
  and youth. Other states have joined in on State and Local reformation with varying approaches
to the public health issue. For instance, in Pennsylvania mentally ill inmates will no longer be
placed in solitary confinement; instead, they will be placed in special treatment units.

Although these laws are progressive, they do not address all of the concerns about solitary
confinement among youth. There has been a huge push by activists and researchers for
Congress and the U.S. Department of Justice to bring forth uniformity across the nation’s
legislation to provide a standard and just approach to juvenile inmates regarding solitary
confinement in the U.S. prison system.\(^10\)

- **Educational Efforts**
  Many medical and research organizations, such as the National Alliance for Suicide Prevention,
have developed recommendations and interventions for “improving the level and quality of
collaboration between the juvenile and mental health systems, primarily for suicide
prevention.”\(^11\) These collaborative efforts are tailored to promoting education, awareness, and
prevention support and services for youth in the juvenile prison system. In these educational
programs, organizations and researchers identify protective factors to decrease mental illness
and suicide. In so doing, many organizations also are promoting data collection and inmate
screening/assessment tools to increase information on solitary confinement in an effort to better
understand and combat the psychological and social impacts of solitary confinement. More
information and knowledge will allow health care professionals and public health practitioners to
monitor the social development and health outcomes for inmates in juvenile facilities.\(^13\)

**Opposition To Reformation Efforts**
Despite evidence of deleterious effects of solitary confinement in the juvenile penal system,
there is still some opposition to reformation efforts. Opponents suggest that solitary confinement
serves pragmatic purposes. For example, when prisons are overloaded with inmates, there is
no physical space for them, or enough staff to run the prison. In this instance, solitary
confinement provides additional housing space for inmates.\(^12\) Others contend that solitary
confinement aids in the rehabilitation of character as it becomes a means of reflection for inmates. Another viewpoint is that solitary confinement offers prison safety for inmates who are a threat to staff, other inmates, or the public. Finally, some believe that solitary confinement provides guards/officers with the means to discipline and maintain order within the prison walls.

**Conclusion**

Nearly half of juveniles placed in the U.S. Prison system experience solitary confinement. As a result, the majority of these juveniles also have detrimental, long-lasting, physical and psychological health outcomes. Education, counseling, and rehab programs are all positive alternatives to solitary confinement that raises health outcomes for youth. Increased State and Federal legislation that actively opposes juvenile solitary confinement will not only positively impact youth outcomes, but society as well when inmates reintegrate into their communities. Opposing solitary confinement and restrictive housing would be a significant step forward in saving lives and improving health and well-being outcomes.

**American Osteopathic Association Policy**

Given the research surrounding the negative impacts of restrictive housing and solitary confinement, the American Osteopathic Association adopts the following policy statements as its official position on opposing restrictive housing and solitary confinement for juvenile inmates of the prison system in the U.S.:

1. The official position of the American Osteopathic Association (AOA) is that youth incarceration is meant to be rehabilitation and that the use of juvenile solitary confinement and/or restrictive housing imparts serious psychological and physical harms.
2. The American Osteopathic Association encourages increased research and data collection surrounding the prevalence of the use of solitary confinement/restrictive housing among juveniles.

**References**


Source: H628-A/19

Status: 2019
Policy Brief on Patient Matching

Overview:
As patient electronic health information can be more easily shared between physicians, health information exchanges, and payers, patient identification (patient matching) remains a persistent problem in ensuring that electronic health record (EHR) data is complete and accurate. Errors and missing information remain common in the electronic health record ecosystem, with approximately 8% of all records being split or duplicate. This error rate is higher (14% to 16%) within large health systems that store vast amounts of data for a large number of patients.\(^1\) When excluding matching within organizations to analyze patient matching rates between organizations, the match rate can drop to 50%.\(^2\) These high duplication and mismatch rates often translate into unnecessary resource use and poor outcomes when patient records are not up-to-date or contain inaccurate information. A 2016 report indicated that 4% of duplicate records result in negative clinical care and outcomes.

Robust and accurate information exchange is central to delivering high quality, cost effective care. Although it requires significant investment, improving patient matching rates will provide benefits to the greater healthcare system that extend far beyond individual encounters. Being able to effectively capture, track, and share data relating to patients’ social determinants of health is crucial to delivering high-value care management and promoting well-being outside of a hospital. Not only would accurate capture and sharing of patient data promote better care coordination once a patient is back in their community, but it also supports better population level analytics.\(^3\) Despite the need to improve patient matching, no clear standards for patient matching exist, and there are numerous legal and operational barriers to driving standardization across the healthcare landscape.

Past and Current Proposals
Policy efforts to improve the matching of patient records in an increasingly digital health care system date back to the mid-1990s. As part of the Health Information Portability and Accountability Act (HIPAA) in 1996, Congress directed the Department of Health and Human Services (HHS) to develop a unique identifier for each individual, employer, provider, and plan within the US healthcare system. However, following the passage of HIPAA, there was significant pushback against this provision due to privacy and security concerns. As a result, Congress walked back the proposal by inserting language into appropriations bills that prohibited HHS from using federal funds to develop unique patient identifiers (UPIs) for individuals.

As the number of digital patient records across the US health care system proliferates, it is becoming increasingly important that providers can de-duplicate records and effectively match them to the proper patient. As of March of 2019, as part of the HHS Centers for Medicare & Medicaid Services (CMS) and the Office of the National Coordinator’s (ONC) Proposed Rule on
Interoperability and Information Blocking, HHS is proposing to improve patient matching by establishing standards for EHR developers regarding demographic data elements necessary within EHRs for patient matching. The rule also includes a request for information on what data elements would be useful in ensuring accurate patient matching and whether national standards for patient identification would be useful. Without a UPI, the most effective way to ensure accuracy of matched patient records is through the use of social security numbers. A study published in Perspectives in Health Information Management asserts that creating a field for at least the last 4 digits of a patient’s social security number, and capturing a patient’s full middle name, would increase match accuracy substantially.4

**Challenges of Each Approach**

While there is a great amount of discussion around national standards for patient demographic data and the need for additional identifying information, there is disagreement on whether it would be more appropriate to encourage the use of social security numbers or to seek legislative action to create unique patient identifiers.

Inclusion of social security numbers in patient records would improve patient matching, and standards that require fields for social security numbers in EHRs would not require legislative action. However, various challenges exist to achieving widespread adoption of this practice. First, individuals are often reluctant to provide SSNs out of concern for identity theft. Under this approach, patients would likely have various records with different providers containing their SSNs, increasing their exposure to identity theft risk. Although this perceived risk may be marginal, the fear is likely to be a deterrent to patients offering this information. Second, many states outlaw the collection of social security numbers for health care purposes, and a federal standard that included SSN collection would not apply in these states. Third, as a result of federal legislation, Medicare now provides patients with Medicare cards and is actively shifting away from having patients provide social security numbers. Alternatively, the use of Medicare cards can improve patient matching for this particular population.5

As an alternative to social security numbers, various groups have proposed using different unique patient identifiers, including numbers that would be issued by CMS, encouraging the use of biometrics as an additional authenticator, or incorporating additional personal authenticators within patient records that patients would then confirm (personal questions or text message authentication). However, these changes would be costly to implement and there is no consensus on what approach would be best.

**Position of the AOA**

In light of the current debate regarding the most effective way to match patient data that does not present privacy and security risks, the AOA supports efforts to develop national standards with appropriate safe guards for authentication, and collection of patient demographic data. In order to make the sharing of patient data more efficient and accurate, all health care organizations must collect the same information and enter it in a standardized format. The AOA will support policies that will achieve standardization of identifying data in patient records.

Additionally, because patient health data is particularly sensitive information and patient records contain large amounts of identifying information, the AOA will support the strengthening of privacy and security standards for the certification of EHRs and application programming interfaces.
References

Source: H632-A/19

Status: 2019
Cooperation of the Veterans Administration and Non-VA Clinicians

Policy Statement

The American Osteopathic Association supports the development and implementation of methodology for the efficient and secure sharing of the data in patient records between all VA and Non-VA clinicians.

Source: H634-A/19

Status: 2019
Addressing the Gender Pay Gap in the Medical Profession

Policy Statement

The American Osteopathic Association (AOA) acknowledge the existence of the “gender pay gap” between male and female physicians in the United States; and, that AOA shall support the adoption of policies and practices that ensure the equitable compensation of physicians who work the same job regardless of gender.

Source: H638-A/19

Status: 2019
Dissemination of Publications in Osteopathic Research

Policy Statement

The American Osteopathic Association (AOA) will widely disseminate publications, research, and evidence based medicine regarding Osteopathic Medicine and Osteopathic Manipulative Treatment (OMT) and its anatomical and physiological basis to the greater public via prominent, designated public information sites, social networking, public information releases, websites, and other media.

Source: H600-A/20

Status: 2015; 2020 Reaffirmed
Proper Badge Identification of Employees in a Hospital Setting

Policy Statement

The American Osteopathic Association (AOA) encourages all healthcare providers and hospital employees to wear hospital-issued identification badges with clear delineation of their professional role and that they verbally introduce and identify themselves and their role in the patient’s treatment process, with the overall goal of improving patient safety and patient communication.

Source: H604-A/20

Status: 2015; 2020 Reaffirmed
Interoperability of Health Information Technology

Policy Statement

The American Osteopathic Association (AOA) supports a new risk-based oversight framework for clinical software, developed through a multi-stakeholder consensus-based process. The framework should take into account risk relative to intended use, cost/benefit of proposed oversight, and the principle of shared responsibility. Patient safety and appropriate improvements in quality, effectiveness, and efficiency of care delivery should be paramount. This framework should not conflict with or duplicate the medical device regulation framework. The AOA does not support data be treated as a medical device, regardless of the category of health it associated with the data. The AOA supports a national network for reporting patient safety events and other information vital to public health, where data can be accessed, analyzed, and communicated in a timely manner. The regulatory framework should promote interoperability, in order for clinical information systems to capture and share quality, outcome, cost, and patient healthcare data. To support coordinated health care and data analytics to promote transition to a value-based healthcare system, the AOA supports a common data structure that will enable interoperability, setting a clear course of action, federal support for an exchange infrastructure, and standards which will make it easier to share information so physicians and patients can make informed decisions.

The AOA will encourage public and private sector stakeholders to develop clinically driven, standardized products that are interoperable by design, do not require costly and time-consuming customization, and for which any upgrades or future needs can be integrated seamlessly without burdensome costs or system modifications. The AOA also supports standardization of prior authorization attachments to alleviate burden and reduce delays to care.

The AOA opposes vendors blocking health care professionals’ ability to access, view, share, or transfer data.
The AOA supports policies and technologies that facilitate person-centered health care.

The AOA will remain vigilant about mitigating the level of administrative burden posed by existing and new government policies.

Source: H605-A/20

Status: 2015; 2020 Reaffirmed
Gifts to Physicians from Industry

Policy Statement

The American Osteopathic Association (AOA) has adopted the following “Guide to Section 17 of the AOA Code of Ethics” as follows and will distribute this information to students of osteopathic medicine and osteopathic physicians.

1. Physicians’ responsibility is to provide appropriate care to patients. This includes determining the best pharmaceuticals to treat their condition. This requires that physicians educate themselves as to the available alternatives and their appropriateness so they can determine the most appropriate treatment for an individual patient. Appropriate sources of information may include journal articles, continuing medical education programs, and interactions with pharmaceutical representatives.

2. It is ethical, for osteopathic physicians to meet with pharmaceutical companies and their representatives for the purpose of product education, such as, side effects, clinical effectiveness and ongoing pharmaceutical research.

3. Pharmaceutical companies may offer gifts to physicians from time to time. These gifts should be appropriate to patient care or the practice of medicine. Gifts unrelated to patient care are generally inappropriate. The use of a product or service based solely on the receipt of a gift shall be deemed unethical.

4. When a physician provides services to a pharmaceutical company, it is appropriate to receive compensation. However, it is important that compensation be in proportion to the services rendered. Compensation should not have the appearance of a relationship to the physician’s use of the company’s products in patient care.

Source: H606-A/20

Physician Competency Retesting

Policy Statement

The American Osteopathic Association (AOA):

(1) Supports the mission of physician competency, the quality movement and patient safety through self-regulation mechanisms rather than through government mandated retesting for purposes of obtaining re-licensure or for receiving payment under a health benefits program.

(2) Continue its voluntary efforts to address and promote physician competency through the teaching of core competencies at the predoctoral and postdoctoral levels, physician assessment through osteopathic continuous certification.

Source: H607-A/20

Health Plan Coverage of Tobacco Cessation Treatment

Policy Statement

The American Osteopathic Association (AOA) encourages all health plans to follow tobacco cessation recommendations of the Centers for Disease Control and Prevention (CDC) and encourages all health care plans to accept CPT, and ICD-10 codes for tobacco use as legitimate codes for payment for services provided for these codes.

Source: H608-A/20

Status: 2010; 2015 Reaffirmed as Amended; 2020 Reaffirmed
Provider Tax

Policy Statement

The American Osteopathic Association (AOA) opposes any effort by a state or the federal government to impose a provider tax of any type.

Source: H611-A/20

Status: 2010; 2015 Reaffirmed; 2020 Reaffirmed
Medicaid Payment

Policy Statement

The American Osteopathic Association (AOA) supports the efforts in each state to uphold their obligation to pay physicians and hospitals at a fair and equitable rate for providing quality care to the state’s Medicaid recipients

Source: H612-A/20

Status: 2010; 2015 Reaffirmed as Amended; 2020 Reaffirmed as Amended
Lay Midwives

Policy Statement

The American Osteopathic Association (AOA) opposes the licensing of lay midwives and will continue providing support to affiliate societies in opposing state’s efforts to license lay midwives.

Source: H613-A/20

Status: 2010; 2015 Reaffirmed; 2020 Reaffirmed
Electronic Health Records – Physician Assistance Programs for Transition to

Policy Statement

The American Osteopathic Association (AOA) will continue to support solo practice physicians and small-group practices in the adoption of health information technology (HIT). The AOA supports incentives or enhanced payments for adoption of innovative hit that improves care delivery, coordination, and value.

Source: H615-A/20

Status: 2005; 2010 Revised; 2015 Reaffirmed as Amended; 2020 Reaffirmed as Amended
Pediatric Psychiatric Care Health Records

Policy Statement

The American Osteopathic Association supports the development of educational programs to assist primary care physicians to identify and initiate appropriate support of pediatric psychiatric care and encourages insurance providers to adequately reimburse counseling and psychiatric care deemed necessary by the patient’s primary care physician.

Source: H617-A/20

Status: 2005; 2010 Reaffirmed; 2015; 2020 Reaffirmed
Attention Deficit Disorder / Attention Deficit Hyperactivity Disorder

Policy Statement

The American Osteopathic Association (AOA) urges insurance carriers to provide coverage for attention deficit disorder/attention deficit hyperactivity disorder (ADD/ADHD) patients by primary care physicians.

Source: H618-A/20

Status: 2005; 2010 Reaffirmed; 2015; 2020 Reaffirmed
Veterans Administration Credentialing of Non-Physician Providers Health Records

Policy Statement

The American Osteopathic Association (AOA) supports the establishment of well-defined credentialing and privileging criteria within the Veterans Administration (VA) that prohibits non-physician providers with expanded scope of practice rights in a minority of states from demanding such privileges in the VA system and supports the establishment of a consistent requirement for the privileging of non-physician providers in the VA system.

Source: H621-A/20

Status: 2005; 2010 Reaffirmed; 2015; 2020 Reaffirmed
Tax Credits for Health Profession Shortage Areas

Policy Statement

The American Osteopathic Association (AOA) supports the establishment of tax credits for physicians who practice full time in federally designated health professions shortage areas (HPSAs) or Medicare defined physician scarcity areas and federally and/or state designated underserved areas and urges that these tax credits be available, on a sliding scale, to physicians who provide services on a part-time basis in these communities.

Source: H622-A/20

Status: 2005; 2010 Reaffirmed; 2015; 2020 Reaffirmed
Prescription of Drugs for Off Label Uses

Policy Statement

The American Osteopathic Association (AOA) believes it is appropriate for physicians to prescribe approved drugs for uses not included in their official labeling when they can be supported as accepted medical practice.

Source: H624-A/20

Newborn and Infant Hearing Screens

Policy Statement

The American Osteopathic Association (AOA) supports adequate funding for universal hearing screening and intervention for newborns and infants.

Source: H625-A/20

Medicare Preventive Medical Screening

Policy Statement

The American Osteopathic Association (AOA) supports coverage of Medicare recipients for routine preventive medical services.

Source: H626-A/20

Confidentiality of Patient Records

Policy Statement

The American Osteopathic Association (AOA) opposes invasion of privacy of the patient record by any unauthorized person or agency; and endorses reasonable programs which seek to protect patient/physician relationships and guarantee confidentiality of patient records.

Source: H627-A/20

Diabetics Confined to Correctional Institutions

Policy Statement

The American Osteopathic Association supports the availability of American Diabetes Association (ADA) diabetic meals, beverages, and other diabetic interventions that follow ADA guidelines for all imprisoned persons with diabetes, who are under the care of a licensed physician, and confined in correctional institutions.

Source: H628-A/20

Status: 2000, 2005 Revised; 2010 Reaffirmed; 2015; 2020 Reaffirmed
Executions in Capital Crimes Criminal Cases

Policy Statement

The American Osteopathic Association deems it an unethical act for any osteopathic physician to deliver or be required to deliver a lethal injection for the purpose of execution in capital crimes.

Source: H630-A/20

Managed Care – All Products Clauses

Policy Statement

The American Osteopathic Association and state osteopathic societies oppose the use of “all products/all products developed in the future” clauses in physician managed care contracts; actively opposes the use of any other clauses that may limit the ability of the physician to choose the plans in which he or she participates; and supports both state and federal legislation as well as regulatory agency regulations and rulings to prohibit the use of “all products/all products developed in the future” clauses in physician managed care contracts.

Source: H631-A/20

Status: 2000; 2005 Revised; 2010 Reaffirmed; 2015; 2020 Reaffirmed
Medical Procedure Patents

Policy Statement

The American Osteopathic Association (AOA) supports measures that restrict medical procedure patents.

Source: H632-A/20

Osteopathic Manipulative Treatment (OMT) Coverage Determination Guidance

Policy Statement

The American Osteopathic Association (AOA) approves the attached policy as the standard guidelines for OMT coverage and encourages all public and private payers to refer to the AOA’s policy when developing new policy or revising existing guidance for OMT coverage.

American Osteopathic Association (AOA) Policy on Osteopathic Manipulative Treatment (OMT)

Introduction to OMT

Osteopathic manipulative treatment (OMT) is a distinct medical procedure used by physicians (DOs/MDs) to treat somatic dysfunction or other conditions. The American Association of Colleges of Osteopathic Medicine (AACOM) Glossary of Osteopathic Terminology defines OMT as the therapeutic application of manually guided forces by a physician to improve physiologic function and/or support homeostasis that has been altered by somatic dysfunction. Somatic dysfunction in one region may lead to compensatory somatic dysfunction in other regions. The AACOM Glossary of Osteopathic Terminology defines somatic dysfunction as:

- Impaired or altered function of related components of the somatic (body framework) system: skeletal, arthrodial and myofascial structures, and their related vascular, lymphatic, and neural elements. Somatic dysfunction is treatable using osteopathic manipulative treatment. The positional and motion aspects of somatic dysfunction are best described using at least one of three parameters: 1). The position of a body part as determined by palpation and referenced to its adjacent defined structure, 2). The directions in which motion is freer, and 3). The directions in which motion is restricted.

Osteopathic manipulative treatment can also be used to treat the somatic component of visceral disease and any organ system, which has the potential to manifest as changes in the skeletal, arthrodial and myofascial tissues. (Example: tight right shoulder muscles in a patient with gallbladder disease). Normalizing musculoskeletal activity (relaxing tense muscles, etc.) can normalize outflows through sympathetic or parasympathetic autonomic nervous systems to visceral systems, resulting in more normal visceral and any organ system function. Somatic dysfunction is identified on the physical exam by one or more elements of TART (Tissue texture changes, positional Asymmetry, Range of motion alterations, or changes in palpatory sensitivity, e.g., Tenderness).

Provider Types Qualified to Perform OMT

To perform OMT a qualified Doctor of Osteopathic Medicine must have graduated from an accredited school of osteopathic medicine or a medical doctor must have completed a board-approved postgraduate osteopathic training program that encompasses osteopathic principles and practices, including hands-on demonstration and competency testing in OMT.

OMT Payment:

---

The decision to utilize osteopathic manipulative treatment (OMT) as part of the overall health care of patients is made on a visit-by-visit basis. As such, it is typical to perform a history and physical examination on initial and subsequent encounters. Based on the history and findings of the physical examination, the physician may decide to use OMT as part of the overall care of the patient. OMT is a paid service when somatic dysfunction is documented in the history and/or the physical examination. OMT is not paid when somatic dysfunction is absent from the patient’s history or physical examination documentation. The method of OMT employed by the physician is determined by the patient’s condition, age and the effectiveness of previous methods of treatment.

**OMT Documentation**

The medical record documentation should include a history and physical. If an E/M service is being reported on the same day as OMT, the documentation should clearly distinguish the services that constitute the E/M service and the OMT service. The documentation should clearly identify the body regions affected and treated with OMT in order to support the procedure code(s) reported.

The selection of body region(s) to which OMT is applied should reflect the region(s) of documented somatic dysfunction. There may be instances when multiple regions are treated due to the occurrence of compensatory changes. When this occurs, the documentation should describe the compensatory changes and the rationale for treating this area, especially if the patient has no complaints related to this area. Treatment should be directed to the areas of documented somatic dysfunction and should not be aimed at areas unrelated to the diagnosis. The type, frequency and duration of OMT should be consistent with current standards of medical practice.

Factors that may affect frequency and duration of treatment are: severity of illness, duration or chronicity of the patient’s condition and the presence of co-morbidities. These factors should be reflected in the medical record if they contribute to the physician’s treatment approach.

The American Osteopathic Association strongly recommends that documentation include a procedure note to detail the regions manipulated, the techniques utilized, and a description of how the patient tolerated the treatment.

**OMT Vignettes and Coding Examples**

In April 2010, the American Medical Association (AMA) Relative Value Update Committee (RUC) requested that the AOA survey the existing OMT codes to develop accurate and unbiased information for the relative value of the physician work involved in performing OMT as part of the Centers for Medicaid and Medicare Services (CMS) forth fifth year review of RBRVS. The survey process required the creation of vignettes to describe the typical patient for OMT CPT® Codes 98925-98929. Additionally, the description of the preservice, intraservice, and postservice work for OMT was included. As of January 2012, the vignettes for the typical patient and the preservice, intraservice and postservice descriptors are contained within the RUC database.

There are five OMT Service Current Procedural Terminology (CPT©) Codes (98925-98929). Below find the vignettes, description for the preservice, intraservice and postservice work and coding examples for the OMT codes 98925-98929.

**Note:** The OMT service codes do not include any elements of the history, examination and medical decision making.
OMT Service Code 98925: Osteopathic manipulative treatment (OMT); to one to two body regions defined.
Vignette:
A 25-year-old female presents with right lower neck pain of two weeks duration. Somatic dysfunction of cervical and thoracic regions are identified on exam.
Description of Preservice Work:
The physician determines which osteopathic techniques (e.g., HVLA, muscle energy, counterstrain, articulatory, etc.) would be most appropriate for this patient, in what order the affected body regions need to be treated and whether those body regions should be treated with specific segmental or general technique approaches. The physician explains the intended procedure to the patient, answers any preliminary questions, and obtains verbal consent for the OMT. The patient is placed in the appropriate position on the treatment table for the initial technique and region(s) to be treated.

Description of Intraservice Work:
Patient is initially in the supine position on the treatment table. Motion restrictions of C6 and C7 are isolated through palpation and treated using muscle energy technique. Dysfunctions of T1 and T2 are treated using passive thrust (HVLA) technique. Patient position is changed as necessary for treatment of the individual somatic dysfunctions. Patient feedback and palpatory changes guide further technique application as appropriate.

Description of Postservice Work:
Post-care instructions related to the procedure are given, including side effects, treatment reactions, self-care, and follow-up. The procedure is documented in the medical record.

OMT Service Code 98926: Osteopathic manipulative treatment (OMT); 3-4 body regions involved
Vignette:
A 39-year-old female presents with right lower back pain of two weeks duration after a lifting injury. Somatic dysfunction of lumbar, pelvis and sacral regions are identified on exam.

Description of Pre-Service Work:
The physician determines which osteopathic techniques (e.g., HVLA, Muscle energy, Counterstrain, articulatory, etc., for a complete list of techniques see the American Association of Colleges of Osteopathic Medicine Glossary of Osteopathic Terminology) would be most appropriate for this patient, in what order the affected body regions need to be treated and whether those body regions should be treated with specific segmental or general technique approaches. The physician explains the intended procedure to the patient, answers any preliminary questions, and obtains verbal consent for the OMT. The patient is placed in the appropriate position on the treatment table for the initial technique and region(s) to be treated.

Description of Intra-Service Work:
The patient is initially in the prone position on the treatment table. Motion restrictions of sacrum and pelvis are isolated through palpation and treated using muscle energy and articulatory techniques. Dysfunctions of L1 and L5 are treated using passive thrust (HVLA) technique. Patient position is changed as necessary for treatment of the individual somatic dysfunctions. Patient feedback and palpatory changes guide further technique application as appropriate.

Description of Post-Service Work:
Post-care instructions related to the procedure are given, including side effects, treatment reactions, self-care, and follow-up. The procedure is documented in the medical record.
OMT service code 98927: Osteopathic manipulative treatment (OMT); five to six body regions defined.
Vignette:
A 17-year-old male presents with pain in the neck, upper and lower back, right shoulder, and right chest following an injury in a high school football game two days ago. Somatic dysfunctions of the right glenohumeral and acromioclavicular joints, as well as the lower cervical, upper thoracic, right upper costal and lumbar areas are identified on exam.
Description of Preservice Work:
The physician determines which osteopathic techniques (eg, HVLA, muscle energy, counterstrain, articulatory, etc) would be most appropriate for this patient, in what order the affected body regions need to be treated and whether those body regions should be treated with specific segmental or general technique approaches. The physician explains the intended procedure to the patient, answers any preliminary questions, and obtains verbal consent for the OMT. The patient is placed in the appropriate position on the treatment table for the initial technique and region(s) to be treated.
Description of Intraservice Work:
The patient is initially in a side-lying position on the treatment table. Motion restrictions of identified joints are isolated through palpation and treated using a variety of techniques as follows: acromioclavicular joint is treated with articulatory technique; glenohumeral and costal dysfunctions are treated with muscle energy technique; cervical spine is treated with counterstrain technique; thoracic and lumbar dysfunctions are treated with passive thrust (HVLA) technique. Patient position is changed as necessary for treatment of the individual somatic dysfunctions. Patient feedback and palpatory changes guide further technique application as appropriate.
Description of Postservice Work:
Post-care instructions related to the procedure are given, including side effects, treatment reactions, self-care, and follow-up. The procedure is documented in the medical record.

OMT service code 98928: Osteopathic manipulative treatment (OMT); seven to eight body regions defined.
Vignette:
A 64-year-old female, in rehabilitation following a left total knee replacement, presents with swelling in the left lower leg, pain in her low back, hips and pelvis with muscle spasms and numbness and bilateral wrist pain with use of a walker. She has a history of widespread degenerative joint disease with stiffness and pain making it difficult for her to actively participate in her rehabilitation program. Somatic dysfunctions of the lumbar, thoracic and cervical spine, sacrum, pelvis, right leg, and bilateral wrist joints are identified on exam.
Description of Preservice Work:
The physician determines which osteopathic techniques (eg, HVLA, muscle energy, counterstrain, articulatory, etc) would be most appropriate for this patient, in what order the affected body regions need to be treated and whether those body regions should be treated with specific segmental or general technique approaches. The physician explains the intended procedure to the patient, answers any preliminary questions, and obtains verbal consent for the OMT. The patient is placed in the appropriate position on the treatment table for the initial technique and region(s) to be treated.
Description of Intraservice Work:
The patient is initially in the supine position on the treatment table. Motion restrictions of identified joints are isolated through palpation and treated using a variety of techniques as follows: radiocarpal joints are treated using articulatory and myofascial release techniques; dysfunctions of L3, L5 and SI joints are treated using balanced ligamentous
tension technique; dysfunction of C5 through T3, the pelvis and lower extremity are treated with muscle energy technique. Lower extremity edema is treated with lymphatic drainage techniques. Patient position is changed as necessary for treatment of the individual somatic dysfunctions. Patient feedback and palpatory changes guide further technique application as appropriate.

Description of Postservice Work:
Post-care instructions related to the procedure are given, including side effects, treatment reactions, self-care, and follow-up. The procedure is documented in the medical record.

**OMT service code 98929**: Osteopathic manipulative treatment (OMT); nine to ten body regions defined.

**Vignette:**
A 40-year-old male presents with sub-occipital headache, and pain in the neck, upper and lower back, left shoulder and chest, and right ankle. He was involved in a rear-end MVA two weeks ago. X-rays in the ED were negative. He has been taking prescribed analgesic and muscle relaxant medications with minimal improvement. On examination, somatic dysfunction is identified at the occipitoatlantal, left glenohumeral and right tibiotalar joints, as well as the cervical, thoracic, costal, lumbar, sacral and pelvic regions.

Description of Preservice Work:
The physician determines which osteopathic techniques (eg, HVLA, muscle energy, counterstrain, articular, etc) would be most appropriate for this patient, in what order the affected body regions need to be treated and whether those body regions should be treated with specific segmental or general technique approaches. The physician explains the intended procedure to the patient, answers any preliminary questions, and obtains verbal consent for the OMT. The patient is placed in the appropriate position on the treatment table for the initial technique and region(s) to be treated.

Description of Intraservice Work:
Patient is initially in the supine position on the treatment table. Motion restrictions of identified joints are isolated through palpation and treated using a variety of techniques as follows: occipitoatlantal joint and sacrum are treated using muscle energy and counterstrain techniques; right glenohumeral joint and pelvis are treated with articular/technique; lumbar, thoracic, cervical and right ankle are treated with passive thrust (HVLA) technique; costal dysfunctions are treated using muscle energy technique. Patient position is changed as necessary for treatment of the individual somatic dysfunctions. Patient feedback and palpatory changes guide selection of further technique application as appropriate.

Description of Postservice Work:
Post-care instructions related to the procedure are given, including side effects, treatment reactions, self-care, and follow-up. The procedure is documented in the medical record.

**Documenting the Patient Visit: S.O.A.P. Note Example**:

Below is an example of a new and established patient encounter and a subjective, objective, assessment and plan (S.O.A.P) note for each to illustrate how to document the patient’s visit in the medical record. Other styles and preferences exist for medical record documentation.

---

Soap Note – New Patient Example
S. A 20-year-old African-American male complains of low back pain that began three days ago after he lifted a heavy object. Cannot straighten up when walking, pain with change of position. The patient denies radiation of pain and areas of numbness, the pain stays along the back and waist. He is comfortable when lying down, aspirin helps some, has used heat with some help. No prior history of back pain or injury. Denies allergies, medical/surgical history is unremarkable.
O. Tenderness noted over lumbar and sacral regions Inability to extend lumbar spine when standing Flexion posture when standing Muscle spasms noted in paraspinals of the lumbar region Decreased range of motion of lumbar spine and sacrum was noted on active and passive motion testing Neurologic exam normal.
A. 1. Lumbosacral sprain/strain 846.0/533.8XXA
   2. Somatic dysfunction lumbar, sacral 739.3/M00.03 739.4/M99.04
P. 1. OMT (appropriate techniques used) applied to the lumbar and sacral regions
   2. Continue aspirin
   3. No lifting, bending or twisting
   4. Follow up in two days to reevaluate patient progress

CODING FOR THIS CASE
Evaluation and Management: new patient 99203
OMT two body regions: lumbar/sacral 98925

Soap Note–Established Patient Example
S: Patient presents to the office for a reevaluation of lower back pain. He states that the pain has decreased in his low back and that he can get around better. He states that he has no radiation of pain in his legs. He does state that he feels stiff and achy if he tries to do his normal daily activities. He is still taking aspirin with some relief. Denies GI symptoms from aspirin use.
O. Tenderness with palpation and stretch of the erector spinae muscles
   Pain with extension and rotation left of L5
   Pain along right SI joint with sacral extension
   Motion restrictions of lower lumbar vertebrae and sacrum identified
   No muscle spasms noted with active or passive range of motion
   Negative neurological exam of lower extremities
A. 1. Lumbosacral sprain/strain 846.0/533.8XXA
   2. Somatic dysfunction lumbar, sacral 739.3/M00.03 739.4/M99.04
P. 1. OMT (appropriate techniques used) applied to the lumbar and sacral regions
   2. Instructed on proper posture when lifting
   3. Increased home activities gradually and to tolerance
   4. Follow up if improvement does not continue

CODING FOR THIS CASE
Evaluation and Management: established 99213
OMT two body regions: lumbar/sacral 98925

Reporting E/M Services:

Patients present to the office on the initial or a subsequent encounter to address complaints of pain, strains or other signs or symptoms or to address unresolved issues. As such, an E/M service is provided on the initial and subsequent encounter. Patients do not present to the office for OMT.

The E/M service is a separate service from the OMT service, both are separately reportable and payable. Make sure to document the three key components (history, examination and medical
decision making). If utilizing an electronic health record (EHR), ensure that it is capable of capturing all of the history, physical examination and medical decision making and any other service(s) provided on each patient visit.

Per CPT © guidance Evaluation and Management services may be reported separately using Modifier- 25 if the patient’s condition requires a significant, separately identifiable E/M service above and beyond the usual preservice and postservice work associated with the (OMT) procedure. The E/M service may be caused or prompted by the same symptoms or condition for which the OMT service was provided. As such, different diagnoses are not required for reporting of the OMT and E/M service on the same date.

Below find the description for the preservice, intraservice and postservice work for the E/M Service Code most frequently reported to CMS in CY 2013. The descriptions illustrate the work of the E/M service is significantly, separately, identifiable and above and beyond the usual preservice and postservice work of the OMT service.

**E/M service code 99213:** Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components:

**Description of Pre-Service Work:**

Review the medical history form completed by the patient and vital signs obtained by clinical staff.

**Description of Intra-Service Work:**

- Obtain an expended problem focused history (including response to treatment at last visit and reviewing interval correspondence or medical records received)*
- Perform an expended problem focused examination*
- Consider relevant data, options, and risks and formulate a diagnosis and develop a treatment plan (low complexity medical decision making)*
- Discuss diagnosis and treatment options with the patient
- Address the preventive health care needs of the patient
- Reconcile medication(s) o Write prescription(s) o Order and arrange diagnostic testing or referral as necessary

**Description of Post-Service Work:**

- Complete the medical record documentation
- Handle (with the help of clinical staff) any treatment failures or adverse reactions to medications that may occur after the visit
- Provide necessary care coordination, telephonic or electronic communication assistance, and other necessary management related to this office visit
- Receive and respond to any interval testing results or correspondence
- Revise treatment plan(s) and communicate with patient, as necessary

**OMT Coding Information:**

CPT/HCPCS Codes
ICD-9/ICD-10 Diagnosis Codes

ICD-9 Codes:

739.0 Head region
739.1 Cervical region
739.2 Thoracic region
739.3 Lumbar region
739.4 Sacral region
739.5 Pelvic region
739.6 Lower extremities
739.7 Upper extremities
739.8 Rib cage region
739.9 Abdomen and viscera region

ICD-10 Codes:

M99.00 Segmental and somatic dysfunction of head region
M99.01 Segmental and somatic dysfunction of cervical region
M99.02 Segmental and somatic dysfunction of thoracic region
M99.03 Segmental and somatic dysfunction of lumbar region
M99.04 Segmental and somatic dysfunction of sacral region
M99.05 Segmental and somatic dysfunction of pelvic region
M99.06 Segmental and somatic dysfunction of lower extremity
M99.07 Segmental and somatic dysfunction of upper extremity
M99.08 Segmental and somatic dysfunction of rib cage
M99.09 Segmental and somatic dysfunction of abdomen and other regions
OMT Techniques are listed below (Please refer to the AACOM Glossary of OMT Terminology for more information)

Active method
Articulatory method
Articulatory treatment
Articulatory (ART)
Balanced ligamentous tension (BLT)
Chapman reflex
Combined method
Combined treatment
Compression of the forth ventricle (CV-4)
Counterstrain (CS)
Cranial Treatment (CR)
CV-4
Dalrymple treatment
Direct method
Exaggeration method
Exaggeration technique
Facilitated oscillatory release technique (FOR)
Facilitated positional release (FPR)
Fascial release treatment
Fascial unwinding
Functional method
Galbreath treatment
Hepatic pump
High velocity/low amplitude technique
Hoover technique
Indirect method (I/IND)
Inhibitory pressure technique
Integrated neuromusculoskeletal release
Jones technique
Ligamentous articular strain technique (LAS)
Liver pump
Lymphatic pump
Mandibular drainage technique
Mesenteric release technique
Muscle energy
Myofascial release (MFR) direct and indirect
Myofascial technique
Myotension
Osteopathic in the Cranial Field (OCF)
Passive method
Pedal pump
Percussion vibrator technique
Positional technique
Progressive inhibition of neuromuscular structure (PINS)
Range of motion technique
Soft tissue technique
Spencer technique
Splenic pump technique
Spontaneous release by positioning
Springing technique
Still technique
Strain-Counterstrain®
Thoracic pump
Thrust technique (HVLA)
Toggle technique
Traction technique
V-spread
Ventral techniques

Sources of Information

American Medical Association (AMA) Relative Value Update Committee (RUC) Database

Source: H635-A/20

Status: 2015; 2020 Reaffirmed
Non-Physician Clinicians

Policy Statement

The American Osteopathic Association (AOA) has adopted the attached policy paper as its position on non-physician clinicians including appropriate onsite supervision.

Over the course of the past century, scientific and technological advancements have led to improvements in the treatment of disease and standards of patient care. As a result, the standardized medical education, supervised postgraduate (“residency”) training and examination series that physicians in the United States are required to complete in order to obtain an unlimited medical license has increased as well. At the same time, however, some states are creating legislative pathways to independent medical practice for other types of clinicians, despite the absence of nationally standardized education, training and testing pathways for these clinician groups, or evidence regarding patient safety outcomes.

The current DO/MD medical model, in which medical students and resident physicians are required to demonstrate their ability to safely provide care to patients under the supervision of fully licensed physicians, leading to greater autonomy over time, has proven its ability to provide physicians with the complete knowledge and skill base needed to ensure patient safety and optimize outcomes. In addition, most states impose additional continuing medical education (CME) requirements, and many physicians elect to undergo rigorous certifying board examinations to demonstrate excellence in a particular specialty, which helps to ensure that physicians remain trained to provide the current highest standard of patient care over the course of their careers.

Thus, it is appropriate that the practice of medicine and the quality of medical care are remain the responsibility of properly licensed physicians, who are the only clinician group properly trained, licensed and regulated according to uniform laws governing medical licensure in the United States. The American Osteopathic Association (AOA) further values the unique training and contributions of all members of the patient care team and supports the concept of uniform licensure pathways for non-physician all clinician groups, based upon scope of practice. The AOA further supports appropriate physician involvement in patient care provided by non-physician clinicians and opposes any legislation or regulations which would authorize the independent practice of medicine by an individual who has not completed the state’s requirements for physician licensure.

As non-physician clinicians continue to seek wider roles, public policy dictates that patient safety and proper patient care should be foremost in mind when the issues encompassing expanded practice rights for non-physician clinicians – autonomy, scopes of practice, prescriptive rights, liability and reimbursement, among others – are addressed.

A. Patient Safety. The AOA supports the “team” approach to medical care, with the physician as the leader of that team. The AOA further supports the position that patients should be made clearly aware at all times whether they are being treated by a non-physician clinician or a physician. The AOA recognizes the growth of non-physician clinicians and supports their rights
to practice with appropriate physician involvement within the scope of the relevant state statutes.

B. Independent Practice. It is the AOA’s position that roles within the “team” framework must be clearly defined, through established state-level supervisory protocols and signed agreements, so physician involvement in patient care is sought when a patient’s case dictates and patients can rest assured that physician involvement in their care will remain the same regardless of practice setting within the state. The AOA feels nonphysician clinician professions that have traditionally been under the supervision of physicians must retain physician involvement in patient care. Those non-physician clinician professions that have traditionally remained independent of physicians must involve physicians in patient care when warranted. Further, all non-physician clinicians must refer a patient to a physician when the patient’s condition is beyond the non-physician clinician’s scope of education, training or expertise.

C. Liability. The AOA endorses the view that physician liability for non-physician clinician actions should be reflective of the quality and degree of supervision being provided and should not exonerate the non-physician clinician from liability. It is the AOA’s position that non-physician clinicians acting providing care in independent practice states autonomously of physicians should be regulated and disciplined by the entities responsible for regulating and disciplining physicians (i.e. state medical boards), to ensure that all clinicians who are independently practicing medicine are held to the same standard of care and the equivalent degree of liability as that of a physician. Within this independent practice framework, to that end, the AOA further also believes that non-physician clinicians should be required to obtain equivalent malpractice insurance in those states that currently require to physicians in states that currently require physicians to possess malpractice insurance.

Source: H640-A/20

Status: 2000, 2005 Revised; 2010 Revised; 2015 Reaffirmed; 2018 Revised; 2020 Reaffirmed as Amended
Prior Authorization

Policy Statement

The American Osteopathic Association has adopted the attached policy paper as its position on non-physician clinicians including appropriate onsite supervision.

Over the course of the past century, scientific and technological advancements have led to improvements in the treatment of disease and standards of patient care. As a result, the standardized medical education, supervised postgraduate ("residency") training and examination series that physicians in the United States are required to complete in order to obtain an unlimited medical license has increased as well. At the same time, however, some states are creating legislative pathways to independent medical practice for other types of clinicians, despite the absence of nationally standardized education, training and testing pathways for these clinician groups, or evidence regarding patient safety outcomes.

The current DO/MD medical model, in which medical students and resident physicians are required to demonstrate their ability to safely provide care to patients under the supervision of fully licensed physicians, leading to greater autonomy over time, has proven its ability to provide physicians with the complete knowledge and skill base needed to ensure patient safety and optimize outcomes. In addition, most states impose additional continuing medical education (CME) requirements, and many physicians elect to undergo rigorous certifying board examinations to demonstrate excellence in a particular specialty, which helps to ensure that physicians remain trained to provide the current highest standard of patient care over the course of their careers.

Thus, it is appropriate that the practice of medicine and the quality of medical care remain the responsibility of physicians, who are the only clinician group properly trained, licensed and regulated according to uniform laws governing medical licensure in the United States. The American Osteopathic Association (AOA) values the unique training and contributions of all members of the patient care team and supports the concept of uniform licensure pathways for all clinician groups, based upon scope of practice. The AOA further supports appropriate physician involvement in patient care provided by non-physician clinicians, and opposes any legislation or regulations which would authorize the independent practice of medicine by an individual who has not completed the state’s requirements for physician licensure.

As non-physician clinicians continue to seek wider roles, public policy dictates that patient safety and proper patient care should be foremost in mind when the issues encompassing expanded practice rights for non-physician clinicians – autonomy, scopes of practice, prescriptive rights, liability and reimbursement, among others – are addressed.

A. Patient Safety. The AOA supports the “team” approach to medical care, with the physician as the leader of that team. The AOA further supports the position that patients should be made clearly aware at all times whether they are being treated by a non-physician clinician or a physician. The AOA recognizes the growth of non-physician clinicians and supports their rights to practice with appropriate physician involvement within the scope of relevant state statutes.
B. Independent Practice. It is the AOA’s position that roles within the “team” framework must be clearly defined, through established state-level supervisory protocols and signed agreements, so physician involvement in patient care is sought when a patient’s case dictates and patients can rest assured that physician involvement in their care will remain the same regardless of practice setting within the state. Further, all non-physician clinicians must refer a patient to a physician when the patient’s condition is beyond the non-physician clinician's scope of education, training or expertise.

C. Liability. The AOA endorses the view that physician liability for non-physician clinician actions should be reflective of the quality and degree of supervision being provided and should not exonerate the non-physician clinician from liability. It is the AOA’s position that non-physician clinicians providing care in independent practice states should be regulated and disciplined by the entities responsible for regulating and disciplining physicians (i.e. state medical boards), to ensure that all clinicians who are independently practicing medicine are held to the same standard of care and the equivalent degree of liability. To that end, the AOA also believes that non-physician clinicians should be required to obtain equivalent malpractice insurance to physicians in states that currently require physicians to possess malpractice insurance.

Source: H642-A/20

Status: 2020
Postpartum Depression

Policy Statement

The American Osteopathic Association (AOA) encourages its members to participate in continuing medical education programs on postpartum depression (PPD); urges colleges of osteopathic medicine (COMs) and osteopathic state and specialty associations to offer CME on PPD as part of their educational offerings; and endorses the use of screening tools and encourage the measurement of outcomes in their use.

Source: H646-A/20

Status: 2003; 2008; 2013 Reaffirmed as Amended; 2020 Reaffirmed
Managed Care Plans – Service, Access and Costs in

Policy Statement

The American Osteopathic Association (AOA) supports efforts to expand the use of variable co-pays that support program costs. The AOA also supports efforts to design benefits that align consumer needs, accountability and individual physician incentives.

Source: H647-A/20

Status: 1999; 2004 Revised; 2009 Reaffirmed as Amended; 2014 Reaffirmed as Amended; Reaffirmed.
The American Osteopathic Association (AOA) encourages independent research on the qualification and outcomes of nurse practitioners and other midlevel providers that practice independently; and that the AOA research & public health staff perform an analysis of current, valid and published research on clinical outcomes, resource utilization and malpractice experience for independently practicing NPS and PAS and provide this information to osteopathic physicians.

Source: H648-A/20

Status: 2020 Reaffirmed as Amended
Support the Bolstering of Veteran Health Administration Resources through Provider Pay Reform

Policy Statement

The American Osteopathic Association (AOA) support both staffing management and competitive pay reform at the Veterans' Health Administration (VHA) to ensure that a full, stable workforces, as budgeted by the Department of Veterans Affairs, is available to meet the health needs of the United States veteran population.

Source: H649-A/20

Status: 2020
A Proclamation Regarding the Inaccurate Portrayals of US Trained DOs in Media

Policy Statement

The leadership and members of the American Osteopathic Association (AOA) condemn the poorly researched and patently incorrect statements regarding the scope of practice of U.S. trained DOs made by journalists.

Proclaimed, that the American Osteopathic Association will continue ongoing efforts using social media and other means to educate the public and dispel inaccuracies of U.S. trained DOs; and that the American Osteopathic Association encourages its members, affiliated organizations, our patients and our Allopathic colleagues to use social media and other means to accurately represent the profession of Osteopathic Medicine to the public.

The American Osteopathic Association will continue to provide online resources and support to its members and advocates to develop a grassroots social media campaign to further the understanding of the profession of Osteopathic Medicine by the public; and that the American Osteopathic Association on behalf of the osteopathic profession expresses appreciation and gratitude to the journalists, organizations, and other persons that support an accurate portrayal of osteopathic medicine and osteopathic physicians in the media.

Source: H651-A/20

Status: 2020
Advocating for Coverage of Elemental Formula in State, Federal, and Private Insurance Programs

Policy Statement

The American Osteopathic Association supports legislation which advocates for the coverage of medically necessary elemental pediatric formula under Medicaid and private insurance plans.

Source: H601-A/21

Status: 2021
Telehealth

Policy Statement

The American Osteopathic Association (AOA) has updated the policy statement on telehealth as outlined below.

Source: H603-A/21

Status: 2021
AOA Telehealth Policy

The COVID-19 public health emergency caused by the highly contagious sars-cov-2 virus has demonstrated the need to broaden and optimize the use and delivery of healthcare services through telehealth to prevent the spread of the outbreak. With the rapid pace of advancement in technology, telehealth is an evolving practice – both in the types of services furnished, and the tools used to expand access to medical care. Telehealth is a tool used not only to provide direct services to a patient via information technology, but also specialist and primary care consultations, the online storage and sharing of medical information, imaging services through digital transmissions and the interpretation of images, remote patient monitoring, and medical education.

The practice of medicine via electronic and technological means has been occurring for decades. As technology advances and the breadth of medical practice in this area expand, there is an increasing call to regulate patient care delivered through technological resources. Advocates for telehealth argue that it provides improved access to medical care and services to patients in rural or underserved areas. They also emphasize that it allows for easier access to care for immobile patients and those with limited mobility. Cost-effectiveness, through reduced travel times, is also noted as a cause for increased patient demand for health care services through telehealth.

Despite its advantages, opponents raise concerns over the lack of regulation and oversight to control this practice. The primary issues involving telehealth are: (1) geographical and site-of-service restrictions; (2) licensure of out-of-state practitioners who use technology to treat patients in a state where they are not licensed to practice; (3) technological problems and barriers; (4) reimbursement issues regarding payment for services rendered; and (5) quality of care.

Access, Efficiency and Quality

The U.S. Department of Health and Human Services (HHS) and the Centers for Disease Control and Prevention (CDC) have identified several benefits of telehealth. Virtual services limit physical contact and exposure to infectious diseases, shorten in-office wait times, eliminate commuting time and travel expenses, reduce time off from work and the need for childcare, and provide access to medical care in rural and underserved communities.

Despite the advances in telecommunication technology, some stakeholders are concerned that a lack of regulation and oversight may undermine the quality of care provided, or create an opportunity for fraud and abuse. Care deemed to be below the acceptable quality standard can be addressed either via the disciplinary action of a state medical board or via civil legal action (medical malpractice claims). Liability rules vary state by state and concerns exist over the determination of venue when a provider is utilizing telehealth across state lines. Additionally, standard of care must be established and may vary between face-to-face encounters and telehealth encounters; although, many providers argue against this variation.
Liability Concerns

One issue that arises under the discussion of advancing telehealth is the question of jurisdiction for liability cases. This includes cases of medical malpractice, where a physician licensed to practice in two or more states practices medicine over state lines through electronic means, and an adverse event occurs.

Current state and federal statutes and case law provide a remedy to overcome this barrier. Patients are provided a pathway to legal recourse in the state where the accident occurred, if there is a reasonable expectation for that harm to have occurred there. If the patient can provide evidence confirming that location, (IP address, for example) and did not attempt to deceive the physician as to their location. Under this established system, any time a physician is choosing to perform telehealth, they should have the expectation that they are choosing to be held liable under another state’s laws if an adverse event occurs.

Licensure

Telehealth is a broad area and is not regulated by one specific board or oversight body. There is no standard for Telehealth education and no certification in the provision of telehealth. Therefore, the burden of oversight currently falls on the state medical boards. Each board defines care that meets an acceptable quality somewhat differently. State licensure requirements also diverge with significant differences in testing, postgraduate education and continuing medical education requirements. Additionally, scopes of practice varies by state with no overall standard in regards to prescription authority or practice rights. Finally, uniformity fails to exist in what constitutes a visit (establishment of the “physician-patient relationship”), with some states requiring a face-to-face visit before a telehealth relationship can be established. Due to these differences, some advocates have promoted the concept of national licensure. They believe that a national license for the practice of medicine would eliminate barriers that prevent widespread use of telehealth.

The AOA supports state-based licensure and discipline oversight, believing that states should have the right to directly regulate and provide oversight for services being provided to their citizens. Concerns have been expressed about who would assume responsibility for disciplinary action against providers if a national medical license was initiated. Currently, protection of the residents of the state is a top function and core value of the state licensing boards.

Conclusion

The AOA recognizes the benefits of online technology to the medical field, and its ability to assist many patients who may not have access to medical care.
The AOA further recognizes the need to provide a broad framework that establishes payment and policy recommendations to effectively advocate for telehealth at the national level, while providing enough flexibility to allow each state to incorporate policies that meet the health care needs of their citizens.

The AOA supports that a physician is practicing medicine, in the absence of physical interaction, when medical services are being provided through simultaneous two-way communication, recognizing that some services may require appropriate and corresponding delays in said communication.

The AOA supports that the utilization of technology in patient care should be used to increase access to care, and must not be used in a way that would diminish patient centered comprehensive personal medical care or the quality of care being provided to the patient. To this end, the AOA supports the concept of telehealth and advocates that public and private payers adopt payment systems that are inclusive of telehealth, and payment parity for professional advice, consultation and development of patient treatment plans provided to patients, family members or designee via telehealth.

The AOA supports that the standard of care provided through the use of technology should be equivalent to that of care provided when the physician and patient are within close physical proximity.

The AOA supports that the technological network being used to deliver patient care must have protocols in place that ensure the stability and security of that network to comply with applicable state and federal laws regarding patient privacy protections.

The AOA supports that the scope of care being delivered by the physician and other health care providers through telehealth should not exceed education training and applicable state and federal law.

The AOA supports that the state-based licensure and ability of states to govern activities within their borders is paramount and would oppose any national licensure or efforts to preempt state statutes.

The AOA supports that malpractice claims that arise from care provided through technological means, when the physician and patient in separate jurisdictions, should be adjudicated under the process currently utilized by the judicial system; whereby, the plaintiff has the ability to determine the venue where the case is filed, within the constraints of that system.

The AOA supports physicians must provide complete transparency to their patients regarding their location, jurisdiction of licensure and any limitations of the technology used to deliver care.

The AOA supports that as physicians provide care in a variety of new ways, including telehealth, advanced technology can be used to improve patient care. The AOA further supports that telehealth policies directly tie into the Patient-Centered Medical Home (PCMH) model for care and other value-based care arrangements, and recognizes that we must simultaneously implement advancements in telehealth in order to be successful in new alternative payment models.
The AOA supports collaboration with the American Medical Association and other stakeholders to advocate for legislation or an executive order to mandate that all health insurance plans, including those issued by the centers for Medicare & Medicaid services and entities covered under Employee Retirement Income Security Act (ERISA) law continue to reimburse for telehealth services at a level that is commensurate with a face-to-face visit.

The AOA supports efforts to address educational and operational barriers that interfere with implementation of telehealth in physician offices, and believes that every effort should be made to allow telehealth services to be provided by the patient’s attending physician, rather than by physicians or clinicians the patient is unaffiliated with or is not referred by the patient’s primary care physician.

The AOA will monitor developments in telehealth on an ongoing basis and update this policy as needed.
Patient Access to Home Health Services

Policy Statement

The American Osteopathic Association (AOA) supports policies that will improve patient access and coverage to home healthcare services while prioritizing patient safety and promoting quality of home health services.

Source: H604-A/21

Status: 2021
Disaster Relief Volunteers

Policy Statement

As part of volunteer service, the American Osteopathic Association recommends: (1) encourage osteopathic physicians seek out appropriate training in disaster response, (2) encourages all osteopathic physicians to enroll as a volunteer to provide medical care during disasters before the next disaster strikes; (3) encourages all DOs to consider joining the U.S. Surgeon General’s Medical Reserve Corps or registering with their state or local Emergency System for Advanced Registration of Volunteer Health Profession Program (ESAR-VHP); (4) encourages osteopathic physicians who wish to volunteer to provide domestic or international emergency medical assistance to contact the humanitarian organizations; and (5) encourages the federal and state governments to work with the medical licensing boards to produce pathways and data resources that can hasten licensed medical aid to disaster victims during public health emergencies.

Source: H605-A/21

Status: 2006; 2011 Reaffirmed as Amended; 2016 Reaffirmed; 2021 Reaffirmed as Amended
Electronic Medical/Health Record Exemption without Penalty

Policy Statement

The American Osteopathic Association supports an exemption to financial penalties to solo and small group practices that do not implement electronic medical records.

Source: H606-A/21

Status: 2011; 2016 Reaffirmed; 2021 Reaffirmed
Physician Administered OMT

Policy Statement

The American Osteopathic Association actively opposes the use of Osteopathic Manipulative Treatment (OMT) / Current Procedural Terminology (CPT) codes by groups other than fully-licensed osteopathic and allopathic physicians and will work diligently to reverse such policies, wherever they exist, that allow non-physicians to utilize OMT/CPT codes for reimbursement.

Source: H607-A/21

Status: 1994; 1999 Reaffirmed as Amended; 2004 Reaffirmed; 2016 Reaffirmed; 2021 Reaffirmed
Mandatory Participation in Insurance Plans

Policy Statement

The American Osteopathic Association opposes any public policy that requires mandatory participation of physicians in any insurance plan, including Medicare or Medicaid and private insurance plans.

Source: H608-A/21

Status: 1994; 1996 Reaffirmed as Amended, 2001; 2006 Reaffirmed; 2011 Reaffirmed as Amended; 2016 Reaffirmed as Amended; 2021 Reaffirmed
Medicare Claims Coding – Centers for Medicare and Medicaid Services
Communications with Physicians

Policy Statement

The American Osteopathic Association urges the Centers for Medicare and Medicaid Services officials to require its Medicare administrative contractors provide thorough, current, written information on the preparation and coding of Medicare claims to all physicians prior to the implementation of any new policies or programs.

Source: H609-A/21

Status: 1999; 2006 Reaffirmed; 2011 Reaffirmed as Amended; 2016 Reaffirmed; 2021 Reaffirmed
Physician Negotiation Rights

Policy Statement

The American Osteopathic Association will support public policies that allow physicians to jointly negotiate with insurers thereby creating an equitable basis for negotiations between these parties.

Source: H610-A/21

Status: 2006; 2011 Reaffirmed as Amended; 2016 Reaffirmed as Amended; 2021 Reaffirmed as Amended
The American Osteopathic Association is opposed to the use of readmission rates as a criterion for deciding payment for physicians and the use of readmission rates as a criterion for ranking the quality of care provided by physicians.

Source: H611-A/21

Status: 2011; 2016 Reaffirmed; 2021 Reaffirmed

Policy Statement

The American Osteopathic Association is opposed to blending of payment rates by insurers for CPT codes.

Source: H612-A/21

Status: 2006; 2011 Reaffirmed as Amended; 2016 Reaffirmed; 2021 Reaffirmed as Amended
Health Insurance Exchanges

Policy Statement

The American Osteopathic Association adopts the following “Principles for State Health Insurance Exchanges” to assist states in the formation of health insurance exchanges and will communicate these principles to the Department of Health and Human Services (HHS), the Centers for Medicare and Medicaid Services (CMS), governors and state legislatures.

Source: H613-A/21

Status: 2011; 2016 Reaffirmed as Amended; 2021 Reaffirmed
Access to Care – Network Adequacy and Coverage

Policy Statement

The American Osteopathic Association (AOA) will advocate for public and private payors ensuring plan coverage for all medically necessary services, regardless of availability within the service area of its beneficiaries, and supporting state regulators as the primary enforcer of network adequacy requirements.

The AOA supports requiring provider terminations without cause be done prior to the enrollment period, allowing physicians to be added to the network at any time, and requiring health insurers to submit and make publicly available, at least quarterly, reports to state regulators that provide data on several measures of network adequacy.

The AOA supports requiring health insurers to indemnify patients for any covered medical expenses provided by out-of-network providers incurred over the co-payments and deductibles that would apply to in-network providers, in the case that a provider network is deemed inadequate by the health plan or appropriate regulatory authorities.

The AOA will advocate for public policies to require out-of-network expenses count toward a participant’s annual deductibles and out-of-pocket maximums when a patient is enrolled in a plan with out-of-network benefits, or forced to go out-of-network due to network inadequacies.

The AOA supports fair and equitable compensation to out-of-network providers in the event that a provider network is deemed inadequate by the health plan or appropriate regulatory authorities; and, that physician and patients have access to adequate and fair appeals processes in the event that they are harmed by inadequate networks.

The AOA supports the development of a mechanism by which health insurance enrollees are able to file formal complaints about network adequacy with appropriate regulatory authorities, and will advocate for laws that prohibit health insurers from falsely advertising that enrollees in their plans have access to physicians of their choosing if the health insurer’s network is limited.

The AOA will advocate that health plans be required to document to regulators that they have met requisite standards of network adequacy for hospital-based physician specialties (i.e. radiology, pathology, emergency medicine, anesthesiologists and hospitalists) at in-network facilities.

Source: H614-A/21

Status: 2016; 2021 Reaffirmed
Third Party Insurer Coverage Process Reform

Policy Statement

The American Osteopathic Association (AOA) supports the development of model legislation and/or regulations to require that Medicare, commercial insurance companies, state Medicaid agencies, or other third party insurers utilize transparent and accountable processes for developing and implementing coverage decisions and policies.

The AOA will advocate that public and private insurers and benefit management companies develop transparent clinical protocols as well as formal processes to write / revise them; that those processes should seek input from the relevant physician organizations; and that such clinical coverage protocols should be easily and publicly accessible on their websites.

The AOA will advocate that when public and private insurers and benefit management companies make changes to or revise clinical coverage protocols, said companies must inform all insured individuals and participating providers in writing no less than 90 days prior to said change(s) going into effect; and, be it further

Through legislative and/or regulatory efforts the AOA will advocate that when Medicare Administrative Contractors (MAC) propose new or revised Local Coverage Determinations (LCD), said Contractors must: 1. Conduct Carrier Advisory Committee meetings in public, with minutes recorded and posted to the Contractor’s website; and 2. Disclose the rationale for the LCD, including the evidentiary standard upon which it is based when releasing an approved LCD. Through legislative and/or regulatory efforts the AOA will advocate that CMS adopt a new LCD reconsideration process that allows for an independent review of a MAC’s payment policies by a third-party empowered to make recommendations to affirm, withdraw or revised said policies to the Secretary of HHS; and that that MACs shall be prohibited from adopting another MAC’s LCD without first undertaking a full and independent review of the underlying science and necessity of such LCD in their jurisdiction.

Source: H615-A/21

Status: 2016; 2021 Reaffirmed as Amended
Merit-Based Incentive Payment System (MIPS) & Alternative Payment Models (APMS)

Policy Statement

The American Osteopathic Association (AOA) will endeavor to educate osteopathic physicians on the Medicare Access and Children’s Health Insurance Program (CHIP) reauthorization act of 2015 (MACRA) and the newly emerging payment models, including Merit Based Incentive Payment System (MIPS) AND Alternative Payment Models (APMS), resulting from the act and how these payment models might affect practicing physicians by developing and disseminating broadly available educational materials on MACRA and resulting payment models.

Source: H616-A/21

Status: 2016; 2021 Reaffirmed
Health Insurer Consolidation

Policy Statement

The American Osteopathic Association (AOA) supports the application of strict and necessary scrutiny by appropriate governmental agencies, including but not limited to the Department of Justice State Attorneys General, Federal Trade Commission, and State Insurance Commissioners, to any consolidation of health insurers and that each health insurer consolidation should be evaluated on protecting the interests and needs of the health care consumer, including patient access, and choice among multiple insurers. The necessity of any merger within the health insurance industry must demonstrate a benefit to patients by improving patient access and by meeting the quadruple-aim of enhancing patient experience, improving population health, reducing costs, and improving the work life of health care providers, including clinicians and staff.

Source: H617-A/21

Status: 2016; 2021 Reaffirmed as Amended
Medicare Medical Necessity Certification Requirements

Policy Statement

The American Osteopathic Association (AOA) supports reasonable efforts to prevent Medicare waste, fraud, and abuse, and thereby calling on the Center for Medicare and Medicaid Services (CMS) to evaluate its medical necessity certification requirements including the amount of waste fraud and abuse detected and prevented by such measures, the administrative burden imposed on physician practices, and the rate of denial of legitimate medical supplies and equipment. The AOA encourages CMS to develop a more efficient and less burdensome approach to medical necessity certification.

Source: H618-A/21

Status: 2016; 2021 Reaffirmed as Amended
Expanding Gender Identity Options on Physician Intake Forms

Policy Statement

The American Osteopathic Association (AOA) supports the inclusion of a two-part demographic inquiry on patient intake forms, requesting patients indicate both their assigned sex at birth (male, female, intersex) and gender identity (male, female, transgender male, transgender female, nonbinary, additional category with blank for patient to complete).

Source: H619-A/21

Status: 2016; 2021 Reaffirmed as Amended
Osteopathic Neurologic and Psychiatric Standard of Care

Policy Statement

The American Osteopathic Association acknowledges the role osteopathic manipulative treatment (OMT) has in the specialty of Osteopathic Neurology and Psychiatry and agrees that when OMT is chosen to be utilized with appropriately selected patients, therapeutic boundaries will be maintained and respected.

Source: H600-A22

Status: 2010; 2017 Reaffirmed; 2022 Reaffirmed
Adjustment to Primary Care Incentive Program

Policy Statement

The American Osteopathic Association is supportive of at least 10% incentive payment to primary care physicians and non-physician providers (NPPs), supervised by primary care physicians, who perform the Primary Care Services.

Source: H603-A22

Status: 2012; 2017 Reaffirmed as Amended; 2022 Reaffirmed as Amended
Physician Depositions

Policy Statement

The American Osteopathic Association believes that physicians being deposed should have the right to review and amend the deposition prior to submission and be provided a complete, final copy of the deposition.

Source: H604-A22

Status: 2012; 2017 Reaffirmed; 2022 Reaffirmed
The Practice of Osteopathic Medicine Discrimination

Policy Statement

The American Osteopathic Association supports the inclusion of osteopathic physicians in all healthcare delivery systems; opposes restraint of trade and supports the ability of all osteopathic physicians to practice freely in all institutions, as qualified by training and experience as defined and specified by the AOA; and opposes discrimination against osteopathic physicians.

Source: H605-A22

Status: 1987; 1992 Reaffirmed as Amended; 1997 Reaffirmed; 2002 Reaffirmed; 2007 Reaffirmed as Amended; 2012 Reaffirmed as Amended; 2017 Reaffirmed as Amended; 2022 Reaffirmed
Drug Prescribing, Including Elderly Patients

Policy Statement

The American Osteopathic Association supports measures to significantly reduce the problems of over-medication, under-medication and/or harmful drug interactions in all patients, including the elderly population.

Source: H606-A22

Status: 2002, 2007 Reaffirmed as Amended; 2012 Reaffirmed; 2017 Reaffirmed as Amended; 2022 Reaffirmed as Amended
Human Immunodeficiency Virus (HIV) – Positive Status as a Disability for Physicians

Policy Statement

The American Osteopathic Association supports efforts to require all disability insurance contracts to recognize HIV positive status as a disability for all physicians, regardless of specialty, provided that the physician can demonstrate that this status has caused a significant loss of patients, income or privileges.

Source: H607-A22

Status: 1992; 1997 Reaffirmed as Amended; 2002 Reaffirmed; 2007 Reaffirmed; 2012 Reaffirmed; 2017 Reaffirmed; 2022 Reaffirmed
Health Care Fraud and Abuse

Policy Statement

The American Osteopathic Association continues to pledge its full cooperation and support of all reasonable and appropriate efforts by the federal government and the states to stop all fraud and abuse in health care.

Source: H608-A22

Status: 1992; 1997 Reaffirmed; 2002 Reaffirmed; 2007 Reaffirmed; 2012 Reaffirmed; 2017 Reaffirmed as Amended; 2022 Reaffirmed
Military Medical Readiness

Policy Statement

The American Osteopathic Association supports efforts by the Department of Defense which encourage the voluntary participation of osteopathic physicians in the military and improves the military medical readiness of America.

Source: H609-A22

Status: 1987; 1992 Reaffirmed as Amended; 1997 Reaffirmed; 2002 Reaffirmed; 2007 Reaffirmed; 2012 Reaffirmed; 2017 Reaffirmed; 2022 Reaffirmed
Payment For Psychiatric Diagnoses and Treatment by Primary Care Physicians

Policy Statement

The American Osteopathic Association strongly objects to any insurance plan refusal to pay primary care physicians for treating patients with psychiatric diagnoses without a referral from the behavioral medicine agency or provider; will make every effort to influence these insurers to reverse this policy and allow primary care physicians to provide care for these patients and be paid for these services; and will communicate with the regulators and respective third-party payers to eliminate the mandatory referral in order to be paid when proper documentation is provided.

Source: H610-A22

Status: 2007; 2012 Reaffirmed as Amended; 2017 Reaffirmed as Amended; 2022 Reaffirmed
Physician Fines Imposed by Third Party Payors

Policy Statement

The American Osteopathic Association opposes all punitive fees, hold backs or other financial penalties levied on physicians for acts committed by patients that are not under the absolute control of the physician.

Source: H611-A22

Status: 2007; 2012 Reaffirmed; 2017 Reaffirmed as Amended; 2022 Reaffirmed
Health Care Insurance Options

Policy Statement

The American Osteopathic Association supports legislation that requires employers who are obligated by law to provide insurance to offer more than one option for health insurance.

Source: H612-A22

Status: 1986; 1991 Reaffirmed as Amended, 1992, 1997; 2002 Reaffirmed as Amended; 2007; 2012 Reaffirmed as Amended; 2017 Reaffirmed as Amended; 2022 Reaffirmed
Human Immunodeficiency Virus (HIV) Consent Form Elimination

Policy Statement

The American Osteopathic Association supports the elimination of the requirement of physicians and healthcare settings to have consent forms completed before an HIV test.

Source: H614-A22

Status: 2017; 2022 Reaffirmed
Direct Primary Care

Policy Statement

The American Osteopathic Association supports the direct primary care model of practice and specifies that it is not insurance. Additionally, the AOA supports patients’ payments to direct primary care practices as qualified medical expenses eligible for Health Savings Accounts through federal changes to Internal Revenue Code 213(d) and 223(c) and a physician’s ability to dispense prescription medications from their office in accordance with applicable federal and state laws. The AOA supports mechanisms allowing Medicaid and Medicare patients access to direct primary care services while preserving physician autonomy.

Source: H615-A22

Status: 2017; 2022 Reaffirmed as Amended
Opposition to the Practice of LGBTQIA2S+ Conversion Therapy or Reparative Therapy

Policy Statement

The American Osteopathic Association affirms that identifying as lesbian, gay, bisexual, transgender, questioning queer, or other than heterosexual (LGBTQIA2S+) is not a mental disorder. Sexual orientation and gender identity are not mental disorders.

The AOA strongly opposes the practice of conversion therapy, reparative therapy, or other techniques aimed at changing a person’s sexual orientation or gender identity as the preferred outcome.

The AOA supports potential legislation, regulations, or policies that oppose the practice of conversion therapy, reparative therapy, or other techniques aimed at changing a person’s sexual orientation or gender identity as the preferred outcome.

Source: H616-A22

Status: 2017; 2022 Reaffirmed as Amended
Patient Interpreters

Policy Statement

The American Osteopathic Association supports efforts to remove from Section 1557 of the Affordable Care Act the unfunded mandate on physicians to provide interpreters for those patients with Limited English Proficiency (LEP) by revising the current federal policy to include adequate reimbursement for physicians for patient interpreters.

Source: H618-A22

Status: 2017; 2022 Reaffirmed
AOA Opposition to Merging of State Osteopathic Licensing Boards with State Medical Licensing Boards

Policy Statement

The American Osteopathic Association stands in opposition to the consolidation of any state osteopathic and medical licensure boards. The AOA will actively monitor for activities that threaten separate state osteopathic licensing boards in the states where they exist and will prioritize its resources to oppose efforts to consolidate state osteopathic and medical licensing boards.

Source: H619-A22

Status: 2017; 2022 Reaffirmed as Amended
Prescription Drug Pricing

Policy Statement

The American Osteopathic Association will advocate for policies that encourage pharmaceutical manufacturers, prescription drug benefit managers, pharmacies, and payers to price drugs and insurance products that cover prescription drugs in order to promote access, affordability, and continued advancement of healthcare quality and innovation.

Source: H620-A/22

Status: 2017; 2022 Reaffirmed as Amended
Reducing the Waiting Period for Credentialing, Re-Credentialing and Enrollment of Health Care Professionals by Health Plans

Policy Statement

The American Osteopathic Association (AOA) advocate for transparent, unburdensome, timely, and cost-effective credentialing processes; and advocate for legislation, and provide sample language, recommending the reduction of the length of time required for credentialing, recredentialing and enrollment by any health plan to 60 days or less when a clean provider application is submitted to the health plan.

Source: H624-A/22

Status: 2022 Reaffirmed as Amended